ঔষধ নিয়ন্ত্রণ কমিটির ১৩ অক্টোবর ২০২৫ তারিখে অনুষ্ঠিত ২৫৭ তম সভার কার্যবিবরণী

স্বাস্থ্য ও পরিবার কল্যাণ মন্ত্রণালয়ের স্বাস্থ্য সেবা বিভাগের সচিব জনাব মোঃ সাইদুর রহমান এঁর সভাপতিত্বে ঔষধ নিয়ন্ত্রণ কমিটির ২৫৭ তম সভা বিগত ১৩ অক্টোবর সোমবার সকাল ১০.০০ ঘটিকায় মন্ত্রণালয়ের সভা কক্ষে অনুষ্ঠিত হয়।

সভায় কমিটির নিম্নবর্ণিত সদস্যগণ উপস্থিত ছিলেন (জ্যেষ্ঠতার ক্রমানুসারে নয়) (উপস্থিতির কপি সংযুক্ত):

১। মেজর জেনারেল মোঃ শামীম হায়দার, মহাপরিচালক, ঔষধ প্রশাসন অধিদপ্তর, মহাখালী, ঢাকা।
২। অধ্যাপক ডা. মোঃ শাহিনুল আলম, উপাচার্য, বাংলাদেশ মেডিকেল বিশ্ববিদ্যালয়, শাহবাগ, ঢাকা।
৩। জনাব মুহাম্মদ মোজাম্মেল হোসেন খান, যুগ্মসচিব ঔষধ প্রশাসন অনুবিভাগ, স্বাস্থ্য সেবা বিভাগ।
৪। ব্রিগেডিয়ার জেনারেল এস এম রাহিদ সারোয়ার, আর্মড ফোর্সেস মেডিকেল সার্ভিসেস, ঢাকা ক্যান্টনমেন্ট, ঢাকা।
৫। ডা. মোঃ শাহিনূর আলম, পরিচালক, প্রাণিসম্পদ অধিদপ্তর, ফার্মগেট, ঢাকা।
৬। অধ্যাপক ড. মোঃ আব্দুর রশিদ, প্রাক্তন ডিন, ফার্মেসী অনুষদ, ঢাকা বিশ্ববিদ্যালয় ও সহ-সভাপতি, বাংলাদেশ ফার্মাসিউটিক্যাল সোসাইটি, ঢাকা।
৭। ডা. ওয়াসিফ আলী খান, ইমেরিটাস বিজ্ঞানী, এন্টেরিক ও রেসপিরেটরি ইনফেকশিয়াস, ইনফেকশিয়াস ডিজিসেস ডিভিশন, আইসিডিডিআর'বি, মহাখালী, ঢাকা।
৮। অধ্যাপক ড. মো. সেলিম রেজা, ডিন, ফার্মেসী অনুষদ, ঢাকা বিশ্ববিদ্যালয়, ঢাকা।
৯। অধ্যাপক ডা. শামীম আহমেদ, রিউমাটোলজি বিভাগ, ডিন, মেডিসিন অনুষদ, বাংলাদেশ মেডিকেল বিশ্ববিদ্যালয়, শাহবাগ, ঢাকা।
১০। অধ্যাপক ডা. ফারুক আহাম্মদ, বিভাগীয় প্রধান, মেডিসিন বিভাগ, ঢাকা মেডিকেল কলেজ, ঢাকা।
১১। অধ্যাপক ডা. মোঃ মোস্তাফিজুর রহমান বিভাগীয় প্রধান, শিশু বিভাগ, স্যার সলিমুল্লাহ মেডিকেল কলেজ, মিটফোর্ড, ঢাকা।
১২। অধ্যাপক ডা. রোজিনা হক, অধ্যাপক ও বিভাগীয় প্রধান, ফার্মাকোলজি বিভাগ, চট্টগ্রাম মা ও শিশু হাসপাতাল মেডিকেল কলেজ, চট্টগ্রাম, প্রতিনিধি, সভাপতি, বাংলাদেশ ফার্মাকোলজিক্যাল সোসাইটি।
১৩। অধ্যাপক ডা. জাকির হোসেন হাবীব, মুখ্য বৈজ্ঞানিক কর্মকর্তা, ভাইরোলজী বিভাগ, আইইডিসিআর, মহাখালী, ঢাকা।
১৪। জনাব মুহাম্মদ মাহবুবুল হক, সচিব,বাংলাদেশ ফার্মেসী কাউন্সিল, ঢাকা।
১৫। হাকীম আ.খ.মাহবুবুর রহমান, ইউনানী বিশেষজ্ঞ, বাংলাদেশ ইউনানী ও আয়ুর্বেদিক বোর্ড, ঢাকা।
১৬। ডা. মোঃ জাহাঙ্গীর আলম, রেজিস্ট্রার, বাংলাদেশ হোমিওপ্যাথিক চিকিৎসা শিক্ষা কাউন্সিল, ঢাকা।

সভার আলোচ্য সূচী :

ক) স্থানীয়ভাবে উৎপাদনের জন্য ৩১১ টি হিউম্যান ঔষধের বিষয়ে টেকনিক্যাল সাব কমিটির সুপারিশের বিষয়ে আলোচনা ও সিদ্ধান্ত গ্রহণ প্রসঙ্গে ।
খ) আমদানীর জন্য ২৯ টি হিউম্যান ঔষধের বিষয়ে টেকনিক্যাল সাব কমিটির সুপারিশের বিষয়ে আলোচনা ও সিদ্ধান্ত গ্রহণ প্রসঙ্গে ।
গ) স্থানীয়ভাবে উৎপাদনের জন্য ১০৩ টি ভেটেরিনারী ঔষধের বিষয়ে টেকনিক্যাল সাব কমিটির সুপারিশের বিষয়ে আলোচনা ও সিদ্ধান্ত গ্রহণ প্রসঙ্গে ।
ঘ) বিবিধ আলোচনা:
১। একই সোর্সের বা একই উৎপাদনকারী প্রতিষ্ঠানের একই ব্রান্ড/জেনেরিক/স্ট্রেংথ/ডোজেস ফরম এর বিদেশী ঔষধ ও মেডিকেল ডিভাইস একাধিক প্রতিষ্ঠান কর্তৃক রেজিস্ট্রেশন গ্রহণ পূর্বক আমদানী অনুমোদন প্রসঙ্গে।
২। ঔষধ নিয়ন্ত্রণ কমিটির ২৫৫, ২৫৬ এবং ২৫৭ তম সভায় বিভিন্ন বিশেষজ্ঞ এর মতামত গ্রহণ প্রসঙ্গে।

সভার আলোচনাঃ

সবাইকে স্বাগত জানিয়ে সভাপতি সভার কার্যক্রম শুরু করেন। অতঃপর তিনি কমিটির সদস্য সচিব ঔষধ প্রশাসন অধিদপ্তরের মহাপরিচালক-কে সভার আলোচ্যসূচী মোতাবেক বিষয়বস্তু উপস্থাপনের জন্য অনুরোধ করেন।

ক) স্থানীয়ভাবে উৎপাদনের জন্য ৩১১ টি হিউম্যান ঔষধের বিষয়ে টেকনিক্যাল সাব কমিটির সুপারিশের বিষয়ে আলোচনা ও সুপারিশ:

স্থানীয়ভাবে উৎপাদনের জন্য হিউম্যান ঔষধের রেজিস্ট্রেশনের নিমিত্তে দাখিলকৃত ৩১১ টি ঔষধ সভায় উপস্থাপন করা হলে বিস্তারিত আলোচনার পর নিম্নলিখিত সুপারিশ করা হয়ঃ

ক। অনুমোদনের জন্য সুপারিশকৃত = ১০৪ টি
খ। নামঞ্জুরের জন্য সুপারিশকৃত = ২০৭ টি;

ঔষধ নিয়ন্ত্রণ কমিটির সভার আলোচনা ও সিদ্ধান্ত: টেকনিক্যাল সাব কমিটির সুপারিশের বিষয়ে বিস্তারিত আলোচনার পর নিম্নলিখিত সুপারিশ করা হয়ঃ

অনুমোদন করা হয়	:	৬৩ টি
নামঞ্জুর করা হয়	:	২৩২ টি
পরবর্তী ঔষধ নিয়ন্ত্রন কমিটির সভায় পুনর্মূল্যায়নের সিদ্ধান্ত গৃহীত হয়	:	০১ টি
পরবর্তী টেকনিক্যাল সাব কমিটির সভায় পুনর্মূল্যায়নের সিদ্ধান্ত গৃহীত হয়	:	০৬ টি
পরবর্তী ঔষধ নিয়ন্ত্রন কমিটির সভায় চক্ষু বিশেষজ্ঞ এর মতামত গ্রহনের সিদ্ধান্ত গৃহীত হয়	:	০২ টি
পরবর্তী ঔষধ নিয়ন্ত্রন কমিটির সভায় স্ত্রীরোগ বিশেষজ্ঞ এর মতামত গ্রহনের সিদ্ধান্ত গৃহীত হয়	:	০১ টি
পরবর্তী ঔষধ নিয়ন্ত্রন কমিটির সভায় এনেসথেসিয়া বিশেষজ্ঞ এর মতামত গ্রহনের সিদ্ধান্ত গৃহীত হয়	:	০১ টি
পরবর্তী ঔষধ নিয়ন্ত্রন কমিটির সভায় সাইকিয়াট্রিস্ট বিশেষজ্ঞ এর মতামত গ্রহনের সিদ্ধান্ত গৃহীত হয়	:	০৫ টি (Annex-A)

খ) আমদানীর জন্য ২৯ টি হিউম্যান ঔষধের বিষয়ে টেকনিক্যাল সাব কমিটির সুপারিশের বিষয়ে আলোচনা ও সুপারিশ:

আমদানীর জন্য নতুন ঔষধ এবং প্রচলিত ঔষধের নতুন আকার ও মাত্রার হিউম্যান ঔষধের রেজিস্ট্রেশনের নিমিত্তে দাখিলকৃত ২৯ টি ঔষধের বিষয়ে সভায় টেকনিক্যাল সাব কমিটির সভায় উপস্থিত সম্মানিত সদস্যগণ বিস্তারিত আলোচনাক্রমে নিম্নলিখিত সিদ্ধান্ত গৃহীত হয়ঃ

অনুমোদনের জন্য সুপারিশকৃতঃ ২২ টি
নামঞ্জুরের জন্য সুপারিশকৃতঃ ০৭ টি;

ঔষধ নিয়ন্ত্রণ কমিটির সভার আলোচনা ও সিদ্ধান্ত:
আমদানীর জন্য হিউম্যান ঔষধের রেজিস্ট্রেশনের নিমিত্তে দাখিলকৃত ২৯ টি ঔষধের টেকনিক্যাল সাব কমিটির সুপারিশের বিষয়ে বিস্তারিত আলোচনার পর নিম্নলিখিত সুপারিশ করা হয়ঃ

ক। অনুমোদনের জন্য সুপারিশকৃত = ১৪ টি
খ। নামঞ্জুরের জন্য সুপারিশকৃত = ১৪ টি;
গ। পরবর্তী ঔষধ নিয়ন্ত্রন কমিটির সভায় স্ত্রীরোগ বিশেষজ্ঞ এর মতামত গ্রহনের সিদ্ধান্ত গৃহীত হয় = ০১ টি; (Annex-B)

গ) আমদানীর জন্য ১০৩ টি ভেটেরিনারী ঔষধের বিষয়ে টেকনিক্যাল সাব কমিটির সুপারিশের বিষয়ে আলোচনা ও সুপারিশ:

স্থানীয় উৎপাদনের জন্য নতুন ঔষধ এবং প্রচলিত ঔষধের নতুন আকার ও মাত্রার ভেটেরিনারী ঔষধের রেজিস্ট্রেশনের নিমিত্তে দাখিলকৃত ১০৩টি ভেটেরিনারী মেডিসিন সভায় উপস্থাপন করা হলে টেকনিক্যাল সাব কমিটির সভায় উপস্থিত সম্মানিত সদস্যগণ ঔষধগুলির Safety, Efficacy and Usefulness বিবেচনা করে বিস্তারিত আলোচনাক্রমে নিম্নলিখিত সিদ্ধান্ত গৃহীত হয়ঃ

ক। অনুমোদনের জন্য সুপারিশকৃতঃ ৬৩ টি
খ। নামঞ্জুরের জন্য সুপারিশকৃতঃ ৪০ টি;

ঔষধ নিয়ন্ত্রণ কমিটির সভার আলোচনা ও সিদ্ধান্ত:

আমদানীর জন্য ভেটেরিনারী ঔষধের রেজিস্ট্রেশনের নিমিত্তে দাখিলকৃত ১০৩ টি ঔষধের টেকনিক্যাল সাব কমিটির সুপারিশের বিষয়ে বিস্তারিত আলোচনার পর নিম্নলিখিত সুপারিশ করা হয়ঃ

অনুমোদন করা হয়	:	৬২ টি
নামঞ্জুর করা হয়	:	৩৯ টি
পরবর্তী টেকনিক্যাল সাব কমিটির সভায় পুনর্মূল্যায়নের সিদ্ধান্ত গৃহীত হয়	:	০২ টি

(Annex-C)

আর কোন আলোচ্য বিষয় না থাকায় সভায় উপস্থিত সবাইকে ধন্যবাদ জানিয়ে সভাপতি সভার সমাপ্তি ঘোষণা করেন।

মেজর জেনারেল মো: শামীম হায়দার
মহাপরিচালক
ঔষধ প্রশাসন অধিদপ্তর
ও
সদস্য-সচিব, ঔষধ নিয়ন্ত্রণ কমিটি

মো: সাইদুর রহমান
সচিব
স্বাস্থ্য সেবা বিভাগ
স্বাস্থ্য ও পরিবার কল্যাণ মন্ত্রণালয়
ও
সভাপতি, ঔষধ নিয়ন্ত্রণ কমিটি

ঔষধ নিয়ন্ত্রণ কমিটির ২৫৭ তম সভার কার্যবিবরণী এর সংযুক্তি

Annex-A: স্থানীয়ভাবে উৎপাদনের জন্য হিউম্যান মেডিসিন এর তালিকা

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
1.	Square Lifesciences Ltd., Hemayetpur, Pabna	Olanzapine 6mg + Fluoxetine 50mg Capsule	Olanzapine USP 6 mg + Fluoxetine Hydrochloride USP 55.9mg eq. to Fluoxetine 50mg	Antidepressants Therapeutic code: 014	It is Indicated for the treatment of Acute Depressive Episodes Associated with Bipolar I Disorder and Treatment Resistant Depression	**Warning:** Suicidal thoughts and behaviors and increased mortality in elderly patients with dementia-related psychosis Contra-indication: Because of the risk of serotonin syndrome, this combination should not be used with MAOIs intended to treat psychiatric disorders or within 5 weeks of stopping treatment with the combination. This combination also should not be used within 14 days of stopping an MAOI intended to treat psychiatric disorders. In addition, do not start the combination in a patient who is being treated with linezolid or intravenous methylene blue. This can't be used along with Pimozide and Thioridazine due to risk of QT interval prolongation. **Adverse Events:** Most common adverse reactions (≥5% and at least twice that for placebo) in adults: sedation, weight increased, appetite increased, dry mouth, fatigue, edema, tremor, disturbance in attention, blurred vision. Children and adolescents: sedation, weight increased, appetite increased, tremor, triglyceride increased, hepatic enzymes increased	Olanzapine 5mg & 10mg Tablet Fluoxetine 20mg Capsule	USFDA	প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
2.	Square Lifesciences Ltd., Hemayetpur, Pabna	Olanzapine 12mg + Fluoxetine 25mg Capsule	Olanzapine USP 12mg + Fluoxetine Hydrochloride USP 27.95mg eq. to Fluoxetine 25mg	Antidepressants Therapeutic code: 014	It is Indicated for the treatment of Acute depressive episodes Associated with Bipolar I Disorder and Treatment Resistant Depression	**Warning:** Suicidal thoughts and behaviors and increased mortality in elderly patients with dementia-related psychosis Contra-indication: Because of the risk of serotonin syndrome, this combination should not be used with MAOIs intended to treat psychiatric disorders or within 5 weeks of stopping treatment with the combination. This combination also should not be used within 14 days of stopping an MAOI intended to treat psychiatric disorders. In addition, do not start the combination in a patient who is being treated with linezolid or intravenous methylene blue. This can't be used along with Pimozide and Thioridazine due to risk of QT interval prolongation. **Adverse Events:** Most common adverse reactions (≥5% and at least twice that for placebo) in adults: sedation, weight increased, appetite increased, dry mouth, fatigue, edema,	Olanzapine 5mg & 10mg Tablet Fluoxetine 20mg Capsule	USFDA	প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						tremor, disturbance in attention, blurred vision. Children and adolescents: sedation, weight increased, appetite increased, tremor, triglyceride increased, hepatic enzymes increased				
3.	Square Lifesciences Ltd., Hemayetpur, Pabna Beacon Pharmaceuticals PLC, Kathali, Bhaluka, Mymensingh	Naldemidine 0.2mg Tablet	Naldemidine Tosylate Ph. Gr. 0.26mg eq. to 0.2mg Naldemidine	Opioid Antagonists Therapeutic Code: 066	It is an opioid antagonist indicated for the treatment of opioid induced constipation (OIC) in adult patients with chronic non-cancer pain.	**Contra-indication**: Patients with known or suspected gastrointestinal obstruction or at increased risk of recurrent obstruction. Patients with a history of a hypersensitivity reaction to naldemedine **Side effects:** Stomach (abdomen) pain, diarrhea, and nausea. **Warnings and Precautions:** Gastrointestinal perforation: Consider the overall risk benefit in patients with known or suspected lesions of the GI tract. Monitor for severe, persistent, or worsening abdominal pain; discontinue if development of symptoms Opioid withdrawal: Consider the overall risk benefit in patients with disruptions to the blood-brain barrier. Monitor symptoms of opioid withdrawal.	New	USFDA	অনুমোদনের সুপারিশ করা হয়।	পরবর্তী টেকনিক্যাল সাবকমিটির সভায় পুনর্মূল্যায়নের সিদ্ধান্ত গৃহীত হয়।
4.	Square Pharmaceuticals PLC, Kaliakoir, Gazipur Beacon Pharmaceuticals PLC, Kathali, Bhaluka, Mymensingh Advanced Chemical Industries Limited, 7 Hajeegonj, Godnyl, Narayangonj Incepta Pharmaceuticals Ltd., Zirabo, Savar, Dhaka Opsonin Pharma Ltd.	Lumateperone 21mg Capsule	Lumateperone Tosylate INN 30mg eqv. To 21mg Lumateperone	Antipsychotic Therapeutic Code: 027	It is indicated for the treatment of schizophrenia in adults and depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults, as monotherapy and as adjunctive therapy with lithium or valproate.	**Warning:** Increased mortality in elderly patients with dementia related psychosis and suicidal thoughts and behaviors. **Contraindication:** Known hypersensitivity to lumateperone **Side effects:** Drowsiness, dizziness, lightheadedness, dry mouth, or nausea may occur.	42mg Capsule	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
	, Barishal									
5.	Synovia Pharma PLC. Station Road, Tongi, Gazipur Incepta Pharmaceuticals Ltd.; Zirabo, Dhaka Opsonin Pharma Ltd., Barishal	Metformin Hydrochloride 500mg + Ertugliflozin 2.5mg Tablet	Metformin Hydrochloride BP 500mg + Ertugliflozin INN 2.5mg	Therapeutic Class: Antidiabetic Therapeutic Code: 015	It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are not adequately controlled on a regimen containing ertugliflozin or metformin, or in patients who are already treated with both ertugliflozin and metformin. It lowers blood sugar levels in adult patients (aged 18 years and older) with type 2 diabetes and prevent heart failure in patients with type 2 diabetes.	**Contra-indication**: Severe renal impairment, end stage renal disease (ESRD), or patients on dialysis and Use in Specific Populations, Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma, History of a serious hypersensitivity reaction to ertugliflozin, or metformin hydrochloride. **Side-effects:** Common side effects may include vomiting, indigestion, diarrhea, weakness, nausea, and stomach discomfort. In some cases, individuals may experience dehydration, urinary tract infection, or low blood sugar. Additionally, occurrences of amputations and yeast infections in the penis and vagina have been reported at times. Diabetic ketoacidosis, Lactic acidosis Necrotising fasciitis of the perineum or Fournier's gangrene have been reported rarely. **Warning and Precautions:** Risk of lactic acidosis: The risk of developing lactic acidosis is also increased with uncontrolled diabetes, serious infections, prolonged fasting or alcohol intake, dehydration liver problems and any medical conditions in which a part of the body has a reduced supply of oxygen. Hypotension: May occur particularly in patients with renal impairment, the elderly, or patients on diuretics. Ketoacidosis: Assess patients who present with signs and symptoms of metabolic acidosis for ketoacidosis, regardless of blood glucose level. Acute Kidney Injury and Impairment in Renal Function: cause intravascular volume contraction and can cause renal impairment Hypoglycemia with Concomitant Use with Insulin and Insulin Secretagogues. Urosepsis and Pyelonephritis, Increases in Low-Density Lipoprotein Cholesterol (LDL-C), Genital mycotic infections.	Metformin Hydrochloride 500mg Tablet	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।
6.	Synovia Pharma PLC. Station Road, Tongi,	Metformin Hydrochloride 500mg + Ertugliflozin 7.5mg Tablet	Metformin Hydrochloride BP 500mg +	Therapeutic Class: Antidiabetic	It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who	**Contra-indication**: Severe renal impairment, end stage renal disease (ESRD), or patients on dialysis and Use in Specific Populations, Acute or chronic metabolic	Metformin Hydrochloride 500mg Tablet	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
	Gazipur Incepta Pharmaceuticals Ltd.; Zirabo, Dhaka		Ertugliflozin INN 7.5mg	Therapeutic Code: 015	are not adequately controlled on a regimen containing ertugliflozin or metformin, or in patients who are already treated with both ertugliflozin and metformin. It lowers blood sugar levels in adult patients (aged 18 years and older) with type 2 diabetes and prevent heart failure in patients with type 2 diabetes.	acidosis, including diabetic ketoacidosis, with or without coma, History of a serious hypersensitivity reaction to ertugliflozin, or metformin hydrochloride. **Side-effects:** Common side effects may include vomiting, indigestion, diarrhea, weakness, nausea, and stomach discomfort. In some cases, individuals may experience dehydration, urinary tract infection, or low blood sugar. Additionally, occurrences of amputations and yeast infections in the penis and vagina have been reported at times. Diabetic ketoacidosis, Lactic acidosis Necrotising fasciitis of the perineum or Fournier's gangrene have been reported rarely. **Warning and Precautions:** Risk of lactic acidosis: The risk of developing lactic acidosis is also increased with uncontrolled diabetes, serious infections, prolonged fasting or alcohol intake, dehydration liver problems and any medical conditions in which a part of the body has a reduced supply of oxygen. Hypotension: May occur particularly in patients with renal impairment, the elderly, or patients on diuretics. Ketoacidosis: Assess patients who present with signs and symptoms of metabolic acidosis for ketoacidosis, regardless of blood glucose level. Acute Kidney Injury and Impairment in Renal Function: cause intravascular volume contraction and can cause renal impairment Hypoglycemia with Concomitant Use with Insulin and Insulin Secretagogues. Urosepsis and Pyelonephritis, Increases in Low-Density Lipoprotein Cholesterol (LDL-C), Genital mycotic infections.				
7.	Synovia Pharma PLC. Station Road, Tongi, Gazipur Incepta	Metformin Hydrochloride 1000mg + Ertugliflozin 7.5mg Tablet	Metformin Hydrochloride BP 1000mg + Ertugliflozin INN 7.5mg	Therapeutic Class: Antidiabetic Therapeutic Code: 015	It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are not adequately controlled on a regimen containing ertugliflozin or metformin, or in patients who are already	**Contra-indication**: Severe renal impairment, end stage renal disease (ESRD), or patients on dialysis and Use in Specific Populations, Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma, History of a serious hypersensitivity reaction to ertugliflozin, or metformin hydrochloride.	Metformin Hydrochloride 1000mg Tablet	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
	Pharmaceuticals Ltd.; Zirabo, Dhaka				treated with both ertugliflozin and metformin. It lowers blood sugar levels in adult patients (aged 18 years and older) with type 2 diabetes and prevent heart failure in patients with type 2 diabetes.	**Side-effects:** Common side effects may include vomiting, indigestion, diarrhea, weakness, nausea, and stomach discomfort. In some cases, individuals may experience dehydration, urinary tract infection, or low blood sugar. Additionally, occurrences of amputations and yeast infections in the penis and vagina have been reported at times. Diabetic ketoacidosis, Lactic acidosis Necrotising fasciitis of the perineum or Fournier's gangrene have been reported rarely. **Warning and Precautions:** Risk of lactic acidosis: The risk of developing lactic acidosis is also increased with uncontrolled diabetes, serious infections, prolonged fasting or alcohol intake, dehydration liver problems and any medical conditions in which a part of the body has a reduced supply of oxygen. Hypotension: May occur particularly in patients with renal impairment, the elderly, or patients on diuretics. Ketoacidosis: Assess patients who present with signs and symptoms of metabolic acidosis for ketoacidosis, regardless of blood glucose level. Acute Kidney Injury and Impairment in Renal Function: cause intravascular volume contraction and can cause renal impairment Hypoglycemia with Concomitant Use with Insulin and Insulin Secretagogues. Urosepsis and Pyelonephritis, Increases in Low-Density Lipoprotein Cholesterol (LDL-C), Genital mycotic infections.				
8.	Synovia Pharma PLC., Station Road, Tongi, Gazipur Incepta Pharmaceuticals Ltd.; Zirabo, Dhaka Opsonin Pharma	Metformin Hydrochloride 1000mg + Ertugliflozin 2.5mg Tablet	Metformin Hydrochloride BP 1000mg + Ertugliflozin INN 2.5mg	Therapeutic Class: Antidiabetic Therapeutic Code: 015	It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are not adequately controlled on a regimen containing ertugliflozin or metformin, or in patients who are already treated with both ertugliflozin and metformin. It lowers blood sugar levels in adult patients (aged 18 years and older)	**Contra-indication**: Severe renal impairment, end stage renal disease (ESRD), or patients on dialysis and Use in Specific Populations, Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma, History of a serious hypersensitivity reaction to ertugliflozin, or metformin hydrochloride. **Side-effects:** Common side effects may include vomiting, indigestion, diarrhea, weakness, nausea, and	Metformin Hydrochloride 1000mg Tablet	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
	Ltd., Barishal				with type 2 diabetes and prevent heart failure in patients with type 2 diabetes.	stomach discomfort. In some cases, individuals may experience dehydration, urinary tract infection, or low blood sugar. Additionally, occurrences of amputations and yeast infections in the penis and vagina have been reported at times. Diabetic ketoacidosis, Lactic acidosis Necrotising fasciitis of the perineum or Fournier's gangrene have been reported rarely. **Warning and Precautions:** Risk of lactic acidosis: The risk of developing lactic acidosis is also increased with uncontrolled diabetes, serious infections, prolonged fasting or alcohol intake, dehydration liver problems and any medical conditions in which a part of the body has a reduced supply of oxygen. Hypotension: May occur particularly in patients with renal impairment, the elderly, or patients on diuretics. Ketoacidosis: Assess patients who present with signs and symptoms of metabolic acidosis for ketoacidosis, regardless of blood glucose level. Acute Kidney Injury and Impairment in Renal Function: cause intravascular volume contraction and can cause renal impairment Hypoglycemia with Concomitant Use with Insulin and Insulin Secretagogues. Urosepsis and Pyelonephritis, Increases in Low-Density Lipoprotein Cholesterol (LDL-C), Genital mycotic infections.				
9.	The Acme Laboratories Lt., Savar Healthcare Pharmaceuticals Ltd EVEREST Pharmaceuticals Ltd. BSCIC I/A, Kanchpur, Narayanagnj	Gepirone 18.2 mg Extended-Release Tablet	Gepirone INN 18.2mg	Antidepressant Therapeutic Code: 014	Gepirone is indicated for the treatment of major depressive disorder (MDD) in adults	**Contraindications:** • Known hypersensitivity to gepirone. • Prolonged QTc interval > 450 msec at baseline • Congenital long QT syndrome. • Concomitant use of strong CYP3A4 inhibitors. • Severe hepatic impairment. • Use with an MAOI or within 14 days of stopping treatment with gepirone. Do not use gepirone within 14 days of discontinuing an MAOI **Side effects:** Most common adverse reactions (incidence of ≥5%	New	USFDA	অনুমোদনের সুপারিশ করা হয়।	পরবর্তী টেকনিক্যাল সাব কমিটির সভায় পুনর্মূল্যায়নের সিদ্ধান্ত গৃহীত হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
	Incepta Pharmaceuticals Ltd.;Savar, Dhaka Advanced Chemical Industries Limited, 7 Hajeegonj, Godnyl, Narayangonj Opsonin Pharma Limited, Rupatali, Barishal					and at least twice incidence of placebo) were dizziness, nausea, insomnia, abdominal pain, and dyspepsia **Warnings and Precautions:** • QT Interval Prolongation: gepirone prolongs the QTc. Correct electrolyte • abnormalities. Perform ECGs prior to initiation, during dose titration, and • periodically during treatment with gepirone. Monitor ECGs more • frequently when gepirone is used concomitantly with drugs known to • prolong the QT interval, in patients who develop QTc ≥ 450 msec during • treatment or are at significant risk of developing torsade de pointes. Do • not escalate dosage if QTc > 450 msec . • Serotonin Syndrome: Increased risk when co-administered with other • serotonergic agents. If serotonin syndrome occurs, discontinue gepirone • and initiate supportive measures. • Activation of Mania/Hypomania: Screen patients for bipolar disorder				
10.	The Acme Laboratories Lt., Savar Healthcare Pharmaceuticals Ltd EVEREST Pharmaceuticals Ltd. BSCIC I/A, Kanchpur, Narayanagnj Incepta	Gepirone 36.3 mg Extended-release Tablet	Gepirone INN 36.30mg	Antidepressant Therapeutic Code: 014	Gepirone is indicated for the treatment of major depressive disorder (MDD) in adults	**Contraindications:** • Known hypersensitivity to gepirone. • Prolonged QTc interval > 450 msec at baseline • Congenital long QT syndrome. • Concomitant use of strong CYP3A4 inhibitors. • Severe hepatic impairment. • Use with an MAOI or within 14 days of stopping treatment with gepirone. Do not use gepirone within 14 days of discontinuing an MAOI **Side effects:** Most common adverse reactions (incidence of ≥5% and at least twice incidence of placebo) were dizziness, nausea, insomnia, abdominal		USFDA	অনুমোদনের সুপারিশ করা হয়।	পরবর্তী টেকনিক্যাল সাব কমিটির সভায় পুনর্মূল্যায়নের সিদ্ধান্ত গৃহীত হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
	Pharmaceuticals Ltd.;Savar, Dhaka Advanced Chemical Industries Limited, 7 Hajeegonj, Godnyl, Narayangonj Opsonin Pharma Limited, Rupatali, Barishal					pain, and dyspepsia **Warnings and Precautions:** • QT Interval Prolongation: gepirone prolongs the QTc. Correct electrolyte • abnormalities. Perform ECGs prior to initiation, during dose titration, and • periodically during treatment with gepirone. Monitor ECGs more • frequently when gepirone is used concomitantly with drugs known to • prolong the QT interval, in patients who develop QTc ≥ 450 msec during • treatment or are at significant risk of developing torsade de pointes. Do • not escalate dosage if QTc > 450 msec . • Serotonin Syndrome: Increased risk when co-administered with other • serotonergic agents. If serotonin syndrome occurs, discontinue gepirone • and initiate supportive measures. Activation of Mania/Hypomania: Screen patients for bipolar disorder				
11.	The ACME Laboratories Ltd. Dhamrai, Dhaka	Chlordiazepoxide HCL USP 5 mg + Clidinium Bromide 2.5 mg Capsule	Chlordiazepoxide HCL USP 5 mg + Clidinium Bromide 2.5 mg	Anticholinergic Therapeutic Code: 011	1. Irritable bowel syndrome 2. peptic ulcer 3. Acute enterocolitis (Associated with hypersecretion, hypermotility and spasm and accompanied by anxiety or tension states).	**Contra-indications:** Hypersensitivity to Chlordiazepoxide and /or Clidinium Bromide. Glaucoma, prostatic hypertrophy and benign bladder neck obstruction. **Side-effects:** As for chlordiazepoxide. In addition, clidinium Bromide may cause dryness of the mouth, blurred vision, urinary hesitancy; constipation particularly when combined with other spasmolytis and/ or low residue diet. **Warnings & Precautions:** As in the case of other preparations containing CNS-acting drugs, patients receiving Chlordiazepoxide HCl/Clidinium Bromide should be cautioned about possible combined effects with alcohol and other CNS depressants.	New	USFDA	প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
12.	The ACME Laboratories Ltd. Dhamrai, Dhaka	Solriamfetol (as Hydrochloride) INN 150 mg Tablet	Solriamfetol (as Hydrochloride) INN 150 mg	Antidepressants Therapeutic Code:014	To improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA).	Contra-indications: Concurrent treatment with a monoamine oxidase inhibitor (MAOI) or use of an MAOI within the preceding 14 days. Side-effects: Headache, nausea, decreased appetite, insomnia, and anxiety. Warning & Precautions: Blood Pressure and Heart Rate Increases: Measure heart rate and blood pressure prior to initiating and periodically throughout treatment. Control hypertension before and during therapy. Avoid use in patients with unstable cardiovascular disease, serious heart arrhythmias, or other serious heart problems.	New	USFDA	প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
13.	The ACME Laboratories Ltd. Dhamrai, Dhaka	Solriamfetol (as Hydrochloride) 75 mg Tablet	Solriamfetol (as Hydrochloride) INN 75mg	Antidepressants Therapeutic Code:014	To improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA).	Contra-indications: Concurrent treatment with a monoamine oxidase inhibitor (MAOI) or use of an MAOI within the preceding 14 days. Side-effects: Headache, nausea, decreased appetite, insomnia, and anxiety. Warning & Precautions:Blood Pressure and Heart Rate Increases: Measure heart rate and blood pressure prior to initiating and periodically throughout treatment. Control hypertension before and during therapy. Avoid use in patients with unstable cardiovascular disease, serious heart arrhythmias, or other serious heart problems.	New	USFDA	প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
14.	The ACME Laboratories Ltd. Dhamrai, Dhaka Ziska Pharmaceuticals Ltd. Beacon Pharmaceuticals PLC, Kathali, Bhaluka, Mymensingh	Acetaminophen 250 mg + Ibuprofen 125 mg Tablet	Acetaminophen BP 250 mg + Ibuprofen BP 125 mg	Analgesics and Antipyretics Therapeutic Code: 006	Temporarily relieves minor aches and pains due to headache, toothache, backache, menstrual cramps, muscular aches, minor pain of arthritis.	**Contra-indications:** This product is contraindicated in-Known hypersensitivity to Paracetamol or Ibuprofen or any other excipients, Hypersensitivity reactions associated with Acetylsalicylic acid or any other NSAIDs, Existing gastrointestinal Ulceration/ Perforation or bleeding, Defect in coagulation, Renal failure.**Side-effects:** Undesirable effects such as dizziness, drowsiness, fatigue and visual disturbances are possible after taking NSAIDs. If affected patients should not drive or operate machinery.**Warning & Precautions:** Some products may interact with this drug are: aliskiren, ACE inhibitors (such as captopril, lisinopril), angiotensin II receptor blockers (such as losartan, valsartan), cidofovir, corticosteroids (such as prednisone), ketoconazole, levoketoconazole, lithium.	New	USFDA	প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
15.	The ACME Laboratories Ltd. Dhamrai, Dhaka	Dronedarone 400 mg Tablet	Dronedarone INN 400 mg	Antiarrythmics Therapeutic Code: 009	Indicated to reduce the risk of hospitalization for atrial fibrillation (AF) in patients in sinus rhythm with a history of paroxysmal or persistent AF.	**Contra-Indications:** Contraindicated in patients with symptomatic heart failure with recent decompensation requiring hospitalization or NYHA Class IV heart failure. **Side-effects:** The side effects of this product is stomach problems such as diarrhea, nausea, vomiting, stomach area (abdominal) pain, indigestion, feeling tired and weak, skin problems such as redness, rash, and itching. **Warning & Precautions:** Determine cardiac rhythm at least once every 3 months. If AF is detected discontinue Dronedarone.		USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।
16.	The ACME Laboratories Ltd. Dhamrai, Dhaka Healthcare Pharmaceuticals Ltd.	Esomeprazole (as Magnesium) USP 10 mg for Delayed-Release Oral Susp (Reconstitute with 5 ml water)	Esomeprazole (as Magnesium) USP 10 mg	Proton Pump Inhibitor Therapeutic Code: 067	GERD & NSAID-associated gastric ulcer, H. pylori eradication & Zollinger-Ellison syndrome.	**Contra-indications:** Patients with known hypersensitivity to proton pump inhibitors (PPIs) (angioedema and anaphylaxis have occurred. **Side-effects:**Pediatric (1 to 17 years) (incidence > 2%) are headache, diarrhea, abdominal pain, nausea and somnolence.**Warning & Precautions:**Atrophic gastritis has been noted Acute interstitial nephritis has been observed in patients taking PPIs. PPI therapy may be associated with increased risk of Clostridium difficile associated diarrhea.	Esomeprazole 20mg,40mg tablet,capsule	USFDA	প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
17.	The ACME Laboratories Ltd. Dhamrai, Dhaka	Metronidazole USP 500mg/ 5 ml Suspension	Metronidazole USP 500 mg/ 5 ml	Antiinfective Therapeutic code: 023	Metronidazole is a nitroimidazole antimicrobial indicated for: * Trichomoniasis in adults *Amebiasis in adults and pediatric patients *Anaerobic Bacterial Infections in adults.	**Contraindications:** Prior history of hypersensitivity to metronidazole or other nitroimidazole derivatives. Patients who have used disulfiram within the last two weeks. Patients who consume alcohol or products containing propylene glycol during and for at least three days after Metronidazole therapy. **Side effects:** Common adverse reactions include nausea, headache, anorexia, vomiting, diarrhea, abdominal cramping, epigastric distress, and constipation. **Warning & Precaution:** Encephalopathy, convulsive seizures, aseptic meningitis and peripheral neuropathy have been reported with metronidazole. Promptly evaluate the benefit/risk of continuation of Metronidazole if abnormal neurological signs develop.	Metronidazole 200mg,500mg tablet, Suspension 200mg/5ml	USFDA	প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
18.	The IBN SINA Pharmaceutical Industries Ltd.	Aflibercept Pre-filled syringe, 0.05% (40mg/ml)	Aflibercept INN 40.00 mg/1 ml, Intravitreal Injection	Eye Preparations Therapeutic	Aflibercept is indicated for the treatment of: Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular	**Condra-Indication:** Ocular or Periocular Infections, Active Intraocular Inflammation & Hypersensitivity.	New	USFDA	অনুমোদনের সুপারিশ করা হয়।	পরবর্তী ঔষধ নিয়ন্ত্রন কমিটির সভায় চক্ষু

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
	Eskayef Pharmaceuticals Limited, Tongi, Gazipur	or Aflibercept 2mg/0.05ml Intravitreal Injection	or Aflibercept INN 2mg/Pre-filled Syringe	Code: 052	Edema Following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), Diabetic Retinopathy (DR) & Retinopathy of Prematurity (ROP).	**Side Effect:** The following potentially serious adverse reactions are described elsewhere in the labeling: Hypersensitivity, Endophthalmitis and retinal detachments, Increase in intraocular pressure, Thromboembolic events.				বিশেষজ্ঞ এর মতামত গ্রহনের সিদ্ধান্ত গৃহীত হয়।
19.	The IBN SINA Pharmaceutical Industries Ltd.	Aflibercept Pre-filled syringe, 0.07% (114.3mg/ml)	Aflibercept INN 114.30 mg/1 ml, Intravitreal Injection	Eye Preparations Therapeutic Code: 052	Aflibercept is indicated for the treatment of: Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema Following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), Diabetic Retinopathy (DR) & Retinopathy of Prematurity (ROP).	**Condra-Indication:** Ocular or Periocular Infections, Active Intraocular Inflammation & Hypersensitivity. **Side Effect:** The following potentially serious adverse reactions are described elsewhere in the labeling: Hypersensitivity, Endophthalmitis and retinal detachments, Increase in intraocular pressure, Thromboembolic events.	New	USFDA	অনুমোদনের সুপারিশ করা হয়।	পরবর্তী ঔষধ নিয়ন্ত্রন কমিটির সভায় চক্ষু বিশেষজ্ঞ এর মতামত গ্রহনের সিদ্ধান্ত গৃহীত হয়।
20.	The IBN SINA Pharmaceutical Industries Ltd.	Cyclosporine 0.1% (1 mg/ml), Ophthalmic Drops	Cyclosporine USP 1.00/1 ml, Ophthalmic Drops	Eye Preparations Therapeutic Code: 052	It is indicated for the treatment of the signs and symptoms of dry eyes.	**Condra-Indication:** Potential for Eye Injury and Contamination. To avoid the potential for eye injury and/or contamination, patients should not touch the bottle tip to the eye or other surfaces. Cyclosporine 0.1% should not be administered while wearing contact lenses. If contact lenses are worn, they should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following administration of cyclosporine 0.1% ophthalmic solution. **Side Effect:** Mild burning or stinging in the eyes, mild redness or itching, blurred vision or feeling like something is in your eye.	New	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।
21.	The Ibn Sina Pharmaceutical Industries Ltd. Healthcare Pharmaceuticals Ltd Eskayef Pharmaceuticals Limited, Rupganj, Narayanganj	Lotilaner 0.25% Opthalmic Solutions	Lotilaner INN 0.250gm/100 ml	Eye Preparations Therapeutic Code: 052	Lotilaner is indicated for the treatment of Demodex blepharitis.	**Condra-Indication:** Do not allow the tip of the dispensing container to contact the eye, surrounding structures, fingers, or any other surface in order to minimize contamination of the solution. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions. **Side Effect:** Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.	New	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
	General Pharmaceutical Ltd., (Unit-2) Gazipur Ziska Pharmaceuticals Ltd. Advanced Chemical Industries Limited, 7 Hajeegonj, Godnyl, Narayangonj The Acme Laboratories Ltd. Dhamrai, Dhaka Aristopharma Ltd. Gazipur									
22.	The IBN SINA Pharmaceutical Industries Ltd.	Deoxycholic acid 20mg/2ml Solution for injections	Deoxycholic Acid USP 20 mg/2ml	Other Classification Therapeutic Code: 075	Indicated to improve the appearance of fullness associated with submental fat (double chin).	**Contra-indication:** Deoxycholic acid injection is contraindicated in the presence of infection at the injection sites. **Side Effect:** The most common side effects include: swelling, bruising, pain, numbness, redness and areas of hardness in the treatment area. Deoxycholic Acid can cause serious side effects including: Nerve injury in the jaw that can cause an uneven smile or facial muscle weakness, trouble swallowing.	New	USFDA	প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
23.	The IBN SINA Pharmaceutical Industries Ltd.	Mexiletine Hydrochloride 150 mg , Capsule	Mexiletine Hydrochloride USP 150 mg, Capsule	Antiarrythmics Therapeutic Code: 009	Mexiletine hydrochloride is indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgement of the physician, are life-threatening.	**Contraindication**: Mexiletine hydrochloride is contraindicated in the presence of cardiogenic shock or pre-existing second- or third-degree AV block (if no pacemaker is present). **Side Effect:** Mexiletine may cause side effects like nausea, vomiting, heartburn, changes in appetite, Lightheadedness or Dizziness, Shaking Of A Part Of Your Body That You Cannot Control, Loss Of Coordination, Numbness Or Tingling Sensation, Headache, Blurred Vision.	New	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।
24.	The IBN SINA Pharmaceutical Industries Ltd.	Mexiletine Hydrochloride 200 mg , Capsule	Mexiletine Hydrochloride USP 200 mg	Antiarrythmics Therapeutic	Mexiletine hydrochloride is indicated for the treatment of documented ventricular arrhythmias, such as sustained	**Contraindication**: Mexiletine hydrochloride is contraindicated in the presence of cardiogenic shock or pre-existing second- or third-degree AV block (if no pacemaker is present).	New	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
				Code: 009	ventricular tachycardia, that, in the judgement of the physician, are life-threatening.	**Side Effect:** Mexiletine may cause side effects like nausea, vomiting, heartburn, changes in appetite, Lightheadedness or Dizziness, Shaking Of A Part Of Your Body That You Cannot Control, Loss Of Coordination, Numbness Or Tingling Sensation, Headache, Blurred Vision.				
25.	The IBN SINA Pharmaceutical Industries Ltd.	Mexiletine Hydrochloride 250 mg Capsule	Mexiletine Hydrochloride USP 250 mg	Antiarrythmics Therapeutic Code: 009	Mexiletine hydrochloride is indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgement of the physician, are life-threatening.	**Contraindication**: Mexiletine hydrochloride is contraindicated in the presence of cardiogenic shock or pre-existing second- or third-degree AV block (if no pacemaker is present). **Side Effect:** Mexiletine may cause side effects like nausea, vomiting, heartburn, changes in appetite, Lightheadedness or Dizziness, Shaking Of A Part Of Your Body That You Cannot Control, Loss Of Coordination, Numbness Or Tingling Sensation, Headache, Blurred Vision.	New	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।
26.	The IBN SINA Pharmaceutical Industries Ltd. Healthcare Pharmaceuticals Ltd The ACME Laboratories Ltd. Dhamrai, Dhaka Aristopharma Ltd. Gachha, Gazipur Sadar, Gazipur Eskayef Pharmaceuticals Limited, Rupganj, Narayanganj Drug International Ltd., 31/1, Satrong, Tongi I/A, Gazipur	Perfluorohexyloctane 100% Ophthalmic Solution	Perfluorohexyloctane INN 1.338gm/ml	Eye Preparations Therapeutic Code: 052	It is indicated for the treatment of the signs and symptoms of dry eyes.	Condra-Indication: Potential for Eye Injury and Contamination. To avoid the potential for eye injury and/or contamination, patients should not touch the bottle tip to the eye or other surfaces. Side Effect: Mild burning or stinging in the eyes, mild redness or itching, blurred vision or feeling like something is in your eye.	New	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
	General Pharmaceutical Ltd., (Unit-2) Gazipur Navana Pharmaceuticals Limited Incepta Pharmaceuticals Ltd.; Dhamrai Unit, Dhaka Square Pharmaceuticals PLC, Kaliakoir, Gazipur Ziska Pharmaceuticals Ltd. Advanced Chemical Industries Limited, 7 Hajeegonj, Godnyl, Narayangonj UNIDO Pharmaceutical Limited, Narsingdi									
27.	UNIDO Pharmaceutical Limited Factory Address: Ollartech, Batpara, Narsingdi Sadar, Narsingdi-1603, Narsingdi	Chloroprocaine Hydrochloride 3% Ophthalmic Gel	Chloroprocaine Hydrochloride USP 3%	Eye Preparation Therapeutic Code: 052	Indicated for ocular surface anesthesia	**Contraindication:** Contraindicated in patients with a history of hypersensitivity to any component of this preparation. **Side Effects:** Most common side effect is mydriasis (approximately 25%) **Warnings and Precautions**: • Not for Injection or Intraocular Administration. • Corneal Injury Due to Insensitivity. • Corneal Opacification.	New	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						For Administration by healthcare provider, not intended for patient self-administration				
28.	Ziska Pharmaceuticals Ltd.	Setmelanotide 10 mg/ml solution for injection	Setmelanotide INN 10 mg/ml	Therapeutic class: melanocortin 4 (MC4) receptor agonist	It is a melanocortin 4 (MC4) receptor agonist indicated for chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency confirmed by genetic testing demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS). **Limitations of Use:** It is not indicated for the treatment of patients with the following conditions as It would not be expected to be effective: • Obesity due to suspected POMC-, PCSK1-, or LEPR-deficiency with POMC, PCSK1, or LEPR variants classified as benign or likely benign • Other types of obesity not related to POMC, PCSK1 or LEPR deficiency, including obesity associated with other genetic syndromes and general (polygenic) obesity	**Contraindications:** None **Side effects:** Most common adverse reactions (incidence ≥20%) included skin hyperpigmentation, injection site reactions, nausea, headache, diarrhea, abdominal pain, vomiting, depression, and spontaneous penile erection. **Warnings and precautions:** Disturbance in Sexual Arousal: Spontaneous penile erections in males and sexual adverse reactions in females have occurred. Inform patients that these events may occur and instruct patients who have an erection lasting longer than 4 hours to seek emergency medical attention. Depression and Suicidal Ideation: Depression and suicidal ideation have occurred. Monitor patients for new onset or worsening depression or suicidal thoughts or behaviors. Consider discontinuing Setmelanotide if patients experience suicidal thoughts or behaviors, or clinically significant or persistent depression symptoms occur. Skin Pigmentation and Darkening of Pre-Existing Nevi: Generalized increased skin pigmentation and darkening of pre-existing nevi have occurred. Perform a full body skin examination prior to initiation and periodically during treatment to monitor pre-existing and new pigmentary lesions. Risk of Serious Adverse Reactions Due to Benzyl Alcohol Preservative in Neonates and Low Birth Weight Infants: Setmelanotide is not approved for use in neonates or infants. Serious and fatal adverse reactions including "gasping syndrome" can occur in neonates and low birth weight infants treated with benzyl alcohol-preserved drugs.	New	USFDA & BNF 85 Page:99-100	প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
29.	Ziska Pharmaceuticals Ltd.	Teriflunomide 7 mg Tablet	Teriflunomide INN 7.0 mg	Therapeutic class: Immunomodulatory agents	Indicated for the treatment of patients with relapsing forms of Multiple Sclerosis to reduce the frequency of clinical relapses and to delay the progression of physical disability.	**Contraindications:** Severe hepatic impairment, Pregnancy, Hypersensitivity, Current leflunomide treatment. **Side effects:** Most common adverse reactions (≥10% and ≥2% greater than placebo): headache, diarrhea, nausea, alopecia, increase in ALT. **Warnings and precautions:** Elimination of	New	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						Teriflunomide can be accelerated by administration of cholestyramine or activated charcoal for 11 days. Teriflunomide may decrease WBC. A recent CBC should be available before starting Teriflunomide. Monitor for signs and symptoms of infection. Consider suspending treatment with Teriflunomide in case of serious infection. Do not start Teriflunomide in patients with active infections. Stop Teriflunomide if patient has anaphylaxis, angioedema, Stevens-Johnson syndrome, toxic epidermal necrolysis; initiate rapid elimination. If patient develops symptoms consistent with peripheral neuropathy, evaluate patient and consider discontinuing Teriflunomide. Teriflunomide may increase blood pressure. Measure blood pressure at treatment initiation and monitor blood pressure during treatment.				
30.	Nuvista Pharma Ltd Renata Limited Mirpur, Dhaka Synovia Pharma PLC.Station Road, Tongi, Gazipur UniMed UniHealth Pharmaceuticals Ltd., B.K Bari, Gazipur Sadar, Gazipur The ACME Laboratories Ltd. Dhamrai, Dhaka	Spinosad 0.9% Topical Suspension	Spinosad USP 0.9% Topical Suspension	Skin & Mucous Preparations Therapeutic Code: 071	This is a pediculicide indicated for the topical treatment of head lice infestations in adult and pediatric patients 6 months of age and older. This is a scabicide indicated for the topical treatment of scabies infestations in adult and pediatric patients 4 years of age and older.	**Contraindication:** None **Side Effects:** • Burning, dryness, flaking, itching, pain, redness, rash, swelling, or soreness at the site of application. • redness of the eye or skin.	New	USFDA	প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
31.	Nuvista Pharma Ltd	Levothyroxine Sodium 88mcg Tablet	Levothyroxine Sodium USP 88 mcg Tablet	Thyroid Therapeutic Code: 074	This is indicated for: • Hypothyroidism: As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism.	**Contraindication:** Uncorrected adrenal insufficiency **Side Effects:** Levothyroxine Sodium therapy are primarily those of hyperthyroidism due to therapeutic overdosage: arrhythmias, myocardial infarction, dyspnea, muscle	12.5mg, 25mg, 50mg, 75mg & 100mg Tablet	US-FDA	অনুমোদনের সুপারিশ করা হয়।	নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
					• Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.	spasm, headache, nervousness, irritability, insomnia, tremors, muscle weakness, increased appetite, weight loss, diarrhea, heat intolerance, menstrual irregularities, and skin rash				
32.	Nuvista Pharma Ltd	Levothyroxine Sodium 125mcg Tablet	Levothyroxine Sodium USP 125mcg Tablet	Thyroid Therapeutic Code: 074	This is indicated for: Hypothyroidism: As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.	**Contraindication:** Uncorrected adrenal insufficiency **Side Effects:** Levothyroxine Sodium therapy are primarily those of hyperthyroidism due to therapeutic overdosage: arrhythmias, myocardial infarction, dyspnea, muscle spasm, headache, nervousness, irritability, insomnia, tremors, muscle weakness, increased appetite, weight loss, diarrhea, heat intolerance, menstrual irregularities, and skin rash	12.5mg, 25mg, 50mg, 75mg & 100mg Tablet	US-FDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।
33.	Nuvista Pharma Ltd. Incepta Pharmaceuticals Ltd.; Dhamrai Unit, Dhaka	Estradiol 1mg + Norethindrone 0.5mg Tablet	Estradiol BP 1mg & Norethindrone acetate BP 0.5mg Tablet	Hormone Therapeutic Code: 056	Estradiol and norethindrone acetate tablets, USP 1 mg/0.5 mg are indicated in women who have a uterus for: 1. Treatment of moderate to severe vasomotor symptoms due to menopause. 2. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause.	**Contraindication:** Estradiol and norethindrone acetate tablets, USP should not be used in women with any of the following conditions: 1. Undiagnosed abnormal genital bleeding. 2. Known, suspected, or history of cancer of the breast. 3. Known or suspected estrogen-dependent neoplasia. 4. Active deep vein thrombosis, pulmonary embolism, or history of these conditions. 5. Active or recent (e.g., within the past year) arterial thromboembolic disease (e.g., stroke, myocardial infarction). 6. Liver dysfunction or disease. 7. Known hypersensitivity to the ingredients of estradiol and norethindrone acetate 1 mg/0.5 mg or estradiol and norethindrone acetate 0.5 mg/0.1 mg. 8. Known or suspected pregnancy. There is no indication for estradiol and norethindrone acetate in pregnancy. There appears to be little or no	New	US-FDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						increased risk of birth defects in children born to women who have used estrogens and progestins from oral contraceptives inadvertently during early pregnancy. **Side Effects:** Common side effects of Estradiol and norethindrone acetate tablets include: • headache, • irregular vaginal bleeding or spotting, • nausea and vomiting, • back pain, • pain in the extremities, • hair loss, • breast pain, • stomach/abdominal cramps, • bloating, • depression, • weight gain, • diarrhea, • runny or stuffy nose, and sore throat				
34.	Nuvista Pharma Ltd	Prednisone 1mg Tablet	Prednisone USP 1mg Delayed Release Tablet	Steroid Therapeutic Code: 072	**Indications:** This corticosteroid indicated: • as an anti-inflammatory or immunosuppressive agent for certain allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, specific infectious diseases or conditions and organ transplantation • for the treatment of certain endocrine conditions • for palliation of certain neoplastic conditions	**Contraindication:** This is contraindicated in patients who have known hypersensitivity to prednisone or to any of the excipients. Rare instances of anaphylaxis have occurred in patients receiving corticosteroid therapy. **Side Effects:** • Aggression. • agitation. • decrease in the amount of urine. • fast, slow, pounding, or irregular heartbeat or pulse. • mood changes.	New	US-FDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						• noisy, rattling breathing. • numbness or tingling in the arms or legs. pounding in the ears.				
35.	Nuvista Pharma Ltd	Prednisone 2mg Tablet	Prednisone USP 2mg Delayed Release Tablet	Steroid Therapeutic Code: 072	**Indications:** This corticosteroid indicated: • as an anti-inflammatory or immunosuppressive agent for certain allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, specific infectious diseases or conditions and organ transplantation • for the treatment of certain endocrine conditions • for palliation of certain neoplastic conditions	**Contraindication:** This is contraindicated in patients who have known hypersensitivity to prednisone or to any of the excipients. Rare instances of anaphylaxis have occurred in patients receiving corticosteroid therapy. **Side Effects:** • Aggression. • agitation. • decrease in the amount of urine. • fast, slow, pounding, or irregular heartbeat or pulse. • mood changes. • noisy, rattling breathing. • numbness or tingling in the arms or legs. pounding in the ears.	New	US-FDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।
36.	Nuvista Pharma Ltd	Prednisone 5mg Tablet	Prednisone USP 5mg Delayed Release Tablet	Steroid Therapeutic Code: 072	**Indications:** This corticosteroid indicated: • as an anti-inflammatory or immunosuppressive agent for certain allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, specific infectious diseases or conditions and organ transplantation • for the treatment of certain endocrine conditions • for palliation of certain neoplastic conditions	**Contraindication:** This is contraindicated in patients who have known hypersensitivity to prednisone or to any of the excipients. Rare instances of anaphylaxis have occurred in patients receiving corticosteroid therapy. **Side Effects:** • Aggression. • agitation. • decrease in the amount of urine. • fast, slow, pounding, or irregular heartbeat or pulse. • mood changes. • noisy, rattling breathing. • numbness or tingling in the arms or legs. pounding in the ears.	New	US-FDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
37.	Nuvista Pharma Ltd General Pharmaceutical Ltd., Gazipur	Polyethylene Glycol (3350) 178.7gm + Sodium Sulfate 7.3gm + Potassium Chloride 1.12gm + Magnesium Sulfate 0.9gm + Sodium Chloride 0.5gm Solution in two Bottles and flavor enhancing packets Oral Solution	Polyethylene Glycol (3350) BP 178.7gm + Sodium Sulfate BP 7.3gm + Potassium Chloride BP 1.12gm + Magnesium Sulfate BP 0.9gm + Sodium Chloride BP 0.5gm Solution in two Bottles and flavor enhancing packets Oral Solution	Laxatives Therapeutic Code: 060	This preparation is an osmotic laxative indicated for cleansing of the colon in preparation for colonoscopy in adults	**Contraindication:** • GI obstruction or ileus. • Bowel perforation. • Toxic colitis or megacolon. • Gastric retention. **Side Effects:** This preparation can cause serious side effects, including serious loss of body fluid (dehydration) and changes in blood salts (electrolytes) in your blood. These changes can cause abnormal heartbeats that can cause death, seizures, and kidney problems.	New	US-FDA	প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
38.	Popular Pharmaceuticals Ltd.,164, Tongi Industrial Area, Monnunagar, Gazipur	Recombinant Follicle Stimulating Hormone (r-FSH) BP 1050 IU/1.26ml Injection	Recombinant Follicle Stimulating Hormone (r-FSH) BP 1050 IU/1.26ml	Therapeutic Class: Hormone Therapeutic code: 056	**In the Female** Ovulation Induction r-FSH administered SC with HCG in a sequential manner, which is indicated for ovulation induction in patients who have previously received pituitary suppression. Multi-follicular Development During ART r-FSH administered SC in conjunction with HCG is indicated for multiple follicular developments (controlled ovarian stimulation) during ART cycles in patients who have previously received pituitary suppression. Polycystic Ovarian Syndrome (PCOS). Used to treat Polycystic Ovarian Syndrome (PCOS) related infertility. **In the Male** Male infertility treatment in combination with HCG Induction of Spermatogenesis in men deficient spermatogenesis due to Hypogonadotrophic-hypogonadism.	**CONTRAINDICATIONS** • Tumours of the ovary, breast, uterus, pituitary or hypothalamus • Pregnancy or lactation • Undiagnosed vaginal bleeding • Hypersensitivity to the active substance or to any of the excipients • Primary ovarian failure • Fibroid tumors of the uterus incompatible with pregnancy • Primary testicular failure **WARNINGS AND PRECAUTIONS:** The presence of uncontrolled non gonadal endocrinopathies (e.g. thyroid, adrenal or pituitary disorders) should be excluded.	75 IU/vial Injection	US-FDA	অনুমোদনের সুপারিশ করা হয়।	পরবর্তী ঔষধ নিয়ন্ত্রন কমিটির সভায় স্ত্রী রোগ বিশেষজ্ঞ এর মতামত গ্রহনের সিদ্ধান্ত গৃহীত হয়।
39.	Ziska Pharmaceuticals Ltd.	Teriflunomide 14 mg Tablet	Teriflunomide INN 14.0 mg	Therapeutic class: Immunomodulatory agents	Indicated for the treatment of patients with relapsing forms of Multiple Sclerosis to reduce the frequency of clinical relapses and to delay the progression of physical	**Contraindications:** Severe hepatic impairment, Pregnancy, Hypersensitivity, Current leflunomide treatment. **Side effects:** Most common adverse reactions (≥10% and ≥2% greater than placebo): headache, diarrhea, nausea,	New	USFDA & TGA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
					disability.	alopecia, increase in ALT. **Warnings and precautions:** Elimination of Teriflunomide can be accelerated by administration of cholestyramine or activated charcoal for 11 days. Teriflunomide may decrease WBC. A recent CBC should be available before starting Teriflunomide. Monitor for signs and symptoms of infection. Consider suspending treatment with Teriflunomide in case of serious infection. Do not start Teriflunomide in patients with active infections. Stop Teriflunomide if patient has anaphylaxis, angioedema, Stevens-Johnson syndrome, toxic epidermal necrolysis; initiate rapid elimination. If patient develops symptoms consistent with peripheral neuropathy, evaluate patient and consider discontinuing Teriflunomide. Teriflunomide may increase blood pressure. Measure blood pressure at treatment initiation and monitor blood pressure during treatment.				
40.	Advanced Chemical Industries Limited, 7 Hajeeganj, Godnyl, Narayangonj.	Pregabalin 110 Extended Release Tablet	Pregabalin BP 110mg	Anti-epileptic Therapeutic Code: 046	• Neuropathic pain associated with diabetic peripheral neuropathy (DPN) Postherpetic neuralgia (PHN)	**Contraindication:**Known hypersensitivity to pregabalin or any of its components. **Side-effects:**The most common side effects are dizziness, somnolence, headache, fatigue, peripheral edema, nausea, blurred vision, dry mouth and weight gain.	Pregabalin 82.5 Extended Release Tablet	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।
41.	Advanced Chemical Industries Limited, 7 Hajeeganj, Godnyl, Narayangonj.	Rabeprazole Sodium 20mg + Domperidone 10 mg SR Capsule	Rabeprazole Sodium BP 20mg + Domperidone Maleate BP 12.73 mg eqv.to Domperidone 10mg	Other Classification Therapeutic Code: 075	This is combination is indicated for the treatment gastro-esophageal reflux disease (GERD) not responding adequately to rabeprazole alone.	**Contraindication:** It is contraindicated in patients with history of known hypersensitivity to rabeprazole or domperidone or any other components of this product. It is also contraindicated in patients with Prolactin-releasing pituitary tumor (prolactinoma), when stimulation of the gastric motility could be harmful e.g. in patients with gastro-intestinal hemorrhages, mechanical obstruction or perforation in patients with moderate or severe hepatic impairment and in patients who have known existing prolongation of cardiac conduction intervals, particularly QTc, patients with significant electrolyte disturbances or underlying cardiac diseases such as congestive heart failure. **18Side-effects:** The most common side effects are headache, abdominal pain, diarrhea, dry mouth and nausea.	Rabeprazole Sodium BP 20mg Capsule Domperidone BP 10mg tablet	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।
42.	Advanced Chemical Industries Limited, 7 Hajeeganj, Godnyl, Narayangonj.	Heparin Sodium 500IU/g gel	Heparin Sodium BP 500IU/g	Anticoagulants and Fibrinolytic Drug Therapeutic Code: 012	This gel is indicated for prevention of formation of blood clots near the skin surface	**Contraindications:** Application of heparin gel is contraindicated in ulcerous-necrotic processes in thrombophlebitis area, traumatic lesions of skin integrity, as well as in case of decreased coagulation, thrombocytopenia. Hypersensitivity to gel components. **Side-effects:**The most common side effect is skin rash.	Heparin Sodium Injection (5mL)	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।
43.	Advanced Chemical Industries Limited, 7	Levosulpiride 75 mg + Rabeprazole Sodium 20	Levosulpiride INN 75mg +	Other Classification	It is indicated for the treatment of gastro-esophageal reflux disease (GERD) in	**Contraindication:** It is contraindicated in patients with hypersensitivity to rabeprazole or to any substituted benzimidazole derivative or	New Molecule	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের	রেফারেন্স নেই বিধায় নামঞ্জুর

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
	Hajeeganj, Godnyl, Narayangonj.	mg SR Capsule.	Rabeprazole Sodium BP 20mg	Therapeutic Code: 075	patients who do not respond to PPI (proton-pump inhibitor) alone.	to levosulpirideand any other components of this product. It is also contraindicated in patients receiving rilpivirine-containing products. This combination is contraindicated in patients with gastrointestinal bleeding and intestinal obstruction, severe renal or hepatic insufficiency, porphyrias, alcohol intoxication, certain tumors like phaeochromocytoma and pituitary prolactinoma. Concurrent use with levodopa or other antiparkinson drugs (including ropinirole) is also contraindicated. **Side-effects:**The most common side effects are pain, pharyngitis, flatulence, infection and constipation.			সুপারিশ করা হয়	করা হয়।
44.	Advanced Chemical Industries Limited, 7 Hajeeganj, Godnyl, Narayangonj	Pranlukast 225.0 mg Capsule	Pranlukast Hemihydrate INN 229.20 mg Eqv to Pranlukast 225.0mg	Drug Use in Bronchial Asthma, COPD Therapeutic Code: 044	For the treatment of Allergic rhinitis, Asthma	**CONTRAINDICATIONS: None** **SIDE EFFECTS:** Headache, increased incidence of resp tract infection, GI disturbances, induced generalized pain, fever, myalgia, arthralgia. **WARNINGS & PRECAUTIONS:** Renal impairment. Possible elevations in liver enzymes. Withdraw treatment in patients showing signs consistent with Churg-Strauss syndrome.	Pranlukast Hydrate 10 gm/100 ml Powder For Suspension	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।
45.	Al-Madina Pharmaceuticals Ltd.; 1/1, Tilargati, Kakil, Sathais, Tongi, Gazipur	Cinnarizine 20mg + Domperidone 15 mg Tablet	Cinnarizine BP 20mg + Domperidone Maleate BP 19.08mg eq. to Domperidone 15mg	Antiemetics and antivertigo preparation	Prevention of symptoms caused by vestibular disorders and vertigo/motion sickness, nausea, dizziness, headache, vomiting, sensation of fullness, when there is a delay in gastric emptying.	**Contraindication:** Hypersensitivity to Domperidone, Cinnarizine or any of the others components of the tablet. **Side-effects:** Common Side effects: Nausea, Dryness in mouth, Indigestion, Sleepiness, Weight gain **Warning & precaution:** Cinnarizine 20mg & Domperidone 15 mg Tablet may lead to drowsiness and impaired concentration, which may be aggravated by simultaneous intake of alcohol or other central nervous system (CNS) depressants. Patients should not operate hazardous machinery or drive motor vehicles or perform potentially hazardous tasks where loss of concentration may lead to accidents.	Cinnarizine 20mg + Dimenhydrinate 40 mg Tablet Cinnarizine 15/25/75mg Tablet Domperidone 10mg Tablet	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।
46.	Aristopharma Ltd. Plot No. 14-22, Road No. 11 & 12, Shampur-Kadamtali I/A, Dhaka-1204, Dhaka Eskayef Pharmaceuticals Limited, Tongi, Gazipur	Tegoprazan 50 mg Film Coated Tablet	Tegoprazan INN 50mg	Potassium-competitive acid blocker Therapeutic Code: 067	It is indicated for the treatment of Erosive Gastroesophageal Reflux Diseases, Non-Erosive Gastroesophageal Reflux Ulcer (GERD). Eradication of *H. pylori* concurrently given with appropriate antibiotic therapy treatment in patients with peptic ulcer disease and Gastric and/or chronic atrophic gastritis.	**Contraindication:** Patients with hypersensitivity to Tegoprazan, any of the product components, or substituted Benzodiazepines, patients who take Atazanavir, Nelfinavir or Rilpivirin containing products. Pregnant women or nursing mother. **Side Effects:** Dyspepsia, chest discomfort, headache.	New	**রেফারেন্স নাই**	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
	EVEREST Pharmaceuticals Ltd. BSCIC I/A, Kanchpur, Narayanagnj, BANGLADESH General Pharmaceutical Ltd., Gazipur Beacon Pharmaceuticals PLC, Kathali, Bhaluka, Mymensingh NIPRO JMI Pharma Ltd.									
47.	Aristopharma Ltd. Plot No. 14-22, Road No. 11 & 12, Shampur-Kadamtali I/A, Dhaka-1204, Dhaka Eskayef Pharmaceuticals Limited, Tongi, Gazipur Beacon Pharmaceuticals PLC Kathali, Bhaluka, Mymensingh EVEREST Pharmaceuticals Ltd. BSCIC I/A,	Itopride Hydrochloride 150 mg Extended Release Tablet	Itopride Hydrochloride INN 150 mg	Antiemetic Therapeutic Code: 018	Treatment of gastrointestinal symptoms of functional, non-ulcer dyspepsia, like feelings of bloating, gastric fullness, discomfort to pain in epigastrium, anorexia, heartburn, nausea and vomiting.	**Contraindication:** Hypersensitivity to the active substance or to any of the excipients of the product. Itopride Hydrochloride 150 mg Extended Release Tablet should not be used in patients in whom increased gastrointestinal motility could be harmful, e.g. in patients with gastrointestinal haemorrhage, mechanical obstruction or perforation. **Side-effect:** Diarrhoea, headache, abdominal pain, dry mouth, drowsiness	Itopride 50 mg Tablet	**রেফারেন্স নাই**	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
	Kanchpur, Narayanagnj Square Pharmaceuticals PLC, Kaliakoir, Gazipur									
48.	Aristopharma Ltd. Plot No. 14-22, Road No. 11 & 12, Shampur-Kadamtali I/A, Dhaka-1204, Dhaka	Sodium Hyaluronate (Injectable Grade) 16 mg + Chondroitin Sulfate Sodium (Injectable Grade) 40 mg per ml Viscoelastic Injection (Prefilled Syringe)	Sodium Hyaluronate (Injectable Grade) BP 16 mg + Chondroitin Sulfate Sodium (Injectable Grade) USP 40 mg per ml	Eye Preparations Therapeutic code: 052	Sodium Hyaluronate & Chondroitin Sulfate Sodium Prefilled syringe is indicated for use as a surgical aid in anterior segment procedures including cataract extraction and intraocular lens implantation. It maintains a deep chamber during anterior segment surgery, enhances visualization during the surgical procedure, and protects the corneal endothelium and other ocular tissues. The viscoelasticity of the solution maintains the normal position of the vitreous face and prevents formation of a flat chamber during surgery.	**Contraindication:** There are no known contraindications to the use of Sodium Hyaluronate & Chondroitin Sulfate Sodium Prefilled syringe when used as recommended. **Side-effect:** It has been extremely well tolerated in human and animal studies. A transient rise in intraocular pressure may be expected due to the presence of sodium hyaluronate, which has been shown to effect such a rise (9.8% > 25 mmHg during 1-3 days after surgery in human clinical trials).	Existing Molecule (Chondroitin Sulfate Sodium 40 mg + Sodium Hyaluronate 30 mg/ml Viscoelastic Solution)	***রেফারেন্স নাই***	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।
49.	Aristopharma Ltd. Gachha, Gazipur Sadar, Gazipur	(Carboxymethylcellulose Sodium 0.5 g + Glycerin 1g + Polysorbate 80 0.5 g)/100ml Eye Drops	(Carboxymethylcellulose Sodium EP 0.5 g + Glycerin BP 1 g + Polysorbate 80 BP 0.5 g)/100 ml	Eye Preparations Therapeutic code: 052	It is indicated for the temporary relief of burning and irritation and discomfort due to dryness of the eye or exposure to wind or sun. It may be used as a protectant against further irritation.	**Contraindication:** It is contraindicated in patients with known hypersensitivity to any ingredient of this formulation. **Side-effect:** Generally, It is well tolerated. It should not be used if allergic condition occurs to any ingredients of the product.	New	***রেফারেন্স নাই***	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।
50.	Beacon Pharmaceuticals PLC Kathali, Bhaluka, Mymensingh	Irsogladine Maleate 4mg Tablet	Irsogladine Maleate INN 4mg	Therapeutic Class: Antacid Therapeutic Code: 007	Improvement of gastric mucosal lesion (erosion, hemorrhage, redness and edema) caused by the following diseases: Acute gastritis and acute exacerbation stage of chronic gastritis.	**Contraindications:** In patient with hypersensivity to Irsogladine or to any of the excipients. **Side-Effect:** Adverse drug reactions to this drug, including abnormalities in laboratory data, were reported in 64 of 10,176 patients (0.63%). The most frequently observed adverse drug reactions were hepatic function abnormal in 12 patients (0.12%), increased ALT (GPT)		রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						in 12 patients (0.12%), increased AST (GOT) in 7 patients (0.07%), constipation in 6 patients (0.06%), rash in 5 patients (0.05%), itching, diarrhea and increased ALP in each 3 patients (0.03%)				
51.	Beacon Pharmaceuticals PLC Kathali, Bhaluka, Mymensingh	Irsogladine Maleate 2mg OD Tablet	Irsogladine Maleate INN 2mg	Therapeutic Class: Antacid Therapeutic Code: 007	Improvement of gastric mucosal lesion (erosion, hemorrhage, redness and edema) caused by the following diseases: Acute gastritis and acute exacerbation stage of chronic gastritis.	**Contraindications:** In patient with hypersensivity to Irsogladine or to any of the excipients. **Side-Effect:** Adverse drug reactions to this drug, including abnormalities in laboratory data, were reported in 64 of 10,176 patients (0.63%). The most frequently observed adverse drug reactions were hepatic function abnormal in 12 patients (0.12%), increased ALT (GPT) in 12 patients (0.12%), increased AST (GOT) in 7 patients (0.07%), constipation in 6 patients (0.06%), rash in 5 patients (0.05%), itching, diarrhea and increased ALP in each 3 patients (0.03%)		রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।
52.	Beacon Pharmaceuticals PLC Kathali, Bhaluka, Mymensingh	Irsogladine Maleate 4mg OD Tablet	Irsogladine Maleate INN 4mg	Therapeutic Class: Antacid Therapeutic Code: 007	Improvement of gastric mucosal lesion (erosion, hemorrhage, redness and edema) caused by the following diseases: Acute gastritis and acute exacerbation stage of chronic gastritis.	**Contraindications:** In patient with hypersensivity to Irsogladine or to any of the excipients. **Side-Effect:** Adverse drug reactions to this drug, including abnormalities in laboratory data, were reported in 64 of 10,176 patients (0.63%). The most frequently observed adverse drug reactions were hepatic function abnormal in 12 patients (0.12%), increased ALT (GPT) in 12 patients (0.12%), increased AST (GOT) in 7 patients (0.07%), constipation in 6 patients (0.06%), rash in 5 patients (0.05%), itching, diarrhea and increased ALP in each 3 patients (0.03%)		রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।
53.	Beacon Pharmaceuticals PLC Kathali, Bhaluka, Mymensingh.	Diluted Nitroglycerin 2.040gm/100gm Gel	Diluted Nitroglycerin USP 2.040gm/100gm	Skin and Mucous Membrane Preparations Therapeutic Code:071	It is used to prevent chest pain (angina) in people with a certain heart condition (coronary artery disease). This medication belongs to a class of drugs known as nitrates. Angina occurs when the heart muscle is not getting enough blood. This drug works by relaxing and widening blood vessels so blood can flow more easily to the heart. This medication will not relieve chest pain once it occurs. It is also not intended to	**Contraindication** **Side-effects:** **WARNING AND PRECAUTIONS**	New	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
					be used just before physical activities (such as exercise, sexual activity) to prevent chest pain. Other medications may be needed in these situations. Consult your doctor for more details.					
54.	Beacon Pharmaceuticals PLC Kathali, Bhaluka, Mymensingh	Pinaverium Bromide 50mg Tablet	Pinaverium Bromide INN 50mg	Therapeutic Class: Anticholinerqic Therapeutic Code:011	It is indicated for the treatment and relief of symptoms associated with irritable bowel syndrome (IBS) including abdominal pain, bowel disturbances and intestinal discomfort; and treatment of symptoms related to functional disorders of biliary tract.	**Contraindications:** PINAVERIUM (pinaverium bromide) is contraindicated in patients with known hypersensitivity to pinaverium bromide or any of the excipients. No other contraindications have been identified at this time. Contact of PINAVERIUM with the oesophageal mucosa may be irritating. **Side effect:** Chest pain, Cough, Headache, Dizziness, Stomach pain, Diarrhea, Nausea, Vomiting, Dry mouth **Warning and Precautions:** Please do not take PINAVERIUM BROMIDE if you are allergic to any of its ingredients. Before taking PINAVERIUM BROMIDE, inform your doctor if you have galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. Inform your doctor before taking PINAVERIUM BROMIDE if you have a hernia	New	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।
55.	Beacon Pharmaceuticals PLC Kathali, Bhaluka, Mymensingh	Pinaverium Bromide 100mg Tablet	Pinaverium Bromide INN 100mg	Therapeutic Class: Anticholinerqic Therapeutic Code:011	It is indicated for the treatment and relief of symptoms associated with irritable bowel syndrome (IBS) including abdominal pain, bowel disturbances and intestinal discomfort; and treatment of symptoms related to functional disorders of biliary tract.	**Contraindications:** PINAVERIUM (pinaverium bromide) is contraindicated in patients with known hypersensitivity to pinaverium bromide or any of the excipients. No other contraindications have been identified at this time. Contact of PINAVERIUM with the oesophageal mucosa may be irritating. **Side effect:** Chest pain, Cough, Headache, Dizziness, Stomach pain, Diarrhea, Nausea, Vomiting, Dry mouth **Warning and Precautions:** Please do not take PINAVERIUM BROMIDE if you are allergic to any of its ingredients. Before taking PINAVERIUM BROMIDE, inform your doctor if you have galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. Inform your doctor before taking PINAVERIUM BROMIDE if you have a hernia	New	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।
56.	Beacon Pharmaceuticals PLC Kathali, Bhaluka, Mymensingh	Lactulose 2.5gm/5ml Syrup	Lactulose USP 2.5gm/5ml	Therapeutic Class: Laxatives Therapeutic Code:060	Lactulose is a synthetic sugar used to treat constipation. It is broken down in the colon into products that pull water out from the body and into the colon. This water softens stools. Lactulose is also used to reduce the amount of ammonia in	**Contraindications:** Galactosemia (patients require low-galactose diet) **Side effect:** Common side effects of lactulose may include: bloating, gas; stomach pain; diarrhea; or nausea, vomiting **Warning and Precautions:** Use only as directed. Tell	3.35gm/5ml	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
					the blood of patients with liver disease	your doctor if you use other medicines or have other medical conditions or allergies.				
57.	Beacon Pharmaceuticals PLC, Kathali, Bhaluka, Mymensingh EVEREST Pharmaceuticals Ltd. BSCIC I/A, Kanchpur, Narayanagnj	Irsogladine Maleate 2mg Tablet	Irsogladine Maleate INN 2mg	Antacid Therapeutic Code: 007	Improvement of gastric mucosal lesion (erosion, hemorrhage, redness and edema) caused by the following diseases: Acute gastritis and acute exacerbation stage of chronic gastritis.	**Contraindications:** In patient with hypersensivity to Irsogladine or to any of the excipients. **Side-Effect:** Adverse drug reactions to this drug, including abnormalities in laboratory data, were reported in 64 of 10,176 patients (0.63%). The most frequently observed adverse drug reactions were hepatic function abnormal in 12 patients (0.12%), increased ALT (GPT) in 12 patients (0.12%), increased AST (GOT) in 7 patients (0.07%), constipation in 6 patients (0.06%), rash in 5 patients (0.05%), itching, diarrhea and increased ALP in each 3 patients (0.03%)	New	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।
58.	Beacon Pharmaceuticals PLC, Kathali, Bhaluka, Mymensingh	Baclofen 15mg Tablet	Baclofen BP 15mg	Skeleton Muscle Relaxan Therapeutic Code:070	It is useful for the alleviation of signs and symptoms of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity. Patients should have reversible spasticity so that treatment with baclofen will aid in restoring residual function. Baclofen may also be of some value in patients with spinal cord injuries and other spinal cord diseases. Baclofen is not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders. The efficacy of Baclofen in stroke, cerebral palsy, and Parkinson's disease has not been established and, therefore, it is not recommended for these conditions.	**Contraindications:** it is contraindicated in patients who are hypersensitive to any component of this product. **Side effect:** The most common adverse reaction during treatment with baclofen is transient drowsiness (10-63%). In one controlled study of 175 patients, transient drowsiness was observed in 63% of those receiving baclofen tablets compared to 36% of those in the placebo group. Other common adverse reactions are dizziness (5-15%), weakness (5-15%) and fatigue (2-4%). Others reported: **Warning and Precautions:** Hallucinations and seizures have occurred on abrupt withdrawal of baclofen. Therefore, except for serious adverse reactions, the dose should be reduced slowly when the drug is discontinued. Impaired Renal Function Because baclofen is primarily excreted unchanged by the kidneys, it should be given with caution and it may be necessary to reduce the dosage in patients with impaired renal function.	5mg, 10mg, 25mg Tablet & 0.1gm/100ml Syrup	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।
59.	Benham Pharmaceuticals Limited,	Mebeverine HCl BP 135 mg & Chlordiazepoxide BP 5 mg film coated	Mebeverine HCl BP 135 mg + Chlordiazepoxide	Anticholinergic Therpaeutic	•For treating the symptoms of irritable bowel syndrome (IBS) and similar problems such as chronic irritable colon,	**Contraindications:** It is contra-indicated in patients with known liver disease, kidney disease.	New	***রেফারেন্স নাই***	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
	Aichanowaddah,Rajashon Road, Savar, Dhaka	Tablet	BP 5 mg	Code: 011	spastic. •For constipation, mucous colitis and spastic colitis. •For relieving the spasm, pain and other symptoms of IBS	**Side-effect:** It can cause some side effects. It may include drowsiness, fatigue, confusion, uncoordinated body movements, skin rash, slurred speech, light headache, tiredness.				
60.	DBL Pharmaceuticals Ltd.	Olmesartan USP 20 mg + Azelnidipine INN 16 mg Tablet	Olmesartan USP 20 mg + Azelnidipine INN 16 mg	Antihypertensive Therpaeutic Code: 022	Indicated for the treatment of Hypertension	Contraindications: • This medicine is contraindicated if patient is allergic to Olmesartan medoxomil and Azelnidipine. • It is contraindicated to use this medicine along with aliskiren in patients with diabetes, and anuria. Side effects: • Peripheral edema • Palpitation • Orthostatic hypotension • Rash • Angioedema • Diarrhea • Jaundice • Ankle swelling Increased potassium level in blood	Olmesartan USP 20 mg, 40 mg Tablet	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।
61.	DBL Pharmaceuticals Ltd.	Olmesartan USP 10 mg + Azelnidipine INN 8 mg Tablet	Olmesartan USP 10 mg + Azelnidipine INN 8 mg	Antihypertensive Therpaeutic Code: 022	Indicated for the treatment of Hypertension	Contraindications: • This medicine is contraindicated if patient is allergic to Olmesartan medoxomil and Azelnidipine. • It is contraindicated to use this medicine along with aliskiren in patients with diabetes, and anuria. Side effects: • Peripheral edema • Palpitation • Orthostatic hypotension • Rash • Angioedema • Diarrhea • Jaundice • Ankle swelling Increased potassium level in blood	New	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
62.	Drug International Ltd 31/1, Satrong, Tongi I/A, Gazipur.	Lansoprazole 15.00mg DL Tablet.	Lansoprazole coated pellets 12%w/w DL Ph. Grade 125.00mg (Contains Lansoprazole USP 15.00mg)	Proton Pump Inhibitor Therapeutic Code: 067	It is used for treatment of duodenal and gastric ulcer, treatment of reflux oesophagitis, Prophylaxis of reflux oesophagitis, Eradication of *Helicobacter pylori* (*H. pylori*) concurrently given with appropriate antibiotic therapy for treatment of *H.pylori*-associated ulcers, Treatment of non-steroidal anti-inflammatory drug (NSAID)-associated benign gastric and duodenal ulcers in patients requiring continued NSAID treatment, Prophylaxis of NSAID-associated gastric ulcers and duodenal ulcers in patients at risk requiring continued therapy, Symptomatic gastroesophageal reflux disease, Zollinger-Ellison syndrome.	**Contraindications**: Lansoprazole tablet are contraindicated in patients with known hypersensitivity to any component of the formulation. **Precautions:** Gastric malignancy: In common with other anti-ulcer therapies, the possibility of malignant gastric tumour should be excluded when treating a gastric ulcer with Lansoprazole because Lansoprazole can mask the symptoms and delay the diagnosis. Gastrointestinal infections caused by bacteria. Lansoprazole, like all proton pump inhibitors (PPIs), might increase the counts of bacteria normally present in the gastrointestinal tract. This may increase the risk of gastrointestinal infections caused by bacteria such as Salmonella, Campylobacter and, especially in hospitalized patients, Clostridium difficile. Human immunodeficiency virus (HIV) protease inhibitors: Co-administration of Lansoprazole is not recommended with HIV protease inhibitors for which absorption is dependent on acidic intragastric pH, such as atazanavir and nelfinavir, due to significant reduction in their If co-administration of Lansoprazole with HIV protease inhibitors is unavoidable, close clinical monitoring is recommended. **Warning:**As per precaution. **Side effects:** The most common side effects are Nausea, headache, diarrhea, constipation, flatulence and skin rashes may occur rarely. This capsule is well tolerated.	New	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।
63.	Drug International Ltd 31/1, Satrong, Tongi I/A, Gazipur.	Lansoprazole 30.00mg DL Tablet.	Lansoprazole coated pellets 12%w/w DL Ph. Grade 300.00mg (Contains Lansoprazole USP 30.00mg)	Proton Pump Inhibitor Therapeutic Code: 067	It is used for treatment of duodenal and gastric ulcer, treatment of reflux oesophagitis, Prophylaxis of reflux oesophagitis, Eradication of *Helicobacter pylori* (*H. pylori*) concurrently given with appropriate antibiotic therapy for treatment of *H.pylori*-associated ulcers, Treatment of non-steroidal anti-inflammatory drug (NSAID)-associated benign gastric and duodenal ulcers in patients requiring continued NSAID	**Contraindications**: Lansoprazole tablet are contraindicated in patients with known hypersensitivity to any component of the formulation. **Precautions:** Gastric malignancy: In common with other anti-ulcer therapies, the possibility of malignant gastric tumour should be excluded when treating a gastric ulcer with Lansoprazole because Lansoprazole can mask the symptoms and delay the diagnosis. Gastrointestinal infections caused by bacteria. Lansoprazole, like all proton pump inhibitors (PPIs), might increase the counts of bacteria normally present	New	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
					treatment, Prophylaxis of NSAID-associated gastric ulcers and duodenal ulcers in patients at risk requiring continued therapy, Symptomatic gastroesophageal reflux disease, Zollinger-Ellison syndrome.	in the gastrointestinal tract. This may increase the risk of gastrointestinal infections caused by bacteria such as Salmonella, Campylobacter and, especially in hospitalized patients, Clostridium difficile. Human immunodeficiency virus (HIV) protease inhibitors: Co-administration of Lansoprazole is not recommended with HIV protease inhibitors for which absorption is dependent on acidic intragastric pH, such as atazanavir and nelfinavir, due to significant reduction in their If co-administration of Lansoprazole with HIV protease inhibitors is unavoidable, close clinical monitoring is recommended. **Warning:**As per precaution. **Side effects:** The most common side effects are Nausea, headache, diarrhea, constipation, flatulence and skin rashes may occur rarely. This capsule is well tolerated.				
64.	Drug International Ltd, 31/1, Satrong, Tongi I/A, Gazipur EVEREST Pharmaceuticals Ltd. BSCIC I/A, Kanchpur, Narayanagnj Eskayef Pharmaceuticals Limited, Tongi, Gazipur	Pranlukast 112.5mgTablet	Pranlukast INN 112.5 mg	Bronchodilator Therpaeutic Code: 044	Pranlukast is usually used to treat bronchial asthma and allergic rhinitis. However, it cannot stop the attack of bronchial Asthma already in progress but prevents the asthma attack.	**Contraindication:** It is contraindicated in patients with Known Acute asthma attacks; hepatic impairment/cirrhosis. **Precaution:** Renal impairment. Possible elevations in liver enzymes. Withdraw treatment in patients showing signs consistent with Chug-Strauss syndrome. **Warning:** As per precaution. **Side effects:** The most commonly reported adverse reactions include nausea, diarrhea, abdominal pain, gastric discomfort, headache, drowsiness, dizziness, rash, itch, hives and erythema exsudativummultiforme.	Pranlukast Hydrate 10gm/100 ml Powder For Suspension	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।
65.	Drug International	Brentuximab Vedotin	Brentuximab	**Anticancer**	**Hodgkin Lymphoma**: It is indicated for	**Contraindications:** No data available.	New	রেফারেন্স নাই	রেফারেন্স নেই	রেফারেন্স নেই

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
	Ltd., 31/1, Satrong, Tongi I/A, Gazipur	Injection	Vedotin INN 50.00mg	Therpaeutic Code: 010	treatment of patients with Hodgkin lymphoma (HL) after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates. Systemic Anaplastic Large Cell Lymphoma: It is indicated for treatment of patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen.	**Precautions: Peripheral neuropathy:** Treating physicians should monitor patients for neuropathy and institute dose modifications accordingly.**Infusion reactions:** If an infusion reaction occurs, the infusion should be interrupted and appropriate medical management instituted. **Neutropenia:** Monitor complete blood counts prior to each dose of it. If Grade 3 or 4 neutropenia develops, manage by dose delays, reductions or discontinuation. **Tumor Lysis Syndrome:** Patients with rapidly proliferating tumor and high tumor burden are at risk of tumor lysis syndrome and these patients should be monitored closely and appropriate measures taken.**Stevens-Johnson syndrome:** If Stevens-Johnson syndrome occurs, discontinue it and administer appropriate medical therapy. **Progressive Multifocal Leukoencephalopathy (PML):** A fatal case of PML has been reported in a patient who received 4 chemotherapy regimens prior to receiving it. **Warning:** As per precaution. **Side effects**:The most common adverse reactions (≥20%) are neutropenia, peripheral sensory neuropathy, fatigue, nausea, anemia, upper respiratory tract infection, diarrhea, pyrexia, rash, thrombocytopenia, cough, and vomiting.			বিধায় নামঞ্জুরের সুপারিশ করা হয়	বিধায় নামঞ্জুর করা হয়।
66.	Drug International Ltd., 31/1, Satrong, Tongi I/A, Gazipur Ziska Pharmaceuticals Ltd., Gazipur	Sitafloxacin 100mg Tablet	Sitafloxacin Hydrate INN 104.40mg (Eqv. to 100.00mg Sitafloxacin)	Antibiotic Therpaeutic Code: 023	It is indicated for the treatment of laryngopharyngitis, tonsillitis (including peritonsillitis and peritonsillar abscess), acute bronchitis, pneumonia, infections secondary to chronic respiratory disease, cystitis, pyelonephritis, urethritis, cervicitis, otitis media, sinusitis, periodontal inflammation, pericoronitis and jaw inflammation.	**Contraindications**: It is contraindicated in patients with a history hypersensitivity to the ingredients of this drug or other quinolone antibiotics, pregnant women or who may be pregnant and children. **Precautions:** Caution regarding patients with specific background such as: Patients with or a history of convulsive disease such as epilepsy, patients with myasthenia gravis, patients with aortic aneurysm or aortic dissection. **Warning:** As per precaution. **Side effects:** There is no data available.	New	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।
67.	Eskayef Pharmaceuticals	Carboxymethylcellulose Sodium 1.0% + Glycerin	Carboxymethylcellulose Sodium USP	Eye Preparations	It is used as a lubricant to relieve irritation and discomfort due to dryness of the eye	**Contraindications:** Hypersensitivity **Side-effect:** Vision may be temporarily blurred when	Carboxymethyl cellulose	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের	রেফারেন্স নেই বিধায় নামঞ্জুর

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
	Limited, Rupganj, Narayanganj	0.9% Ophthalmic Solution	1gm + Glycerol (Glycerin) BP 0.9gm/100ml	Therapeutic code: **052**	or due to exposure to wind or sun.	this product is first used. **Warnings and Precautions:** Consult doctor if irritation, eye pain or visual changes worsen or persist beyond 72 hours.	Sodium 0.5% + Glycerin 0.9% Ophthalmic Solution		সুপারিশ করা হয়	করা হয়।
68.	Eskayef Pharmaceuticals Limited, Rupganj, Narayanganj	Zinc 3.4mg + Ascorbic Acid 90mg + Cyanocobalamin 2.4mcg + Vitamin E 7.5mg + Potassium 370mg + Chloride 840mg + Sodium 650mg Powder for Oral Solution	Zinc 3.4mg + Ascorbic Acid 90mg + Cyanocobalamin 2.4mcg + Vitamin E 7.5mg + Potassium 370mg + Chloride 840mg + Sodium 650mg	Minerals & Vitamins Therpaeutic Code: 062	It delivers advanced rehydration with 4 key nutrients to support your immune system. It also provides 100% of the Daily Value of vitamins C & B12 per serving. 4 key nutrients for immune support: • Zinc builds new immune cells • Vitamin C promotes cell health • Vitamin B12 helps activate immune cells Vitamin E supports cell membranes	**CONTRAINDICATIONS:** Hypersensitivity **SIDE-EFFECT:** Unknown	-	**রেফারেন্স নাই**	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।
69.	Eskayef Pharmaceuticals Limited, Salna, Gazipur	Clobetasol 0.05% + Fusidic Acid 2% Cream	Clobetasol Propionate USP 0.05gm + Fusidic Acid BP 2gm/100gm	Therapeutic Class: **Skin and Mucous Membrane Preparations** Therapeutic code: **071**	It is used for the effective management of skin related disorders like severe eczema or psoriasis with bacterial infections (including deep skin infections).	**CONTRAINDICATIONS:** Known hypersensitivity, occlusive Wrappings. **SIDE-EFFECT:** Site rections like burning, irritaions, itching and redness	Clobetasol Propionate 0.05% + Salicylic Acid 3% Ointment	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।
70.	Eskayef Pharmaceuticals Limited, Tongi, Gazipur	Sodium Chloride 2.6gm + Sodium Citrate 2.9gm + Potassium Chloride 1.5gm + Anhydrous Glucose 13.5gm per Liter Oral Solution	Sodium Chloride BP 2.6gm + Sodium Citrate (as Dihydrate) BP 2.9gm + Potassium Chloride BP 1.5gm + Anhydrous Glucose BP 13.5gm/ Liter	**Metals, Salts, Minerals & Calcium Preparations** Therapeutic code: **062**	It is used for restoring fluids and electrolytes in the body that are lost due to dehydration during diarrhoea and vomiting or other conditions. It contains a combination of salt and sugar (sodium citrate, sodium chloride, potassium chloride and dextrose). It is an oral rehydration salt (ORS) based on the WHO formula. The combination of electrolytes and sugar stimulates water and electrolyte absorption from the gut. It, therefore, prevents or reverses dehydration and replaces lost salts in conditions such as diarrhoea and	**CONTRAINDICATIONS:** • allergic to any of the components of this supplement. **SIDE-EFFECT:** • pregnant, breastfeeding or have any existing medical conditions such as diabetes, hypertension, liver or heart problem • problems with your kidney. • severe uncontrollable vomiting or diarrhoea.	**New**	***রেফারেন্স নাই***	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
					vomiting.					
71.	Eskayef Pharmaceuticals Limited, Tongi, Gazipur	Luliconazole 1% + Salicylic Acid 3% Cream	Luliconazole INN 1.0 gm + Salicylic Acid BP 3.0gm/100gm	Skin and Mucous Membrane Preparations Therapeutic code: 071	It belongs to a class of drugs called antifungals. It primarily treats fungal skin infections, including ringworm, jock itch, and athlete's foot. Fungal infection is a skin disease in which a fungus attacks the tissue and causes infection. Fungal infections may be contagious (spread from one person to another).	**CONTRAINDICATIONS:** It is recommended not to use if you are allergic to any components present in it. If you are pregnant or a nursing mother, it is advised to consult a doctor before using this. It is not recommended for children until your doctor recommends it. Let your doctor know about your medical history and other medications you are currently taking to rule out any potential negative effects. **SIDE-EFFECT:** Some people may experience application site reactions such as redness, swelling, irritation, or burning skin sensation at the site. Most of these side effects do not require medical attention and gradually resolve over time. However, if the side effects persist or worsen, please consult your doctor.	**New**	***রেফারেন্স নাই***	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।
72.	Eskayef Pharmaceuticals Limited, Tongi, Gazipur	Sodium Chloride 2.6gm + Sodium Citrate 3.0gm + Potassium Chloride 1.6gm + Anhydrous Glucose 13.5gm per Liter Oral Solution	Sodium Chloride BP 2.6gm + Sodium Citrate BP 3.0gm + Potassium Chloride BP 1.6gm + Anhydrous Glucose BP 13.5gm per Liter	Therapeutic Class: **Antidiarrhoeal Agents** Therapeutic code: **016**	It is primarily used to treat diarrhoea and dysentery.	**CONTRAINDICATIONS:** Hypersensitivity **SIDE-EFFECT:** Unknown	Sodium Chloride 1.75gm + Potassium Chloride 0.75gm + Trisodium Citrate 1.45gm + Glucose anhydrous 6.75gm Sodium Chloride 1.30gm + Potassium Chloride 0.75gm + Sodium Citrate 1.45gm + Anhydrous Glucose 6.75gm/Sachet	***রেফারেন্স নাই***	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।
73.	Eskayef Pharmaceuticals Limited, Tongi,	Telmisartan 40mg + Levamlodipine 2.5mg Tablet	Telmisartan USP 40mg + Levamlodipine	Antihypertensive Therapeutic	For the treatment of high blood pressure.	**CONTRAINDICATIONS:** Known hypersensitivity (e.g., anaphylaxis or angioedema) to Telmisartan, amlodipine or any other	Telmisartan 20, 40, 80mg Tablet	***রেফারেন্স নাই***	রেফারেন্স নেই বিধায় নামঞ্জুরের	রেফারেন্স নেই বিধায় নামঞ্জুর

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
	Gazipur		Maleate INN 3.210 (Equivalent to 2.5mg Levamlodipine)	code:022		component of this product. **SIDE-EFFECT:** Common cold, backache, diarrhoea, dizziness, drowsiness, confusion, rashes, and weakness. **WARNINGS AND PRECAUTIONS:** Caution must be taken while using this medicine in patient with have any kidney or liver problems or severe dehydration, pregnant or breastfeeding women then consultation with doctor is needed before taking this medicine.	Telmisartan 40mg + Hydrochlorothiazide 12.50mg Tablet Telmisartan 80mg + Hydrochlorothiazide 12.50mg Tablet Telmisartan 80mg + Hydrochlorothiazide 25mg Tablet Telmisartan 80mg + Amlodipine 5mg Tablet Telmisartan 40mg + Amlodipine 5mg Tablet Telmisartan 40mg + Amlodipine 10mg Tablet Telmisartan 80mg + Amlodipine 10mg Tablet		সুপারিশ করা হয়	করা হয়।
74.	Eskayef Pharmaceuticals Limited, Tongi, Gazipur	Vitamin C Ester (Ascorbyl Tetraisopalmitate) 1% Topical Gel	Vitamin C Ester (Ascorbyl Tetraisopalmitate) Pharma Grade 1gm/100gm	Therapeutic Class: **Other Classification** Therapeutic code: **075**	It reduces the appearance of everyday scars from cuts, burns and scratches – as well as surgical scars from c sections, operations and aesthetic procedures – can be lightened, soften and flatten within months.	**CONTRAINDICATIONS:** • Should not be applied to unhealed open wounds • Should not be used too closed to the eyes. • Should not be applied over other skin treatments.		***রেফারেন্স নাই***	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						SIDE-EFFECT: Redness, pain, irritation				
75.	Eskayef Pharmaceuticals Limited, Tongi, Gazipur	Vitamin C Ester (Ascorbyl Tetraisopalmitate) 1% + Vitamin E 10% Topical Gel	Vitamin C Ester (Ascorbyl Tetraisopalmitate) Pharma Grade 1gm + Vitamin E BP 10gm per 100gm	Therapeutic Class: **Other Classification** Therapeutic code: **075**	It is used to aid in the management of keloids and hypertrophic scars, after the wound has healed and the skin surface is intact.	**CONTRAINDICATIONS:** • Should not be applied to unhealed open wounds • Should not be used too closed to the eyes. • Should not be applied over other skin treatments. **SIDE-EFFECT:** Redness, pain, irritation		***রেফারেন্স নাই***	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।
76.	Eskayef Pharmaceuticals Limited, Tongi, Gazipur	Aluminium Hydroxide 800mg + Magnesium Hydroxide 800mg + Simethicone 80mg/10ml Oral Suspension	Dried Aluminium Hydroxide Gel USP 10gm (Eq. to 8gm Aluminium Hydroxide) + Magnesium Hydroxide USP 8gm + Simethicone 30% Emulsion USP 2.667gm (Eq. to 0.8gm Simethicone)	Therapeutic Class: **Antacid** Therapeutic code: **007**	It relieves - • heartburn • acid indigestion • sour stomach • upset stomach due to these symptoms **pressure & bloating commonly referred to as gas**	**CONTRAINDICATIONS:** • Hypersensitivity **SIDE-EFFECT:** • Constipation • Diarrhea **WARNINGS AND PRECAUTIONS:** • Kidney Disease • Magnesium-Restricted Diet	Aluminium Oxide 200mg + Magnesium Hydroxide 400mg + Simethicone 30mg/5ml Suspension	***রেফারেন্স নাই***	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।
77.	Eskayef Pharmaceuticals Limited, Tongi, Gazipur	Calcium Carbonate 400mg + Simethicone 40mg Chewable Tablet	Calcium Carbonate USP 400mg + Simethicone USP 66.666mg (Eq. to 40mg Simethicone)	Therapeutic Class: **Antacid** Therapeutic code: **007**	This combination medication is used to treat symptoms caused by too much stomach acid such as heartburn, upset stomach, or indigestion. It is also used to treat symptoms of extra gas such as bloating and feelings of pressure/discomfort in the stomach/gut. Calcium carbonate is an antacid that works by lowering the amount of acid in the stomach. Simethicone works by breaking up gas bubbles in the gut.	**CONTRAINDICATIONS:** • Constipation • Hypersensitivity **SIDE-EFFECT:** • Constipation Decreased Appetite	**New**	***রেফারেন্স নাই***	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।
78.	Eskayef Pharmaceuticals	Calcium Carbonate 400mg + Simethicone	Calcium Carbonate USP 8gm +	Therapeutic Class: **Antacid**	This combination medication is used to treat symptoms caused by too much	**CONTRAINDICATIONS:** • Constipation	**New**	***রেফারেন্স নাই***	রেফারেন্স নেই বিধায় নামঞ্জুরের	রেফারেন্স নেই বিধায় নামঞ্জুর

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
	Limited, Tongi, Gazipur	40mg/5ml Emulsion	Simethicone USP 2.666gm/100ml	Therapeutic code:**007**	stomach acid such as heartburn, upset stomach, or indigestion. It is also used to treat symptoms of extra gas such as bloating and feelings of pressure/discomfort in the stomach/gut. Calcium carbonate is an antacid that works by lowering the amount of acid in the stomach. Simethicone works by breaking up gas bubbles in the gut.	• Hypersensitivity **SIDE-EFFECT:** • Constipation Decreased Appetite			সুপারিশ করা হয়	করা হয়।
79.	Eskayef Pharmaceuticals Limited, Tongi, Gazipur Orion Pharma Ltd., D/28/2, Sumilpara, Siddhirganj, Narayanganj	Diflucortolone Valerate 0.1% w/w + Isoconazole Nitrate 1% w/w	Diflucortolone Valerate BP 1mg + Isoconazole Nitrate BP 10mg/100gm	Antifungal Agent Therapeutic code: **020**	Fungal infections of hairless and hairy skin, e.g. in the region of the hands, the interdigital spaces of the feet, and in the inguinal and genital regions. Because of the addition of diflucortolone valerate, it is indicated for the initial or intermediate treatment of those fungal diseases which are accompanied by highly inflammatory or eczematous skin conditions.	**CONTRAINDICATIONS:** Hypersensitivity to the active substances or to any of the excipients. Corticosteroids have been shown to be teratogenic in animals following dermal application. As these agents are absorbed percutaneously, teratogenicity following topical application cannot be excluded. Therefore, Diflucortolone valerate and Isoconazole nitrate should not be used during pregnancy. **SIDE-EFFECT:** Local symptoms such as itching, burning, erythema or Vesiculation may occur in isolated cases under treatment with Diflucortolone valerate and Isoconazole nitrate. The following side effects may occur in rare cases: Folliculitis, hypertrichosis perioral dermatitis, skin discoloration, allergic skin reactions to any of the ingredients of the formulation.	New	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।
80.	Eskayef Pharmaceuticals Limited, Tongi, Gazipur	Luliconazole 1% + Terbinafine 1% Cream	Luliconazole INN 1gm + Terbinafine Hydrochloride BP 1gm/100gm	Therapeutic Class: **Skin and Mucous Membrane Preparations** Therapeutic code: **071**	Different fungal infections including Tinea Corporis, Tinea Cruris, Tinea Pedis.	**CONTRAINDICATIONS:** Known hypersensitivity **SIDE-EFFECT:** Contact dermatitis, cellulitis	Luliconazole 1% Cream Terbinafine HCl 1% Cream	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।
81.	Eskayef Pharmaceuticals	Glucosamine Sulfate 750mg + Mecobalamin	Glucosamine Sulfate Potassium	Other Classifications	The salt combination Glucosamine Sulphate & Mecobalamin is used for the	**CONTRAINDICATIONS:** • History of liver disease	Chondroitin 600mg +	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের	রেফারেন্স নেই বিধায় নামঞ্জুর

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
	Limited, Tongi, Gazipur	0.75mg + Calcium Carbonate 625mg Film Coated Tablet	Chloride USP 995mg (Eq. to Glucosamine Sulfate 750mg) + Mecobalamin INN 0.75mg + Calcium Carbonate USP 625mg (Eq. to 250mg Elemental Calcium)	Therapeutic code: **075**	treatment of Osteoarthritis, Low Hemoglobin, Loss of Sensation, Pain In Extremities, Adjunct Therapy In Severe Muscle Tightness, Decrease In Muscle Mass and other conditions. Glucosamine Sulphate & Mecobalamin is used for the treatment, control, prevention, improvement of the following diseases, conditions and symptoms: • Osteoarthritis • Low Hemoglobin • Loss Of Sensation • Pain in Extremities • Decrease in Muscle Mass Adjunct Therapy In Severe Muscle Tightness	• Pregnant or breastfeeding • Pregnant, planning to get pregnant or breastfeeding **SIDE-EFFECT:** The following is a list of possible side-effects that may occur in medicines that contain Glucosamine Sulphate & Mecobalamin. This is not a comprehensive list. These side-effects are possible, but do not always occur. Some of the side-effects may be rare but serious. Consult your doctor if you observe any of the following side-effects, especially if they do not go away. Gas, Bloating, Cramps, Nausea, Allergic Reactions, Vomiting **WARNINGS AND PRECAUTIONS:** Before using this drug, inform your doctor about your current list of medications, over the counter products (e.g. vitamins, herbal supplements, etc.), allergies, pre-existing diseases, and current health conditions (e.g. pregnancy, upcoming surgery, etc.). Some health conditions may make you more susceptible to the side-effects of the drug. If anyone take other drugs or over the counter products at the same time, the effects of Glucosamine Sulphate and Mecobalamin may change. This may increase your risk for side-effects or cause your drug not to work properly.	Glucosamine 750mg Tablet		সুপারিশ করা হয়	করা হয়।
82.	Eskayef Pharmaceuticals Limited, Tongi, Gazipur	Benzalkonium Chloride 0.13% + Lidocaine HCl 0.5% Cream	Benzalkonium Chloride BP 0.13gm + Lidocaine Hydrochloride USP 0.5gm/100gm	Skin and Mucous Membrane Preparations Therapeutic code: **071**	***Purpose:*** • First aid antiseptic • Topical analgesic ***Uses:*** • for the temporary relief of pain associated with minor burns helps protect against harmful bacteria	**CONTRAINDICATIONS:** history of hypersensitivity **Side-effect:** Unknown **WARNINGS AND PRECAUTIONS:** For external use only. ***Do not use:*** • in the eyes • in large quantities • over raw surfaces or blistered areas, or on deep puncture wounds, animal bites, or serious burns • for more than 1 week unless directed by a	Benzalkonium Chloride 0.1% + Chlorhexidine Hydrochloride 0.1% + Isopropyl Myristate 10% + Liquid Paraffin 10% Cream	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						doctor ***Stop use and ask doctor if*** • the condition worsens or if symptoms persists for more than 7 days or clear up and occur again within a few days ***Keep out of reach of children:*** If ingested, get medical help or contact a Poison Control Center right away.				
83.	Eskayef Pharmaceuticals Limited, Tongi, Gazipur	Lidocaine Hydrochloride 4% (w/w) Lotion	Lidocaine Hydrochloride USP 4gm/100gm	Therapeutic Class: **Anaesthetics** Therapeutic code: **004**	It is indicated for the production of topical anesthesia of accessible mucous membranes of the oral and nasal cavities and proximal portions of the digestive tract.	**CONTRAINDICATIONS:** Lidocaine HCl is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type or to other components of Lidocaine Hydrochloride. **SIDE-EFFECT:** Adverse experiences following the administration of Lidocaine HCl are similar in nature to those observed with other amide local anesthetic agents. These adverse experiences are, in general, doserelated and may result from high plasma levels caused by excessive dosage or rapid absorption, or may result from a hypersensitivity, idiosyncrasy or diminished tolerance on the part of the patient. Serious adverse experiences are generally systemic in nature. The following types are those most commonly reported: ***Central Nervous System***: CNS manifestations are excitatory and/or depressant and may be characterized by lightheadedness, nervousness, apprehension, euphoria, confusion, dizziness, drowsiness, tinnitus, blurred or double vision, vomiting, sensations of heat, cold or numbness, twitching, tremors, convulsions, unconsciousness, respiratory depression and arrest. The excitatory manifestations may be very brief or may not occur at all, in which case the first manifestation of toxicity may be drowsiness merging into unconsciousness and respiratory arrest. Drowsiness following the administration of Lidocaine HCl is usually an early sign of a high blood level of the drug and may occur as a consequence of rapid absorption. ***Cardiovascular System:*** Cardiovascular manifestations are usually depressant and are	Lidocaine 2% Gel Lidocaine 1% Solution Lidocaine 4% Injection	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						characterized by Bradycardia, hypotension, and cardiovascular collapse, which may lead to cardiac arrest. ***Allergic:*** Allergic reactions are characterized by cutaneous lesions, urticaria, and edema or anaphylactoid reactions. Allergic reactions may occur as a result of sensitivity either to the local anesthetic agent or to other ingredients in the formulation. Allergic reactions as a result of sensitivity to Lidocaine HCl are extremely rare and, if they occur, should be managed by conventional means. The detection of sensitivity by skin testing is of doubtful value. **WARNINGS AND PRECAUTIONS:** In order to manage possible adverse reactions, resuscitative equipment, oxygen and other resuscitative drugs must be immediately available when local anesthetic agents, such as Lidocaine HCl, are administered to mucous membranes. Lidocaine hydrochloride topical solution, 4% should be used with extreme caution if there is sepsis or severely traumatized mucosa in the area of application, since under such conditions there is the potential for rapid systemic absorption. • Methemoglobinemia • Carcinogenesis, Mutagenesis, Impairment of Fertility • Use in Pregnancy • Labor and Delivery • Nursing Mothers Pediatric Use				
84.	Eskayef Pharmaceuticals Limited, Tongi, Gazipur General Pharmaceutical Ltd., (Unit-2) Gazipur	Ramosetron Hydrochloride 300mcg per 2ml IV Injection	Ramosetron Hydrochloride INN 300mcg/Vial	Antiemetic Therapeutic code: **018**	This medicine acts on the serotonin receptors and relieves nausea and vomiting. It is usually used for the treatment of gastrointestinal symptoms (nausea and vomiting) associated with the administration of medicines. (Medicines used to treat your disease may cause severe nausea and vomiting.)	**CONTRAINDICATIONS:** • If you have previously experienced any allergic reactions (itch, rash, etc.) to any medicines or foods. • If you are pregnant or breastfeeding. • If you are taking any other medicinal products. (Some medicines may interact to enhance or diminish medicinal effects. Beware of over-the-counter	Ramosetron Hydrochloride 2.5, 5mcg FC Tablet Ramosetron Hydrochloride 2.5, 5mcg OD	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						medicines and dietary supplements as well as other prescription medicines.) **SIDE-EFFECT:** The most commonly reported adverse reactions include skin rash, itch, redness, headache, dull headache, diarrhea, constipation, body heat, hiccups, hot flashes of the head and numbness of tongue.	Tablet			
85.	Eskayef Pharmaceuticals Limited, Tongi, Gazipur	Tegoprazan 25mg Film Coated tablet	Tegoprazan INN 25mg	Potassium-competitive acid blocker Therapeutic Code: 067	Treatment of erosive and non-erosive gastroesophageal reflux diseases (GERD) and gastric ulcer. Eradication of Helicobacter pylori concurrently given with appropriate antibiotic therapy treatment in patients with peptic ulcer and/or chronic atrophic gastritis.	**CONTRAINDICATIONS:** Hypersensitivity to tegoprazan, or substituted benzimidazoles. Patients taking atazanavir, nelfinavir, or rilpivirine-containing products. Pregnancy and lactation. **SIDE-EFFECT:** Nausea, diarrhea, dyspepsia, nasopharyngitis, viral URTI, and chest discomfort. **WARNINGS AND PRECAUTIONS:** Elderly	**New**	**রেফারেন্স নাই**	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।
86.	Eskayef Pharmaceuticals Limited, Tongi, Gazipur	Magnesium Hydroxide 300mg + Liquid Paraffin 1.25ml + Sodium Picosulfate 3.33mg/5ml Suspension	Magnesium Hydroxide USP 6gm + Liquid Paraffin (Heavy) BP 21.475gm (Eq. to Liquid Paraffin Heavy 25ml, considering weight per ml of the same as 0.859gm/ml) + Sodium Picosulfate BP 0.067gm	Therapeutic Class: **Laxatives** Therapeutic code: **060**	Used for a short time to treat occasional constipation. It is a laxative that is thought to work by drawing water in to the intestines, an effect that helps to cause movement of the intestine. Also used as a stool softener. It s contact stimulant laxative used as a treatment for contact stimulant laxative used as a treatment for constipation or to prepare the large bowel.	**CONTRAINDICATIONS:** • Hypersensitivity to any ingredient of composition. • Contraindicated in children. **SIDE-EFFECT:** • Hypermagnesemia • Abdominal pain Diarrhea	(Sodium Picosulfate 10mg+ Magnesium Oxide 3.50gm + Anhydrous Citric Acid 12.0gm)/160ml Bottle Sodium Picosulfate 5mg/5ml Oral Solution	**রেফারেন্স নাই**	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।
87.	Eskayef Pharmaceuticals Limited, Tongi, Gazipur	Magnesium 40mg + Potassium 280mg + Selenium 12mcg + Zinc 2.8mg + Chloride 690mg Oral Solution	Magnesium Chloride Hexahydrate BP 338.32mg (Eq. to Magnesium 40mg and Chloride 118.329mg) + Potassium Citrate USP 774.480mg (Eq. to Potassium	Minerals Therpaeutic Code: 062	It delivers advanced rehydration with 3 key nutrients to support your immune system – zinc, magnesium, and selenium. 3 key nutrients for immune support: • Zinc helps build new immune cells and supports their function • Magnesium supports immune response Selenium helps protect cells	**CONTRAINDICATIONS:** Hypersensitivity **SIDE-EFFECT:** Unknown	-	**রেফারেন্স নাই**	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
			280mg) + Sodium Selenate Pharma Grade 0.029mg (Eq. to 12mcg) + Zinc Sulfate (Monohydrate) USP 7.683mg (Eq. to Zinc 2.8mg) + Sodium Chloride BP 942.685mg (Eq. to Chloride 571.671mg)							
88.	The ACME Laboratories Ltd. Dhamrai, Dhaka Beacon Pharmaceuticals PLC, Kathali, Bhaluka, Mymensingh Beximco Pharmaceuticals Ltd., Tongi, Gazipur DBL Pharmaceuticals Ltd. Gazipur Drug International Ltd, 31/1, Satrong, Tongi I/A, Gazipur Eskayef	Resmetirom 80mg Film Coated Tablet	Resmetirom INN 80mg	Thyroid hormone receptor-β Therpaeutic Class: 074	Resmetirom is a thyroid hormone receptor (THR) β selective agonist in development for the treatment of nonalcoholic steatohepatitis (NASH) with liver fibrosis. Resmetirom works in the treatment of NASH by acting as an agonist of THR–β in the liver. THR-β action is key to proper liver function, including regulation of mitochondrial activity such as breakdown of liver fat and control of the level of normal, healthy mitochondria. People with NASH have reduced levels of THR-β receptor activity in the liver. **Clinical Efficacy & Safety Data:** • In MAESTRO-NASH, a 52-week serial liver biopsy Phase 3 study in more than 950 patients, resmetirom achieved both primary endpoints and potentially clinically meaningful effects with both daily oral doses, 80 mg and 100 mg, relative to placebo	**CONTRAINDICATIONS:** Unknown **SIDE-EFFECT:** The most common adverse events reported as mild and transient diarrhea and nausea at the beginning of therapy.	New	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
	Pharmaceuticals Limited, Tongi, Gazipur EVEREST Pharmaceuticals Ltd. BSCIC I/A, Kanchpur, Narayanagnj Healthcare Pharmaceuticals Ltd. Rajendrapur, Gazipur Incepta Pharmaceuticals Ltd., Savar, Dhaka Navana Pharmaceuticals Ltd., Rupganj, Narayanaganj Nipro JMI Pharma Ltd., Cumilla Opsonin Pharmaceuticals Ltd., Barishal Pharmasia Ltd., Gazipur Popular				➢ NASH resolution (ballooning of 0, inflammation of 0-1) and ≥2-point NAS reduction with no worsening of fibrosis (p<0.0001 at both doses) ➢ Fibrosis improvement by at least one stage with no worsening of NAS (p=0.0002 and <0.0001 at 80 and 100 mg, respectively) • Potentially clinically meaningful LDL-lowering, a key secondary endpoint (p<0.0001) • Multiple positive effects on NASH biomarkers and imaging • Resmetirom was safe and well-tolerated in the MAESTRO-NASH study, consistent with the overall safety in Phase 3 MAESTRO trials, expanding the large safety database Madrigal intends to file a new drug application seeking accelerated approval of resmetirom for the treatment of non-cirrhotic NASH with liver fibrosis				

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
	Pharmaceuticals Ltd., 164, Tongi Industrial Area, Monnunagar, Gazipur Square Pharmaceuticals, PLC, Kaliakor, Gazipur Team Pharmaceuticals Ltd., BSCIC, Rajshahi Ziska Pharmaceuticals Ltd., Gazipur									
89.	The ACME Laboratories Ltd. Dhamrai, Dhaka Beacon Pharmaceuticals PLC, Kathali, Bhaluka, Mymensingh Beximco Pharmaceuticals Ltd., Tongi, Gazipur	Resmetirom 100mg Film Coated Tablet	Resmetirom INN 100mg	Thyroid hormone receptor-β Therpaeutic Class: 074	Resmetirom is a thyroid hormone receptor (THR) β selective agonist in development for the treatment of nonalcoholic steatohepatitis (NASH) with liver fibrosis. Resmetirom works in the treatment of NASH by acting as an agonist of THR–β in the liver. THR-β action is key to proper liver function, including regulation of mitochondrial activity such as breakdown of liver fat and control of the level of normal, healthy mitochondria. People with NASH have reduced levels of THR-β	**CONTRAINDICATIONS:** Unknown **SIDE-EFFECT:** The most common adverse events reported as mild and transient diarrhea and nausea at the beginning of therapy.	New	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
	DBL Pharmaceuticals Ltd. Gazipur Drug International Ltd. 31/1, Satrong, Tongi I/A, Gazipur Eskayef Pharmaceuticals Limited, Tongi, Gazipur Eskayef Pharmaceuticals Limited, Tongi, Gazipur EVEREST Pharmaceuticals Ltd. BSCIC I/A, Kanchpur, Narayanagnj Healthcare Pharmaceuticals Ltd. Rajendrapur, Gazipur Incepta Pharmaceuticals Ltd., Savar, Dhaka Navana Pharmaceuticals Ltd., Rupganj, Narayanaganj				receptor activity in the liver. **<u>Clinical Efficacy & Safety Data:</u>** • In MAESTRO-NASH, a 52-week serial liver biopsy Phase 3 study in more than 950 patients, resmetirom achieved both primary endpoints and potentially clinically meaningful effects with both daily oral doses, 80 mg and 100 mg, relative to placebo ➢ NASH resolution (ballooning of 0, inflammation of 0-1) and ≥2-point NAS reduction with no worsening of fibrosis ($p<0.0001$ at both doses) ➢ Fibrosis improvement by at least one stage with no worsening of NAS ($p=0.0002$ and <0.0001 at 80 and 100 mg, respectively) • Potentially clinically meaningful LDL-lowering, a key secondary endpoint ($p<0.0001$) • Multiple positive effects on NASH biomarkers and imaging • Resmetirom was safe and well-tolerated in the MAESTRO-NASH study, consistent with the overall safety in Phase 3 MAESTRO trials, expanding the large safety database Madrigal intends to file a new drug application seeking accelerated approval of resmetirom for the treatment of non-cirrhotic NASH with					

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
	Nipro JMI Pharma Ltd., Cumilla Opsonin Pharmaceuticals Ltd., Barishal Pharmasia Ltd., Gazipur Popular Pharmaceuticals Ltd., 164, Tongi Industrial Area, Monnunagar, Gazipur Square Pharmaceuticals, PLC, Kaliakor, Gazipur Team Pharmaceuticals Ltd., BSCIC, Rajshahi Ziska Pharmaceuticals Ltd., Gazipur				liver fibrosis					
90.	Eskayef Pharmaceuticals Limited, Tongi, Gazipur	Calcium 260mg (Coral source) + Ascorbic Acid 1000mg Effervescent Tablet	Calcium Carbonate (Coral source) USP 327mg (Eq. to Elemental Calcium	Metals, Salts, Minerals & Calcium Preparations Therapeutic	This is indicated in- • Increased demand for Calcium and Vitamin-C, e.g. pregnancy, lactation, periods of rapid growth (childhood, adolescence), in old age	**CONTRAINDICATIONS:** • Hypercalcemia (e.g. in hyperparathyroidism, Vitamin-D over dosage, decalcifying tumors such as plasmocytoma, bone metastases); severe hypercalciuria; severe renal failure.	Ascorbic Acid 500mg + Calcium Carbonate 327mg + Calcium	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
			130.8mg) + Calcium Lactate Gluconate Pharma Grade 1046.15mg (Eq. to Elemental Calcium 129.2mg) + Ascorbic Acid USP 1000mg	code: 062	• During infectious disease and convalescence • Treatment of calcium and vitamin-C deficiency • Osteoporosis • Premenstrual syndrome • Postmenopausal problems Adjuvant in colds and influenza.	• Patients with hyperoxalauria, glucose-6-phosphate dehydrogenase deficiency, or iron overload. Larger doses may lead to gastrointestinal tract upset. **SIDE-EFFECT:** In rare cases, mild gastrointestinal disturbances (bloating, diarrhoea) can occur. In predisposed patients prolonged treatment with high doses may promote the formation of calculi in the urinary tract. **WARNINGS AND PRECAUTIONS:** For patients with mild hypercalciuria (exceeding 300 mg = 7.5 mmol/24 hours), with mild or moderate impairment of renal function or with a history of urinary concrements, monitoring of calcium excretion in the urine is required. If necessary, the dosage should be reduced or therapy should be discontinued. High doses of Vitamin-D and derivatives should be avoided during treatment with this preparation unless especially indicated. Since citrate salts have been reported to increase aluminium absorption, this medicine should be used with caution in patients with severely impaired renal function, especially those receiving aluminium-containing preparations. The sugar content should be taken into account by diabetic patients.	Gluconate 578mg + Calcium Lactate 422mg Tablet			
91.	EVEREST Pharmaceuticals Ltd. BSCIC I/A, Kanchpur, Narayanagnj, BANGLADESH	Acetaminophen 300 mg+ Ethenzamide 380 mg + Caffeine 60 mg Tablet	Acetaminophen USP 300 mg+ Ethenzamide INN 380 mg + Caffeine USP 60 mg Tablet	Analgesic and Antipyretics Therapeutic Code: 006	Menstrual pain, headache, back pain, toothache, sore throat and joint pain, muscle pain, neuralgia and neck stiffness.	**CONTRAINDICATIONS:** (1) Patients who have had an allergic symptom to this drug or its ingredients. (2) Patients who have experienced asthma from taking this drug, other antipyretic analgesics, cold remedies. (3). People who have received the following diagnosis-heart disease, liver disease, stomach/duodenal ulcer.	New	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						SIDE EFFECTS: Rash, itching, Nausea, vomiting, loss of appetite. **WARNINGS & PRECAUTIONS:** (1). Do not drink alcohol before/after taking this medicine (2). Do not take this medicine for a long time				
92.	EVEREST Pharmaceuticals Ltd. BSCIC I/A, Kanchpur, Narayanagnj, BANGLADESH Advanced Chemical Industries Limited, 7 Hajeeganj, Godnyl, Narayangonj	Pranlukast 112.5 mg Capsule	Pranlukast Hemihydrate INN 114.60 mg Eqv to Pranlukast 112.5mg	Drug Use in Bronchial Asthma, COPD Therapeutic Code: 044	For the treatment of Allergic rhinitis, Asthma	**CONTRAINDICATIONS: None** **SIDE EFFECTS:** Headache, increased incidence of resp tract infection, GI disturbances, induced generalized pain, fever, myalgia, arthralgia. **WARNINGS & PRECAUTIONS:** Renal impairment. Possible elevations in liver enzymes. Withdraw treatment in patients showing signs consistent with Churg-Strauss syndrome.	Pranlukast Hydrate 10 gm/100 ml Powder For Suspension	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।
93.	EVEREST Pharmaceuticals Ltd. BSCIC I/A, Kanchpur, Narayanagnj, BANGLADESH	Meclizine Hydrochloride USP 50 mg + Scopolamine Hydrobromide INN 0.25 mg Tablet	Meclizine Hydrochloride USP 50 mg + Scopolamine Hydrobromide Hydrate INN 0.279 mg Eqv. To Scopolamine Hydrobromide 0.25 mg Tablet	Antiemetic Therapeutic Code: 018	Prevention and alleviation of dizziness, nausea and headaches associated with motion sickness	**CONTRAINDICATION:** Renal impairment, Hepatic impairment, IOP increased, Glaucoma, COPD asthma, PUD, Hyperthyroidism, Hypertension, Lower resp. tract SX, GI obstruction, Prostatic hypertrophy, Bladder neck obstruction, High environmental temperature. **SIDE EFFECTS:** Dry mouth, thickened bronchial secretions, constipation, GI upset, urinary retention, drowsiness, Rare: anaphylaxis/anaphylactoid reaction, hemolytic anemia, thrombocytopenia, agranulocytosis, pancytopenia, leukopenia, arrhythmias, seizures, blurred vision, diplopia, tachycardia, photosensitivity, palpitations, diaphoresis, rash, difficulty swallowing, hives. **WARNINGS & PRECAUTIONS:** After taking this medicine, the following symptoms may appear or If such symptoms persist or increase, discontinue taking this medicine and talk to your doctor: Dry mouth, constipation, drowsiness, blurred vision.	New	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।
94.	EVEREST Pharmaceuticals Ltd. BSCIC I/A, Kanchpur, Narayanagnj,	Rebamipide 100 mg Tablet	Rebamipide INN 100 mg Tablet	Antacid Therapeutic Code:007	In is prescribed for the treatment of peptic ulcer, gastroduodenal ulcers and gastric disorder. It is indicated during bleeding, erosion, redness and edema that occur in	**Contraindication**: it is contraindicated in patients who are allergic to the drug. **Side-Effect:** Skin: Rash, Pruritsus, drug-eruption-like eczema.	New	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
	BANGLADESH General Pharmaceutical Ltd., Gazipur Incepta Pharmaceuticals Ltd.;,Zirabo, Dhaka				acute gastritis and acute exacerbation of chronic gastritis.	Constipation, Bloating, Diarrhea, nausea and Vomiting.				
95.	EVEREST Pharmaceuticals Ltd. BSCIC I/A, Kanchpur, Narayanagnj, BANGLADESH	Fosmanogepix INN 600mg Tablet	Fosmanogepix INN 600mg Tablet	Antifungal Therapeutic Code: 020	Treatment of Invasive candidiasis.	**CONTRAINDICATION:** Hepatic dysfunction. Ketoconazole, fluconazole, posaconazole, and Terbinafine can cause serious hepatic toxicity. **SIDE EFFECTS:** An allergic reaction- face, neck or tongue may swell and may have difficulty breathing. A severe skin reaction- such as peeling or blistering skin. Liver damage (very rarely)- may have loss of appetite, vomiting, nausea, jaundice, dark pee or pale poo, tiredness or weakness. **WARNINGS & PRECAUTIONS:** Endocrine or fertility problems, Pregnancy and lactation, Patients taking drugs that can prolong QTc interval.	New	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।
96.	EVEREST Pharmaceuticals Ltd. BSCIC I/A, Kanchpur, Narayanagnj, Bangladesh	Itraconazole 130 mg Capsule	Itraconazole Granules 40% w/w Ph. Grade 325.00 mg Eqv. to Itraconazole 130 mg Capsule	**Therapeutic Class:** Antifungal Agent **Therapeutic code: 020**	It is an azole antifungal indicated for the treatment of the following fungal infections in immunocompromised and non-immunocompromised adult patients: ● Blastomycosis, pulmonary and extrapulmonary ● Histoplasmosis, including chronic cavitary pulmonary disease and disseminated, non-meningeal histoplasmosis, and ● Aspergillosis, pulmonary and extrapulmonary, in patients who are intolerant of or who are refractory to	**CONTRAINDICATIONS:** ● Co-administration with certain drugs that either affect metabolism of Itraconazole or whose metabolism is affected by Itraconazole ● Hypersensitivity to Itraconazole **SIDE-EFFECT:** Nausea, rash, vomiting, edema, headache, diarrhea, fatigue, fever, pruritus, hypertension, abnormal hepatic function, abdominal pain, dizziness, hypokalemia, anorexia, malaise, decreased libido, somnolence, albuminuria, impotence. **WARNINGS AND PRECAUTIONS:**	100mg Capsule 200mg Tablet 65 mg Tablet	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
					amphotericin B therapy. **Limitations of Use:** ● It is not indicated for the treatment of onychomycosis It is not interchangeable or substitutable with other Itraconazole products	Hepatotoxicity: Serious hepatotoxicity, including liver failure and death were reported with the use of itraconazole. Discontinue treatment if signs of liver dysfunction occur Cardiac Dysrhythmias: Life-threatening cardiac dysrhythmias and/or sudden death have occurred in patients using certain drugs that are metabolized by human CYP450 enzymes concomitantly with oral itraconazole and/or other CYP3A4 inhibitors Peripheral Neuropathy: This has been reported in patients on long-term therapy with itraconazole. Monitor and promptly evaluate neurologic symptoms Hearing Loss: Reversible or permanent has been reported in patients. Discontinue treatment if hearing loss occurs				
97.	General Pharmaceutical Ltd., (Unit-2) Gazipur	Xylometazoline Hydrochloride 0.05% + Dexpanthenol 5% Nasal Spray	Xylometazoline Hydrochloride USP 0.05g + Dexpanthenol USP 5g/100ml	Nasal Decongestant Therapeutic code: 050	Indicated for the temporary symptomatic treatment of nasal congestion due to rhinitis or sinusitis and for the treatment of impaired nasal respiration after nasal surgery	**Contraindications:** Hypersensitivity to the ingredients of the preparation. Do not use in children under 6 years of age **Side-effect:** The following adverse reactions are discussed in more detail in other sections of the labeling: **Uncommon:** Hypersensitivity reactions (skin rash, itching, swelling of skin and mucous membrane) **Rare:** palpitations, accelerated heart activity (tachycardia), increased blood pressure (hypertension) Very rare: Restlessness, insomnia, tiredness (drowsiness, sedation), headache, hallucinations (mainly in children), convulsions (especially in children) Cardiac rhythm disorders (arrhythmias) Burning or dryness of the nasal mucosa, sneezing	New	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						After the effect has worn off, increased swelling of the mucous membranes, nosebleeds **Warnings and Precautions:** Do not use during simultaneous therapy with monoamine oxidase inhibitors (MAO) and tricyclic antidepressants. Diabetes mellitus, pheochromocytoma. Use during pregnancy and lactation Considering that there is no data on the reproductive toxicity of the drug, its use during pregnancy and lactation is not recommended. Directions for use and doses Intranasally.				
98.	General Pharmaceutical Ltd., Gazipur	Ramipril 2.5 mg + Amlodipine 2.5 mg Capsule	Ramipril BP 2.5 mg + Amlodipine Besilate BP 3.465 mg equivalent to Amlodipine 2.5 mg	Antihypertensive drugs Therapeutic code: 022	To treat Mild to severe hypertension, Congestive Heart failure. To reduce the risk of stroke, myocardial infarction and death from cardiovascular events in patients with a history of cardiovascular disease. Used in Proteinuric non-diabetic nephropathy.	**Contraindications:** It is contraindicated in patients who are hypersensitive to any component of this product and in patients with a history of angioedema related to previous treatment with an ACE inhibitor. **Warnings and precautions:** AMLODIPINE+RAMIPRIL may interact with drugs reducing cholesterol (simvastatin), corticosteroids (prednisolone), painkillers (ibuprofen, naproxen), anti-hypertensive drugs (ramipril, metoprolol, bendroflumethiazide), drugs treating impotence (sildenafil), gout medicine (allopurinol), diabetic drugs (Insulin glargine, metformin, sitagliptin), water pills (furosemide) and fits medicine (pregabalin). AMLODIPINE+RAMIPRIL may interact or may have decreased effect when used with alcohol and high potassium foods. Before using AMLODIPINE+RAMIPRIL, let your doctor know if have heart, kidney or liver diseases, high potassium levels (hyperkalemia), bone marrow suppression and aortic stenosis (heart valve problem). Do not use AMLODIPINE+RAMIPRIL if allergic to AMLODIPINE+RAMIPRIL or any of its components. Let doctor know if any history of severe heart, kidney or liver diseases, high potassium levels (hyperkalaemia), bone marrow suppression, and aortic stenosis (heart valve problem). AMLODIPINE+RAMIPRIL can increase	New	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						the chances of light-headedness so rise slowly if patient is sitting/lying and avoid operating any machine or doing any work that needs mental alertness. **Side effects:** Not Available				
99.	General Pharmaceutical Ltd., Gazipur	Ramipril 5 mg & Amlodipine 5 mg Capsule	Ramipril BP 5 mg + Amlodipine Besilate BP 6.930 mg equivalent to Amlodipine 5 mg	Antihypertensive drugs Therapeutic code: 022	To treat Mild to severe hypertension, Congestive Heart failure. To reduce the risk of stroke, myocardial infarction and death from cardiovascular events in patients with a history of cardiovascular disease. Used in Proteinuric non-diabetic nephropathy.	**Contraindications:** It is contraindicated in patients who are hypersensitive to any component of this product and in patients with a history of angioedema related to previous treatment with an ACE inhibitor. **Warnings and precautions:** AMLODIPINE+RAMIPRIL may interact with drugs reducing cholesterol (simvastatin), corticosteroids (prednisolone), painkillers (ibuprofen, naproxen), anti-hypertensive drugs (ramipril, metoprolol, bendroflumethiazide), drugs treating impotence (sildenafil), gout medicine (allopurinol), diabetic drugs (Insulin glargine, metformin, sitagliptin), water pills (furosemide) and fits medicine (pregabalin). AMLODIPINE+RAMIPRIL may interact or may have decreased effect when used with alcohol and high potassium foods. Before using AMLODIPINE+RAMIPRIL, let your doctor know if have heart, kidney or liver diseases, high potassium levels (hyperkalemia), bone marrow suppression and aortic stenosis (heart valve problem). Do not use AMLODIPINE+RAMIPRIL if allergic to AMLODIPINE+RAMIPRIL or any of its components. Let doctor know if any history of severe heart, kidney or liver diseases, high potassium levels (hyperkalemia), bone marrow suppression, and aortic stenosis (heart valve problem). AMLODIPINE+RAMIPRIL can increase the chances of light-headedness so rise slowly if patient is sitting/lying and avoid operating any machine or doing any work that needs mental alertness. **Side effects:** Not Available	New	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।
100.	General Pharmaceutical Ltd.,	Selenium 200 mcg Capsule	Selenium (L-Selenomethionine)	Vitamins & Combinations	Contribute to normal spermatogenesis Contribute to the maintenance of normal	**Contraindications:** Selenium is not advised if you are having surgery or	New	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের	রেফারেন্স নেই বিধায় নামঞ্জুর

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
	Gazipur		BP 200 mcg	Therapeutic code: 078	hair Contribute to the maintenance of normal nails Contribute to the normal function of the immune system and normal thyroid function Contribute to the protection of cells from oxidative stress	after surgery to prevent bleeding problems. – People who have had skin cancer should not take selenium without consulting with their doctor. There are suspicions that selenium may make this type of cancer. **Side effects:** Not Available **Warning and Precautions:** Selenium is likely safe when taken in doses less than 400 mcg daily, short-term. But selenium is possibly unsafe when taken in high doses or for a long time. Taking doses above 400 mcg daily can increase the risk of developing selenium toxicity. Taking lower doses for a long time can increase the risk of developing diabetes. Selenium can cause stomach discomfort, headache, and rash. High doses can cause hair loss, fatigue, nausea, vomiting, and weight loss. Extremely high doses can lead to organ failure and death.			সুপারিশ করা হয়	করা হয়।
101.	General Pharmaceutical Ltd., Gazipur	L-Methylfolate 7.5mg Tablet	L-Methylfolate INN 7.5mg	Other Classification Therapeutic code: 075	L-Methylfolate is indicated for the treatment of nutritional requirements of patients in need of dietary folate (Vitamin B9) supplementation. Low folate levels can lead to certain types of anemia. Conditions that can cause low folate levels include poor diet, pregnancy, alcoholism, liver disease, certain stomach/intestinal problems, kidney dialysis, among others. Folate plays an important role in forming red blood cells and maintaining brain health. Folate also supports a healthy pregnancy and lowers the risk of birth defects of the brain and spine.	**Contraindication** L-Methylfolate is contraindicated in patients with known hypersensitivity to any of the components contained in this product. **Warning and Precautions:** This product contains FD&C Yellow No. 5 (tartrazine) which may cause allergic-type reactions (including bronchial asthma) in certain susceptible persons. Although the overall incidence of FD&C Yellow No. 5 (tartrazine) sensitivity in the general population is low, it is frequently seen in patients who also have aspirin sensitivity.	New	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।
102.	**General Pharmaceutical Ltd., Gazipur**	L-Methylfolate 15 mg Tablet	L-Methylfolate INN 15 mg	Other Classification Therapeutic code: 075	L-Methylfolate is indicated for the treatment of nutritional requirements of patients in need of dietary folate (Vitamin B9) supplementation. Low folate levels can lead to certain types of anemia. Conditions that can cause low folate	Contraindication L-Methylfolate is contraindicated in patients with known hypersensitivity to any of the components contained in this product. Warning and Precautions: This product contains FD&C Yellow No. 5 (tartrazine) which may cause allergic-type	New	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
					levels include poor diet, pregnancy, alcoholism, liver disease, certain stomach/intestinal problems, kidney dialysis, among others. Folate plays an important role in forming red blood cells and maintaining brain health. Folate also supports a healthy pregnancy and lowers the risk of birth defects of the brain and spine.	reactions (including bronchial asthma) in certain susceptible persons. Although the overall incidence of FD&C Yellow No. 5 (tartrazine) sensitivity in the general population is low, it is frequently seen in patients who also have aspirin sensitivity.				
103.	Incepta Pharmaceuticals Ltd., Zirabo, Dhaka Advanced Chemical Industries Limited, 7 Hajeegonj, Godnyl, Narayangonj	Biapenem for Injection (sterile) 300mg/vial solution for Intravenous Injection	Biapenem for Injection (sterile) INN 300mg/vial	Therapeutic Class: Anti-infective Therapeutic Code: 023	Treatment of bacterial infection, sepsis, pneumonia, pulmonary abscess, secondary infection in chronic respiratory lesions. complicated cystitis, pyelonephritis.	**Contraindication:** Biapenem is well tolerated **Side-effects:** The following serious adverse reactions are discussed elsewhere in the label: Skin eruptions/rashes, Nausea, Diarrhoea, Eosinophilia, ALT/AST level increased **Warnings and Precautions**: This product should be used with caution by patients who are allergic to carbopenems, penicillins and cephalosporins; This product should be used with caution by patients who or whose direct relatives are susceptible to induced hypersensitivities including bronchial asthma, rash, urticaria and so on; Patients with severe renal inadequacy take precautions before using this product; Senile patients should use this product with cautions (see “Medication for senile patients”); When this product is used by the patients with eating difficulty and poor body condition, symptoms of Vitamin k Deficiency may occur; Patients with history of epilepsy and illness of central nervous system shall use this product with caution; False positive findings may occur during clinical Urine Glucose Test, Benedict's test and Fehling’s test for reducing sugar; Positive findings may occur in Kveim test.	New	PMDA (2001)	অনুমোদনের সুপারিশ করা হয়।	নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
104.	Incepta Pharmaceuticals Ltd.; Zirabo, Dhaka Square Pharmaceuticals PLC, Kaliakoir, Gazipur	Zinc Bisglycinate 200 mg eqv. to elemental Zinc 50 mg Tablet	Zinc Bisglycinate INN/In-house 200 mg eqv. to elemental Zinc 50 mg	Therapeutic Class: Metals, Salts, Minerals and Calcium Preparations Therapeutic Code: 062	This medication is used as an immunity booster and antioxidant.	**Contraindication:** No known contraindications. **Side Effect:** No data available **Warnings and Precautions:** Always read the label and follow the directions for use. If symptoms persist, talk to your health professional. Vitamin and mineral supplements should not replace a balanced diet. WARNING: Contains zinc which may be dangerous if taken in large amounts or for a long period.	Zinc 10 mg Tablet, Zinc 20 mg Tablet	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।
105.	Incepta Pharmaceuticals Ltd.; Zirabo, Dhaka Square Pharmaceuticals PLC, Kaliakoir, Gazipur	Zinc Bisglycinate 100 mg eqv. to elemental Zinc 25 mg Tablet	Zinc Bisglycinate INN/In-house 100 mg eqv. to elemental Zinc 25 mg	Therapeutic Class: Metals, Salts, Minerals and Calcium Preparations Therapeutic Code: 062	Zinc Bisglycinate is used as a dietary supplement to treat zinc deficiency. It is also used to treat zinc deficiency anemia. Zinc is essential for the proper functioning of the nervous system, the immune system, and the brain. It plays a vital role in immunity, wound healing, acne prevention, and digestion. Furthermore, it provides essential nutrients and plays a vital role in the formation of red blood cells, which carry oxygen throughout the body.	**Contraindication:** Zinc Bisglycinate, like other zinc supplements, is generally safe for most people when used as directed. However, it's important to note that taking too much zinc can lead to harmful side effects. These can include nausea, vomiting, diarrhea, metallic taste, kidney and stomach damage, and other adverse effects. **Side Effect:** No data available **Warnings and Precautions:** When taking Zinc Bisglycinate tablets, there are several precautions to keep in mind: Food Interactions: When zinc combines with certain foods, it may not be absorbed into your body and it will do you no good. If you are taking zinc, the following foods should be avoided or taken 2 hours after you take zinc: Bran, Fiber-containing foods, Phosphorus-containing foods such as milk or poultry, Whole-grain breads and cereals. Supplement Interactions: Do not take zinc supplements and copper, iron, or phosphorus supplements at the same time. It is best to space doses of these products 2 hours apart, to get the full benefit from each dietary supplement.	Zinc 10 mg Tablet, Zinc 20 mg Tablet	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
106.	Incepta Pharmaceuticals Ltd.,Dhamrai Unit, Dhaka	(Zinc Oxide 6.6g + Lidocaine Hydrochloride 0.8627g eqv.to Lidocaine 0.7g)/100g Cream	(Zinc Oxide BP/Ph. Eur 6.6g + Lidocaine Hydrochloride USP 0.8627g eqv.to Lidocaine 0.7g)/100g	Unclassified Agents Therapeutic Code: 075	The cream you mentioned contains Zinc Oxide (6.6% w/w) and Lidocaine (0.7% w/w). These ingredients have different purposes: Zinc Oxide: It's an astringent that helps relieve pain, and protect sore skin. Lidocaine: It's a local anesthetic that reduces pain This combination medicine can be used to relieve internal and external hemorrhoids (also known as piles), and to relieve itching and irritation around the anus. The cream is applied to the rectal and anal area. If your symptoms do not go away within 14 days, you should see a doctor.	**Contraindication:** The cream you mentioned contains Zinc Oxide (6.6% w/w) and Lidocaine (0.7% w/w). Here are some contraindications for its use: Allergy: Do not use if you are allergic to any of the ingredients. Pregnancy: If you are pregnant, you should seek the advice of your doctor or pharmacist before using this medicine. Breastfeeding: You can use this medicine if you are breastfeeding, but as with all medicines at this time, you should discuss it with your doctor first **Side-effects:** The mentioned cream contains Zinc Oxide (6.6% w/w) and Lidocaine (0.7% w/w). Here are some potential side effects: Hives, Itching, Skin rash, Worsening of diaper rash, Rectal bleeding or continued pain. These are not all the possible side effects. If you notice other effects not listed above, contact your healthcare provider immediately. In case of an allergic reaction, symptoms may include hives, difficulty breathing, and swelling of your face, lips, tongue, or throat. **Warnings and Precautions:** Allergy: Do not use if you are allergic to any of the ingredients. Pregnancy: If you are pregnant, you should seek the advice of your doctor or pharmacist before using this medicine. Breastfeeding: You can use this medicine if you are breastfeeding, but as with all medicines at this time, you should discuss it with your doctor first. Avoid Constipation: When you have hemorrhoids, you should try to avoid getting constipation as it can make the symptoms worse. Wash Hands: Wash your hands thoroughly before and after using the ointment. External Use Only: Apply only to the rectal and anal area. Symptoms Persistence: You must see a doctor if your symptoms do not go away within 14 days.	New	MHRA EMC	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
107.	Incepta Pharmaceuticals Ltd.;,Zirabo, Dhaka	Midazolam USP 0.5mg/0.1ml solution Nasal Spray	Midazolam USP 0.5mg/0.1ml	Therapeutic Class: Hypnotics, Sedatives & Anxiolytic Therapeutic Code : 057	Midazolam Nasal Spray is indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in patients with epilepsy 12 years of age and older.	**Contraindication:** Midazolam Nasal Spray is contraindicated in patients with: Known hypersensitivity to midazolam. Acute narrow-angle glaucoma. **Side Effect:** The most common adverse reactions (≥5% in any Midazolam treatment group) were somnolence, headache, nasal discomfort, throat irritation, and rhinorrhea **Warnings and Precautions:** CNS Depression From Concomitant Use With Other CNS Depressants or Moderate or Strong CYP3A4 Inhibitors: May cause an increased CNSdepressant effect when used with alcohol or other CNS depressants. Concomitant use with moderate or strong CYP3A4 inhibitors may result in prolonged sedation because of a decrease in plasma clearance of midazolam. ♣ Suicidal Behavior and Ideation: Antiepileptic drugs increase the risk of suicidal ideation and behavior. ♣ Impaired Cognitive Function: Midazolam is associated with a high incidence of partial or complete impairment of recall for the next several hours.	Midazolam 15mg Tablet, Midazolam 1gm/ml Injection	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।
108.	Incepta Pharmaceuticals Ltd.;,Zirabo, Dhaka	(Zinc Citrate Dihydrate 0.6224 g eqv. to Zinc 0.2 g + Ascorbic Acid (Powder) 2.00 g + Colecalciferol concentrate (oily form)/ Vitamin D3 oily 0.008 g eqv. to Vitamin D3 400 IU)/ 100 ml Syrup	(Zinc Citrate Dihydrate USP 0.6224 g eqv. to Zinc 0.2 g + Ascorbic Acid (Powder) BP/Ph. Eur. 2.00 g + Colecalciferol concentrate (oily form)/ Vitamin D3 oily BP/Ph. Eur. 0.008 g eqv. to Vitamin D3 400 IU)/ 100ml	Therapeutic Class: Vitamin & Combinations Therapeutic Code: 078	Zinc Syrup is used as a dietary supplement to treat zinc deficiency. It is also used to treat zinc deficiency anemia. Zinc is essential for the proper functioning of the nervous system, the immune system, and the brain. It plays a vital role in immunity, wound healing, acne prevention, and digestion. Furthermore, it provides essential nutrients and plays a vital role in the formation of red blood cells, which carry oxygen throughout the body.	**Contraindication:** Zinc Syrup, like other zinc supplements, is generally safe for most people when used as directed. However, it's important to note that taking too much zinc can lead to harmful side effects. These can include nausea, vomiting, diarrhea, metallic taste, kidney and stomach damage, and other adverse effects. Certain individuals should be cautious with zinc supplementation: People with a zinc allergy should not take zinc supplements. Individuals with kidney disease should be cautious as they may have trouble excreting zinc, potentially leading to an accumulation of zinc in the body. Zinc can interact with certain medications, including	New	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						certain antibiotics and diuretics. Therefore, individuals taking these medications should speak with a healthcare provider before starting zinc supplementation. **Side Effect:** Zinc Syrup, like other zinc supplements, is generally well-tolerated. However, it can cause some side effects, especially when taken in large doses. Here are some potential side effects: Gastrointestinal Issues: These can include nausea, vomiting, diarrhea, and stomach pain. Flu-like Symptoms: Exceeding 40 mg per day of elemental zinc can cause flu-like symptoms like fever, coughing, headache, and fatigue. Indigestion: Some people may experience indigestion. Headache: Zinc supplements can sometimes cause headaches. Copper Deficiency: When oral zinc is taken long-term and in high doses it can cause copper deficiency. People with low copper levels might experience neurological issues, such as numbness and weakness in the arms and legs. **Warnings and Precautions:** No data available				
109.	Incepta Pharmaceuticals Ltd.;,Zirabo, Dhaka	Zinc Gluconate 2.8g/100ml eqv.to elemental zinc 0.4g/100ml (20mg/5ml) syrup	Zinc Gluconate USP 2.8g/100ml eqv.to elemental zinc 0.4g/100ml (20mg/5ml)	Therapeutic Class: Metals, Salts, Minerals and Calcium Preparations Therapeutic Code: 062	Zinc Gluconate Syrup is used as a dietary supplement to treat zinc deficiency. It is also used to treat zinc deficiency anemia. Zinc is essential for the proper functioning of the nervous system, the immune system, and the brain. It plays a vital role in immunity, wound healing, acne prevention, and digestion. Furthermore, it provides essential nutrients and plays a vital role in the formation of red blood cells, which carry oxygen throughout the body.	**Contraindication:** Zinc Gluconate Syrup, like other zinc supplements, is generally safe for most people when used as directed. However, it's important to note that taking too much zinc can lead to harmful side effects. These can include nausea, vomiting, diarrhea, metallic taste, kidney and stomach damage, and other adverse effects. Certain individuals should be cautious with zinc supplementation: People with a zinc allergy should not take zinc supplements. Individuals with kidney disease should be cautious as they may have trouble excreting zinc, potentially leading to an accumulation of zinc in the body.	New	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						Zinc can interact with certain medications, including certain antibiotics and diuretics. Therefore, individuals taking these medications should speak with a healthcare provider before starting zinc supplementation. **Side Effect:** Zinc Gluconate Syrup, like other zinc supplements, is generally well-tolerated. However, it can cause some side effects, especially when taken in large doses. Here are some potential side effects: Gastrointestinal Issues: These can include nausea, vomiting, diarrhea, and stomach pain. Flu-like Symptoms: Exceeding 40 mg per day of elemental zinc can cause flu-like symptoms like fever, coughing, headache, and fatigue. Indigestion: Some people may experience indigestion. Headache: Zinc supplements can sometimes cause headaches. Copper Deficiency: When oral zinc is taken long-term and in high doses it can cause copper deficiency. People with low copper levels might experience neurological issues, such as numbness and weakness in the arms and legs. **Warnings and Precautions:** No data available				
110.	Navana Pharmaceuticals Limited	Calcium 610 mg, Magnesium 30 mg and Vitamin D3 400 IU chewable tablet	Calcium 610 mg, Magnesium 30 mg and Vitamin D3 400 IU	Vitamin & Combinations Therapeutic Code: 078	Treatment and prevention of hypocalcemia, magnesium deficiency, Osteoporosis, Osteomalacia and others bone related disease.	**Contraindications:** Hypercalcemia, Hypermagnesemia and hyperparathyroidism; Hypercalciuria and nephrolithiasis; Hypersensitivity to the component of this preparation; Severe renal insufficiencies; Concomitant digoxin therapy (requires careful monitoring of serum Calcium level).	New	***রেফারেন্স নাই***	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						Side Effects: Many people have no side effects or only have minor side effects. The common side effects include- Upset stomach or throwing up, constipation, and diarrhea. **Warnings and Precautions:** If patients are allergic to calcium/magnesium/vitamin D; any part of calcium/magnesium/vitamin D.				
111.	Navana Pharmaceuticals Limited	Calcium 610 mg, Magnesium 150 mg and Vitamin D3 0.1 mg tablet	Calcium 610 mg, Magnesium 30 mg and Vitamin D3 400 IU	Vitamin & Combinations Therapeutic Code: 078	Treatment and prevention of hypocalcemia, magnesium deficiency, Osteoporosis, Osteomalacia and others bone related disease.	**Contraindications:** Hypercalcemia, Hypermagnesemia and hyperparathyroidism; Hypercalciuria and nephrolithiasis; Hypersensitivity to the component of this preparation; Severe renal insufficiencies; Concomitant digoxin therapy (requires careful monitoring of serum Calcium level). **Side Effects:** Many people have no side effects or only have minor side effects. The common side effects include- Upset stomach or throwing up, constipation, and diarrhea. **Warnings and Precautions:** If patients are allergic to calcium/magnesium/vitamin D; any part of calcium/magnesium/vitamin D.	New	***রেফারেন্স নাই***	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।
112.	Navana Pharmaceuticals Limited EVEREST Pharmaceuticals Ltd. BSCIC I/A, Kanchpur, Narayanagnj, BANGLADESH	Fimasartan 60 mg Tablet	Fimasartan Potassium Trihydrate INN equivalent to Fimasartan Potassium 60 mg Tablet	Antihypertensive Therapeutic code: 022	Essential hypertension	Contraindications: Patients who are hypersensitive to any component of this product. Pregnant or nursing mothers. Patients with moderate to severe hepatic impairment. Patients with hepatobiliary obstruction. Patients with diabetes or renal impairment (GFR <60 mL/min) who are taking aliskiren. Patients with diabetic nephropathy who are taking angiotensin converting enzyme (ACE) inhibitors. Side Effects: Fimasartan can cause side effects such as dizziness, headache, abdominal pain, nausea, palpitation, fatigue, diarrhea, and coughing. Warnings and Precautions:	New	**রেফারেন্স নাই**	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						• Renal Impairment: Patients who are sensitive to drugs inhibiting the renin angiotensin system may experiencechanges in the renal function. • Hepatic Impairment: The pharmacokinetics of Fimasartan was compared in patients with mild and moderate hepatic impairment to healthy volunteers. A 20% decrease in AUC and 10% increase in Cmax were observed in patients with mild hepatic impairment. The AUC and Cmax in moderate hepatic impairment were increased by 6.5-fold and 5-fold, respectively. • Fimasartan potassium is not recommended to moderate to severe hepatic impairment.				
113.	Navana Pharmaceuticals Limited EVEREST Pharmaceuticals Ltd. BSCIC I/A, Kanchpur, Narayanagnj, BANGLADESH	Fimasartan 120 mg Tablet	Fimasartan Potassium Trihydrate INN equivalent to Fimasartan Potassium 120 mg Tablet	Antihypertensive Therapeutic Code: 022	Essential hypertension	Contraindications: Patients who are hypersensitive to any component of this product. Pregnant or nursing mothers. Patients with moderate to severe hepatic impairment. Patients with hepatobiliary obstruction. Patients with diabetes or renal impairment (GFR <60 mL/min) who are taking aliskiren. Patients with diabetic nephropathy who are taking angiotensin converting enzyme (ACE) inhibitors. Side Effects: Fimasartan can cause side effects such as dizziness, headache, abdominal pain, nausea, palpitation, fatigue, diarrhea, and coughing. Warnings and Precautions: • Renal Impairment: Patients who are sensitive to drugs inhibiting the renin angiotensin system may experiencechanges in the renal function. • Hepatic Impairment: The pharmacokinetics of Fimasartan was compared in patients with mild and moderate hepatic impairment to healthy volunteers. A 20% decrease in AUC and 10% increase in Cmax were observed in patients with mild hepatic impairment. The AUC and Cmax in moderate hepatic impairment were increased by 6.5-fold and 5-fold, respectively.	New	**রেফারেন্স নাই**	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						• Fimasartan potassium is not recommended to moderate to severe hepatic impairment.				
114.	Navana Pharmaceuticals Limited EVEREST Pharmaceuticals Ltd. BSCIC I/A, Kanchpur, Narayanagnj, BANGLADESH	Tosufloxacin Tosilate150mg Tablet	Tosufloxacin Tosilate INN 150mg Tablet	Antibiotic Therapeutic Code: 023	It is usually used to treat various infections such as skin/urinary tract/otolaryngologic infections.	Side Effects: The most commonly reported adverse reactions include rash, hives, itch, photosensitivity, fever, numbness, tremor and hallucination. Warnings and Precautions: • If patients have previously experienced any allergic reactions (itch, rash, etc.) to any medicines or foods. If you have convulsive disorders such as epilepsia, history of that or renal disorder. • If patients are pregnant or breastfeeding. If patients are taking any other medicinal products.	New	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।
115.	Navana Pharmaceuticals Limited EVEREST Pharmaceuticals Ltd. BSCIC I/A, Kanchpur, Narayanagnj, BANGLADESH	Fenbufen 300 mg Tablet	Fenbufen BP 300 mg Tablet	NSAID Therapeutic Code: 050	It is used primarily to treat inflammation in osteoarthritis, ankylosing spondylitis, and tendinitis. It can also be used to relieve backaches, sprains, and fractures.	Contraindications: Hypersensitivity to propionic acid anti-inflammatory drugs or aspirin. Side Effects: Fenbufen is well tolerated by most patients. Gastro-intestinal symptoms, and occasionally skin rash are the most commonly reported. Warnings and Precautions: • If you are pregnant, or trying to become pregnant or breast-feeding. • If you have ever had a bad reaction, such as itching or breathing problems (wheezing or asthma) or stomach pains, after taking aspirin, Ibuprofen or other medicines used to treat painful conditions affecting the joints and muscles. • If you have or have ever had a stomach ulcer. • If you have liver, heart or kidney problems. • If you are taking warfarin (to prevent blood clots), certain antibiotics called quinolones, or lithium. Also if you are taking any drugs to lower your blood sugar (hypoglycaemics or sulphonylureas) aspirin or aspirin-like drugs or methotrexate. If you are taking any other medicines or tablets including those you have bought without a prescription.	New	**রেফারেন্স নাই**	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
116.	Navana Pharmaceuticals Limited EVEREST Pharmaceuticals Ltd. BSCIC I/A, Kanchpur, Narayanagnj, BANGLADESH	Fenbufen	Fenbufen BP 450 mg Tablet	NSAID Therapeutic Code: 050	It is used primarily to treat inflammation in osteoarthritis, ankylosing spondylitis, and tendinitis. It can also be used to relieve backaches, sprains, and fractures.	Contraindications: Hypersensitivity to propionic acid anti-inflammatory drugs or aspirin. Side Effects: Fenbufen is well tolerated by most patients. Gastro-intestinal symptoms, and occasionally skin rash are the most commonly reported. Warnings and Precautions: • If you are pregnant, or trying to become pregnant or breast-feeding. • If you have ever had a bad reaction, such as itching or breathing problems (wheezing or asthma) or stomach pains, after taking aspirin, Ibuprofen or other medicines used to treat painful conditions affecting the joints and muscles. • If you have or have ever had a stomach ulcer. • If you have liver, heart or kidney problems. • If you are taking warfarin (to prevent blood clots), certain antibiotics called quinolones, or lithium. Also if you are taking any drugs to lower your blood sugar (hypoglycaemics or sulphonylureas) aspirin or aspirin-like drugs or methotrexate. If you are taking any other medicines or tablets including those you have bought without a prescription.	New	**রেফারেন্স নাই**	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।
117.	Navana Pharmaceuticals Limited EVEREST Pharmaceuticals Ltd. BSCIC I/A, Kanchpur, Narayanagnj, Square Pharmaceuticals PLC, Kaliakoir, Gazipur	Gepotidacin 1500 mg Tablet	Gepotidacin INN 1500 mg Tablet	Antibiotic Therapeutic Code: 023	A drug of choice in the treatment of uncomplicated UTI (Urinary tract infection).	Contraindications: Gepotidacin is contraindicated in patients with a history of hypersensitivity to any ingredient of this drug. Side Effects: Diarrhoea was the most common (16% of subjects), followed by nausea (9%). Nausea, diarrhea, and vomiting were the most common mild-to-moderate adverse events associated with the 10 days of gepotidacin treatment. Warnings and Precautions: Use during Pregnancy, Delivery, or Lactation: The safety data on pregnancy has not been established. Use in the Elderly: Special care is required in elderly patients to minimize the risk of gastrointestinal disorders, because these patients may be physiologically more sensitive to this drug than younger patients.	New	**রেফারেন্স নাই**	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
118.	Navana Pharmaceuticals Limited	Albaconazole 400 mg Tablet	Albaconazole 400 mg Tablet	Antifungal Therapeutic Code: 022	Albaconazole is a triazole antifungal agent used as a neuroprotectant. The compound has shown very potent activity against species of Candida, Cryptococcus and Aspergillus.	The common side-effects noticed after Albaconazole use is headache, myalgia, abdominal pain, nausea and vomiting. Hypersensitivity was seen in less than 1% of patients. This drug should not be used during pregnancy. Albaconazole can be prescribed for the patients who are in 18 years or above.	NEW	**রেফারেন্স নাই**	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।
119.	Navana Pharmaceuticals Limited	Bilastine 0.6% Ophthalmic Solution	Bilastin INN 0.6%	Antihistamine Therapeutic Code: 021	Treatment of ocular signs and symptoms of seasonal and perennial allergic conjunctivitis.	**Contraindications:** Hypersensitivity to the active substance or to any of the excipients **Side Effects:** In clinical studies involving bilastine 6 mg/mL eye drops, solution, 682 patients received one dose per day up to 8 weeks. Approximately 9.7% of patients can be expected to experience adverse reactions associated with the use of bilastine 6 mg/ml eye drops, solution. No serious or severe adverse event was reported. **Warnings and Precautions:** Bilastine is an antiallergic/ antihistaminic active substance and, although administered topically, it is absorbed systemically. If signs of serious reactions or hypersensitivity occur, treatment should be discontinued. After dropping Drynol antiallergic eye drops into the conjunctival sac of the eye, the visual acuity can deteriorate for a few minutes due to the formation of streaks. Reactions at administration site: If adverse events at the administration site, such as eye irritation, pain, redness or change in vision occur or if the patient´s condition is worsened, discontinuation of the treatment should be considered. Paediatric population Efficacy and safety of bilastine eye drops in children and adolescents have not been established, therefore this medicinal product should not be used in these age groups.	New	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।
120.	Nuvista Pharma Ltd	Calcium L-Methyl Folate 7.5mg Tablet	Calcium L-Methyl Folate USP 7.5mg Tablet	Drug used in anemia Therapeutic	• Folate-deficient Megaloblastic anemia. • Prophylaxis of megaloblast-tic anemia in pregnancy.	**Contraindication:** • **Undiagnosed megaloblastic anemia** • **Pernicious** • **Aplastic or normocytic anemias**	New	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
				Class: 045	• Prophylaxis of neural tube defect in pregnancy. • Malabsorption syndromes. • Antiepileptic therapy.	**Side Effects:** • Upset stomach or throwing up. • Belly pain. • Not hungry. • Diarrhea. • Feeling sleepy. • Headache. Pimples (acne).				
121.	Nuvista Pharma Ltd	Calcium L-Methyl Folate 15mg Tablet	Calcium L-Methyl Folate USP 15mg Tablet	Drug used in anemia Therapeutic Class: 045	• Folate-deficient Megaloblastic anemia. • Prophylaxis of megaloblastic anemia in pregnancy. • Prophylaxis of neural tube defect in pregnancy. • Malabsorption syndromes. • Antiepileptic therapy.	**Contraindication:** • **Undiagnosed megaloblastic anemia** • **Pernicious** • **Aplastic or normocytic anemias** **Side Effects:** • Upset stomach or throwing up. • Belly pain. • Not hungry. • Diarrhea. • Feeling sleepy. • Headache. Pimples (acne).	New	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।
122.	Nuvista Pharma Ltd	Calcium L-Methyl Folate 5mg Tablet	Calcium L-Methyl Folate USP 5mg Tablet	Drug used in anemia Therapeutic Class: 045	Folate-deficient Megaloblastic anemia. Prophylaxis of megaloblastic anemia in pregnancy. Prophylaxis of neural tube defect in pregnancy. Malabsorption syndromes. Antiepileptic therapy.	**Contraindication:** Undiagnosed megaloblastic anemia, Pernicious, Aplastic or normocytic anemias **Side Effects:** Upset stomach or throwing up, Belly pain, Not hungry, Diarrhea, Feeling sleepy, Headache, Pimples (acne).	New	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।
123.	Nuvista Pharma Ltd.	Ketoconazole 2% Lotion	Ketoconazole USP 2%	Antifungal Therapeutic Code: 071	It is an azole antifungal indicated for topical treatment of seborrheic dermatitis in immunocompetent adults and children 12 years of age and older.	**Contraindication:** None **Side Effects:**	2% Cream approved in DCC-189	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						• Acne. • Bleeding from sore in the mouth. • Blistering, crusting, irritation, itching, or reddening of the skin. • Burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings. • Cracked, dry, or scaly skin. • Discoloration of the fingernails or toenails. • Eye dryness, irritation, or swelling.	2% Shampoo approved in DCC-238			
124.	Opsonin Pharma Limited, Rupatali, Barishal.	Finasteride 250mg/100ml Solution	Finasteride USP 250mg/100ml Solution	Skin & Mucous Membrane Preparation Therapeutic Code: **071**	Androgenic Alopecia	**Contraindication:** Finasteride is contraindicated in patients with a known sensitivity or allergy to finasteride or any of its components **Side Effects:** Scalp irritation, Headache, Dizziness, Sexual dysfunction, Breast tenderness or enlargement. **Precautions & Warning:** Finasteride can be absorbed through the skin and cause birth defects in male babies.	New	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।
125.	Opsonin Pharma Limited, Rupatali, Barishal.	Tranexamic Acid 5.0% Cream	Tranexamic Acid BP 5gm/100 gm	Skin & Mucous Membrane Preparation Therapeutic Code: **071**	Treatment of Post inflammatory Hyperpigmentation Due to Acne Vulgaris and melasma.	**Contraindication:** Active thromboembolic disease, such as deep vein thrombosis, pulmonary embolism and cerebral thrombosis. Subarachnoid hemorrhage. **Side Effects:** Dose-dependent, gastrointestinal discomfort is the most commonly reported undesirable effect, but it is usually of mild and temporary in nature. Allergic skin reactions have been reported as an uncommon undesirable effect. Hypotension may occur after fast injection. **Precautions & Warning:** Patients with irregular menstrual bleeding, patients with a high risk of thrombosis (a previous thromboembolic event and a family history of thromboembolic disease) should use it only if there is a strong medical indication and under strict medical supervision. Patients with disseminated intravascular coagulation (DIC), who require treatment with it must be under the strict supervision.	250mg & 500mg Tablet/Capsule 250 mg/5 ml Injection 500 mg/5 ml Injection	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।
126.	Opsonin Pharma Limited, Rupatali,	Cefcapene Pivoxil Hydrochloride Hydrate 200 mg Tablet	Cefcapene Pivoxil Hydrochloride Hydrate INN 200mg	Anti-infective Therapeutic	It is indicated for the treatment of Cystitis, pyelonephritis, Urethritis, cervicitis. It is also indicated in superficial skin infection,	**Contraindications:** It is contraindicated in patients with known allergy to the cephalosporin class of antibiotics or any of its components.	New	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
	Barishal Square Pharmaceuticals PLC, Kaliakoir, Gazipur			Code: 023	deep skin infection, lymphangitis, lymphadentitis, and chronic pyoderma.	**Side effects:** Common side effects are includes: diarrhea, headache, nausea, vomiting, stomach pain or upset, constipation, belching, dry mouth, appetite changes & dizziness. **Precautions & warnings:** Hepatitis fulminant, hepatic function disorder, jaundice: Severe hepatitis such as hepatitis fulminant, hepatic function disorder with increase in AST (GOT), ALT (GPT) and Al-P etc., jaundice may occur. Patients should be closely observed by periodically conducting laboratory tests. If any abnormality is observed, the treatment should be discontinued and appropriate measures should be taken. Before therapy with Cefcapene Pivoxil is instituted, careful inquiry should be made to determine whether the patient has had previous hypersensitivity reactions to cefcapene pivoxil, other cephalosporin's, penicillin's, or other drugs. If cefcapene pivoxil is to be given to penicillin sensitive patients, caution should be exercised because cross-hypersensitivity among β-lactam antibiotics may occur penicillin allergy. If an allergic reaction, including anaphylaxis, to cefcapene pivoxil occurs, the drug should be discontinued. Serious acute hypersensitivity reactions may require treatment with epinephrine and other emergency measures.				
127.	Opsonin Pharma Limited, Rupatali, Barishal Square Pharmaceuticals PLC, Kaliakoir, Gazipur	Cefcapene Pivoxil Hydrochloride Hydrate 75mg Tablet	Cefcapene Pivoxil Hydrochloride Hydrate INN 75 mg	Anti-infective Therapeutic Code: 023	It is indicated for the treatment of Cystitis, pyelonephritis, Urethritis, cervicitis. It is also indicated in superficial skin infection, deep skin infection, lymphangitis, lymphadentitis, and chronic pyoderma.	**Contraindications:** It is contraindicated in patients with known allergy to the cephalosporin class of antibiotics or any of its components. **Side effects:** Common side effects are includes: diarrhea, headache, nausea, vomiting, stomach pain or upset, constipation, belching, dry mouth, appetite changes & dizziness. **Precautions & warnings:** Hepatitis fulminant, hepatic function disorder, jaundice: Severe hepatitis such as hepatitis fulminant, hepatic function disorder with increase in AST (GOT), ALT (GPT) and Al-P etc., jaundice may occur. Patients should be closely observed by periodically conducting laboratory tests. If any abnormality is observed, the treatment should be	New	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						discontinued and appropriate measures should be taken. Before therapy with Cefcapene Pivoxil is instituted, careful inquiry should be made to determine whether the patient has had previous hypersensitivity reactions to cefcapene pivoxil, other cephalosporin's, penicillin's, or other drugs. If cefcapene pivoxil is to be given to penicillin sensitive patients, caution should be exercised because cross-hypersensitivity among β-lactam antibiotics may occur penicillin allergy. If an allergic reaction, including anaphylaxis, to cefcapene pivoxil occurs, the drug should be discontinued. Serious acute hypersensitivity reactions may require treatment with epinephrine and other emergency measures.				
128.	Opsonin Pharma Limited, Rupatali, Barishal.	Ferrous Bisglycinate INN 311.12 mg Capsule	Ferrous bisglycinate INN 311.12 mg	Vitamins & combinations Therapeutic Code: 078	Ferrous Bisglycinate is used in the treatment of iron deficiency anemia and anemia due to chronic kidney disease.	**Contraindication:** Hemochromatosis and hemosiderosis are contraindicated to iron therapy. Side Effects: Constipation, diarrhea, stomach cramps, or upset stomach may occur. These effects are usually temporary and may disappear as your body adjusts to this medication. If any of these effects last or get worse, contact your doctor or pharmacist promptly. Precaution & warnings: Before taking this medication, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.	New Molecule	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।
129.	Opsonin Pharma Limited, Rupatali, Barishal	Iron protein succinylate 40mg/15 ml Oral Solution	Iron protein succinylate INN 40mg/15 ml	Drug used in anemia and other blood disorder Therapeutic Code: 045	Treatment of iron deficiency and iron deficiency anemia: latent or overt iron deficiency anemia in children and adults, secondary to chronic blood loss, pregnancy; breast-feeding.	**Contraindications:** Hypersensitivity to the active substance or to any of the excipients. Haemosiderosis, haemochromatosis. Aplastic and haemolytic anemias, anemias due to disturbances of iron utilization (sideroachrestic anemias). Chronic pancreatitis and liver cirrhosis secondary to haemochromatosis. **Side effects**: Very rarely gastrointestinal disorders such as diarrhoea, stipsis, nausea, epigastric pain may occur; these adverse reactions can be abated by dose reduction or treatment withdrawal. Iron products may turn the colour of stools into black or dark grey. **Precautions & warnings:** No particular warnings are required about risks of tolerance or addiction. The treatment should not exceed 6 months, unless in case of persisting bleeding, menorrhagia or pregnancy. Any disease possibly underlying iron deficiency or iron deficiency anemia must be ascertained and properly treated. As the product contains milk proteins, it must be used with	New	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						caution in patients suffering from milk-protein intolerance, who may have allergic reactions.				
130.	Opsonin Pharma Limited, Rupatali, Barisal	Quetiapine 12.5 mg Tablet	Quetiapine Fumarate USP 12.5 mg	Antipsychotic Therapeutic Code: 028	Quetiapine is an atypical antipsychotic indicated for the treatment of: 1. Schizophrenia 2. Bipolar I disorder manic episodes and 3. Bipolar disorder, depressive episodes	Contraindication: Known hypersensitivity to Quetiapine or any components in the formulation Side effects: The more common side effects of the immediate-release tablets can include: Dry mouth, dizziness, pain in your stomach area, constipation, nausea, vomiting, weight gain, increased appetite etc. Precautions & Warnings: Quetiapine should be used with caution in patients with cardiovascular disease, cerebrovascular disease, seizure, tardive dyskinesia and neuroleptic malignant syndrome. In such an event dose reduction or dose discontinuation of Quetiapine should be considered.	25mg 50mg 100mg 200mg Tablet	***রেফারেন্স নাই***	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।
131.	Opsonin Pharma Limited, Rupatali, Barishal	Domperidone BP 30mg + Esomeprazole USP 20 mg Capsule	Domperidone BP 30 mg Sustained Release Pellets + Esomeprazole USP 20 mg Enteric Coated Pellets	Unclassified Agents Code: 075	Dyspepsia, GERD, Nausea associated with acid peptic disorders, post operative nausea, Duodenal ulcer, gastric ulcer, esophagitis & Zollinger Ellison Syndrome	**Contraindications:** ESOMEPRAZOLE + DOMPERIDONE is contraindicated in patients with known hypersensitivity to Esomeprazole or other substituted benzimidazoles or to Domperidone or other dopamine antagonists. ESOMEPRAZOLE + DOMPERIDONE should not be used whenever stimulation of gastrointestinal motility might be dangerous such as in the presence of gastrointestinal hemorrhage, mechanical obstruction, or perforation. ESOMEPRAZOLE + DOMPERIDONE is contraindicated in patients with prolactinoma (a prolactin-releasing pituitary tumor). **Side effects:** Adverse effects with Esomeprazole are mild to moderate in intensity and include malaise, diarrhea, nausea, skin eruptions, headache &	Esomeprazole 20 mg Capsule, Domperidone 10 mg Tablet	***রেফারেন্স নাই***	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						dizziness, etc **Precautions & warnings**: Patients should be cautioned that Esomeprazole + Domperidone capsules should not be chewed or crushed, but should be swallowed whole. Co-administration of this combination with atazanavir, ketoconazole, erythromycin or other potent CYP3A4 inhibitors are not recommended.				
132.	Opsonin Pharma Limited, Rupatali, Barishal	Fexofenadine Hydrochloride USP 120 mg + Montelukast USP 10 mg Tablet	Fexofenadine Hydrochloride USP 120 mg + Montelukast USP 10 mg Tablet	Antihistamine Therapeutic Code: 021	a combination medicine used in the treatment of allergy symptoms such as runny nose, stuffy nose, sneezing, watery eyes, and congestion or stuffiness	Most side effects do not require any medical attention and disappear as body adjusts to the medicine. Common side effects • Nausea • Flu-like symptoms • Headache Drowsiness	New	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।
133.	Opsonin Pharma Limited, Rupatali, Barishal	Dexrabeprazole Sodium 5 mg Tablet	Dexrabeprazole Sodium INN 5 mg	Proton Pump Inhibitor Code: 067	Gastro-esophageal reflux disease, Healing of gastric ulcer, Healing of duodenal ulcer, Ulcerative Colitis.	**Contraindications:** Dexrabeprazole is contraindicated in patients with known hypersensitivity to Dexrabeprazole, or to any component of the formulation. **Side effects:** Gastrointestinal: Nausea, vomiting, stomach pain, diarrhea and gas. **Precautions & warnings:** 1. Caution required in administration to patient with severe hepatic dysfunction. 2. Gastric or esophageal malignancy should be excluded Several published observational studies suggest that proton pump inhibitor (PPI) therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist, or spine. The risk of fracture was increased in patients who received high dose, defined as multiple daily doses, and long-term PPI therapy (a year or longer).	New	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
134.	Opsonin Pharma Limited, Rupatali, Barishal	Dexrabeprazole Sodium 10 mg Tablet	Dexrabeprazole Sodium INN 10mg	Proton Pump Inhibitor Code: 067	Gastro-esophageal reflux disease, Healing of gastric ulcer, Healing of duodenal ulcer, Ulcerative Colitis.	**Contraindications:** Dexrabeprazole is contraindicated in patients with known hypersensitivity to Dexrabeprazole, or to any component of the formulation. **Side effects:** Gastrointestinal: Nausea, vomiting, stomach pain, diarrhea and gas. **Precautions & warnings:** 1. Caution required in administration to patient with severe hepatic dysfunction. 2. Gastric or esophageal malignancy should be excluded Several published observational studies suggest that proton pump inhibitor (PPI) therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist, or spine. The risk of fracture was increased in patients who received high dose, defined as multiple daily doses, and long-term PPI therapy (a year or longer).	New	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।
135.	Opsonin Pharma Limited, Rupatali, Barishal	Domperidone BP 30 mg + Esomeprazole USP 20 mg Tablet	Domperidone BP 30 mg Sustained Release Pellets + Esomeprazole USP 20 mg Enteric Coated Pellets	Unclassified Agents Code: 075	Dyspepsia, GERD, Nausea associated with acid peptic disorders, post operative nausea, Duodenal ulcer, gastric ulcer, esophagitis & Zollinger Ellison Syndrome	**Contraindications:** ESOMEPRAZOLE + DOMPERIDONE is contraindicated in patients with known hypersensitivity to Esomeprazole or other substituted benzimidazoles or to Domperidone or other dopamine antagonists. ESOMEPRAZOLE + DOMPERIDONE should not be used whenever stimulation of gastrointestinal motility might be dangerous such as in the presence of gastrointestinal hemorrhage, mechanical obstruction, or perforation. ESOMEPRAZOLE + DOMPERIDONE is contraindicated in patients with prolactinoma (a prolactin releasing pituitary tumor). **Side effects:** Adverse effects with Esomeprazole are	Esomeprazole 20 mg Tablet, Domperidone 10 mg Tablet	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						mild to moderate in intensity and include malaise, diarrhea, nausea, skin eruptions, headache & dizziness, etc **Precautions & warnings**: Patients should be cautioned that Esomeprazole + Domperidone capsules should not be chewed or crushed, but should be swallowed whole. Co-administration of this combination with atazanavir, ketoconazole, erythromycin or other potent CYP3A4 inhibitors are not recommended.				
136.	Opsonin Pharma Limited, Rupatali, Barishal	Domperidone BP 30 mg + Esomeprazole USP 40 mg Tablet	Domperidone BP 30 mg Sustained Release Pellets + Esomeprazole USP 40 mg Enteric Coated Pellets	Unclassified Agents Code: 075	Dyspepsia, GERD, Nausea associated with acid peptic disorders, post operative nausea, Duodenal ulcer, gastric ulcer, esophagitis & Zollinger Ellison Syndrome	Contraindications: ESOMEPRAZOLE + DOMPERIDONE is contraindicated in patients with known hypersensitivity to Esomeprazole or other substituted benzimidazoles or to Domperidone or other dopamine antagonists. ESOMEPRAZOLE + DOMPERIDONE should not be used whenever stimulation of gastrointestinal motility might be dangerous such as in the presence of gastrointestinal hemorrhage, mechanical obstruction, or perforation. ESOMEPRAZOLE + DOMPERIDONE is contraindicated in patients with prolactinoma (a prolactin releasing pituitary tumor). **Side effects:** Adverse effects with Esomeprazole are mild to moderate in intensity and include malaise, diarrhea, nausea, skin eruptions, headache & dizziness, etc **Precautions & warnings**: Patients should be cautioned that Esomeprazole + Domperidone capsules should not be chewed or crushed, but should be swallowed whole. Co-administration of this combination with atazanavir, ketoconazole, erythromycin or other	Esomeprazole 40 mg Tablet, Domperidone 10 mg Tablet	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						potent CYP3A4 inhibitors are not recommended.				
137.	Opsonin Pharma Limited, Rupatali, Barishal	Domperidone BP 30 mg + Esomeprazole USP 40 mg Capsule	Domperidone BP 30 mg Sustained Release Pellets + Esomeprazole USP 40 mg Enteric Coated Pellets	Unclassified Agents Code: 075	Dyspepsia, GERD, Nausea associated with acid peptic disorders, post operative nausea, Duodenal ulcer, gastric ulcer, esophagitis & Zollinger Ellison Syndrome	**Contraindications:** ESOMEPRAZOLE + DOMPERIDONE is contraindicated in patients with known hypersensitivity to Esomeprazole or other substituted benzimidazoles or to Domperidone or other dopamine antagonists. ESOMEPRAZOLE + DOMPERIDONE should not be used whenever stimulation of gastrointestinal motility might be dangerous such as in the presence of gastrointestinal hemorrhage, mechanical obstruction, or perforation. ESOMEPRAZOLE + DOMPERIDONE is contraindicated in patients with prolactinoma (a prolactin releasing pituitary tumor). **Side effects:** Adverse effects with Esomeprazole are mild to moderate in intensity and include malaise, diarrhea, nausea, skin eruptions, headache & dizziness, etc **Precautions & warnings**: Patients should be cautioned that Esomeprazole + Domperidone capsules should not be chewed or crushed, but should be swallowed whole. Co-administration of this combination with atazanavir, ketoconazole, erythromycin or other potent CYP3A4 inhibitors are not recommended.	Esomeprazole 40 mg Capsule, Domperidone 10 mg Tablet	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।
138.	Opsonin Pharma Limited, Rupatali, Barishal	Rabeprazole Sodium BP 20 mg + Domperidone BP 30 mg Capsule	Rabeprazole Sodium BP 20 mg + Domperidone BP 30 mg	Unclassified Agents Code: 075	GERD, Heart Burn & Hyperacidity, Reflux esophagitis, Regurgitation & flatulence, Gastric & Peptic Ulcer.	**Contraindications:** Contraindicated in patients with known hypersensitivity to Rabeprazole, Domperidone or substituted benzimidazole or to any excipient used in the formulation. It is also contraindicated in patients with hepatic and/or renal impairment, prolactin-releasing pituitary tumour (prolactinoma). It should not be used when stimulation of the gastric motility could be harmful, like gastrointestinal hemorrhage, mechanical obstruction or perforation. **Side effects:** Generally well tolerated. Most common side effects are somnolence, dizziness, dry mouth and blurring of vision malaise, diarrhea, nausea, skin eruptions, headache and dizziness. Domperidone has	Rabeprazole BP 20 mg Capsule Domperidone BP 30 mg Tablet	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						been found to be associated with increased serum prolactin, which may be associated with galactorrhea, less frequently gynecomastia, breast enlargement and soreness. **Precaution & Warning:** Patients should be cautioned that Rabeprazole + Domperidone capsules should not be chewed or crushed, but should be swallowed whole. Co-administration of this combination with Atazanavir, ketoconazole, erythromycin or other potent CYP3A4 inhibitors are not recommended.				
139.	Opsonin Pharma Limited, Rupatali, Barishal	Ibuprofen BP 250 mg + Paracetamol BP 500 mg Tablet	Ibuprofen BP 250 mg + Paracetamol BP 500 mg	Analgesics & Antipyretics Code: 006	Mild to moderate pain associated with migraine, headache, backache, period pain, dental pain, rheumatic and muscular pain, pain of non-serious arthritis, cold and flu symptoms, sore throat and fever.	**Contraindication:** In patients with a known hypersensitivity to ibuprofen, paracetamol or any other excipients. Patients with severe hepatic failure, severe renal failure or severe heart failure. In concomitant use with other NSAID containing products, including cyclo-oxygenase-2 (COX-2) specific inhibitors and doses of acetylsalicylic acid above 75 mg daily – increased risk of adverse reactions. **Side Effect:** Clinical trials with this product have not indicated any other undesirable effects other than those for ibuprofen or paracetamol alone. **Precautions & warnings:** Caution is required in patients with certain conditions: Respiratory disorders, Cardiovascular, renal and hepatic impairment, Cardiovascular and cerebrovascular effects, Gastrointestinal bleeding, ulceration and perforation.	Paracetamol 500 mg Tablet Ibuprofen 200mg & 400mg Tablet	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।
140.	Opsonin Pharma Limited, Rupatali, Barishal.	Pristinamycin 500mg Tablet	Pristinamycin INN 500 mg	Antiinfective Therapeutic Code: 023	Acute maxillary sinusitis, acute exacerbation of chronic bronchitis, a mild to moderate community-acquired pneumonia, skin and soft tissue infections	**Contraindications:** Hypersensitivity to Pristinamycin or to any other streptogramins. **Side effects:** Vomiting, diarrhoea, sense of abdominal fullness, urticaria, anaphylactic shock **Precautions & warnings:** Increase in blood concentrations of the immunosuppressant due to inhibition of the hepatic metabolism.	New	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।
141.	Opsonin Pharma Limited, Rupatali, Barishal.	Domperidone BP 10 mg + Esomeprazole USP 20 mg Tablet	Domperidone BP 10 mg + Esomeprazole USP 20 mg Enteric Coated Pellets	Unclassified Agents Code: 075	Dyspepsia, GERD, Nausea associated with acid peptic disorders, post operative nausea, Duodenal ulcer, gastric ulcer, esophagitis & Zollinger Ellison Syndrome	**Contraindications:** ESOMEPRAZOLE + DOMPERIDONE is contraindicated in patients with known hypersensitivity to Esomeprazole or other substituted benzimidazoles or to Domperidone or other dopamine antagonists.	Esomeprazole 20 mg Tablet, Domperidone 10 mg Tablet	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						ESOMEPRAZOLE + DOMPERIDONE should not be used whenever stimulation of gastrointestinal motility might be dangerous such as in the presence of gastrointestinal hemorrhage, mechanical obstruction, or perforation. ESOMEPRAZOLE + DOMPERIDONE is contraindicated in patients with prolactinoma (a prolactin releasing pituitary tumor). **Side effects:** Adverse effects with Esomeprazole are mild to moderate in intensity and include malaise, diarrhea, nausea, skin eruptions, headache & dizziness, etc **Precautions & warnings**: Patients should be cautioned that Esomeprazole + Domperidone capsules should not be chewed or crushed, but should be swallowed whole. Co-administration of this combination with atazanavir, ketoconazole, erythromycin or other potent CYP3A4 inhibitors are not recommended.				
142.	Orion Pharma Ltd., D/28/2, Sumilpara, Siddhirganj, Narayanganj NIPRO JMI Pharma Ltd, Rajandrapur, Chaddagram, Cumilla	Clopidogrel 150mg Tablet	Clopidogrel INN 150mg	Antiplatelet Therapeutic Code: 026	Acute Coronary Syndrome (ACS) and Recent MI, Recent Stroke, or Established Peripheral Arterial Disease.	**Contraindication:** Active Bleeding: Clopidogrel is contraindicated in patients with active pathological bleeding such as peptic ulcer or intracranial hemorrhage. Hypersensitivity: Clopidogrel is contraindicated in patients with hypersensitivity (e.g., anaphylaxis) to Clopidogrel or any component of the product. **Side effects:** A blood clotting problem called Thrombotic Thrombocytopenic Purpura (TTP). Other side effects are nausea, vomiting, diarrhea, headache, etc.	75 mg Tablet	***রেফারেন্স নাই***	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।
143.	Pharmasia Limited, Bhawal, Mirzapur, Gazipur	Polycarbofil 500 Tablet	Calcium Polycarbophil USP 625.00 mg eq. to 500mg Polycarbofil	Laxatives	Constipation, IBS-C, IBS-D	**Contraindication:** Should not use polycarbophil if you are allergic to polycarbophil or to mineral oil, sodium laurel sulfate, or povidone (such as Betadine). **Side-effects:**	New	**রেফারেন্স নাই**	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						▪ Allergic reactions: skin rash, itching, hives, swelling of the face, lips, tongue, or throat ▪ Choking: chest pain, trouble swallowing or breathing, vomiting Side effects that usually do not require medical ▪ Bloating ▪ Diarrhea ▪ Gas ▪ Nausea ▪ Stomach pain				
144.	Pharmasia Limited, Bhawal, Mirzapur, Gazipur Orion Pharma Ltd. D/28/2, Sumilpara, Siddhirganj, Narayanganj NIPRO JMI Pharma Ltd.	Zaltoprofen 80 mg Tablet	Zaltoprofen INN 80mg	Non-Steroidal Anti-Inflammatory Drug (NSAID)	It is indicated for its analgesic and anti-inflammatory activities against following diseases and symptoms- Rheumatoid arthritis: Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by joint swelling, joint tenderness, and destruction of synovial joints, leading to severe disability and premature mortality. Zaltoprofen is highly safe an deficient drug for the treatment of chronic rheumatoid arthritis. Osteoarthritis: Knee osteoarthritis is a degenerative disease of the knee joint. It is more common in people older than 40 years. Women have greater chance to be affected. Some of the signs and symptoms associated with knee osteoarthritis include: Pain, Stiffness, Decreasing range of motion, Muscle weakness and atrophy (particularly of quadriceps femoris, muscle on front of thigh) due to inactivity or stiffness, Crepitus, Effusion-increase in quantity of synovial fluid leading to swelling. Zaltoprofen shows excellent effect in treatment of knee osteoarthritis by	Contraindication: • Previous history of hypersensitivity to any of the components of the medicine. • Active peptic ulcer or GI bleeding or history of peptic ulcer disease. • Severe blood abnormalities (dysemia). • Severe hepatic impairment. • Severe renal impairment. • Severe heart failure or cardiac insufficiency. • Chronic ulcerative colitis or Crohn's disease • Patients who have experienced asthma, urticaria, or other allergic type reactions aftertaking aspirin or other NSAIDs. Side-effects: Major side effects such as rashes, skin irritation, stomach discomfort, stomachache, the digestive symptoms, such as heart pain, diarrhea, and heartburn, shock as a serious side effect, anaphylactic-like symptoms, acute renal failure, nephrotic syndrome, hepatic dysfunction, digestive crushing indemnity, small intestine / colon ulcer, hemorrhagic colitis, atherosclerosis, leukopenia, thrombocytopenia may occur. Also, as a serious side effect of drugs, skin mucosal ocular syndrome (Stevens-Johnson syndrome), toxic epidermal necrosis (Lyell syndrome), hemolytic anemia, aplastic anemia have been reported to appear.	New	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
					inhibiting B2 receptor. Musculoskeletal joint disorder: Musculoskeletal pain affects the bones, muscles, ligaments, tendons, and nerves. It can be acute (having a rapid onset with severe symptoms) or chronic (long-lasting). Musculoskeletal pain can be localized in one area, or widespread. It is most often caused by an injury to the bones, joints, muscles, tendons, ligaments, or nerves. This can be caused by jerking movements, car accidents, falls, fractures, sprains, dislocations, and direct blows to the muscle. Limited shoulder movement in breast cancer : The painful disorders that contribute to limited shoulder movement in breast cancer survivors have various etiologies, including rotator cuff tendonitis, adhesive capsulitis, axillary tightness, lymphatic cording, and phlebitis. Unless the pain is resolved, PT will not be effective in extending the joint range of motion (ROM). After taking zaltoprofen, the active shoulder movements in each direction were improved without ROM exercises. Dental inflammation: Dental inflammation: Usually due to inflammation of the tooth pulp which contains blood vessels and nerve fibers which is responsible for pain and inflammation. Pulpitis is the medical symptom in which the dental pulp becomes inflamed. It is also indicated for its analgesic and anti-inflammatory activities after surgery, injury and after tooth extraction.	Serious side effects (Frequency unknown) • Shock, anaphylactoid symptoms: Shock, anaphylactoid-like symptoms may occur, cold sweat, chills, rash, itching, flushing, facial edema, measles, etc. appear. If so, discontinue administration and take appropriate measures. • Acute renal failure, nephrotic syndrome: Acute renal failure, nephrotic syndrome and other kidney problems, blood creatinine rise, oliguria, edema, proteinuria may occur, so observe thoroughly. If abnormalities such as hematoses are observed, discontinue administration and take appropriate measures. • Liver function disorder: AST (GOT) elevation, ALT (GPT) elevation, Al - P elevation, γ - GTP elevation may occur, so observe thoroughly and if abnormality is found take appropriate measures, such as discontinue administration. • Peptic ulcer cancer, small intestine / colon ulcer cancer, hemorrhagic colitis: digestive ulcer and small intestine / colon ulcer (which may accompany bleeding and perforation), hemorrhagic colitis may appear, observe adequately, if abnormalities are observed discontinue administration and take appropriate measures. • Leukocytopenia, thrombocytopenia: Granulocytosis, leucopenia, thrombocytopenia may occur, so observe thoroughly, regular blood tests and abnormalities are observed. If so, discontinue administration and take appropriate measures. • Skin mucosa ocular syndrome, toxic epidermal necrosis: It is reported that other non-steroidal anti-inflammatory analgesics, skin mucosa ocular syndrome (Stevens-Johnson syndrome), toxic epidermal necrosis (Lyell syndrome) appears. Therefore, in such a case, discontinue administration and take appropriate measures. • Haemolytic anaemia, aplastic anaemia: Since it is reported that haemolytic anaemia and				

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						aplastic anaemia appear in other non-steroidal anti-inflammatory analgesics, observe thoroughly by conducting blood tests, etc. If abnormality is observed, discontinue the administration immediately and take appropriate measures. If such symptoms appear, discontinue the administration. Warnings and precautions: • The treatment with anti-inflammatory painkillers is only symptomatic. • When using this drug for chronic diseases (rheumatoid arthritis, osteoarthritis, etc.), consider the following considerations: • Periodic clinical examination (urine test, blood test, and liver function inspection, etc.) are performed in case of long-term • administration. In addition, if an abnormality is recognized, the appropriate measures can be taken. • To consider other therapies other than drug therapy. • When using this drug for acute diseases, consider the following matters: • Take into account the degree of acute inflammation, pain and fever. • Avoid long-term administration of the same drug in principle. • Observe the condition of the patient sufficiently and keep the expression of side effects in mind. • It is desirable to avoid combination with other anti-inflammatory painkillers. • Care should be given to the elderly with special attention to the expression of side effects and to minimize the use.				

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
145.	Pharmasia Limited, Bhawal, Mirzapur, Gazipur Orion Pharma Ltd. D/28/2, Sumilpara, Siddhirganj, Narayanganj	Thiamine Mononitrate (Vitamin B1) 100 mg, Pyridoxine Hydrochloride (Vitamin B6) 100 mg and Cyanocobalamin (Vitamin B12) 5000 mcg Tablet	Thiamine Mononitrate BP 100mg + Pyridoxine Hydrochloride BP 100mg + Cyanocobalamin BP 5000 mcg	Vitamin supplement	It is indicated for- • Diabetic neuropathy • Neuralgias and neuritis • Algias of rheumatic and traumatic origin • Degenerative conditions of the spine or surgical operations carried out thereon • Herpes zoster, hemicrania and facial paresis • Nausea and vomiting of pregnancy.	**Contraindication:** The patient should not take this medicine if the patient is hypersensitive to any of the active ingredients or excipients of this product. This should not be taken by children below 14 years of age. Consult physician if symptoms persist, use in pregnant women or planning pregnancy and patients under treatment **Side-effects:** Generally, well tolerated but hypersensitive (allergic) reaction may be observed in few patients. **Precaution and Warning:** The clinical picture as well as the laboratory parameters of funicular myelosis or of pernicious anaemia can lose specificity by administration of vitamin B12. If symptoms of peripheral sensory neuropathy (paraesthesia) occur, the dosage should be reviewed and treatment with the medicinal product discontinued, if necessary. Neuropathies have been observed under long-term intake (over 6-12 months) of daily dosages exceeding 50 mg vitamin B6 as well as in short-term intake (over 2 months) of more than 1 g vitamin B6 per day. Therefore, regular monitoring is recommended under long-term treatment	New	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।
146.	Pharmasia Limited, Bhawal, Mirzapur, Gazipur	Feropenem 1.08gm/100ml Dry Syrup	Feropenem Sodium Hydrate INN 1.08gm/100ml	Beta-lactam antibiotics	It is indicated for- • Lower respiratory tract infections • Ear, nose and throat (ENT) infections • Genito-urinary infections • Upper respiratory tract infections • Skin and skin structure infections • Gynecological infections	**Contraindication:** Faropenem is contraindicated in patients with known hypersensitivity to any of the components of this product or to other drugs in the same class, or in patients who have demonstrated anaphylactic reactions to beta-lactams. **Side-effects:** Faropenem is generally well tolerated. The most frequently reported adverse reactions are diarrhea, abdominal pain, loose bowel movements, nausea and rash.	Faropenem 150mg Tablet	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।
147.	Popular Pharmaceuticals	Vonoprazan 20mg + Aspirin BP 100mg Tablet	Vonoprazan Fumarate INN	Therapeutic Class:	For inhibiting thrombus/Embolization formation in the following diseases or	**CONTRAINDICATIONS** Aspirin: In patients with a hypersensitivity to	Vonoprazan 10mg, 20	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের	রেফারেন্স নেই বিধায় নামঞ্জুর

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
	Ltd.,164, Tongi Industrial Area, Monnunagar, Gazipur NIPRO JMI Pharma Ltd.		26.720 equivalent to Vonoprazan 10mg + Aspirin BP 100mg	Uncalssified Agents Therapeutic code: 075	post-operations (for use only inpatients with a history of gastric ulcer or duodenal ulcer)/Angina pectoris (chronic stable angina, unstable angina), myocardial infarction, or ischemic cerebrovascular disease (transient ischemic attack [TIA], cerebral infarction)/coronary artery bypass graft (CABG) or percutaneous transluminal coronary angioplasty (PTCA).	nonsteroidal anti-inflammatory drugs (NSAIDs). In patients with the syndrome of asthma, rhinitis, and nasal polyps. Aspirin may cause severe urticaria, angioedema, or bronchospasm. Vonoprazan: Vonoprazan is contraindicated in: Patients with hypersensitivity to Vonoprazan or to any excipient of the product and Patients receiving atazanavir sulphate, nelfinavir or rilpivirine hydrochloride. **WARNINGS AND PRECAUTIONS** Pregnancy: Avoid use during the third trimester Hepatic Impairment: Avoid use in patients with severe impairment Renal Impairment: Avoid use in patients with GFR less than 10 mL/min	Tablet		সুপারিশ করা হয়	করা হয়।
148.	Renata Limited Mirpur, Dhaka	Luliconazole 1% Lotion (10mg/gm)	Luliconazole USP 1% Lotion (10mg/gm)	Antifungal Therapeutic code: 020	Luliconazole is an azole antifungal indicated for the topical treatment of interdigital tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum and Epidermophyton floccosum, in patients 18 years of age and older	**Contraindications:** None **Side effects:** The most common adverse reactions observed in clinical trials were application site reactions, which occurred in less than 1% of subjects.	Luliconazole 1% Cream	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।
149.	Renata Limited Mirpur, Dhaka Eskayef Pharmaceuticals Limited, Mirpur, Dhaka	Luliconazole 1% Spray (10mg/gm)	Luliconazole USP 1% Spray (10mg/gm)	Antifungal Therapeutic code: 020	Luliconazole is an azole antifungal indicated for the topical treatment of interdigital tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum and Epidermophyton floccosum, in patients 18 years of age and older	**Contraindications:** None **Side effects:** The most common adverse reactions observed in clinical trials were application site reactions, which occurred in less than 1% of subjects.	Luliconazole 1% Cream	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।
150.	Renata Limited Mirpur, Dhaka	Trazodone Hydrochlorid 150 mg Extended Release Tablet	Trazodone Hydrochlorid USP 150 mg	Antidepressant Therapeutic Code: 014	Trazodone is a selective serotonin reuptake inhibitor indicated for the treatment of major depressive disorder (MDD)	**Contraindications:** Concomitant use of monoamine oxidase inhibitors (MAOIs), or use within 14 days of stopping MAOIs. Side effects: Most common adverse reactions (incidence ≥5% and twice that of placebo) are: edema, blurred vision, syncope, drowsiness, fatigue, diarrhea, nasal congestion, weight loss. **Warning & Precaution:** • Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents (e.g., SSRI, SNRI, triptans), but also when taken alone. If it	New	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						occurs, discontinue Trazodone and initiate supportive treatment • Cardiac Arrhythmias: Increases the QT interval. Avoid use with drugs that also increase the QT interval and in patients with risk factors for prolonged QT interval • Orthostatic Hypotension and Syncope: Warn patients of risk and symptoms of hypotension • Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk • Priapism: Cases of painful and prolonged penile erections and priapism have been reported. Immediate medical attention should be sought if signs and symptoms of prolonged penile erections or priapism are observed • Activation of Mania or Hypomania: Screen for bipolar disorder and monitor for mania or hypomania • potential for Cognitive and Motor Impairment: Has potential to impair judgment, thinking, and motor skills. Advise patients to use caution when operating machinery • Angle-Closure Glaucoma: Avoid use of antidepressants, including Trazodone, in patients with untreated anatomically narrow angles.				
151.	Renata Limited Mirpur, Dhaka	Trazodone Hydrochlorid 300 mg Extended Release Tablet	Trazodone Hydrochlorid USP 300 mg	Antidepressant Therapeutic Code: 014	Trazodone is a selective serotonin reuptake inhibitor indicated for the treatment of major depressive disorder (MDD)	**Contraindications:** Concomitant use of monoamine oxidase inhibitors (MAOIs), or use within 14 days of stopping MAOIs. Side effects: Most common adverse reactions (incidence ≥5% and twice that of placebo) are: edema, blurred vision, syncope, drowsiness, fatigue, diarrhea, nasal congestion, weight loss. **Warning & Precaution:** • Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents (e.g., SSRI, SNRI, triptans), but also when taken alone. If it occurs, discontinue Trazodone and initiate supportive treatment • Cardiac Arrhythmias: Increases the QT interval. Avoid use with drugs that also increase the QT interval and in patients with risk factors for prolonged QT interval • Orthostatic Hypotension and Syncope: Warn patients of risk and symptoms of hypotension •	New	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk • Priapism: Cases of painful and prolonged penile erections and priapism have been reported. Immediate medical attention should be sought if signs and symptoms of prolonged penile erections or priapism are observed • Activation of Mania or Hypomania: Screen for bipolar disorder and monitor for mania or hypomania • potential for Cognitive and Motor Impairment: Has potential to impair judgment, thinking, and motor skills. Advise patients to use caution when operating machinery • Angle-Closure Glaucoma: Avoid use of antidepressants, including Trazodone, in patients with untreated anatomically narrow angles.				
152.	Square Pharmaceuticals PLC, Kaliakoir, Gazipur	Cefcapene Pivoxil Hydrochloride Hydrate 100 mg Tablet	Cefcapene Pivoxil Hydrochloride Hydrate INN 100mg	Anti-infective Therapeutic Code: 023	It is indicated for the treatment of Cystitis, pyelonephritis, Urethritis, cervicitis. It is also indicated in superficial skin infection, deep skin infection, lymphangitis, lymphadentitis, and chronic pyoderma.	**Contraindications:** It is contraindicated in patients with known allergy to the cephalosporin class of antibiotics or any of its components. **Side effects:** Common side effects are includes: diarrhea, headache, nausea, vomiting, stomach pain or upset, constipation, belching, dry mouth, appetite changes & dizziness. **Precautions & warnings:** Hepatitis fulminant, hepatic function disorder, jaundice: Severe hepatitis such as hepatitis fulminant, hepatic function disorder with increase in AST (GOT), ALT (GPT) and Al-P etc., jaundice may occur. Patients should be closely observed by periodically conducting laboratory tests. If any abnormality is observed, the treatment should be discontinued and appropriate measures should be taken. Before therapy with Cefcapene Pivoxil is instituted, careful inquiry should be made to determine whether the patient has had previous hypersensitivity reactions to cefcapene pivoxil, other cephalosporin's, penicillin's, or other drugs. If cefcapene pivoxil is to be given to penicillin sensitive patients, caution should be exercised because cross-hypersensitivity among β-	New	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						lactam antibiotics may occur penicillin allergy. If an allergic reaction, including anaphylaxis, to cefcapene pivoxil occurs, the drug should be discontinued. Serious acute hypersensitivity reactions may require treatment with epinephrine and other emergency measures.				
153.	Square Pharmaceuticals PLC, Salgaria, Pabna	Paracetamol 500 mg + Ibuprofen 97.5 mg Tablet	Paracetamol BP 500 mg + Ibuprofen BP 97.5 mg	Analgesic and Antipyretic Therapeutic Code: 006	Indicated for short time management of mild to moderate acute pain in adults.	**Warning:** Hepatotoxicity, cardiovascular and gastrointestinal risk. **Contraindications**: 1. patients with known hypersensitivity to acetaminophen, ibuprofen, other NSAIDs, or to any of the excipients in this product 2. patients with a history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients 3. the setting of coronary artery bypass graft (CABG) surgery **Adverse Reactions**: Common adverse reactions are nausea, vomiting, headache, dizziness, somnolence, post-procedural hemorrhage, and swelling of the face	New	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।
154.	The ACME Laboratories Ltd. Dhamrai, Dhaka	Testosterone 30 mg Buccal Tablet (Extended Release)	Testosterone INN 30 mg	Hormone Therapeutic Code: 056	1. Rreplacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone. 2. Primary hypogonadism (congenital or acquired) 3.Hypogonadotropic hypogonadism (congenital or acquired)	**Contra-indications:** Contraindicated for the men of carcinoma of brast & prostate. **Side-effects:** Possible adverse effect may include headace & dizziness, Lethargy **Warning & Precautions:** Prolonged use of high doses of orally active 17-alpha-alkyl androgens (e.g., methyltestosterone) have been associated with serious hepatic adverse effects (peliosis hepatis, hepatic neoplasms, cholestatic hepatitis, and jaundice). Peliosis hepatis can be a life-threatening or fatal complication.	Testosterone INN 10mg/gm gel	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।
155.	The ACME Laboratories Ltd. Dhamrai, Dhaka	Calcium [from Calcium carbonate (Coral Source)] BP 800 mg + Colecalciferol USP (Vitamin D3 1000IU) 25 micrograms + Menaquinone-7 (Vitamin K2) BP 180 micrograms	Calcium (from Calcium carbonate) BP 800 mg + Colecalciferol USP (Vitamin D3 1000IU) 25 micrograms + Menaquinone-7	Metals, Salts, Minerals & Calcium Preparations Therapeutic Code: 062	*People at risk of Vitamin D, Vitamin K or Calcium insufficiency. *Those who identify as older adults/ postmenopausal women. *People who want to support healthy bones.	**Contra-indications:** Contraindicated in patients with a known hypersensitivity to any of the ingredients. **Side effects:** Allergic sensitization has been reported following administration of folic acid **Warning & Precautions:**	New	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
		Tablets	(Vitamin K2) BP 180 micrograms			Always read the label and follow the directions for use. Do not take while on warfarin therapy without medical advice.				
156.	The ACME Laboratories Ltd. Dhamrai, Dhaka	Calcium [from Calcium carbonate (Coral Source)] BP 600 mg + Colecalciferol USP (Vitamin D3 1000IU) 25 micrograms + Menaquinone-7 (Vitamin K2) BP 180 micrograms Tablets	Calcium (from Calcium carbonate) BP 600 mg + Colecalciferol USP (Vitamin D3 1000IU) 25 micrograms + Menaquinone-7 (Vitamin K2) BP 180 micrograms	Metals, Salts, Minerals & Calcium Preparations Therapeutic Code: 062	*People at risk of Vitamin D, Vitamin K or Calcium insufficiency. *Those who identify as older adults/ postmenopausal women. *People who want to support healthy bones.	**Contra-indications:** Contraindicated in patients with a known hypersensitivity to any of the ingredients. **Side effects:** Allergic sensitization has been reported following administration of folic acid **Warning & Precautions:** Always read the label and follow the directions for use. Do not take while on warfarin therapy without medical advice.	New	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।
157.	The ACME Laboratories Ltd. Dhamrai, Dhaka	Calcium [from Calcium carbonate (Eggshell Source)] BP 800 mg + Colecalciferol USP (Vitamin D3 1000IU) 25 micrograms + Menaquinone-7 (Vitamin K2) BP 180 micrograms Tablets	Calcium (from Calcium carbonate) BP 800 mg + Colecalciferol USP (Vitamin D3 1000IU) 25 micrograms + Menaquinone-7 (Vitamin K2) BP 180 micrograms	Metals, Salts, Minerals & Calcium Preparations Therapeutic Code: 062	*People at risk of Vitamin D, Vitamin K or Calcium insufficiency. *Those who identify as older adults/ postmenopausal women. *People who want to support healthy bones.	**Contra-indications:** Contraindicated in patients with a known hypersensitivity to any of the ingredients. **Side effects:** Allergic sensitization has been reported following administration of folic acid **Warning & Precautions:** Always read the label and follow the directions for use. Do not take while on warfarin therapy without medical advice.	New	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।
158.	The ACME Laboratories Ltd. Dhamrai, Dhaka	Calcium [from Calcium carbonate (Eggshell Source)] BP 600 mg + Colecalciferol USP (Vitamin D3 1000IU) 25 micrograms + Menaquinone-7 (Vitamin K2) BP 180 micrograms Tablets	Calcium (from Calcium carbonate) BP 600 mg + Colecalciferol USP (Vitamin D3 1000IU) 25 micrograms + Menaquinone-7 (Vitamin K2) BP 180 micrograms	Metals, Salts, Minerals & Calcium Preparations Therapeutic Code: 062	*People at risk of Vitamin D, Vitamin K or Calcium insufficiency. *Those who identify as older adults/ postmenopausal women. *People who want to support healthy bones.	**Contra-indications:** Contraindicated in patients with a known hypersensitivity to any of the ingredients. **Side effects:** Allergic sensitization has been reported following administration of folic acid **Warning & Precautions:** Always read the label and follow the directions for use. Do not take while on warfarin therapy without medical advice.	New	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।
159.	The ACME Laboratories Ltd. Dhamrai, Dhaka	Elemental Calcium (as Calcium Carbonate BP (from Oyster Shell	Elemental Calcium (as Calcium Carbonate BP	Metals, Salts, Minerals & Calcium	1. Used for the treatment of . Bone loss (osteoporosis) . Weak bones (osteomalacia, osteopenia)	**Contra-indications:** Hypercalcemia & hyperparathyroidism, Hypercalciuria & nephrolithiasis, Severe renal insufficiencies,	New	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
		source) BP 500 mg + Vitamin D3 (as Cholecalciferol concentrate (powder form) BP 200 IU Tablet	(from Oyster Shell source) BP 500 mg + Vitamin D3 (as Cholecalciferol concentrate (powder form) BP 200 IU	Preparations Therapeutic Code: 062	. Rickets 2. To ensure adequate Calcium and Vitamin D, it may also be used in cetain conditions such as . Pregnancy and lactatron . Postmenopausal osteoporosis	concomitant Digoxin therapy. **Side-effects**: Generally orally administered Calcium Carbonate may be irritating to the GI tract and it may also cause constipatition but eggshell Calcium is safe for long term use without causing any GI discomfort or constipation. **Warning and Precautions:** When hypercalcemia occurs, discontinuation of drug is required. Patients with a history of kidney stone formation should also be recommended to increase their fluid intake.				
160.	The ACME Laboratories Ltd. Dhamrai, Dhaka	Elemental Calcium (as Calcium Carbonate BP (from Oyster Shell source) BP 600 mg + Vitamin D3 (as Cholecalciferol concentrate (powder form) BP 400 IU Tablet	Elemental Calcium (as Calcium Carbonate BP (from Oyster Shell source) BP 600 mg + Vitamin D3 (as Cholecalciferol concentrate (powder form) BP 400 IU	Metals, Salts, Minerals & Calcium Preparations Therapeutic Code: 062	1. Used for the treatment of . Bone loss (osteoporosis) . Weak bones (osteomalacia, osteopenia) . Rickets 2. To ensure adequate Calcium and Vitamin D, it may also be used in cetain conditions such as . Pregnancy and lactatron . Postmenopausal osteoporosis	**Contra-indications:** Hypercalcemia & hyperparathyroidism, Hypercalciuria & nephrolithiasis, Severe renal insufficiencies, concomitant Digoxin therapy. **Side-effects**: Generally orally administered Calcium Carbonate may be irritating to the GI tract and it may also cause constipatition but eggshell Calcium is safe for long term use without causing any GI discomfort or constipation. **Warning and Precautions:** When hypercalcemia occurs, discontinuation of drug is required. Patients with a history of kidney stone formation should also be recommended to increase their fluid intake.	New	রেফারেন্স নাই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।
161.	Ziska Pharmaceuticals Ltd.	Ulinastatin 50000 IU Injection	Ulinastatin 50000 IU JP	Therapeutic class: A serine protease inhibitor	Indicated in severe sepsis and mild and severe acute pancreatitis.	**Contraindications:** Hypersensitivity to drug. **Side effects:** rare cases of rash, itching and pain at the site of injection, rare cases of allergy, rare cases of elevation of SGOT and SGPT, rare cases of nausea, vomiting and diarrhea. **Warnings and precautions:** Not to be used for patients who are hypersensitive, not to use in lactating mother, it should be administered with caution if patient has history of allergy, it cannot replace the traditional therapeutic methods (transfusion, oxygen therapy and antibiotics) for shocks.	New	**রেফারেন্স নাই**	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।
162.	The IBN SINA Pharmaceutical Industries Ltd.	Quizartinib 17.70 mg Tablet	Quizartinib Dihydrochloride INN 20.00 mg Eqv. to 17.70 mg	Anticoagulants and Fibrinolytic Drug	It is indicated in the treatment of Acute Myeloid Leukemia/ Blood Cancer	**Condra-Indication:** Quizartinib is contraindicated in patients with severe hypokalemia, severe hypomagnesemia, long QT syndrome, or in patients with a history of ventricular arrhythmias	New	রেফারেন্স নেই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
	Drug International Ltd.,Plot # 13A & 14A, Tongi I/A, Tongi, Gazipur		Quizartinib	Therapeutic Code: 012		**Side Effect:** 1.Low white blood cell counts with fever, 2.changes in levels of electrolytes in the blood, 3.changes in liver function tests, 4.diarrhea, 5.mouth sores, 6.nausea, 7.stomach (abdominal) pain.				
163.	The IBN SINA Pharmaceutical Industries Ltd. Drug International Ltd.; Plot # 13A & 14A, Tongi I/A, Tongi, Gazipur	Quizartinib 26.50 mg Tablet	Quizartinib Dihydrochloride INN 30.00 mg Eqv. to 26.50 mg Quizartinib	Anticoagulants and Fibrinolytic Drug Therapeutic Code: 012	It is indicated in the treatment of Acute Myeloid Leukemia/ Blood Cancer	**Condra-Indication:** Quizartinib is contraindicated in patients with severe hypokalemia, severe hypomagnesemia, long QT syndrome, or in patients with a history of ventricular arrhythmias **Side Effect:** 1.Low white blood cell counts with fever, 2.changes in levels of electrolytes in the blood, 3.changes in liver function tests, 4.diarrhea, 5.mouth sores, 6.nausea, 7.stomach (abdominal) pain.	New	রেফারেন্স নেই	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।
164.	Advanced Chemical Industries Limited, 7 Hajeegonj, Godnyl, Narayangonj	Flucloxacillin Sodium 1g/Vial Injection	Flucloxacillin Sodium Monohydrate BP 1.09 g eqv. to 1g Flucloxacillin/Vial	Anti-infective Therapeutic Code: 023	It is indicated for treatment of skin and soft tissue infections caused by susceptible organisms and infections due to penicillinase producing staphylococci and for Prophylaxis of staphylococcal infections during major surgical procedures, particularly in cardiothoracic or orthopedic surgery	**Contraindication:** Contraindicated in patients with history of hypersensitivity to flucloxacillin or cephalosporins or penicillin and flucloxacillin associated jaundice/hepatic dysfunction. **Side-effects:** The most common side effects are gastrointestinal upsets (e.g. Nausea, vomiting, diarrhoea, dyspepsia, constipation, abdominal pain, heart burn and loss of appetite.) and skin rashes. **Warnings and Precautions**: Patient should be monitored for any signs of hepatitis, cholestatic jaundice, cutaneous adverse reactions, hypokalemia, hypernatremia and metabolic acidosis if administrated concomitantly with paracetamol. During treatment with flucloxacillin injection, allergic reactions, dizziness and convulsions may occur which may influence the ability to drive and use machines. Patients should be cautious when driving or operating machinery.	250mg/Vial 500mg/Vial Injectionj	BNF-85 Page: 613	অনুমোদনের সুপারিশ করা হয়।	অনুমোদনের সুপারিশ করা হয়।
165.	The ACME Laboratories Ltd. Dhamrai, Dhaka	Vernakalant Hydrochloride 500mg/25mL Vial solution for Injection,	Vernakalant Hydrochloride BP 500mg/25mL Vial	Antiarrhythmics Therapeutic Code: 009	Atrial fibrillation	**Contraindications:** Severe aortic stenosis, systolic blood pressure (SBP) < 100 mmHg, NYHA Class III or IV heart failure **Side-effects:** Heart failure, problems with the	NEW	EMA	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						rhythm of your heart or the electrical system in your heart,enlarged heart muscles or heart muscle disease,swelling of the lining of the heart **Precautions:** Patients should be carefully observed during infusion, and for at least 2 hours after administration of treatment,with assessment of vital signs and continuous cardiac rhythm monitoring.				
166.	Incepta Pharmaceuticals Ltd.;, Zirabo, Dhaka	Bevacizumab 25mg/1ml Vial Solution for Intravitreal Injection	Bevacizumab (25mg/ml) Ready to fill bulk* INN/In-house 1ml/Vial eqv. to Bevacizumab 25mg/Vial in 1ml Solution	Anticancer Therpaeutic Class: 010	Bevacizumab is a vascular endothelial growth factor-specific angiogenesis inhibitor indicated for the treatment of: • Metastatic colorectal cancer, with intravenous 5-fluorouracil–based chemotherapy for first- or second-line treatment. • Non-squamous non-small cell lung cancer, with carboplatin and paclitaxel for first line treatment of unresectable, locally advanced, recurrent or metastatic disease. • Metastatic breast cancer, with paclitaxel for treatment of patients who have not received chemotherapy for metastatic HER2-negative breast cancer. -Effectiveness based on improvement in progression-free survival. No data available demonstrating improvement in disease-related symptoms or survival with Bevacizumab. -Not indicated for disease progression following anthracycline and taxane chemotherapy administered for metastatic disease.	**Contraindication:** None. **Side-effects:** Most common adverse reactions incidence (>10% and at least twice the control arm rate) are epistaxis, headache, hypertension, rhinitis, proteinuria, taste alteration, dry skin, rectal hemorrhage, lacrimation disorder, and exfoliative dermatitis. **Warnings and Precautions:** Non-Gastrointestinal Fistula Formation: Discontinue Bevacizumab if fistula formation occurs. Arterial Thromboembolic Events (e.g., myocardial infarction, cerebral infarction): Discontinue Bevacizumab for severe ATE. Hypertension: Monitor blood pressure and treat hypertension. Temporarily suspend Bevacizumab if not medically controlled. Discontinue Bevacizumab for hypertensive crisis or hypertensive encephalopathy. Reversible Posterior Leukoencephalopathy Syndrome (RPLS): Discontinue Bevacizumab. Proteinuria: Monitor urine protein. Discontinue for nephrotic syndrome. Temporarily suspend Bevacizumab for moderate proteinuria. Infusion Reactions: Stop for severe infusion reactions.	Bevacizumab 100 mg/4 ml Injection, Bevacizumab 400 mg/16 ml Injection	EMA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
					• Glioblastoma, as a single agent for patients with progressive disease following prior therapy. -Effectiveness based on improvement in objective response rate. No data available demonstrating improvement in disease-related symptoms or survival with Bevacizumab.					
167.	Beximco Pharmaceuticals Ltd., Tongi, Gazipur Popular Pharmaceuticals Ltd., 164, Tongi Industrial Area, Monnunagar, Gazipur	Potassium Citrate BP 3gm/Sachet Oral Solution	Potassium Citrate BP 3gm/Sachet	Metals, Salts, Minerals and Calcium Preparations Therapeutic Code: 062	For the symptomatic relief of mild urinary tract infections (cystitis).	**CONTRAINDICATIONS:** Potassium Citrate granules for oral solution are contraindicated in patients with: • Use in patients with renal insufficiency. **PRECAUTIONS:** This product is intended for short term treatment. Patients should seek doctor's advice if symptoms persist after 48 hours treatment. This product should only be used with caution in patients with cardiac disease. This product contains a source of phenylalanine. May be harmful for people with phenylketonuria.	New	MHRA EMC	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।
168.	Eskayef Pharmaceuticals Limited, Tongi, Gazipur	Ursodeoxycholic acid 500mg Film Coated Tablet	Ursodeoxycholic acid BP 500mg	**Other Classification** Therapeutic code: 075	Ursodeoxycholic acid is a chemical present naturally in the body and it helps to control the amount of cholesterol in the blood. Ursodeoxycholic acid. For the dissolution of cholesterol gallstones in the gall bladder. The gallstones must not show as shadows on X-ray images and should not exceed 15 mm in diameter. Gall bladder function must not be significantly impaired,	**CONTRAINDICATIONS:** It should not be used in patients with: acute inflammation of the gall bladder or biliary tract; occlusion of the biliary tract (occlusion of the common bile duct or a cystic duct); Frequent episodes of biliary colic; Radio-opaque calcified gallstones; Impaired contractility of the gall bladder; Hypersensitivity to bile acids or any excipient of the formulation. **SIDE-EFFECT:**	Ursodeoxycholic acid 150 & 300mg Tablet	MHRA	অনুমোদনের সুপারিশ করা হয়।	প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
					despite the gallstones. For the symptomatic treatment of primary biliary cirrhosis (PBC), provided there is no decompensated hepatic cirrhosis.	The common side effects with Ursodeoxycholic acid Tablets (which may affect up to 1 in 10 people) are diarrhoea and pasty stools. **WARNINGS AND PRECAUTIONS:** During the first three months of therapy, it is advisable to monitor the liver parameters of AST (SGOT), ALT (SGPT), and GGT every 4 weeks, subsequently every 3 months. Apart from allowing for identification of responders and non-responders in patients being treated for primary biliary cholangitis, this monitoring would also enable early detection of potential hepatic deterioration, particularly in patients with advance stage primary biliary cholangitis.				
169.	Incepta Pharmaceuticals Ltd.;,Zirabo, Dhaka	Tebipenem Pivoxil 10% Granules for Pediatric	Tebipenem Pivoxil 10% Granules for Pediatric	Anti-infective Therapeutic code: 023	Tebipenem pivoxil is an oral carbapenem antibiotic, use to treat otolaryngologic and respiratory infection	**Contraindication:** History of significant hypersensitivity or allergic reaction to beta-lactam antibiotics, product excipients or any contraindication to the use of other carbapenem. **Side-effects:** Diarrhea, Headache & nausea. **Warnings and Precautions:** No data found.	New	PMDA	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
170.	Nuvista Pharma Ltd.	Ozenoxacin JP 2% Lotion	Ozenoxacin JP 2% Lotion	Skin and Mucous Membrane Preparations Code: 071	A drug with a new active ingredient indicated for the treatment of superficial skin infections and acne (accompanied by purulent inflammation)	**Contraindication:** None **Side Effects:** • Dry, flaky, scaling skin on the scalp, eyebrows, near the ears and around the nose. • Dry, Irritated or swollen eyes • Redness of the face Swollen red bumps on the face	New	PMDA	অনুমোদনের সুপারিশ করা হয়।	নামঞ্জুর করা হয়।
171.	Opsonin Pharma Limited, Rupatali, Barishal	Oxybutynin Hydrochloride 20% Lotion	Oxybutynin hydrochloride INN 20%	Skin & Mucous Membrane Preparation **Code: 071**	Indicated for the treatment of primary palmar hyperhidrosis	**Contraindications:** • Patients with angle-closure glaucoma [anticholinergic effects may increase intraocular pressure and worsen symptoms.] • Patients with urinary dysfunction due to lower urinary tract obstructive disease (prostatic	5 mg Tablet	PMDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						hypertrophy, etc.) [Anticholinergic effects may inhibit bladder contraction during urination and worsen symptoms.] • Patients with serious heart disease [Anticholinergic effects may cause tachycardia and heart palpitations, leading to increased cardiac workload.] • Patients with intestinal obstruction or paralytic ileus [Anticholinergic effects may suppress the contraction and movement of gastrointestinal smooth muscles, which may worsen symptoms.] • Patients with myasthenia gravis [anticholinergic effects may cause a decrease in muscle tone and worsen symptoms.] • Patients with a history of hypersensitivity to the ingredients of this drug. **Side effects:** 1% to less than 5%: Skin: Application site dermatitis, application site itching, application site eczema, sebum deficiency Digestive organ: Dry mouth. 0.1 to less than 1%: Skin: Application site erythema, skin exfoliation Digestive organ: Angular cheilitis Others: Urinary glucose positive. **Precautions & warnings**: Anticholinergic effects may cause ocular accommodation disorders (visual impairment, blurred vision, etc.), dizziness, and drowsiness, so patients should be careful when engaging in dangerous machinery operations. In environments where sweating is promoted, body temperature may rise due to the antiperspirant effect of this drug. If symptoms				

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						suggestive of heat stroke appear, instruct the patient to take appropriate measures. Anticholinergic effects may inhibit the contraction and movement of gastrointestinal smooth muscle, leading to decreased gastrointestinal motility. If gastrointestinal symptoms occur, instruct the patient to discontinue use and consult a medical institution.				
172.	Navana Pharmaceuticals Ltd., Rupganj, Narayanaganj	Rebamipide 2% Eye Drops	Rebamipide INN 2%	Eye Preparations Therapeutic Code: 052	It is usually used to treat dry eye.	**Contraindications:** • This medicine is not recommended for use in patients with a known allergy to Rebamipide or any other inactive ingredients present along with it. • If patients wear contact lenses. **Side Effects:** The most commonly reported adverse reactions include bitter taste, eye irritation, eye itching and vision blurred (foggy vision). **Warnings and Precautions:** ・Since the medicine is a white aqueous suspension, patient's vision may temporarily turn white or be blurred after instillation. Patients should pay attention when they operate machines or drive a car. ・The active ingredient of the medicine may be adsorbed onto the surface of soft contact lenses. If patients experience an unusual ocular sensation, patients should consult with their doctor.	New	PMDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।
173.	Square Pharmaceuticals PLC, Kaliakor, Gazipur	Lipase 40,000 Units + Amylase 25,000 Units + Protease 1,600 Units Capsule	Pancrelipase enteric coated pellets Ph. Grade 560mg eq. to.	Enzymes Therapeutic code: 051	It is indicated as pancreatic enzyme replacement in paediatric and adult patients with pancreatic exocrine insufficiency (PEI). Pancreatic	**Contraindication:** Contraindicated in patients who are known to be hypersensitive to porcine or any of the ingredients.	150mg, 300mg, 325 mg Capsule	TGA	অনুমোদনের সুপারিশ করা হয়।	পরবর্তী টেকনিক্যাল সাব কমিটির সভায় পুনর্মূল্যায়নের

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
	Beacon Pharmaceuticals PLC, Kathali, Bhaluka, Mymensingh		Pancrelipase Ph. Eur. 400 mg contains Lipase 40,000 Ph. Eur. Units + Amylase 25,000 Ph. Eur. Units + Protease 1,600 Ph Eur. Units		exocrine insufficiency is often associated with, but not limited to: cystic fibrosis, chronic pancreatitis, pancreatic surgery, gastrointestinal bypass surgery (eg. Bilroth II gastroenterostomy), ductal obstruction of the pancreas or common bile duct (e.g. from neoplasm)	**Side effects:** Major and minor side effects are- stomach pain, nausea or vomiting, diarrhea, rash, itching.				সিদ্ধান্ত গৃহীত হয়।
174.	DBL Pharmaceuticals Ltd., Surabari, Kashimpur, Gazipur	Methylprednisolone Aceponate 0.1% Ointment (Opaque, yellowish-White Ointment)	Methylprednisolone Aceponate INN 0.1% (1mg/gm)	Skin and Mucous Membrane Preparation **Therapeutic** Code: 071	Indicated for the topical treatment of eczema and psoriasis in adults and children.	**Contraindication:** Methylprednisolone Aceponate cream is contraindicated in viral diseases (e.g. vaccinia, varicella/herpes zoster) and when tuberculous or syphilitic processes and post-vaccination skin reactions are present in the area to be treated. If rosacea, ulcera, atrophic skin diseases, acne vulgaris or perioral dermatitis are present, It must not be applied to the face. **Side effects:** Burning, pruritus, dryness, erythema, vesicles **Warnings:** Methylprednisolone aceponate cream should not be allowed to come into contact with deep open wounds, muscosae or the eyes when being applied to the face.	New	TGA	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
175.	DBL Pharmaceuticals Ltd., Surabari, Kashimpur, Gazipur	Methylprednisolone Aceponate 0.1% Fatty Ointment (White to yellowish Fatty Ointment)	Methylprednisolone Aceponate INN 0.1% (1mg/gm)	Skin and Mucous Membrane Preparation **Therapeutic** Code: 071	Indicated for the topical treatment of eczema and psoriasis in adults and children.	**Contraindication:** Methylprednisolone Aceponate cream is contraindicated in viral diseases (e.g. vaccinia, varicella/herpes zoster) and when tuberculous or syphilitic processes and post-vaccination skin reactions are present in the area to be treated. If rosacea, ulcera, atrophic skin diseases, acne vulgaris or perioral dermatitis are present, It must not be applied to the face. **Side effects:** Burning, pruritus, dryness, erythema, vesicles **Warnings:** Methylprednisolone aceponate cream	New	TGA	অনুমোদনের সুপারিশ করা হয়।	প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						should not be allowed to come into contact with deep open wounds, muscosae or the eyes when being applied to the face.				
176.	The ACME Laboratories Ltd. Dhamrai, Dhaka	Calcium Carbonate (Oyster Shell source) BP 1390 mg eqv. to Calcium 500 mg + Cholecalciferol (Vitamin D3) BP 3.12mcg Tablet	Calcium Carbonate (Oyster Shell source) BP 1390 mg eqv. to Calcium 500 mg + Cholecalciferol (Vitamin D3) BP 3.12 mcg Tablet	Metals, Salts, Minerals and Calcium preparations Therapeutic Code: 062	Calcium as vitamin D3 supplement	**Contra-indications:** Hypercalcemia & hyperparathyroidism, Hypercalciuria & nephrolithiasis, Severe renal insufficiencies, concomitant Digoxin therapy. **Side-effects**: Generally orally administered Calcium Carbonate may be irritating to the GI tract and it may also cause constipatition but eggshell Calcium is safe for long term use without causing any GI discomfort or constipation. **Warning and Precautions:** When hypercalcemia occurs, discontinuation of drug is required. Patients with a history of kidney stone formation should also be recommended to increase their fluid intake.	New	TGA	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
177.	The ACME Laboratories Ltd. Dhamrai, Dhaka	Alpha Lipoic acid 150mg + Ascorbic acid 250mg + Colecalciferol 6.25 microgram + Levomefolate glucosamine 0.478 mg + Ubidecarenone 150mg Capsule	Alpha Lipoic Acid USP 150mg + Ascorbic acid BP 250mg + Colecalciferol BP 6.25 microgram + Levomefolate glucosamine INN 0.478 mg + Ubidecarenone In-house 150mg	Metals, Salts, Minerals & Calcium Preparations Therapeutic Code: 062	1. Antioxidant/Reduce free radicals formed in the body in females 2. Maintain/support healthy immune system function in females 3. Maintain/support female reproductive system health 4. Maintain/support preconception health in females 5. Helps prepare the body for pregnancy	**Contraindication:** Contraindicated for the patient with known hypersensitivity to these vitamins. **Side-effects:** Generally well-tolerated in recommended dose. **Warnings & Precautions: N/A**	New	TGA	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
178.	Incepta Pharmaceuticals Ltd.;,Zirabo, Dhaka	Ascorbic Acid 50mg + DI-Alpha-Tocopheryl Acetate 11.2 mg eqv.to DI-Alpha-Tocopherol 7.5 mg +	Ascorbic Acid BP/Ph. Eur. 50mg + DI-Alpha-Tocopheryl Acetate BP/Ph.	Vitamins & Combinations Therapeutic	used as antioxidant help in reducing skin dryness Support in skin fairness maintain skin elasticity	**Contraindication:** No data available **Side-effects:** No data available **Warnings and Precautions:** The recommended daily dose of this medicine contains [state quantity and units] of sodium (or	New	TGA	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
		Sodium Hyaluronate 60mg Effervescent tablet	Eur. 11.2 mg eqv.to DI-Alpha-Tocopherol 7.5 mg + Sodium Hyaluronate BP/Ph. Eur. 60mg	code: 078		words to that effect). Keep out of reach of children (or words to that effect). Vitamins and minerals can only be of assistance if dietary intake is inadequate OR Vitamin and/or mineral supplements should not replace a balanced diet.				
179.	Incepta Pharmaceuticals Ltd.;,Zirabo, Dhaka	Betacarotene 0.0802mg + Sodium Ascorbate 7.92mg eqv.to Ascorbic Acid 7mg + Zinc Glycinate 3.27mg eqv.to Zinc 1mg/ml Oral Solution	Betacarotene BP/Ph. Eur. 0.0802mg + Sodium Ascorbate USP 7.92mg eqv.to Ascorbic Acid 7mg + Zinc Glycinate INN/In-house 3.27mg eqv.to Zinc 1mg/ml	Vitamins and Combinations Therapeutic code: 078	• Antioxidant • Collagen formation • Support eye health • Hair, nail health • Support immune system • Maintain skin health • Support wound healing etc.	**Contraindication:** Known hypersensitivity to Itraconazole or to any excipients in Tablet. **Side-effects:** •headache, dizziness, drowsiness •Skin discoloration (yellowing that eventually goes away) •Loose stools. •Bruising. •Joint pain. Etc **Warnings and Precautions:** •High doses of beta-carotene can turn skin yellow or orange.	New	TGA	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
180.	**Incepta Pharmaceuticals Ltd.;,Zirabo, Dhaka**	Glucose 1.3455gm + Inulin USP 0.4947gm + Potassium Chloride 0.1495g eqv.to Potassium 0.0784g + Sodium chloride 0.2591gm eqv.to Sodium 0.1019gm + Sodium citrate dihydrate 0.289gm eqv.to Sodium 0.0678gm + Zinc gluconate 0.005gm eqv.to 0.0007gm/100ml Oral solution	Glucose BP/Ph.Eur. 1.3455gm + Inulin USP 0.4947gm + Potassium Chloride BP/Ph.Eur. 0.1495g eqv.to Potassium 0.0784g + Sodium chloride BP/Ph.Eur. 0.2591gm eqv.to Sodium 0.1019gm + Sodium citrate	Water for Injection, Electrolytes, Blood Volume Restorers and Caloric Agents Therapeutic Code: 079	Maintain/support immune system health Aids/assists with recovery from illness/convalescence Restore body fluid balance Helps restore body electrolyte balance Maintain/support healthy digestive system function Nourish good/beneficial/friendly intestinal flora Maintain/support (state vitamin/mineral/nutrient) levels in the body	**Contraindication:** The recommended daily dose of this medicine contains [state quantity and units] of sodium (or words to that effect). Vitamins and minerals can only be of assistance if dietary intake is inadequate OR Vitamin and/or mineral supplements should not replace a balanced diet. The recommended daily amount of vitamin A form all sources is 700 micrograms retinol equivalents for women and 900 micrograms retinol equivalents for men. If symptoms persist consult your healthcare practitioner (or words to that effect). **Side-effects:** No data available **Warnings and Precautions:** No data available	New	TGA	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
			dihydrate USP 0.289gm eqv.to Sodium 0.0678gm + Zinc gluconate BP/Ph.Eur. 0.005gm eqv.to 0.0007gm/100ml							
181.	Incepta Pharmaceuticals Ltd.;,Zirabo, Dhaka	Magnesium glycinate 177mg eqv. to Magnesium 25mg + Manganese sulfate monohydrate 6.16mg eqv. to Manganese 2mg + Pyridoxine hydrochloride 12.2mg eqv. to Pyridoxine 10mg + Retinol acetate 0.86mg eqv. to Vitamin A 750mcg Retinol equivalent + Zinc glycinate 81.6mg eq.to Zinc 25mg Effervescent Tablet	Magnesium glycinate INN/In-house 177mg eqv. to Magnesium 25mg + Manganese sulfate monohydrate BP/Ph.Eur. 6.16mg eqv. to Manganese 2mg + Pyridoxine hydrochloride BP/Ph.Eur. 12.2mg eqv. to Pyridoxine 10mg + Retinol acetate BP/Ph.Eur. 0.86mg eqv. to Vitamin A 750mcg Retinol equivalent + Zinc glycinate INN/In-house 81.6mg eq.to Zinc 25mg	Vitamins and Combinations Therapeutic Code: 078	Antioxidant/Reduce free radicals formed in the body Maintain/support heat/energy production/thermogenesis Maintain/support general health and wellbeing Maintain/support healthy immune system function Maintain/support muscle health Maintain/support reproductive system healthMaintain/support testosterone level when dietary intake is inadequate Maintainsupport skin health	**Contraindication:** The recommended daily dose of this medicine contains [state quantity and units] of sodium (or words to that effect). Vitamins and minerals can only be of assistance if dietary intake is inadequate OR Vitamin and/or mineral supplements should not replace a balanced diet. The recommended daily amount of vitamin A from all sources is 700 micrograms retinol equivalents for women and 900 micrograms retinol equivalents for men. If symptoms persist consult your healthcare practitioner (or words to that effect). **Side-effects:** No data available **Warnings and Precautions:** No data available	New	TGA	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
182.	Incepta Pharmaceuticals	Citric Acid (Anhydrous) (Crushed)	Citric Acid (Anhydrous)	Water for Injection,	Decrease/reduce/relieve symptoms of dehydration	**Contraindication:** No data available **Side-effects:** No data available	New	TGA	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ	বর্তমানে প্রয়োজন নেই

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
	Ltd.;,Zirabo, Dhaka	720mg + Glucose 1870mg + Potassium Chloride 149mg eqv.to Potassium 78mg + Sodium Bicarbonate 378mg + Sodium Chloride 87.5mg Effervescent tablet	(Crushed) BP/Ph.Eur. 720mg + Glucose BP/Ph.Eur. 1870mg + Potassium Chloride BP/Ph.Eur. 149mg eqv.to Potassium 78mg + Sodium Bicarbonate BP/Ph.Eur. 378mg + Sodium Chloride BP/Ph.Eur. 87.5mg	Electrolytes, Blood Volume Restorers and Caloric Agents Therapeutic Code: 079	Maintain/support body electrolyte balance Helps restore body electrolyte balance after exercise	**Warnings and Precautions:** Keep out of reach of children (or words to that effect). Use only as directed Adults only. The recommended daily dose of this medicine contains [state quantity and units] of sodium (or words to that effect). If diarrhoea persists, seek medical advice If diarrhoea persists for more than 6 hours in infants under 6 months, 12 hours in children under 3 years, 24 hours in children aged 3-6 years or 48 hours in adults and children over 6 years, seek medical advice (or words to that effect). If symptoms persist consult your healthcare practitioner (or words to that effect). (If medicine contains one sugar) contains [insert name of sugar] OR (If medicine contains two or more sugars) Contains sugars [or words to that effect]. Contains potassium. If you have kidney disease or are taking heart or blood pressure medicines, consult your doctor or pharmacist before use. Keep out of reach of children.			করা হয়।	বিধায় নামঞ্জুর করা হয়।
183.	**Incepta Pharmaceuticals Ltd.;,Zirabo, Dhaka**	Ascorbic Acid (powder) BP/Ph.Eur.80mg + Biotin BP/Ph.Eur. 0.05mg + Caffeine BP/Ph.Eur. 74mg + Calcium Carbonate BP/Ph.Eur. 250mg eqv.to calcium 100mg + Calcium Pantothenate BP/Ph.Eur. 6.52mg	Ascorbic Acid (powder) BP/Ph.Eur.80mg + Biotin BP/Ph.Eur. 0.05mg + Caffeine BP/Ph.Eur. 74mg + Calcium Carbonate BP/Ph.Eur. 250mg eqv.to	Vitamins and Combinations Therapeutic Code: 078	used as antioxidant help in energy balance balance heat production maintain general health condition	**Contraindication:** No data available **Side-effects:** No data available **Warnings and Precautions:** The recommended daily dose of this medicine contains [state quantity and units] of sodium (or words to that effect). Caffeine intake more than 200 mg per day is not recommended during pregnancy or breastfeeding. Keep out of reach of children (or words to that effect). Vitamins and minerals can only be of assistance if dietary intake is inadequate OR Vitamin and/or	New	TGA	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
		eqv.to Pantothenic Acid 6mg + Cyanocobalamine BP/Ph.Eur. 0.0025mg + DI-Alpha-Tocopheryl Acetate BP/Ph.Eur. 17.9 mg eqv.to DI-Alpha-Tocopherol 12mg + Follic Acid BP/Ph.Eur. 0.2mg + Magnesium Carbonate Hydrate 400mg eqv.to Magnesium 100mg + Nicotinamide 16mg + Paullinia Cupana seed Powder 27.3mg + Pyridoxine hydrochloride 1.7mg eqv. to Pyridoxine 1.4mg + Riboflavin Sodium Phosphate 1.78mg eqv.to Riboflavin 1.4mg + Thiamine Hydrochloride 1.4mg eqv.to Thiamine 1.1mg + Zinc Sulfate Monohydrate 24.7mg eqv.to Zinc 10mg Effervescent Tablet	calcium 100mg + Calcium Pantothenate BP/Ph.Eur. 6.52mg eqv.to Pantothenic Acid 6mg + Cyanocobalamine BP/Ph.Eur. 0.0025mg + DI-Alpha-Tocopheryl Acetate BP/Ph.Eur. 17.9 mg eqv.to DI-Alpha-Tocopherol 12mg + Follic Acid BP/Ph.Eur. 0.2mg + Magnesium Carbonate Hydrate BP/Ph.Eur. 400mg eqv.to Magnesium 100mg + Nicotinamide USP-NF 16mg + Paullinia Cupana seed Powder USP-NF 27.3mg + Pyridoxine hydrochloride BP/Ph.Eur. 1.7mg eqv. to Pyridoxine 1.4mg + Riboflavin			mineral supplements should not replace a balanced diet. If symptoms persist consult your healthcare practitioner (or words to that effect). Contains caffeine [state quantity per dosage unit or per mL or per gram of product] total caffeine [per dosage unit or per mL or per gram]. A cup of instant coffee contains approximately 80mg of caffeine.				

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
			Sodium Phosphate BP/Ph.Eur 1.78mg eqv.to Riboflavin 1.4mg + Thiamine Hydrochloride BP/Ph.Eur 1.4mg eqv.to Thiamine 1.1mg + Zinc Sulfate Monohydrate USP-NF 24.7mg eqv.to Zinc 10mg							
184.	Navana Pharmaceuticals Ltd., Rupganj, Narayanaganj	Levomefolic Acid 500mcg Capsule	Levomefolate Calcium INN 514.4mcg eq. to 500 mcg Levomefolic Acid	Vitamin & Combinations Therapeutic Code: 078	It is indicated for folic acid deficiency & anaemia.	**Contraindications:** It is contraindicated to patients with known hypersensitivity to calcium folinate or any other components of this product. It is also contraindicated in pernicious anemia or other megaloblastic anemia where vitamin B12 is deficient. Patients with rare hereditary problems of galactose intolerance, the lapp lactase deficiency or glucose-galactose malabsorption should not take calcium folinate tablets. **Side Effects:** Folic acid side effects include nausea, loss of appetite, bloating, gas, stomach pain, bitter or unpleasant taste in your mouth, confusion, trouble concentrating, sleep problems, depression, and feeling low vitamin B12 levels may occur in patients receiving prolonged folic acid therapy.	New	TGA	অনুমোদনের সুপারিশ করা হয়।	নামঞ্জুর করা হয়।
185.	Navana Pharmaceuticals Ltd., Rupganj, Narayanaganj	Zinc Gluconate USP 11.6 mg eq to Zinc 1.5mg + Ascorbic Acid BP 20 mg + Calcium	Zinc Gluconate USP 11.6 mg eq to Zinc 1.5mg + Ascorbic Acid BP	Vitamin & Combinations Therapeutic	Maintain/support healthy growth and development in children.	Contraindications: Zinc and ascorbic acid is contraindicated in patients with a known hypersensitivity to any of the ingredients of this product.	New	TGA	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
		Ascorbate Dihydrate BP8.mg eq. to 6.5mg/ml Oral Liquid	20 mg + Calcium Ascorbate Dihydrate BP8.mg eq. to 6.5mg/ml	Code: 078		Side Effects: Diarrhoea, abdominal bloating, iron over-absorption that is harmful in patients with thalassaemia, sideroblastic anemia, and haemochromatosis; hyperoxaluria, hyperuricosuria, and hemolysis in patients with glucose-6 phosphate dehydrogenase deficiency. In acute renal failure, zinc accumulation may occur, so dosage adjustment is needed. This is not intended for the treatment of severe specific deficiencies.				
186.	Renata Limited Mirpur, Dhaka	Testosterone Undecanoate 750mg/3ml Intramascular Injection	Testosterone Undecanoate INN 750mg/3ml	Hormone Therapeutic Code: 056	Testosterone undecanoate is an androgen indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.	**Contra-indication:** Men with carcinoma of the breast or known or suspected carcinoma of the prostate. Women who are pregnant testosterone can cause virilization of the female fetus when administered to a pregnant woman. Men with hypogonadal conditions, such as "age-related hypogonadism", that are not associated with structural or genetic etiologies. The efficacy of this medication has not been established for these conditions, and can increase BP which can increase the risk of MACE **Side-effects:** Headache, Nausea, Edema, Hypertension, Hematocrit increased, High-density lipoprotein decreased.	40mg Capsule 112.5mg Soft Gelatin Capsule	USFDA	অনুমোদনের সুপারিশ করা হয়।	নামঞ্জুর করা হয়।
187.	Renata Limited Mirpur, Dhaka	Testosterone Undecanoate 158 mg Soft gel capsule	Testosterone Undecanoate INN 158 mg	Hormone Therapeutic Code: 056	Testosterone undecanoate is an androgen indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.	**Contra-indication:** Men with carcinoma of the breast or known or suspected carcinoma of the prostate. Women who are pregnant testosterone can cause virilization of the female fetus when administered to a pregnant woman. Men with hypogonadal conditions, such as "age-related hypogonadism", that are not associated with structural or genetic etiologies. The efficacy of this medication has not been established for these conditions, and can increase BP which can	40mg Capsule 112.5mg Soft Gelatin Capsule	USFDA	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						increase the risk of MACE **Side-effects:** Headache, Nausea, Edema, Hypertension, Hematocrit increased, High-density lipoprotein decreased.				
188.	Renata Limited Mirpur, Dhaka	Testosterone Undecanoate 198 mg Soft gel capsule	Testosterone Undecanoate INN 198 mg	Hormone Therapeutic Code: 056	Testosterone undecanoate is an androgen indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.	**Contra-indication:** Men with carcinoma of the breast or known or suspected carcinoma of the prostate. Women who are pregnant testosterone can cause virilization of the female fetus when administered to a pregnant woman. Men with hypogonadal conditions, such as “age-related hypogonadism”, that are not associated with structural or genetic etiologies. The efficacy of this medication has not been established for these conditions, and can increase BP which can increase the risk of MACE **Side-effects:** Headache, Nausea, Edema, Hypertension, Hematocrit increased, High-density lipoprotein decreased.	40mg Capsule 112.5mg Soft Gelatin Capsule	USFDA	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
189.	Renata Limited Mirpur, Dhaka	Testosterone Undecanoate 237 mg Soft gel capsule	Testosterone Undecanoate INN 237 mg	Hormone Therapeutic Code: 056	Testosterone undecanoate is an androgen indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.	**Contra-indication:** Men with carcinoma of the breast or known or suspected carcinoma of the prostate. Women who are pregnant testosterone can cause virilization of the female fetus when administered to a pregnant woman. Men with hypogonadal conditions, such as “age-related hypogonadism”, that are not associated with structural or genetic etiologies. The efficacy of this medication has not been established for these conditions, and can increase BP which can increase the risk of MACE **Side-effects:** Headache, Nausea, Edema, Hypertension, Hematocrit increased, High-density lipoprotein decreased.	40mg Capsule 112.5mg Soft Gelatin Capsule	USFDA	অনুমোদনের সুপারিশ করা হয়।	প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
190.	Renata Limited Mirpur, Dhaka	Testosterone Cypionate 200mg/ml	Testosterone Cypionate USP	Hormone Therapeutic	Testosterone Cypionate Injection is an androgen indicated for	**Contra-indication:** Men with carcinoma of the breast or known or suspected carcinoma of the	40mg Capsule	USFDA	অনুমোদনের সুপারিশ করা হয়।	প্রয়োজন নেই বিধায় নামঞ্জুর

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
		Injection	200mg/ml	Code: 056	testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.	prostate. Women who are pregnant testosterone can cause virilization of the female fetus when administered to a pregnant woman. Men with hypogonadal conditions, such as "age-related hypogonadism", that are not associated with structural or genetic etiologies. The efficacy of this medication has not been established for these conditions, and can increase BP which can increase the risk of MACE **Side-effects:** Headache, Nausea, Edema, Hypertension, Hematocrit increased, High-density lipoprotein decreased.	112.5mg Soft Gelatin Capsule			করা হয়।
191.	Renata Limited Rajendrapur, Gazipur	Abiraterone Acetate 500 mg Tablet	Abiraterone Acetate USP 500 mg	Anticancer Therapeutic Code: 010	Abiraterone Acetate in combination with prednisone is indicated for the treatment of patients with metastatic castration resistant prostate cancer (CRPC) who have received prior chemotherapy containing docetaxel.	**Contra-indication:** Pregnancy **Side-effects:** Hypertension, Hypokalemia and Fluid Retention Due to Mineralocorticoid Excess, Adrenocortical Insufficiency, Hepatotoxicity.	250 mg Tablet	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।
192.	Renata Limited Mirpur, Dhaka	Levothyroxine Sodium 137 mcg Tablet	Levothyroxine Sodium USP 137 mcg	Thyroid and Antithyroid Therapeutic Code: 074	Hypothyroidism: As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotrophic (Thyroid Stimulating Hormone, TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of thyrotrophic dependent well-differentiated thyroid cancer.	**Contraindications:** Levothyroxine is contraindicated in patients with untreated subclinical (suppressed serum TSH level with normal T3 and T4 levels) or overt thyrotoxicosis of any etiology and in patients with acute myocardial infarction. Levothyroxine is contraindicated in patients with uncorrected adrenal insufficiency since thyroid hormones may precipitate an acute adrenal crisis by increasing the metabolic clearance of glucocorticoids. Levothyroxine sodium tablets, USP is contraindicated in patients with hypersensitivity to any of the inactive ingredients in Levothyroxine sodium tablets. Side effects: Fatigue, increased appetite, weight loss, heat intolerance, fever, excessive sweating. Central nervous system: headache, hyperactivity, nervousness, anxiety, irritability, emotional	12.5mcg, 25mcg, 50mcg, 75mcg and 100mcg Tablet	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						liability, insomnia. Musculoskeletal: tremors, muscle weakness, muscle spasm.				
193.	Beacon Pharmaceuticals PLC, Kathali, Bhaluka, Mymensingh Beximco Pharmaceuticals Ltd., Tongi, Gazipur DBL Pharmaceuticals Ltd. Gazipur Drug International Ltd, 31/1, Satrong, Tongi I/A, Gazipur EVEREST Pharmaceuticals Ltd. BSCIC I/A, Kanchpur, Narayanagnj Healthcare Pharmaceuticals Ltd. Rajendrapur, Gazipur Incepta Pharmaceuticals Ltd., Savar, Dhaka	Resmetirom 60mg Film Coated Tablet	Resmetirom INN 60mg	Thyroid hormone receptor-β Therpaeutic Class: 074	Resmetirom is a thyroid hormone receptor (THR) β selective agonist in development for the treatment of nonalcoholic steatohepatitis (NASH) with liver fibrosis. Resmetirom works in the treatment of NASH by acting as an agonist of THR–β in the liver. THR-β action is key to proper liver function, including regulation of mitochondrial activity such as breakdown of liver fat and control of the level of normal, healthy mitochondria. People with NASH have reduced levels of THR-β receptor activity in the liver. **Clinical Efficacy & Safety Data:** • In MAESTRO-NASH, a 52-week serial liver biopsy Phase 3 study in more than 950 patients, resmetirom achieved both primary endpoints and potentially clinically meaningful effects with both daily oral doses, 80 mg and 100 mg, relative to placebo ➢ NASH resolution (ballooning of 0, inflammation of 0-1) and ≥2-point NAS reduction with no worsening of fibrosis (p<0.0001 at both doses) ➢ Fibrosis improvement by at least one stage with no worsening of NAS (p=0.0002 and <0.0001 at 80	**CONTRAINDICATIONS:** Unknown **SIDE-EFFECT:** The most common adverse events reported as mild and transient diarrhea and nausea at the beginning of therapy.	New	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
	Navana Pharmaceuticals Ltd., Rupganj, Narayanaganj Nipro JMI Pharma Ltd., Cumilla Opsonin Pharmaceuticals Ltd., Barishal Pharmasia Ltd., Gazipur Popular Pharmaceuticals Ltd., 164, Tongi Industrial Area, Monnunagar, Gazipur Renata Limited, Mirpur, Dhaka Team Pharmaceuticals Ltd., BSCIC, Rajshahi Ziska Pharmaceuticals Ltd., Gazipur				and 100 mg, respectively) • Potentially clinically meaningful LDL-lowering, a key secondary endpoint (p<0.0001) • Multiple positive effects on NASH biomarkers and imaging • Resmetirom was safe and well-tolerated in the MAESTRO-NASH study, consistent with the overall safety in Phase 3 MAESTRO trials, expanding the large safety database Madrigal intends to file a new drug application seeking accelerated approval of resmetirom for the treatment of non-cirrhotic NASH with liver fibrosis					
194.	Beximco Pharmaceuticals	Aprocitentan 12.5mg Tablet	Aprocitentan INN 12.5mg	Antihypertensive drugs	It is an endothelin receptor antagonist indicated for the treatment of	**Contraindications**: Pregnancy & Hypersensitivity **Warnings**: EMBRYO–FETAL TOXICITY	New	USFDA	অনুমোদনের সুপারিশ করা হয়।	নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
	Ltd., Tongi, Gazipur Team Pharmaceuticals Ltd., BSCIC, Rajshahi Popular Pharmaceuticals Ltd., 164, Tongi Industrial Area, Monnunagar, Gazipur Advanced Chemical Industries Limited, 7 Hajeegonj, Godnyl, Narayangonj The ACME Laboratories Ltd. Dhamrai, Dhaka Incepta Pharmaceuticals Ltd., Savar, Dhaka Opsonin Pharma Ltd., Barishal Drug International Ltd 31/1, Satrong, Tongi I/A, Gazipur			Therapeutic code: 022	hypertension in combination with other antihypertensive drugs, to lower blood pressure in adult patients who are not adequately controlled on other drugs. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions	**Adverse Events:** Most common adverse reactions (more frequent than placebo and ≥ 2% in its treated patients) are edema/fluid retention and anemia.				

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
195.	Beacon Pharmaceuticals PLC, Kathali, Bhaluka, Mymensingh DBL Pharmaceuticals Ltd., Surabari, Kashimpur, Gazipur The ACME Laboratories Ltd. Dhamrai, Dhaka Eskayef Pharmaceuticals Limited, Tongi, Gazipur Opsonin Pharma Limited, Rupatali, Barishal	Tenapanor 10mg Tablet	Tenapanor HCl INN 10.60 mg Eqv. to Tenapanor 10.0mg Tablet	Others Classification **Therapeutic Code: 075**	Tenapanor is a sodium hydrogen exchanger 3 (NHE3) inhibitor indicated to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy	**Contraindication:** •Pediatric patients less than 6 years of age. •Patients with known or suspected mechanical gastrointestinal obstruction. **Side effects:** Most common adverse reactions (≥2%) are diarrhea, abdominal distension, flatulence and dizziness. **warnings and precautions** Patients may experience severe diarrhea	50 mg Tablet	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।
196.	Beacon Pharmaceuticals PLC, Kathali, Bhaluka, Mymensingh DBL Pharmaceuticals Ltd., Surabari, Kashimpur,	Tenapanor 20mg Tablet	Tenapanor HCl INN 21.30 mg Eqv. to Tenapanor 20.0mg Tablet	Others Classification **Therapeutic Code: 075**	Tenapanor is a sodium hydrogen exchanger 3 (NHE3) inhibitor indicated to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy	**Contraindication:** •Pediatric patients less than 6 years of age. •Patients with known or suspected mechanical gastrointestinal obstruction. **Side effects:** Most common adverse reactions (≥2%) are diarrhea, abdominal distension, flatulence and dizziness. **warnings and precautions** Patients may experience severe diarrhea	50 mg Tablet	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
	Gazipur The ACME Laboratories Ltd. Dhamrai, Dhaka Eskayef Pharmaceuticals Limited, Tongi, Gazipur Opsonin Pharma Limited, Rupatali, Barishal									
197.	Beacon Pharmaceuticals PLC, Kathali, Bhaluka, Mymensingh	Eltrombopag 12.5mg Powder for Oral Suspension	Eltrombopag Olamine INN 16.0mg eq. to Eltrombopag 12.5mg	Anticoagulants Therapeutic Code: 012	Eltrombopag is a thrombopoietin receptor agonist indicated for the treatment of: •thrombocytopenia in adult and pediatric patients 6 years and older with chronic immune (idiopathic) thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. Thrombocytopenia in patients with chronic hepatitis C to allow the initiation and maintenance of interferon -based therapy. Patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy. Limitations of Use: • Eltrombopag should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increase the risk for	**Contraindication:** None **Side effect:** In adult patients with ITP, the most common adverse reactions (greater than or equal to 5% and greater than placebo) were: nausea, diarrhea, upper respiratory tract infection, vomiting, increased ALT, myalgia, and urinary tract infection. In pediatric patients age 6 years and older with ITP, the most common adverse reactions (greater than or equal to 10% and greater than placebo) were upper respiratory tract infection, nasopharyngitis, and rhinitis. •In patients with chronic hepatitis C - associated thrombocytopenia, the most common adverse reactions (greater than or equal to 10% and greater than placebo) were: anemia, pyrexia, fatigue, headache, nausea, diarrhea, decreased appetite, influenza -like illness, asthenia, insomnia, cough, pruritus, chills, myalgia, alopecia and peripheral edema. In patients with severe aplastic anemia, the most common adverse reactions (greater than or equal to 20%) were:	Eltrombopag 12.5mg 25mg 50mg Tablet	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
					leeding. • Eltrombopag should be used only in patients with chronic hepatitis C whose degree of thrombocytopenia prevents the initiation of interferon - based therapy or limits the ability to maintain interferon -based therapy. •Safety and efficacy have not been established in combination with direct -acting antiviral agents used without interferon for treatment of chronic hepatitis C infection.	nausea, fatigue, cough, diarrhea, and headache.				
198.	Beacon Pharmaceuticals PLC, Kathali, Bhaluka, Mymensingh.	Taurolidine 40.5mg + Heparin 3000 USP Units/3ml Injection	Taurolidine INN 40.5mg + Heparin USP 3000 USP Units/3ml	Antimicrobial & Anticoagulants (012)	It is a combination of taurolidine, a thiadiazinane antimicrobial, and heparin, an anti-coagulant, indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis (HD) through a central venous catheter (CVC). This drug is indicated for use in a limited and specific population of patients. **Limitations of Use:** The safety and effectiveness of its have not been established for use in populations other than adult patients with kidney failure receiving chronic HD through a CVC.	**Contraindications:** • Known heparin-induced thrombocytopenia. • Known hypersensitivity to taurolidine, heparin or the citrate excipient (components of DEFENCATH), or pork products **WARNINGS AND PRECAUTIONS:** • Heparin-Induced Thrombocytopenia (HIT): HIT was reported in Trial 1 at an incidence rate of 0.3% in patients using heparin, a component of DEFENCATH as a CLS. If HIT occurs, discontinue Taurolidine & Heparin and institute appropriate supportive measures. • Drug Hypersensitivity Reactions: Drug hypersensitivity reactions were reported in Trial 1 at an incidence rate of 0.5% in patients using heparin, a component of Taurolidine & Heparin, as a CLS. If a hypersensitivity reaction occurs, discontinue Taurolidine & Heparin and institute appropriate supportive measures. ADVERSE REACTIONS: The most frequently reported adverse reactions occurring in greater than or equal to 2% of patients in Trial 1 using Taurolidine & Heparin as a CLS were	Heparin 5000 IU/ml 25000 IU/5ml Injection	USFDA	অনুমোদনের সুপারিশ করা হয়।	নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						hemodialysis catheter malfunction, hemorrhage/ bleeding, nausea, vomiting, dizziness, musculoskeletal chest pain, and thrombocytopenia				
199.	Beacon Pharmaceuticals PLC Kathali, Bhaluka, Mymensingh.	Taurolidine 67.5mg + Heparin 5000IU/5ml Injection	Taurolidine INN 67.5mg + Heparin USP 5000 USP Units/5ml Injection	Antimicrobial & Anticoagulants (012)	It is a combination of taurolidine, a thiadiazinane antimicrobial, and heparin, an anti-coagulant, indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis (HD) through a central venous catheter (CVC). This drug is indicated for use in a limited and specific population of patients. Limitations of Use: The safety and effectiveness of its have not been established for use in populations other than adult patients with kidney failure receiving chronic HD through a CVC.	**Contraindications:** • Known heparin-induced thrombocytopenia. • Known hypersensitivity to taurolidine, heparin or the citrate excipient (components of DEFENCATH), or pork products **WARNINGS AND PRECAUTIONS:** • Heparin-Induced Thrombocytopenia (HIT): HIT was reported in Trial 1 at an incidence rate of 0.3% in patients using heparin, a component of DEFENCATH as a CLS. If HIT occurs, discontinue Taurolidine & Heparin and institute appropriate supportive measures. • Drug Hypersensitivity Reactions: Drug hypersensitivity reactions were reported in Trial 1 at an incidence rate of 0.5% in patients using heparin, a component of Taurolidine & Heparin, as a CLS. If a hypersensitivity reaction occurs, discontinue Taurolidine & Heparin and institute appropriate supportive measures. ADVERSE REACTIONS: The most frequently reported adverse reactions occurring in greater than or equal to 2% of patients in Trial 1 using Taurolidine & Heparin as a CLS were hemodialysis catheter malfunction, hemorrhage/ bleeding, nausea, vomiting, dizziness, musculoskeletal chest pain, and thrombocytopenia	Heparin 5000 IU/ml 25000 IU/5ml Injection	USFDA	অনুমোদনের সুপারিশ করা হয়।	নামঞ্জুর করা হয়।
200.	Beacon Pharmaceuticals PLC, Kathali,	Elafibranor 80mg Tablet	Elafibranor INN 80mg	Unclassified Agent	It is a peroxisome proliferator-activated receptor (PPAR) agonist indicated for the treatment of primary	**Contraindication:** None **WARNINGS AND PRECAUTIONS:** Myalgia, Myopathy, and Rhabdomyolysis: Assess	New	USFDA	অনুমোদনের সুপারিশ করা হয়।	নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
	Bhaluka, Mymensingh			Therapeutic Code: 075	biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA. This indication is approved under accelerated approval based on reduction of alkaline phosphatase (ALP). Improvement in survival or prevention of liver decompensation events have not been demonstrated. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). **Limitations of Use**: Use of Elafibranor 80mg Tablet is not recommended in patients who have or develop decompensated cirrhosis (e.g., ascites, variceal bleeding, hepatic encephalopathy).	for muscle pain and myopathy prior to IQIRVO initiation. Consider periodic assessment (clinical exam, CPK measurement). Interrupt IQIRVO if there is new onset or worsening of muscle injury, or muscle pain. • Fractures: The risk of fracture should be considered in the care of patients treated with IQIRVO. Apply current standards of care for assessing and maintaining bone health. • Adverse Effects on Fetal and Newborn Development: May cause fetal harm. Verify that a female of reproductive potential is not pregnant prior to initiating Elafibranor. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception. • Drug-Induced Liver Injury: Obtain clinical and laboratory assessments at treatment initiation and monitor thereafter according to routine patient management. Interrupt the treatment if liver tests worsen, or patients develop signs and symptoms consistent with clinical hepatitis. Consider permanent discontinuation if liver tests worsen after restarting Elafibranor. • Hypersensitivity Reactions: If severe hypersensitivity reactions occur, permanently discontinue IQIRVO. If a mild or moderate hypersensitivity reaction occurs, interrupt Elafibranor and treat promptly. Monitor until signs and symptoms resolve. • Biliary Obstruction: Avoid use in patients with complete biliary obstruction. If biliary obstruction is suspected, interrupt Elafibranor and treat as clinically indicated. **Side effects:** Most common adverse reactions with Elafibranor (reported in ≥ 5% and higher compared to placebo) are weight gain, diarrhea,				

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						abdominal pain, nausea, vomiting, arthralgia, constipation, muscle injury, fracture, gastroesophageal reflux disease, dry mouth, weight loss, and rash.				
201.	UniMed UniHealth Pharmaceuticals Ltd. B.K Bari, Gazipur Sadar, Gazipur	Formoterol Fumarate 20mcg/2ml Nebulizer Solution	Formoterol Fumarate Dihydrate BP 0.02089mg eqv. to 0.020mg Formoterol Fumarate/2ml Nebulizer Solution	Beta2 Agonists	Formoterol fumarate Inhalation Solution is a long-acting beta2-adrenergic agonist (beta2-agonist) indicated for: • Long-term, twice daily (morning and evening) administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. **Important Limitations of Use**: This Inhalation Solution is not indicated to treat acute deteriorations of chronic obstructive pulmonary disease. This Inhalation Solution is not indicated to treat asthma. The safety and effectiveness of this Inhalation Solution in asthma have not been established.	**Side Effects:** Most common adverse reactions are diarrhea, nausea, nasopharyngitis, dry mouth, vomiting, dizziness, and insomnia **Contraindications:** Use of a LABA, including formoterol fumarate, without an inhaled corticosteroid is contraindicated in patients with asthma. formoterol fumarate is not indicated for the treatment of asthma. **Warning:** INCREASED RISK OF ASTHMA-RELATED DEATH Long-acting beta2-adrenergic agonists may increase the risk of asthma-related death. Data from a large placebocontrolled US study that compared the safety of another long-acting beta2-adrenergic agonist (salmeterol) or placebo added to usual asthma therapy showed an increase in asthma-related deaths in patients receiving salmeterol. This finding with salmeterol may apply to formoterol (a long-acting beta2-adrenergic agonist), the active ingredient in PERFOROMIST Inhalation Solution. Do not initiate formoterol fumarate Inhalation Solution in acutely deteriorating patients. • Do not use for relief of acute symptoms. Concomitant short-acting beta2-agonists can be used as needed for acute relief.	12 mcg Inhalation Capsule	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।
202.	EVEREST Pharmaceuticals Ltd. BSCIC I/A, Kanchpur,	Encorafenib 75 mg Capsule	Encorafenib INN 75 mg	Anticancer Therapeutic	Encorafenib is a kinase inhibitor indicated, in combination with binimetinib, for the treatment of patients with unresectable or	**CONTRAINDICATIONS:** None **WARNINGS AND PRECAUTIONS:**	**New**	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
	Narayanagnj			Code: 010	metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. **Limitations of Use:** Encorafenib is not indicated for treatment of patients with wild-type BRAF melanoma	• New Primary Malignancies, cutaneous and non-cutaneous: Can occur. Monitor for malignancies and perform dermatologic evaluations prior to, while on therapy, and following discontinuation of treatment. • Tumor Promotion in BRAF Wild-Type Tumors: Increased cell proliferation can occur with BRAF inhibitors. • Hemorrhage: Major hemorrhagic events can occur. • Uveitis: Perform ophthalmologic evaluation at regular intervals and for any visual disturbances. • QT Prolongation: Monitor electrolytes before and during treatment. Correct electrolyte abnormalities and control for cardiac risk factors for QT prolongation. Withhold Encorafenib for QTc of 500 ms or greater. Embryo-Fetal • Toxicity: Can cause fetal harm. Advise females with reproductive potential of potential risk to the fetus and to use effective non-hormonal method of contraception **SIDE-EFFECT:** The most common side effect is fatigue, nausea, vomiting, abdominal pain, and arthralgia etc.				
203.	EVEREST Pharmaceuticals Ltd. BSCIC I/A, Kanchpur, Narayanagnj	Binimetinib 15 mg Tablet	Binimetinib INN 15 mg	Anticancer Therapeutic Code: 010	Binimetinib is a kinase inhibitor indicated, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test	**CONTRAINDICATIONS:** None **WARNINGS AND PRECAUTIONS:** • Cardiomyopathy: Assess left ventricular ejection fraction (LVEF) before initiating treatment, after one month of treatment, then every 2 to 3 months thereafter. The safety of Binimetinib has not been established in patients with LVEF below 50%. • Venous Thromboembolism: Deep vein	New	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						thrombosis and pulmonary embolism can occur • Ocular Toxicities: Serous retinopathy, retinal vein occlusion (RVO) and uveitis have occurred. Perform an ophthalmologic evaluation at regular intervals and for any visual disturbances. • Interstitial Lung Disease (ILD): Assess new or progressive unexplained pulmonary symptoms or findings for possible ILD. • Hepatotoxicity: Monitor liver function tests before and during treatment and as clinically indicated. • Rhabdomyolysis: Monitor creatine phosphokinase and creatinine periodically and as clinically indicated. • Hemorrhage: Major hemorrhagic events can occur. • Embryo-Fetal Toxicity: Can cause fetal harm. Advise females with reproductive potential of potential risk to the fetus and to use effective contraception. **SIDE-EFFECT:** The most common side effect is fatigue, nausea, vomiting, abdominal pain, and arthralgia etc.				
204.	EVEREST Pharmaceuticals Ltd. BSCIC I/A, Kanchpur, Narayanagnj	Momelotinib 150mg Tablet	Momelotinib INN 150mg	Drug used in Anemia and other Blood disorder Therapeutic Code: 045	Indicated for the treatment of intermediate or high-risk myelofibrosis (MF), including primary MF or secondary MF [post-polycythemia vera (PV) and post-essential thrombocythemia (ET)], in adults with anemia.	**Contraindications:** Hypersensitivity to this product or any of its components. **Side effects:** Low blood platelets, bleeding, fatigue, dizziness, diarrhea, nausea, abdominal pain, itching, elevated liver enzymes, rash, kidney and urinary tract infection (UTI), irregular heartbeats (arrhythmias), and low white blood	New	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						cells (neutropenia). Precautions & warnings: Do not initiate Momelotinib in patients with an active infection. Monitor for signs and symptoms of infection. Thrombocytopenia and Neutropenia, Hepatotoxicity, Major Adverse Cardiovascular Events (MACE), Thrombosis.				
205.	EVEREST Pharmaceuticals Ltd. BSCIC I/A, Kanchpur, Narayanagnj	Iptacopan 200 mg Capsule	Iptacopan Hydrochloride INN 225.800 mg Eqv. to Iptacopan 200 mg Capsule	Drug used in Anaemia and other Blood disorder **Therapeutic Code:** 045	Iptacopan is a complement factor B inhibitor, indicated for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH).	**CONTRAINDICATIONS:** Serious hypersensitivity to iptacopan or any of the excipients. Initiation in patients with unresolved serious infection caused by encapsulated bacteria. **WARNINGS AND PRECAUTIONS:** WARNING: SERIOUS INFECTIONS CAUSED BY ENCAPSULATED BACTERIA It increases the risk of serious and life-threatening infections caused by encapsulated bacteria, including Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae type B. • Complete or update vaccination for encapsulated bacteria at least 2 weeks prior to the first dose of it, unless the risks of delaying Iptacopan 200 mg Capsule outweigh the risk of developing a serious infection. Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for vaccinations against encapsulated bacteria in patients receiving a complement inhibitor. Patients receiving Iptacopan 200 mg Capsule are at increased risk for invasive disease caused by encapsulated bacteria, even if they develop antibodies following vaccination. Monitor patients for early signs and symptoms of serious infections and evaluate immediately if infection is suspected.	New	USFDA	অনুমোদনের সুপারিশ করা হয়।	পরবর্তী টেকনিক্যাল সাব কমিটির সভায় পুনর্মূল্যায়নের সিদ্ধান্ত গৃহীত হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						Monitoring of PNH Manifestations After Iptacopan Discontinuation: Monitor for signs of hemolysis after discontinuation. Hyperlipidemia: Monitor serum lipid parameters periodically during treatment and initiate cholesterol-lowering medication, if indicated **SIDE EFFECTS:** Most common adverse reactions in adults with PNH (incidence ≥ 10%) were headache, nasopharyngitis, diarrhea, abdominal pain, bacterial infection, viral infection, nausea and rash.				
206.	Advanced Chemical Industries Limited, 7 Hajeegonj, Godnyl, Narayangonj Opsonin Pharma Ltd., Barishal	Desflurane 100% Inhalation solution	Desflurane USP 100%	Anaesthetics General Therapeutic Code: 004	It is a general anesthetic, is an inhalation agent indicated: • for induction and/or maintenance of anesthesia in adults for maintenance of anesthesia in pediatric patients following induction with agents other than Desflurane and intubation.	**Contraindication:** It is contraindicated in patients with Known or suspected genetic susceptibility to malignant hyperthermia. Patients in whom general anesthesia is contraindicated. Induction of anesthesia in pediatric patients. Patients with known sensitivity to Desflurane or to other halogenated agents. Patients with a history of moderate to severe hepatic dysfunction following anesthesia with Desflurane or other halogenated agents and not otherwise explained. **Side-effects:** The most common side effects are coughing, breath holding, apnea, nausea, vomiting, laryngospasm, pharyngitis. **Warnings and Precautions**: In susceptible individuals, volatile anesthetic agents, including Desflurane, may trigger malignant hyperthermia, a skeletal muscle hypermetabolic state leading to high oxygen demand. Caution should be taken. When Desflurane was tested as the primary anesthetic induction agent, the incidence of upper airway irritation (apnea, breathholding, laryngospasm, coughing and secretions) was high. Caution should be taken. Use of inhaled anesthetic agents has been associated with rare increases in serum potassium levels that have resulted in cardiac arrhythmias and death in pediatric patients during the postoperative period. Patients with latent as well as	New	USFDA	অনুমোদনের সুপারিশ করা হয়।	পরবর্তী ঔষধ নিয়ন্ত্রন কমিটির সভায় এনেস্থেশিয়া বিশেষজ্ঞ এর মতামত গ্রহনের সিদ্ধান্ত গৃহীত হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						overt neuromuscular disease, particularly Duchenne muscular dystrophy, appear to be most vulnerable. Concomitant use of succinylcholine has been associated with most, but not all, of these cases.				
207.	The ACME Laboratories Ltd. Dhamrai, Dhaka	Tiopronin 100 mg Delayed Release Tablet	Tiopronin INN 100 mg	Unclassified Agents Therapeutic Code: 075	Tiopronin is a reducing and complexing thiol indicated, in combination with high fluid intake, alkali, and diet modification, for the prevention of cystine stone formation in adults and pediatric patients 20 kg and greater with severe homozygous cystinuria, who are not responsive to these measures alone	**CONTRAINDICATIONS**: Hypersensitivity to tiopronin or any component of Tiopronin **WARNINGS AND PRECAUTIONS:** Proteinuria, including nephrotic syndrome, and membranous nephropathy, has been reported with tiopronin use. Pediatric patients receiving greater than 50 mg/kg of tiopronin per day may be at increased risk for proteinuria Hypersensitivity reactions have been reported during tiopronin treatment. **ADVERSE REACTIONS:** Most common adverse reactions (≥10%) are nausea, diarrhea or soft stools, oral ulcers, rash, fatigue, fever, arthralgia, proteinuria, and emesis.	New	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।
208.	The ACME Laboratories Ltd. Dhamrai, Dhaka	Budesonide 2mg/10ml Oral Suspension	Budesonide 2mg/10 ml	Adrenocortical Steroids Antagonist Therapeutic Code: 011	Used for the treatment of eosinophilic esophagitis.	**Contraindication:** It is contraindicated in patients with hypersensitivity to budesonide. Serious hypersensitivity reactions, including anaphylaxis, have occurred with oral budesonide products **Side-effects:** Respiratory tract infection, gastrointestinal mucosal candidiasis, headache, gastroenteritis, throat irritation, adrenal suppression, and erosive esophagitis. **Warnings & Precautions:** Hypercorticism and Adrenal Axis Suppression: May occur with treatment; monitor for signs and symptoms and consider reducing the dosage. Immunosuppression and Increased Risk of	500 mcg/2 ml Nebuliser suspension 1 mg/2 ml Nebuliser Solution	USFDA	অনুমোদনের সুপারিশ করা হয়।	পরবর্তী টেকনিক্যাল সাব কমিটির সভায় পুনর্মূল্যায়নের সিদ্ধান্ত গৃহীত হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						Infection: Increased risk of viral, bacterial, fungal, protozoan, and helminthic infections, including potentially fatal varicella and measles infection. Erosive Esophagitis: Advise patients or caregivers to report new or worsening signs or symptoms of erosive esophagitis; consider endoscopic evaluation as appropriate.				
209.	Square Pharmaceuticals PLC, Kaliakor, Gazipur The ACME Laboratories Ltd. Dhamrai, Dhaka Incepta Pharmaceuticals Ltd.; Savar Unit, Dhaka Healthcare Pharmaceuticals Ltd., Rajedrapur, Gazipur Drug International Ltd. Unit-2, Tongi, Gazipur Healthcare Pharmaceuticals Ltd, Gazariapara, Rajendrapur, Gazipur	Cefepime 2g + Enmetazobactam 0.5gm/Vial IV Injection	Cefepime (as Hydrochloride USP) 2g + Enmetazobactam INN 0.5 gm/Vial	Anti-infective Therapeutic code: 023	It is a combination of cefepime, a cephalosporin antibacterial, and enmetazobactam, a beta-lactamase inhibitor, indicated for the treatment of patients 18 years and older with complicated urinary tract infections (cUTI) including pyelonephritis caused by designated susceptible microorganisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefepime 2g + Enmetazobactam 0.5gm/Vial IV Injection and other antibacterial drugs, Cefepime 2g + Enmetazobactam 0.5gm/Vial IV Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.	**Contraindication:** Contraindicated in patients with a history of serious hypersensitivity reactions to the components of cefepime and Taniborbactam, or other beta-lactam antibacterial drugs **Side-effects: H**eadache, diarrhea, anemia, hypersensitivity, vomiting and nausea **Warnings & Precautions:** Hypersensitivity reactions, Neurotoxicity, Clostridioides difficile-Associated Diarrhea	Cefepime 500mg/vial 1 gm/vial 2 gm/vial Injection	USFDA EMA MHRA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
	Nuvista Pharma Ltd.									
210.	The ACME Laboratories Ltd. Dhamrai, Dhaka	Nadolol 40mg Tablet	Nadolol USP 40mg	Antihypertensive Therapeutic Code: 022	Nadolol is indicated for the long-term management of patients with angina pectoris. Also indicated for Hypertension, Arrhythmias, Migraine prophylaxis, Thyrotoxicosis (adjunct)	**Contra-indications:** Nadolol is contraindicated in bronchial asthma, sinus bradycardia, and greater than first-degree conduction block, cardiogenic shock, and overt cardiac failure. **Side-effects:** **Uncommon-**Appetite decreased . behaviour abnormal. constipation. cough. dry mouth. dyspepsia. facial swelling. flatulence. hyperhidrosis. nasal congestion. sedation. sexual dysfunction. skin reactions. speech slurred .tinnitus . vision blurred. weight increased. Nadolol should be used with caution in patients with impaired renal function	New	USFDA	অনুমোদনের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
211.	The ACME Laboratories Ltd. Dhamrai, Dhaka	Nadolol 80mg Tablet	Nadolol USP 80mg	Antihypertensive Therapeutic Code: 022	Nadolol is indicated for the long-term management of patients with angina pectoris. Also indicated for Hypertension, Arrhythmias, Migraine prophylaxis, Thyrotoxicosis (adjunct)	**Contra-indications:** Nadolol is contraindicated in bronchial asthma, sinus bradycardia, and greater than first-degree conduction block, cardiogenic shock, and overt cardiac failure. **Side-effects:** **Uncommon-**Appetite decreased . behaviour abnormal. constipation. cough. dry mouth. dyspepsia. facial swelling. flatulence. hyperhidrosis. nasal congestion. sedation. sexual dysfunction. skin reactions. speech slurred .tinnitus . vision blurred. weight increased. Nadolol should be used with caution in patients with impaired renal function	New	USFDA	অনুমোদনের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
212.	Incepta Pharmaceuticals	Ensifentrine 3 mg /2.5 ml nebulizer	Ensifentrine 3mg /2.5 ml	Drug used in Bronchial	Ensifentrine is a phosphodiesterase 3 (PDE3) inhibitor and	**Contraindication:** Ensifentrine is contraindicated in patients with hypersensitivity to Ensifentrine or	New	USFDA	অনুমোদনের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
	Ltd.;,Dhamrai Unit, Dhaka	Suspension		Asthma, Chronic obstructive pulmonary disease (COPD) Therpaeutic Class: 044	phosphodiesterase 4 (PDE4) inhibitor indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients.	any Component of this product. **Side-effects:** Commonly observed adverse events included pneumonia, gastrointestinal effects and cardiovascular events. **Warnings and Precautions:** • Should not use Ensifentrine to treat acute symptoms of Bronchospasm • if paradoxical bronchospasm occurs, discontinue Ensifentrine and institute alternative therapy. An increase in psychiatric adverse reactions, including suicidality, were reported with use of Ensifentrine. Carefully weigh the risks and benefits of treatment with Ensifentrine in patients with a history of depression and/or suicidal thoughts or behavior.				বিধায় নামঞ্জুর করা হয়।
213.	Incepta Pharmaceuticals Ltd.;,Zirabo, Dhaka	Tranylcypromine 10mg Tablet	Tranylcypromine Sulfate BP 13.68mg eqv. to Tranylcypromine 10mg	Antidepressants Therpaeutic Class: 14	TRANYLCYPROMINE is a monoamine oxidase inhibitor (MAOI) indicated for the treatment of major depressive disorder (MDD) in adult patients who have not responded adequately to other antidepressants. TRANYLCYPROMINE is not indicated for the initial treatment of MDD due to the potential for serious adverse reactions and drug interactions, and the need for dietary restrictions	**CONTRAINDICATIONS:** Concomitant use or use in rapid succession with other MAOIs; selective serotonin reuptake inhibitors; serotonin and norepinephrine reuptake inhibitors; tricyclic antidepressants; sympathomimetic drugs; and numerous other drugs. See Full Prescribing Information for the full list of contraindicated products. **WARNINGS AND PRECAUTIONS:** **Activation of Mania/Hypomania:** May be precipitated by antidepressant treatment in patients with bipolar disorder. Screen patients prior to treatment **Hypotension (including syncope):** Monitor patients and adjust TRANYLCYPROMINE dosage or concomitant medication as necessary.	New	USFDA	অনুমোদনের সুপারিশ করা হয়।	পরবর্তী ঔষধ নিয়ন্ত্রণ কমিটির সভায় সাইক্রিয়াটিস্টের মতামতসহ পুনর্মূল্যায়নের সিদ্ধান্ত গৃহীত হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						Hypotension and Hypertension during Anesthesia and Perioperative Care: If possible, discontinue TRANYLCYPROMINE prior to elective surgery **Hepatitis and Elevated Liver Enzymes:** Monitor accordingly				
214.	Incepta Pharmaceuticals Ltd.;,Dhamrai Unit, Dhaka	Topical gel: 10.3% berdazimer supplied as two tubes. Tube A contains berdazimer gel and Tube B contains hydrogel.	Tube A: Berdazimer Sodium INN 10.9g/100g eqv.to Berdazimer 10.30g/100g + Tube B: Hydrogel	Skin and Mucous membrane preparations Therapeutic Code: 071	Berdazimer is a nitric oxide (NO) releasing agent indicated for the topical treatment of molluscum contagiosum (MC) in adults and pediatric patients 1 year of age and older.	**CONTRAINDICATIONS:** None **WARNINGS AND PRECAUTIONS:** Application Site Reactions: Application site reactions, including allergic contact dermatitis, occurred. Discontinue ZELSUVMI and initiate appropriate therapy.	New	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।
215.	Incepta Pharmaceuticals Ltd.;,Zirabo, Dhaka	Pegloticase 8mg/1ml Vial Injection, for intravenous infusion	Pegloticase (8mg/ml) ready to fill bulk* INN/In-house1ml/vial eqv.to Pegloticase 8mg/Vial in 1ml	Chronic gout Therapeutic code: 075	Pegloticase is indicated, for the treatment of chronic gout in adult patient's refractory to conventional therapy. Gout refractory to conventional therapy occurs in patients who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these drugs are contraindicated.	**Contraindication:** Pegloticase is contraindicated in: •Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. •Patients with history of serious hypersensitivity reactions, including anaphylaxis, to Pegloticase or any of its components. **Side-effects:** chest pain; orflushing (warmth, redness, or tingly feeling). Common side effects of pegloticase may include: •COVID-19 symptoms such as fever or chills, cough, sore throat, shortness of breath, fatigue, muscle or body aches, headache, loss of taste or smell; hives, shortness of breath, chest pain or discomfort, skin redness, or itching; joint pain; allergic reactions; new gout flares; nausea, vomiting, constipation; or bruising. **Warnings and Precautions:** No data available	New	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।
216.	Incepta	Trientine	Trientine	Wilson's	Trientine tetrahydrochloride is a	**Contraindication:** Hypersensitivity to trientine or	New	USFDA	অনুমোদনের	অনুমোদন করা

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
	Pharmaceuticals Ltd.,Zirabo, Dhaka	Tetrahydrochloride 300mg Tablet	Tetrahydrochloride INN/In-house 300mg	disease Therapeutic code: 075	copper chelator indicated for the treatment of adult patients with stable Wilson's disease who are de-coppered and tolerant to penicillamine.	to any of the excipients in Trientine tetrahydrochloride. **Side-effects:** Most common adverse reactions (>5%) are abdominal pain, change of bowel habits, rash, alopecia, and mood swings. **Warnings and Precautions:** •Potential for Worsening of Clinical Symptoms at Initiation of Therapy: May include neurological deterioration. Adjust dosage or discontinue Trientine tetrahydrochloride if clinical condition worsens. •Copper Deficiency: Periodic monitoring is required. •Iron Deficiency: If iron deficiency develops, a short course of iron supplementation may be given. •Hypersensitivity Reactions: If rash or other hypersensitivity reaction occurs, consider discontinuing Trientine tetrahydrochloride.			সুপারিশ করা হয়।	হয়।
217.	Incepta Pharmaceuticals Ltd.,Zirabo, Dhaka	Sotorasib 320 mg Tablet	Sotorasib INN/In-house 320 mg	Anticancer Therapeutic Code: 010	Sotorasib is an inhibitor of the RAS GTPase family indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy. (1) This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DOR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s)	**Contraindication:** None. **Side-effects:** The most common side effects of Sotorasib include: • diarrhea • liver problems • muscle or bone pain • cough • nausea • changes in liver function tests • tiredness • changes in certain other blood tests **Warnings and Precautions:** Sotorasib can cause hepatotoxicity, which may lead to drug-induced liver injury and hepatitis. Sotorasib can cause **Interstitial Lung Disease (ILD)**//pneumonitis that can be fatal.	New	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
218.	Incepta Pharmaceuticals Ltd.;,Zirabo, Dhaka Drug International Ltd 31/1, Satrong, Tongi I/A, Gazipur	Macitentan 10mg + Tadalafil 20 mg Tablet	Macitentan INN/In-house 10mg + Tadalafil USP 20 mg	Unclassified Agents Therapeutic Code:075	It is a combination of macitentan, an endothelin receptor antagonist (ERA), and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor, indicated for chronic treatment of pulmonary arterial hypertension (PAH, WHO Group I) in adult patients of WHO functional class (FC) II-III. (1.1) Individually, macitentan reduces the risk of clinical worsening events and hospitalization, and tadalafil improves exercise ability.	**Contraindication:** Drug comes with a Boxed Warning for embryo-fetal toxicity because it can cause major birth defects. It must not be taken during pregnancy and acceptable forms of contraception should be used before initiation of treatment, during treatment, and for one month after stopping treatment. Pregnancy must be excluded before treatment initiation. **Side-effects:** Headache, Nausea, Discomfort **Warnings and Precautions:** must not be used during pregnancy	New	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।
219.	Incepta Pharmaceuticals Ltd.;,Zirabo, Dhaka Drug International Ltd 31/1, Satrong, Tongi I/A, Gazipur	Macitentan 10mg + Tadalafil 40 mg Tablet	Macitentan INN/In-house 10mg + Tadalafil USP 40 mg	Unclassified Agents Therapeutic Code:075	It is a combination of macitentan, an endothelin receptor antagonist (ERA), and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor, indicated for chronic treatment of pulmonary arterial hypertension (PAH, WHO Group I) in adult patients of WHO functional class (FC) II-III. (1.1) Individually, macitentan reduces the risk of clinical worsening events and hospitalization, and tadalafil improves exercise ability.	**Contraindication:** Drug comes with a Boxed Warning for embryo-fetal toxicity because it can cause major birth defects. It must not be taken during pregnancy and acceptable forms of contraception should be used before initiation of treatment, during treatment, and for one month after stopping treatment. Pregnancy must be excluded before treatment initiation. **Side-effects:** Headache, Nausea, Discomfort **Warnings and Precautions:** must not be used during pregnancy	New	USFDA	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
220.	Incepta Pharmaceuticals Ltd.;,Zirabo, Dhaka	Rivastigmine 0.2g/100ml Solution	Rivastigmine Tartrate USP 0.32g eqv.to Rivastigmine 0.2g/100ml	Cholinergic Therapeutic Code:037	Rivastigmine Tartrate is an acetylcholinesterase inhibitor indicated for treatment of: Mild-to-moderate dementia of the Alzheimer's type (AD)	**Contraindication:** Known hypersensitivity to rivastigmine, other carbamate derivatives or other components of the formulation. History of application site reaction with rivastigmine transdermal patch suggestive of	1.5 mg, 3mg, 4.5 mg, 6mg, Capsule, 4.5 mg Tablet	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
					Mild-to-moderate dementia associated with Parkinson's disease (PD).	allergic contact dermatitis, in the absence of negative allergy testing. **Side-effects:** Most common adverse reactions (greater than 5% and 2 times greater than placebo): nausea, vomiting, anorexia, dyspepsia, and asthenia. **Warnings and Precautions:** Gastrointestinal adverse reactions may include significant nausea, vomiting, diarrhea, anorexia/decreased appetite, and weight loss, and may necessitate treatment interruption. Dehydration may result from prolonged vomiting or diarrhea and can be associated with serious outcomes. In patients with suspected allergic contact dermatitis after transdermal rivastigmine use, switch to oral rivastigmine only after negative allergy testing.				
221.	Beximco Pharmaceuticals Ltd., Tongi, Gazipur	Gadobutrol 1 mmol/ml Injection	Gadubutrol Monohydrate USP 622.73 mg eqv. to 1.0 mmol Gadubutrol (604.72 mg)/ml	Diagnostic agents **Therapeutic Code:** 041	Gadobutrol is a gadolinium-based contrast agent indicated for intravenous use in diagnostic MRI in adults and children (2 years of age and older) to detect and visualize areas with disrupted blood brain barrier (BBB) and/or abnormal vascularity of the central nervous system.	**Contraindication:** None **Side effects:** Gadobutrol may cause side effects including: -Reactions along the venous injection site, such as mild and transient burning or pain or feeling of warmth or coldness at the injection site -Headache, nausea, abnormal taste and feeling hot **Warning and Precaution:** Nephrogenic Systemic Fibrosis has occurred in patients with impaired elimination of GBCAs. Higher than recommended dosing or repeated dosing appears to increase the risk. Hypersensitivity: Anaphylactoid/anaphylactic reactions with cardiovascular, respiratory or cutaneous manifestations, ranging from mild to severe, including death, have uncommonly	New	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						occurred. Monitor patients closely for need of emergency cardiorespiratory support				
222.	Radiant Pharmaceuticals Limited B-34 & B-46, BSCIC I/E, Tongi, Gazipur Healthcare Pharmaceuticals Ltd., Rajendrapur, Gazipur	Naproxen 750mg ER Tablet	Naproxen Sodium USP 821.600mg eqv. to Naproxen 750mg	Nonsteroidal antiinflamatory and drugs used in arthritis Therapeutic code: 064	It is a nonsteroidal anti-inflammatory drug indicated for the treatment of: • rheumatoid arthritis (RA) • osteoarthritis (OA) • ankylosing spondylitis (AS) • tendinitis, bursitis • acute gout • primary dysmenorrhea (PD) the relief of mild to moderate pain	**Side Effects:** The most frequent adverse events were headache (15%), followed by dyspepsia (14%), and flu syndrome (10%) **Contraindication:** Known hypersensitivity to naproxen or any components of the drug product • History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs In the setting of CABG surgery **WARNING:** RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use • It is contraindicated in the setting of coronary artery bypass graft (CABG) surgery • NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at	250mg & 500mg Tablet	USFDA	অনুমোদনের সুপারিশ করা হয়।	পরবর্তী ঔষধ নিয়ন্ত্রন কমিটির সভায় পুনর্মূল্যায়নের সিদ্ধান্ত গৃহীত হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						greater risk for serious GI events.				
223.	Healthcare Pharmaceuticals Ltd, Gazariapara, Rajendrapur, Gazipur Drug International Ltd 31/1, Satrong, Tongi I/A, Gazipur	Givinostat 8.86 mg/mL Oral Suspension	Givinostat Hydrochloride Monohydrate INN 1.0g eq. to Givinostat 0.886gm/100 mL	Anti-inflammatory drugs Therapeutic code: 064	Givinostat is a histone deacetylase inhibitor indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 6 years of age and older	**Contraindications:** None **Side-effects:** Most common adverse reactions (≥10%) are diarrhea, abdominal pain, thrombocytopenia, nausea/vomiting, hypertriglyceridemia, and pyrexia. **WARNINGS AND PRECAUTIONS:** Hematological Changes: Givinostat can cause dose-related thrombocytopenia and other signs of myelosuppression, including anemia and neutropenia. Monitor platelets; dosage adjustment or discontinuation may be needed.	New	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।
224.	Healthcare Pharmaceuticals Ltd, Gazariapara, Rajendrapur, Gazipur Eskayef Pharmaceuticals Ltd. Rupganj, Narayanganj	Sugammadex Sodium Injection 200mg/2 mL Injection	Sugammadex Sodium INN 217.60mg eq. to 200mg Sugammadex/2ml	Neuromuscular blocking agent Therapeutic code: 063	Sugammadex is used to reverse the effects of the muscle relaxants rocuronium and vecuronium. These medicines are given to patients during surgery	**Contraindications:** Sugammadex is contraindicated for patients with a history of hypersensitivity reactions, ranging from isolated skin reactions to anaphylaxis. **Side-effects:** The most common adverse reactions are vomiting, dry mouth, tachycardia, dizziness and hypotension . On the other hand, there has been report of severe hypotension following the administration of sugammadex, with systolic blood pressure falling to 50 mmHg or below. **WARNINGS AND PRECAUTIONS:** This medicine may increase your risk of bleeding problems. Tell your doctor right away if you have sudden or severe headache, problems with vision, speech, or walking, or unusual bleeding or bruising. Before you have any medical tests, tell the medical doctor in charge that you were given this medicine	New	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
225.	Healthcare Pharmaceuticals Ltd, Gazariapara, Rajendrapur, Gazipur Eskayef Pharmaceuticals Ltd. Rupganj, Narayanganj	Sugammadex Sodium Injection 500mg/5 mL Injection	Sugammadex Sodium INN 544.00mg eq. to 500mg Sugammadex/5ml	Neuromuscular blocking agent Therapeutic code: 063	Sugammadex is used to reverse the effects of the muscle relaxants rocuronium and vecuronium. These medicines are given to patients during surgery.	**Contraindications:** Sugammadex is contraindicated for patients with a history of hypersensitivity reactions, ranging from isolated skin reactions to anaphylaxis. **Side-effects:** The most common adverse reactions are vomiting, dry mouth, tachycardia, dizziness and hypotension . On the other hand, there has been report of severe hypotension following the administration of sugammadex, with systolic blood pressure falling to 50 mmHg or below. **WARNINGS AND PRECAUTIONS:** This medicine may increase your risk of bleeding problems. Tell your doctor right away if you have sudden or severe headache, problems with vision, speech, or walking, or unusual bleeding or bruising. Before you have any medical tests, tell the medical doctor in charge that you were given this medicine	New	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।
226.	Eskayef Pharmaceuticals Limited, Rupganj, Narayanganj	Pegaspargase 3750IU/ 5ml Injection	Pegaspargase INN 3750Iu/5ml Vial	**Anticancer** Therapeutic code:**010**	Pegaspargase is an asparagine specific enzyme indicated as a component of a multi agent chemotherapeutic regimen for treatment of pediatric and adult patients with: • First-line acute lymphoblastic leukemia Acute lymphoblastic leukemia and hypersensitivity to asparaginase	**CONTRAINDICATIONS:** • History of serious hypersensitivity reactions to Pegaspargase. • History of serious thrombosis with prior L-asparaginase therapy. • History of pancreatitis with prior L-asparaginase therapy. • History of serious hemorrhagic events with prior L-asparaginase therapy. • Severe hepatic impairment. **SIDE-EFFECT:** The most common (>5%) grade >3 adverse	New	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						reactions with Pegaspargase are hypoalbuminemia, elevated transaminase, febrile neutropenia, hypertriglyceridemia, hyperglycemia, bilirubin increased, pancreatitis, abnormal clotting studies, embolic and thrombotic events, hypersensitivity, sepsis, and infections. **WARNINGS AND PRECAUTIONS:** • Anaphylaxis or serious hypersensitivity reactions: Observe patients for 1 hour after administration. Discontinue Pegaspargase in patients with serious hypersensitivity reactions. • Thrombosis: Discontinue Pegaspargase in patients with serious thrombotic events. • Pancreatitis: Evaluate patients with abdominal pain for pancreatitis. Discontinue Pegaspargase in patients with pancreatitis. • Glucose intolerance: Monitor serum glucose. • Hemorrhage: Discontinue Pegaspargase for severe or life-threatening hemorrhage. Evaluate for etiology and treat. Hepatotoxicity, including hepatic veno-occlusive disease (VOD): Monitor for toxicity through recovery from cycle. Discontinue Pegaspargase for severe liver toxicity.				
227.	Eskayef Pharmaceuticals Limited, Rupganj, Narayanganj	Toripalimab 240mg/6ml IV Injection	Toripalimab-tpzi INN 240mg/6ml Vial	**Anticancer** Therapeutic code: **010**	Toripalimab is a programmed death receptor-1 (PD-1) blocking antibody indicated: • in combination with cisplatin and gemcitabine, for first-line treatment of adults with metastatic or with recurrent locally advanced nasopharyngeal carcinoma (NPC). • as a single agent for the treatment of adults with recurrent unresectable or metastatic NPC with	**CONTRAINDICATIONS:** None **SIDE-EFFECT:** • Toripalimab in Combination with Cisplatin and Gemcitabine: The most common adverse reactions (≥ 20%) are nausea, vomiting, decreased appetite, constipation, hypothyroidism, rash, pyrexia, diarrhea, peripheral neuropathy, cough, musculoskeletal pain, upper respiratory infection, insomnia, dizziness, and malaise. • Toripalimab as a Single Agent: The most common adverse reactions (≥ 20%) are	New	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
					disease progression on or after a platinum containing chemotherapy. **USE IN SPECIFIC POPULATIONS** Lactation: Advise not to breastfeed.	fatigue, hypothyroidism and musculoskeletal pain. **WARNINGS AND PRECAUTIONS:** • Immune-Mediated Adverse Reactions: a) Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue, including the following: immune-mediated pneumonitis, immune-mediated colitis, immune-mediated hepatitis, immune mediated endocrinopathies, and immune-mediated nephritis with renal dysfunction, immune-mediated dermatologic adverse reactions, and solid organ transplant rejection. b) Monitor for early identification and management. Evaluate liver enzymes, creatinine, and thyroid function at baseline and periodically during treatment. • Infusion-related reactions: Interrupt, slow the rate of infusion, or permanently discontinue Complications of allogeneic HSCT: Fatal and other serious complications • Complications of allogeneic HSCT: Fatal and other serious complications can occur in patients who receive allogeneic HSCT before or after being treated with a PD-1/PD-L1 blocking antibody. Embryo-fetal toxicity: Can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective method of contraception.				
228.	Eskayef Pharmaceuticals Limited, Tongi, Gazipur	Cyclobenzaprine Hydrochloride 15mg Extended Release Capsule	Cyclobenzaprine Hydrochloride USP 15mg	**Skeleton Muscle Relaxant** Therapeutic code:	Cyclobenzaprine is a muscle relaxant indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief	**CONTRAINDICATIONS:** • Hyperthyroidism. • Hypersensitivity to any component of this product. • Concomitant use of monoamine oxidase (MAO) inhibitors or within 14 days after their	Cyclobenzaprine HCl 5mg Tablet Cyclobenzaprine HCl	USFDA	অনুমোদনের সুপারিশ করা হয়।	প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
				070	of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, and limitation of motion. **Limitations of Use:** • should be used only for short periods (up to 2 or 3 weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. has not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease or in children with cerebral palsy.	discontinuation. • During acute recovery phase of myocardial infarction, and in patients with arrhythmias, heart block or conduction disturbances, or congestive heart failure. **SIDE-EFFECT:** Most common adverse reactions (incidence ≥3% in any treatment group and greater than placebo): dry mouth, dizziness, fatigue, constipation, nausea, dyspepsia, and somnolence. **WARNINGS AND PRECAUTIONS:** • Serotonin syndrome has been reported with Cyclobenzaprine when used in combination with other serotonergic drugs. • Cyclobenzaprine is structurally related to tricyclic antidepressants which have been reported to produce adverse cardiovascular effects or CNS depressant effects. • Use in the elderly is not recommended. • Use in patients with hepatic impairment is not recommended. Use with caution in patients with a history of urinary retention, angle-closure glaucoma, increased intraocular pressure and in patients taking anticholinergic medications.	10mg Tablet			
229.	Eskayef Pharmaceuticals Limited, Tongi, Gazipur	Cyclobenzaprine Hydrochloride 30mg Extended Release Capsule	Cyclobenzaprine Hydrochloride USP 30mg	**Skeleton Muscle Relaxant** Therapeutic code: **070**	Cyclobenzaprine is a muscle relaxant indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain,	**CONTRAINDICATIONS:** • Hyperthyroidism. • Hypersensitivity to any component of this product. • Concomitant use of monoamine oxidase (MAO) inhibitors or within 14 days after their discontinuation. • During acute recovery phase of	Cyclobenzaprine HCl 5mg Tablet Cyclobenzaprine HCl 10mg Tablet	USFDA	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
					tenderness, and limitation of motion. **Limitations of Use:** • should be used only for short periods (up to 2 or 3 weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. has not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease or in children with cerebral palsy.	myocardial infarction, and in patients with arrhythmias, heart block or conduction disturbances, or congestive heart failure. **SIDE-EFFECT:** Most common adverse reactions (incidence ≥3% in any treatment group and greater than placebo): dry mouth, dizziness, fatigue, constipation, nausea, dyspepsia, and somnolence. **WARNINGS AND PRECAUTIONS:** • Serotonin syndrome has been reported with Cyclobenzaprine when used in combination with other serotonergic drugs. • Cyclobenzaprine is structurally related to tricyclic antidepressants which have been reported to produce adverse cardiovascular effects or CNS depressant effects. • Use in the elderly is not recommended. • Use in patients with hepatic impairment is not recommended. Use with caution in patients with a history of urinary retention, angle-closure glaucoma, increased intraocular pressure and in patients taking anticholinergic medications.				
230.	Sun Pharmaceutical (EZ) Ltd, Meghna Industrial Economic Zone, Tipordi, Mograpara, Sonargaon, Narayangonj	Lacosamide 150 mg Tablet	Lacosamide BP 150 mg	Antidepressant	Indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalization in adults, adolescents and children from 2 years of age with epilepsy. Lacosamide is indicated as adjunctive therapy • in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. • in the treatment of primary generalised tonic-clonic seizures in adults,	Contra-indication: Known hypersensitivity to Lacosamide, Known second- or third-degree atrioventricular (AV) block. Side effects: **Blood and lymphatic disorders:** Agranulocytosis, **Immune system disorders:** Drug hypersensitivity, Drug reaction with eosinophilia and systemic symptoms (DRESS)· **Psychiatric disorders:** Depression, Confusional state, Insomnia· Aggression, Agitation(1), Euphoric mood(1), Psychotic disorder(1), Suicide attempt(1), Suicidal ideation, Hallucination, **Nervous system disorders:**· Dizziness, Headache, Myoclonic seizures(3), Ataxia, Balance disorder	50mg & 100mg Tablet	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
					adolescents and children from 4 years of age with idiopathic generalised epilepsy	Memory impairment, Cognitive disorder, Somnolence, Tremor, Dysarthria, Syncope(2), Coordination abnormal, Dyskinesia Disturbance in attention, Paraesthesia Nystagmus, Hypoesthesia, Convulsion, **Eye disorders:** Diplopia, Vision blurred, Vertigo, Tinnitus, **Cardiac disorders:** Atrioventricular block(1,2), Bradycardia(1,2), Atrial Fibrillation (1,2), Atrial Flutter , Ventricular tachyarrhythmia **Gastrointestinal disorders:** Nausea, Vomiting, Constipation, Flatulence, Dyspepsia, Dry mouth, Diarrhoea, **Hepatobiliary disorders:** Liver function test abnormal, Hepatic enzyme increased (> 2x ULN), Pruritus, Rash, Angioedema(1), Urticaria, Stevens-Johnson syndrome, **General disorders and administration site conditions:** Gait disturbance, Asthenia Fatigue, Irritability, Feeling drunk, Toxic epidermal necrolysis, **Injury, poisoning and procedural complications:** Fall, Skin laceration, Contusion				
231.	Sun Pharmaceutical (EZ) Ltd, Meghna Industrial Economic Zone, Tipordi, Mograpara, Sonargaon, Narayangonj	Lacosamide 200 mg Tablet	Lacosamide BP 200mg	Antidepressant	Indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalization in adults, adolescents and children from 2 years of age with epilepsy. Lacosamide is indicated as adjunctive therapy • in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. • in the treatment of primary generalised tonic-clonic seizures in	Contra-indication: Known hypersensitivity to Lacosamide, Known second- or third-degree atrioventricular (AV) block. Side effects: **Blood and lymphatic disorders:** Agranulocytosis, **Immune system disorders:** Drug hypersensitivity, Drug reaction with eosinophilia and systemic symptoms (DRESS) · **Psychiatric disorders:** Depression, Confusional state, Insomnia· Aggression, Agitation(1), Euphoric mood(1), Psychotic disorder(1), Suicide attempt (1), Suicidal ideation, Hallucination, **Nervous system disorders:**· Dizziness, Headache, Myoclonic seizures(3), Ataxia, Balance disorder Memory impairment, Cognitive disorder, Somnolence, Tremor, Dysarthria, Syncope(2), Coordination abnormal, Dyskinesia Disturbance in attention, Paraesthesia	50mg & 100mg Tablet	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
					adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy	Nystagmus, Hypoesthesia, Convulsion, **Eye disorders:** Diplopia, Vision blurred, Vertigo, Tinnitus, **Cardiac disorders:** Atrioventricular block(1,2), Bradycardia(1,2), Atrial Fibrillation (1,2), Atrial Flutter , Ventricular tachyarrhythmia **Gastrointestinal disorders:** Nausea, Vomiting, Constipation, Flatulence, Dyspepsia, Dry mouth, Diarrhoea, **Hepatobiliary disorders:** Liver function test abnormal, Hepatic enzyme increased (> 2x ULN), Pruritus, Rash, Angioedema(1), Urticaria, Stevens-Johnson syndrome, **General disorders and administration site conditions:** Gait disturbance, Asthenia Fatigue, Irritability, Feeling drunk, Toxic epidermal necrolysis, **Injury, poisoning and procedural complications:** Fall, Skin laceration, Contusion				
232.	Sun Pharmaceutical (EZ) Ltd, Meghna Industrial Economic Zone, Tipordi, Mograpara, Sonargaon, Narayangonj	Clonazepam USP 1.0mg ODT Tablet	Clonazepam USP 1 mg	Anti-epileptic	Panic attack, Epilepsy, Status epilepticus, Lennox-Gastaut syndrome, Infantile spasm, Absence seizure, Myoclonic seizure, Tonic-clonic seizure, Akinetic and atonic seizure, Partial Seizure, Bipolar affective disorder, Drug-induced dyskinesia, , Choreiform movement, , Fulgurant pain, Tourette's syndrome, , Resistant depression, , Nocturnal myoclonus, Trigeminal neuralgia	**Contra-indication:** History of sensitivity to benzodiazepines or any other component of the formulation, Acute narrow angle glaucoma. Acute pulmonary insufficiency, Severe respiratory insufficiency, Sleep apnea syndrome, Myasthenia gravis, Severe hepatic insufficiencySide effects: The most frequently reported side effects with clonazepam are related to CNS depression including drowsiness and ataxia. In some cases, these may diminish with time; behavior problems have been reported in some patients. Other adverse effects reported are abnormal eye movements, aphonia, choreiform movements, coma, diplopia, dysarthria, dysdiadochokinesis, "glassy eyed" appearance, headache, hemiparesis, hypotonia, nystagmus, respiratory depression, slurred speech, tremor, vertigo,	0.5 mg, 1.0mg & 2.0mg Tablet 0.5mg ODT Tablet	USFDA	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						confusion, depression, amnesia, hallucinations, hysteria, increased libido, decreased libido, delayed ejaculation, insomnia, psychosis, suicidal attempt paradoxical reactions including excitability, irritability, aggressive behavior, agitation, nervousness, hostility, anxiety, abnormal coordination, dizziness, emotional lability, reduced intellectual ability, sleep disturbances, nightmares and vivid dreams. Chest congestion, rhinorrhea, shortness of breath, hypersecretion in upper respiratory passages, upper respiratory tract infections, sinusitis, rhinitis, coughing, pharyngitis, bronchitis, palpitations, hair loss, hirsutism, skin rash, fatigue, ankle and facial edema, anorexia, coated tongue, constipation, diarrhea, dry mouth, encopresis, gastritis, increased appetite, abdominal pain, decreased appetite, nausea, sore gums, dysuria, enuresis, micturition frequency, urinary tract infection, nocturia, urinary retention, dysmenorrhoea, colpitis, blurred vision, muscle weakness, pains, dehydration, general deterioration, fever, lymphadenopathy weight loss or gain, anemia, leukopenia, thrombocytopenia, eosinophilia, influenza, hepatomegaly, transient elevations of serum trasaminases and alkaline phosphatase are also reported.				
233.	Sun Pharmaceutical (EZ) Ltd, Meghna Industrial Economic Zone, Tipordi, Mograpara, Sonargaon,	Clonazepam USP 2.0mg ODT Tablet	Clonazepam USP 2.0 mg	Anti-epileptic	Panic attack, Epilepsy, Status epilepticus, Lennox-Gastaut syndrome, Infantile spasm, Absence seizure, Myoclonic seizure, Tonic-clonic seizure, Akinetic and atonic seizure, Partial Seizure, Bipolar affective disorder, Drug-induced dyskinesia, Choreiform movement,	**Contra-indication:** History of sensitivity to benzodiazepines or any other component of the formulation, Acute narrow angle glaucoma. Acute pulmonary insufficiency, Severe respiratory insufficiency, Sleep apnea syndrome, Myasthenia gravis, Severe hepatic insufficiency Side effects: The most frequently reported side effects with clonazepam are related to CNS	0.5 mg, 1.0mg & 2.0mg Tablet 0.5mg ODT Tablet	USFDA	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
	Narayangonj				Fulgurant pain, Tourette's syndrome, Resistant depression,, Nocturnal myoclonus, Trigeminal neuralgia	depression including drowsiness and ataxia. In some cases, these may diminish with time; behavior problems have been reported in some patients. Other adverse effects reported are abnormal eye movements, aphonia, choreiform movements, coma, diplopia, dysarthria, dysdiadochokinesis, "glassy eyed" appearance, headache, hemiparesis, hypotonia, nystagmus, respiratory depression, slurred speech, tremor, vertigo, confusion, depression, amnesia, hallucinations, hysteria, increased libido, decreased libido, delayed ejaculation, insomnia, psychosis, suicidal attempt paradoxical reactions including excitability, irritability, aggressive behavior, agitation, nervousness, hostility, anxiety, abnormal coordination, dizziness, emotional lability, reduced intellectual ability, sleep disturbances, nightmares and vivid dreams. Chest congestion, rhinorrhea, shortness of breath, hypersecretion in upper respiratory passages, upper respiratory tract infections, sinusitis, rhinitis, coughing, pharyngitis, bronchitis, palpitations, hair loss, hirsutism, skin rash, fatigue, ankle and facial edema, anorexia, coated tongue, constipation, diarrhea, dry mouth, encopresis, gastritis, increased appetite, abdominal pain, decreased appetite, nausea, sore gums, dysuria, enuresis, micturition frequency, urinary tract infection, nocturia, urinary retention, dysmenorrhoea, colpitis, blurred vision, muscle weakness, pains, dehydration, general deterioration, fever, lymphadenopathy weight loss or gain, anemia, leukopenia, thrombocytopenia, eosinophilia, influenza, hepatomegaly, transient elevations of serum trasaminases and alkaline phosphatase are also reported.				

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
234.	Ziska Pharmaceuticals Ltd.	Sofpironium Bromide 12.45% Gel	Sofpironium INN 12.45%	Miscellaneous topical agents	Sofpironium is an anticholinergic indicated for the treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older	**Contraindications:** Medical conditions that can be exacerbated by the anticholinergic effect of Sofpironium (e.g., glaucoma, paralytic ileus, unstable cardiovascular status in acute hemorrhage, severe ulcerative colitis, toxic megacolon complicating ulcerative colitis, myasthenia gravis, Sjögren's syndrome). **Warnings and precautions:** • Urinary Retention: Use with caution in patients with a history or presence of documented urinary retention. Discontinue use immediately and consult a healthcare provider should any signs or symptoms of urinary retention develop. • Control of Body Temperature: Watch for generalized lack of sweating when in hot or very warm environmental temperatures and avoid using Sofpironium if not sweating under these conditions • Operating Machinery or an Automobile: Transient blurred vision may occur with use of SOFDRA. If blurred vision occurs, discontinue use and avoid operating a motor vehicle or other machinery until symptoms resolve	New	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।
235.	Ziska Pharmaceuticals Ltd.	Polidocanol 180mg/18ml Injectable foam for intravenous use	Polidocanol INN 180mg/18 ml	Other Classification Therapeutic code: **075**	Polidocanol is indicated to uncomplicated spider veins (varicose veins ≤1 mm in diameter) and uncomplicated reticular veins (varicose veins 1 to 3 mm in diameter) in the lower extremity.	**Contraindications:** Polidocanol is contraindicated for patients with known allergy (anaphylaxis) to polidocanol and patients with acute thromboembolic diseases. **Side effects:** Local effects, including tissue necrosis, may occur following extravasation; therefore, care should be taken in intravenous needle placement and the smallest effective volume at each injection site should be used **Warning and precautions:** Anaphylaxis: Severe allergic reactions have been reported following	New	USFDA	অনুমোদনের সুপারিশ করা হয়।	নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						polidocanol use, including anaphylactic reactions, some of them fatal. Severe reactions are more frequent with use of larger volumes (> 3 mL). The dose of Polidocanol should therefore be minimized. Be prepared to treat anaphylaxis appropriately. Severe adverse local effects, including tissue necrosis, may occur following extravasation; therefore, care should be taken in intravenous needle placement and the smallest effective volume at each injection site should be used.				
236.	Ziska Pharmaceuticals Ltd., Gazipur	Talazoparib 0.5mg Capsule	Talazoparib Tosylate INN 0.727mg Eqv. to 0.5mg Talazoparib	Anticancer Therpaeutic Code: 010	**BRCA-mutated (gBRCAm) HER2-negative Locally Advanced or Metastatic Breast Cancer**: It is indicated as a single agent for the treatment of adult patients with deleterious or suspected deleterious germline breast cancer susceptibility gene (BRCA)-mutated (gBRCAm) human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. **HRR Gene-mutated mCRPC**: It is indicated in combination with Enzalutamide for the treatment of adult patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC).	**Contraindications**: It is contraindicated in patients with known hypersensitivity to Talazoparib or any other components of this product. **Precautions: •Myelodysplastic Syndrome/ Acute Myeloid Leukemia (MDS/AML):** MDS/AML occurred in patients exposed to Talazoparib, and some cases were fatal. Monitor patients for hematological toxicity and discontinue if MDS/AML is confirmed. **•Myelosuppression:** It may affect hematopoiesis and can cause anemia, neutropenia, and/or thrombocytopenia. **•Embryo-Fetal Toxicity:** It can cause fetal harm. Advise of the potential risk to the fetus and to use effective contraception. **Warning:** As per precaution. **Side effects:** • Myelodysplastic Syndrome/Acute Myeloid Myelosuppression	New	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।
237.	Ziska Pharmaceuticals Ltd., Gazipur	Talazoparib 1.0mg Capsule	Talazoparib Tosylate INN 1.453 mg Eqv. to	Anticancer Therpaeutic	**BRCA-mutated (gBRCAm) HER2-negative Locally Advanced or Metastatic Breast Cancer**: It is	**Contraindications**: It is contraindicated in patients with known hypersensitivity to Talazoparib or any other components of this	New	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
			1.0mg Talazoparib	Code: 010	indicated as a single agent for the treatment of adult patients with deleterious or suspected deleterious germline breast cancer susceptibility gene (BRCA)-mutated (gBRCAm) human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. **HRR Gene-mutated mCRPC**: It is indicated in combination with Enzalutamide for the treatment of adult patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC).	product. **Precautions: •Myelodysplastic Syndrome/ Acute Myeloid Leukemia (MDS/AML):** MDS/AML occurred in patients exposed to Talazoparib, and some cases were fatal. Monitor patients for hematological toxicity and discontinue if MDS/AML is confirmed. **•Myelosuppression:** It may affect hematopoiesis and can cause anemia, neutropenia, and/or thrombocytopenia. **•Embryo-Fetal Toxicity:** It can cause fetal harm. Advise of the potential risk to the fetus and to use effective contraception. **Warning:** As per precaution. **Side effects:** Myelodysplastic Syndrome/Acute Myeloid Myelosuppression				
238.	Opsonin Pharma Limited, Rupatali, Barishal	Betamethasone 0.05% Topical Spray	Betamethasone BP 0.5mg/gm	Skin and Mucous Membrane Preparations Therpaeutic Code: 071	Indicated for the treatment of mild to moderate plaque psoriasis	**Precautions & Warnings:** It can produce reversible HPA axis suppression with the potential for glucocorticosteroid insufficiency during or after treatment. Cushing's syndrome, hyperglycemia, and unmasking of latent diabetes mellitus can result from systemic absorption of topical corticosteroids. Use of topical corticosteroids may require periodic evaluation for HPA axis suppression. Modify use if HPA axis suppression develops. High potency corticosteroids, large treatment surface areas, prolonged use, use of occlusive dressings, altered skin barrier, liver failure and young age may predispose patients to HPA axis suppression. **Side Effect:** The most common side effects include itching, burning, stinging, pain, and thinning of skin (atrophy) at the treated site.	0.5% Cream 0.5% Ointment	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
239.	Opsonin Pharma Limited, Rupatali, Barishal	Fluconazole 200mg/5ml Powder for Suspension	Fluconazole USP 200mg/5ml	Antifungal **Code:** 020	Indicated for the treatment fungal infections in children of 6 months and older.	Hypersensitivity to the active substance, to related azole substances, or to any of the excipients listed in section Coadministration of terfenadine is contraindicated in patients receiving fluconazole at multiple doses of 400 mg per day or higher based upon results of a multiple dose interaction study. Coadministration of other medicinal products known to prolong the QT interval and which are metabolised via the cytochrome P450 (CYP) 3A4 such as cisapride, astemizole, pimozide, quinidine, and erythromycin are contraindicated in patients receiving fluconazole	50 mg/5 ml Powder For Suspension	USFDA	অনুমোদনের সুপারিশ করা হয়।	নামঞ্জুর করা হয়।
240.	Opsonin Pharma Limited, Rupatali, Barishal	Ketoconazole 2% Gel	Ketoconazole BP 20mg/gm	Skin and Mucous Membrane Preparations **Code:** 071	Indicated for the topical treatment of seborrheic dermatitis in immunocompromised adults.	**Contraindications:** It is contraindicated in those patients with a history of sensitivity reactions to any of its components. It should be discontinued if hypersensitivity is noted.	2% Cream	USFDA	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
241.	Drug International Ltd., Plot # 13A & 14A, Tongi I/A, Tongi, Gazipur	Pegulicianine 39.00mg/vial Lyophilized powder for IV infusion	Pegulicianine INN 39.00mg/vial	**Anticancer** Code No: 010	It is indicated for fluorescence imaging in adults with breast cancer as an adjunct for the intraoperative detection of cancerous tissue within the resection cavity following removal of the primary specimen during lumpectomy surgery.	**Contraindication:** It is contraindicated in patients with a history of hypersensitivity reaction to Pegulicianine. Reactions have included anaphylaxis. **Precaution:** Caution should be exercised when Pegulicianine is used in patients with Anaphylaxis and Other Serious Hypersensitivity Reactions. **Warning:** As per precaution. **Side effects:** Most common side effects are: Anaphylaxis and Other Serious Hypersensitivity Reactions.	New	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।
242.	Drug International Ltd. Plot # 13A & 14A,	Pivmecillinam 185mg Tablet	Pivmecillinam HCl INN 200mg Eqv. to	Antibiotic Code No: 023	It is a penicillin class antibacterial indicated for the treatment of female patients 18 years of age and older	Contraindications: It is contraindicated in patient having Serious hypersensitivity reactions (e.g., anaphylaxis or Stevens-Johnson syndrome),	200mg Tablet	USFDA	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
	Tongi I/A, Tongi, Gazipur.		Pivmecillinam 185mg		with uncomplicated urinary tract infections (uUTI) caused by susceptible isolates of Escherichia coli, Proteus mirabilis and Staphylococcus saprophyticus.	Primary or secondary carnitine deficiency resulting from inherited disorders of mitochondrial fatty acid oxidation and carnitine metabolism, and other inborn errors of metabolism, Acute porphyria. Precautions: Precaution should be taken to patients with Severe Cutaneous Adverse Reactions (SCAR), Carnitine Depletion, Clostridioides Difficile-Associated Diarrhea (CDAD). Warning: As per precaution. Side effects: • Nausea Diarrhea				করা হয়।
243.	Drug International Ltd 31/1, Satrong, Tongi I/A, Gazipur.	Vomorolone 4.00gm/100ml Oral Suspension	Vamorolone INN 4.00gm/100ml	Steroid Code No: 072	It of is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older.	**Contraindications**: It is contraindicated in patients with a known hypersensitivity to Vamorolone or any components of this product. **f) Precautions:**Caution should be exercised when using this medicine in patients with Alterations in Endocrine Function, Immunosuppression and Increased Risk of Infection, Alterations in Cardiovascular/Renal Function, Gastrointestinal Perforation etc. **Warning:**As per precaution. **Side effects:** The most common adverse reactions (>10% for THIS medicine and greater than placebo) are cushingoid features, psychiatric disorders, vomiting, weight increased, and vitamin D deficiency.	New	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।
244.	Drug International Ltd	Sotatercept-csrk INN 45mg/vial Injection	Sotatercept-csrk INN 45mg/vial	Anti-Hypertensive	It is is an activin signaling inhibitor indicated for the treatment of adults	**Contraindications**: There are no data in available.	New	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
	31/1, Satrong, Tongi I/A, Gazipur.			Code No: 022	with pulmonary arterial hypertension to increase exercise capacity, improve WHO functional class (FC) and reduce the risk of clinical worsening events.	**Side effects:** The most common (≥10% in patients receiving this medicine and 5% more than placebo) adverse reactions were headache, epistaxis, rash, telangiectasia, diarrhea, dizziness, and erythema.				
245.	Drug International Ltd 31/1, Satrong, Tongi I/A, Gazipur.	Sotatercept-csrk INN 60mg/vial Injection	Sotatercept-csrk INN 60mg/vial	Anti-Hypertensive Code No:022	It is is an activin signaling inhibitor indicated for the treatment of adults with pulmonary arterial hypertension to increase exercise capacity, improve WHO functional class (FC) and reduce the risk of clinical worsening events.	**Contraindications**: There are no data in available. **Side effects:** The most common (≥10% in patients receiving this medicine and 5% more than placebo) adverse reactions were headache, epistaxis, rash, telangiectasia, diarrhea, dizziness, and erythema.	New	USFDA	অনুমোদনের সুপারিশ করা হয়।	নামঞ্জুর করা হয়।
246.	Drug International Ltd 31/1, Satrong, Tongi I/A, Gazipur.	Somapacitan-beco 10mg/1.5ml Pre-filled Syringe pen Injection	Somapacitan-beco INN 10mg/1.5ml Pre-filled Syringe or pen Injection.	**Hormone** Code: 056	It is a human growth hormone analog indicated for treatment of **Pediatric Patients:** Treatment of pediatric patients aged 2.5 years and older who have growth failure due to inadequate secretion of endogenous growth hormone (GH). **Adults:** Replacement of endogenous growth hormone in adults with growth hormone deficiency.	**Contraindications**: It is Contraindicated in this drug is contraindicated in- Acute critical illness, Active malignancy, Hypersensitivity to somapacitan-beco or excipients, Active proliferative or severe non-proliferative diabetic retinopathy etc. **Precautions:** It should not be administered in the following conditions: Severe Hypersensitivity, Increased Risk of Neoplasms, Glucose Intolerance and Diabetes Mellitus, Intracranial Hypertension (IH) etc. **Warning:** As per precaution. **Side effects:** Pediatric patients with GHD: Adverse reactions reported in ≥5% of patients treated with SOGROYA are: nasopharyngitis, headache, pyrexia, pain in extremity, and injection site reaction. • Adult patients with GHD: Adverse reactions	New	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						reported in >2% of patients treated with SOGROYA are: back pain, arthralgia, dyspepsia, sleep disorder, dizziness, tonsillitis, peripheral edema, vomiting, adrenal insufficiency, hypertension, blood creatine phosphokinase increase, weight increase, anemia				
247.	Drug International Ltd., 31/1, Satrong, Tongi I/A, Gazipur	Amlodipine 5.00mg + Valsartan 160.00mg + Hydrochlorothiazide 12.50mg Tablet	Amlodipine Besylate 6.94mg (Eqv. to 5.00mg Amlodipine + Valsartan USP 160.00mg + Hydrochlorothiazide USP 12.50mg	**Antihypertensive** Code No:-022	It is indicated for the treatment of Hypertension. Not indicated for initial therapy	**Contraindications**: This Tablet is contraindicated in patients with Anuria; Hypersensitivity to sulfonamide-derived drugs. **Precautions:** Avoid fetal or neonatal exposure, Symptomatic hypotension with volume- or salt-depletion. Correct volume-depletion prior to administration. Increased angina and/or myocardial infarction. Avoid in patients with severely impaired hepatic or renal function (creatinine clearance ≤30 mL/min). Observe for signs of fluid or electrolyte imbalance. Thiazide diuretics may cause an exacerbation or activation of systemiclupuserythematosus. Hydrochlorothiazide has been associated with acute angle-closure glaucoma **Warning:** As per precaution. **Side effects:** The most common adverse events (≥2% incidence) are dizziness, peripheral edema, headache, dyspepsia, fatigue, muscle spasms, back pain, nausea and nasopharyngitis.	Amlodipine 5mg + Valsartan 80mg Tablet Amlodipine 10mg + Valsartan 320mg Tablet Hydrochlorothiazide 12.5 mg + Valsartan 160 mg Tablet	USFDA	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
248.	Drug International Ltd., 31/1, Satrong,	Amlodipine 10.00mg + Valsartan 160.00mg +	Amlodipine Besylate	**Antihypertensive** Code No:-	It is indicated for the treatment of Hypertension. Not indicated for initial	**Contraindications**: This Tablet is contraindicated in patients with Anuria;	Amlodipine 5mg +	USFDA	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ	বর্তমানে প্রয়োজন নেই

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
	Tongi I/A, Gazipur	Hydrochlorothiazide 12.50mg Tablet	13.89mg (Eqv. to 10.00mg Amlodipine + Valsartan USP 160.00mg + Hydrochlorothiazide USP 12.50mg	022	therapy	Hypersensitivity to sulfonamide-derived drugs. **Precautions:** Avoid fetal or neonatal exposure, Symptomatic hypotension with volume- or salt-depletion. Correct volume-depletion prior to administration. Increased angina and/or myocardial infarction. Avoid in patients with severely impaired hepatic or renal function (creatinine clearance ≤30 mL/min). Observe for signs of fluid or electrolyte imbalance. Thiazide diuretics may cause an exacerbation or activation of systemiclupuserythematosus. Hydrochlorothiazide has been associated with acute angle-closure glaucoma **Warning:** As per precaution. **Side effects:** The most common adverse events (≥2% incidence) are dizziness, peripheral edema, headache, dyspepsia, fatigue, muscle spasms, back pain, nausea and nasopharyngitis.	Valsartan 80mg Tablet Amlodipine 10mg + Valsartan 320mg Tablet Hydrochlorothiazide 12.5 mg + Valsartan 160 mg Tablet		করা হয়।	বিধায় নামঞ্জুর করা হয়।
249.	Drug International Ltd., 31/1, Satrong, Tongi I/A, Gazipur	Amlodipine 5.00mg + Valsartan 160.00mg + Hydrochlorothiazide 25mg Tablet	Amlodipine Besylate 6.94mg (Eqv. to 5.00mg Amlodipine + Valsartan USP 160.00mg + Hydrochlorothiazide USP 25mg	**Antihypertensive** Code No:-022	It is indicated for the treatment of Hypertension. Not indicated for initial therapy	**Contraindications**: This Tablet is contraindicated in patients with Anuria; Hypersensitivity to sulfonamide-derived drugs. **Precautions:** Avoid fetal or neonatal exposure, Symptomatic hypotension with volume- or salt-depletion. Correct volume-depletion prior to administration. Increased angina and/or myocardial infarction. Avoid in patients with severely impaired hepatic or renal function (creatinine clearance ≤30 mL/min). Observe for signs of fluid or electrolyte imbalance. Thiazide diuretics may cause an exacerbation or activation of systemiclupuserythematosus.	Amlodipine 5mg + Valsartan 80mg Tablet Amlodipine 10mg + Valsartan 320mg Tablet Hydrochlorothiazide 12.5 mg +	USFDA	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						Hydrochlorothiazide has been associated with acute angle-closure glaucoma **Warning:** As per precaution. **Side effects:** The most common adverse events (≥2% incidence) are dizziness, peripheral edema, headache, dyspepsia, fatigue, muscle spasms, back pain, nausea and nasopharyngitis.	Valsartan 160 mg Tablet			
250.	Drug International Ltd., 31/1, Satrong, Tongi I/A, Gazipur	Amlodipine 10.00mg + Valsartan 160.00mg + Hydrochlorothiazide 25 mg Tablet	Amlodipine Besylate 13.89mg (Eqv. to 10.00mg Amlodipine + Valsartan USP 160.00mg + Hydrochlorothiazide USP 25.0mg	**Antihypertensive** Code No:-022	It is indicated for the treatment of Hypertension. Not indicated for initial therapy	**Contraindications**: This Tablet is contraindicated in patients with Anuria; Hypersensitivity to sulfonamide-derived drugs. **Precautions:** Avoid fetal or neonatal exposure, Symptomatic hypotension with volume- or salt-depletion. Correct volume-depletion prior to administration. Increased angina and/or myocardial infarction. Avoid in patients with severely impaired hepatic or renal function (creatinine clearance ≤30 mL/min). Observe for signs of fluid or electrolyte imbalance. Thiazide diuretics may cause an exacerbation or activation of systemiclupuserythematosus. Hydrochlorothiazide has been associated with acute angle-closure glaucoma **Warning:** As per precaution. **Side effects:** The most common adverse events (≥2% incidence) are dizziness, peripheral edema, headache, dyspepsia, fatigue, muscle spasms, back pain, nausea and nasopharyngitis.	Amlodipine 5mg + Valsartan 80mg Tablet Amlodipine 10mg + Valsartan 320mg Tablet Hydrochlorothiazide 12.5 mg + Valsartan 160 mg Tablet	USFDA	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
251.	Drug International Ltd 31/1, Satrong, Tongi I/A, Gazipur Navana Pharmaceuticals	Minoxidil 2.50mg Tablet	Minoxidil INN 2.50mg	Antihypertensive Code No: 022	It is indicated for the treatment of severe Hypertension. It should not be used a the sole agent of initiate therapy.It is a peripheral vasodilator and should be given in conjunction with a diuretic, to control salt and water retention, and a beta	**Contraindications**: This Tablet is contraindicated in patients with minoxidil or any other excipients of minoxidil. It is also contraindicated in patients with a phaeochromocytoma because it may stimulate secretion of catecholamines from the tumor through its antihypertensive action.	2%, 5% Scalp Lotion	USFDA	অনুমোদনের সুপারিশ করা হয়।	নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
	Ltd., Rupganj, Narayanaganj				adrenergic blocking agent or appropriate substitute to control reflex tachycardia.	**Precautions:** Salt and water retension, Thrombocytopenia and leucopenia have been rarely reported. Pericarditis, pericardial effusion and tamponade: there is no evidence of casual relationship and there have multiple reports of pericarditis occurring in association with minoxidil. Pateints with rare hereditary problems of galactose intolerance, total lactose deficiency or glucose-galactosemalabsorption should not take this medicine. **Warning:** As per precaution. **Side effects:** The most common adverse events are fluid retention, oedema, tachycardia, pericarditis, breast tenderness.				
252.	Drug International Ltd 31/1, Satrong, Tongi I/A, Gazipur.	Minoxidil 10.0mg Tablet	Minoxidil INN 10.00mg	Antihypertensive Code No: 022	It is indicated for the treatment of severe Hypertension. It should not be used a the sole agent of initiate therapy.It is a peripheral vasodilator and should be given in conjunction with a diuretic, to control salt and water retention, and a beta adrenergic blocking agent or appropriate substitute to control reflex tachycardia.	**Contraindications**: This Tablet is contraindicated in patients with minoxidil or any other excipients of minoxidil. It is also contraindicated in patients with a phaeochromocytoma because it may stimulate secretion of catecholamines from the tumor through its antihypertensive action. **Precautions:** Salt and water retension, Thrombocytopenia and leucopenia have been rarely reported. Pericarditis, pericardial effusion and tamponade: there is no evidence of casual relationship and there have multiple reports of pericarditis occurring in association with minoxidil. Pateints with rare hereditary problems of galactose intolerance, total lactose deficiency or glucose-galactosemalabsorption should not take this medicine. **Warning:** As per precaution. **Side effects:** The most common adverse events are fluid retention, oedema, tachycardia,	2%, 5% Scalp Lotion	USFDA	অনুমোদনের সুপারিশ করা হয়।	নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						pericarditis, breast tenderness.				
253.	Drug International Ltd 31/1, Satrong, Tongi I/A, Gazipur	Lofexidine 0.18mg Tablet	Lofexidine INN 0.18mg	**Antihypertensive** Code No:- 022	It is a central alpha-2 adrenergic agonist indicated for mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults.	**Contraindications**: Lofexidine is contraindicated in patients with Hypersensitivity to Lofexidine or other ingredients. **Precautions:** Risk of Hypotension, Bradycardia, and Syncope: May cause a decrease in blood pressure, a decrease in pulse, and syncope. Monitor vital signs before dosing and advise patients on how to minimize the risk of these cardiovascular effects and manage symptoms, should they occur. Monitor symptoms related to bradycardia and orthostasis. When using in outpatients, ensure that patients are capable of self-monitoring signs and symptoms. Avoid use in patients with severe coronary insufficiency, recent myocardial infarction, cerebrovascular disease, or chronic renal failure, as well as in patients with marked bradycardia. Risk of QT Prolongation: LUCEMYRA prolongs the QT interval. Avoid use in patients with congenital long QT syndrome. Monitor ECG in patients with electrolyte abnormalities, congestive heart failure, bradyarrhythmias, hepatic or renal impairment, or in patients taking other medicinal products that lead to QT prolongation. Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs: LUCEMYRA potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. Increased Risk of Opioid Overdose after Opioid Discontinuation: Patients who complete opioid discontinuation are at an increased risk of fatal overdose should they resume opioid use. Use in conjunction with comprehensive management	New	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						program for treatment of opioid use disorder and inform patients and caregivers of increased risk of overdose. **Warning:** As per precaution. **Side effects:** Most common adverse reactions (incidence ≥ 10% and notably more frequent than placebo) are orthostatic hypotension, bradycardia, hypotension, dizziness, somnolence, sedation, and dry mouth.				
254.	Drug International Ltd 31/1, Satrong, Tongi I/A, Gazipur.	Atogepant 10mgTablet	Atogepant INN 10mg	CNS Code No: 047	It is indicated for is a calcitonin gene-related peptide receptor antagonist indicated for the preventive treatment of episodic migraine in adults.	**Contraindications**: It is contraindicated in patients with a known hypersensitivity to Atogepant or any components of this product. **Side effects:** The most common adverse reactions (at least 4% and greater than placebo) are nausea, constipation, and fatigue	New	USFDA	অনুমোদনের সুপারিশ করা হয়।	নামঞ্জুর করা হয়।
255.	Drug International Ltd 31/1, Satrong, Tongi I/A, Gazipur.	Atogepant 30mgTablet	Atogepant INN 30mg	CNS Code No: 047	It is indicated for is a calcitonin gene-related peptide receptor antagonist indicated for the preventive treatment of episodic migraine in adults.	**Contraindications**: It is contraindicated in patients with a known hypersensitivity to Atogepant or any components of this product. **Side effects:** The most common adverse reactions (at least 4% and greater than placebo) are nausea, constipation, and fatigue	New	USFDA	অনুমোদনের সুপারিশ করা হয়।	প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
256.	Drug International Ltd 31/1, Satrong, Tongi I/A, Gazipur	Atogepant 60mgTablet	Atogepant INN 60mg	CNS Code No: 047	It is indicated for is a calcitonin gene-related peptide receptor antagonist indicated for the preventive treatment of episodic migraine in adults.	**Contraindications**: It is contraindicated in patients with a known hypersensitivity to Atogepant or any components of this product. **Side effects:** The most common adverse reactions (at least 4% and greater than placebo) are nausea, constipation, and fatigue	New	USFDA	অনুমোদনের সুপারিশ করা হয়।	প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
257.	Synovia Pharma PLC., Station Road, Tongi, Gazipur	Cariprazine 1.5mg Capsule	Cariprazine Hydrochloride INN1.628 mg eqv. to Cariprazine 1.5mg	Antipsychotic Therapeutic Code: 028	Treatment of schizophrenia in adults, Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults, Treatment of depressive episodes associated with bipolar I disorder (bipolar depression) in adults, Adjunctive therapy to	**Contra-indication**: Cariprazine is contraindicated in patients with a history of a hypersensitivity reaction to Cariprazine. Reactions have ranged from rash, pruritus, urticaria, and reactions suggestive of angioedema (e.g., swollen tongue, lip swelling, face edema, pharyngeal edema, and swelling face).	New	USFDA, MHRA, EMA	অনুমোদনের সুপারিশ করা হয়।	পরবর্তী ঔষধ নিয়ন্ত্রণ কমিটির সভায় সাইক্রিয়াটিস্টের মতামতসহ পুনর্মূল্যায়নের সিদ্ধান্ত গৃহীত

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
					antidepressants for the treatment of major depressive disorder (MDD) in adults.	**Side-effects:** Extrapyramidal symptoms (muscle spasms, muscle rigidity, tremor, jerking movements), agitation, indigestion, nausea, vomiting, sleepiness, restlessness, fatigue, constipation, increased appetite, dizziness, weight Gain, headache, and insomnia. Consult with doctor if have the following serious side effects: • Serious eye symptoms such as sudden vision loss, blurred vision, tunnel vision, eye pain or swelling, or seeing halos around lights. • Serious heart symptoms such as fast, irregular, or pounding heartbeats; fluttering in your chest; shortness of breath; and sudden dizziness, lightheadedness, or passing out. • Severe headache, confusion, slurred speech, arm or leg weakness, trouble walking, loss of coordination, feeling unsteady, very stiff muscles, high fever, profuse sweating, or tremors. **Warning and Precautions:** Increased Mortality in Elderly Patients with Dementia-Related Psychosis: Antipsychotic drugs increase the all-cause risk of death in elderly patients with dementia-related psychosis. Analyses of 17 dementia-related psychosis placebo-controlled trials (modal duration of 10 weeks and largely in patients taking atypical antipsychotic drugs) revealed a risk of death in the drug-treated patients of between 1.6 to 1.7 times that in placebo-treated patients. Over the				হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in placebo-treated patients. Cerebrovascular Adverse Reactions, including Stroke, in elderly patients with Dementia-Related Psychosis: In placebo-controlled trials in elderly patients with dementia, patients randomized to risperidone, aripiprazole, and olanzapine had a higher incidence of stroke and transient ischemic attack, including fatal stroke. Cariprazine is not approved for the treatment of patients with dementia-related psychosis. Neuroleptic Malignant Syndrome (NMS): NMS, a potentially fatal symptom complex, has been reported in association with administration of antipsychotic drugs. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, delirium, and autonomic instability. Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. If NMS is suspected, immediately discontinue cariprazine and provide intensive symptomatic treatment and monitoring. Hyperglycemia And Diabetes Mellitus: Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics. Assess fasting plasma glucose before or soon after initiation of antipsychotic medication and monitor periodically during long-term treatment.				

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						Seizures: Like other antipsychotic drugs, Cariprazine may cause seizures. This risk is greatest in patients with a history of seizures or with conditions that lower the seizure threshold. Conditions that lower the seizure threshold may be more prevalent in older patients.				
258.	Synovia Pharma PLC. Station Road, Tongi, Gazipur	Cariprazine 3mg Capsule	Cariprazine Hydrochloride INN 3.255mg eqv. to Cariprazine 3mg	Antipsychotic Therapeutic Code: 028	Treatment of schizophrenia in adults, Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults, Treatment of depressive episodes associated with bipolar I disorder (bipolar depression) in adults, Adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults.	Do	USFDA, UKMHRA, EMA	অনুমোদনের সুপারিশ করা হয়।		পরবর্তী টেকনিক্যাল সাব কমিটির সভায় সাইক্রিয়াটিস্টের মতামতসহ পুনর্মূল্যায়নের সিদ্ধান্ত গৃহীত হয়।
259.	Synovia Pharma PLC. Station Road, Tongi, Gazipur	Cariprazine 4.5mg Capsule	Cariprazine Hydrochloride INN 4.883mg eqv. to Cariprazine 4.5mg	Therapeutic Class: Antipsychotic Therapeutic Code: 028	Treatment of schizophrenia in adults, Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults, Treatment of depressive episodes associated with bipolar I disorder (bipolar depression) in adults, Adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults.	Do	USFDA, UKMHRA, EMA	অনুমোদনের সুপারিশ করা হয়।		পরবর্তী টেকনিক্যাল সাব কমিটির সভায় সাইক্রিয়াটিস্টের মতামতসহ পুনর্মূল্যায়নের সিদ্ধান্ত গৃহীত হয়।
260.	Synovia Pharma PLC. Station Road, Tongi, Gazipur	Cariprazine 6mg Capsule	Cariprazine Hydrochloride INN 6.510mg eqv. to Cariprazine 6mg	Therapeutic Class: Antipsychotic Therapeutic Code: 028	Treatment of schizophrenia in adults, Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults, Treatment of depressive episodes associated with bipolar I disorder (bipolar depression) in adults, Adjunctive therapy to	Do	USFDA, UKMHRA, EMA	অনুমোদনের সুপারিশ করা হয়।		পরবর্তী টেকনিক্যাল সাব কমিটির সভায় সাইক্রিয়াটিস্টের মতামতসহ পুনর্মূল্যায়নের সিদ্ধান্ত গৃহীত

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
					antidepressants for the treatment of major depressive disorder (MDD) in adults.					হয়।
261.	Renata Limited Mirpur, Dhaka	Testosterone Enanthate 1000 mg/ 5 mL Injection	Testosterone Enanthate USP 1000 mg/ 5mL	Hormone Therapeutic Code: 056	Testosterone enanthate injection is an androgen indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.	**Contra-indication:** Men with carcinoma of the breast or known or suspected carcinoma of the prostate. Women who are pregnant testosterone can cause virilization of the female fetus when administered to a pregnant woman. Men with hypogonadal conditions, such as "age-related hypogonadism", that are not associated with structural or genetic etiologies. The efficacy of this medication has not been established for these conditions, and can increase BP which can increase the risk of MACE **Side-effects:** Headache, Nausea, Edema, Hypertension, Hematocrit increased, High-density lipoprotein decreased.	40mg Capsule 112.5mg Soft Gelatin Capsule	রেফারেন্স নাই	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
262.	Opsonin Pharma Limited, Rupatali, Barishal	Terbinafine 250mg + Itraconazole 100 mg Tablet	Terbinafine USP 250mg + Itraconazole BP 100 mg	Antifungal **Code:** 020	Indicated for the Topical fungal infection (Tinea infection)	**Contraindication**: **Terbinafine Tablet** is contraindicated in individuals with a history of allergic reaction to oral terbinafine because of the risk of anaphylaxis. **Itraconazole Capsules** should not be administered for the treatment of onychomycosis in patients with evidence of ventricular dysfunction such as congestive heart failure (CHF) or a history of CHF. **Side Effects:** **Terbinafine** may cause serious side effects, including: liver problems that can lead to the need for liver transplant, or death. Change in taste or loss of taste. Change in smell or loss of smell may happen. Serious skin or allergic reactions. New or worsening lupus (an autoimmune disease). **Itraconazole** can cause serious side effects, including: Heart failure. Do not take it if you have	Terbinafine 125 mg Tablet, Itraconazole 200 mg Tablet	রেফারেন্স নাই	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						had heart failure, including congestive heart failure. Liver problems etc. **Precautions and Warning: Terbinafine:** Liver failure, sometimes leading to liver transplant or death, has occurred with the use of oral terbinafine. Obtain pretreatment serum transaminases. Discontinue Terbinafine Tablets if liver injury develops. Taste disturbance, including taste loss, has been reported with the use of Terbinafine Tablets. Taste disturbance can be severe, may be prolonged, or may be permanent. Discontinue Lamisil Tablets if taste disturbance occurs. Smell disturbance, including loss of smell, has been reported with the use of Terbinafine Tablets. Smell disturbance may be prolonged. **Itraconazole** Capsules should be administered after a full meal. Under fasted conditions, itraconazole absorption was decreased in the presence of decreased gastric acidity. The absorption of itraconazole may be decreased with the concomitant administration of antacids or gastric acid secretion suppressors. Rare cases of serious hepatotoxicity have been observed with Itraconazole. If neuropathy occurs that may be attributable to Itraconazole Capsules, the treatment should be discontinued. In some immunocompromised patients (e.g., neutropenic, AIDS or organ transplant patients), the oral bioavailability of Itraconazole capsules may be decreased. Therefore, the dose should be adjusted based on the clinical response in these patients				
263.	Eskayef Pharmaceuticals	Tofogliflozin 40mg Tablet	Tofogliflozin Hydrate INN	**Anti-diabetes**	Treatment of adult patients with type 2 diabetes mellitus.	**CONTRAINDICATIONS:** Pregnant or breastfeeding women, patients with	Tofogliflozin 20mg Tablet	রেফারেন্স নাই	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ	বর্তমানে প্রয়োজন নেই

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
	Limited, Tongi, Gazipur		41.864mg (Eq. to Tofogliflozin 40mg)	Therapeutic code: **015**		ketosis, diabetic coma or precoma, patients with infection or injury, patients in the pre-/postoperative period. **SIDE-EFFECT:** Urinary tract infections, hypoglycemia, dehydration, and skin complications. **WARNINGS AND PRECAUTIONS:** Hypersensitivity to Tofogliflozin.			করা হয়।	বিধায় নামঞ্জুর করা হয়।
264.	Eskayef Pharmaceuticals Limited, Mirpur, Dhaka	Luliconazole 1% w/w Dusting Powder	Luliconazole INN 1gm/100gm	**Anaesthetics** Therapeutic code: 004	Luliconazole dusting Powder is primarily used to treat a variety of fungal infections of the skin such as Dhobie Itch, ringworm, athlete's foot, thrush, itch, dry, and flaky skin. A common skin fungal infection called ringworm spreads easily and manifests as a rash with a worm-like appearance. Due to a scaly rash, an athlete's foot typically begins between the toes and provides an itching, burning, or stinging feeling. The dosage and dosage and duration of *Luliconazole 1 % w/w dusting Powder* will depend on the severity of your fungal infection and how your body responds to the given treatment.	**CONTRAINDICATIONS:** If any patient allergic to luliconazole or any other components of this preparations. **SIDE-EFFECT:** • Skin peeling • Dry Skin • Blisters on skin • Any applications site reactions **WARNINGS AND PRECAUTIONS:** • Pregnancy Breast Feeding	Luliconazole 1% cream	রেফারেন্স নাই	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
265.	Eskayef	Famotidine MUPS	Famotidine USP	**H2 Receptor**	is a histamine-2 (H 2) receptor	**CONTRAINDICATIONS:**	Famotidine	রেফারেন্স নাই	বর্তমানে প্রয়োজন নেই বিধায়	বর্তমানে

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
	Pharmaceuticals Limited, Tongi, Gazipur	20mg Tablet	20mg	**Blocking** Therapeutic code:**055**	antagonist indicated: In adult and pediatric patients 40kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer. • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. In adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). reduction of the risk of DU recurrence.	History of serious hypersensitivity reactions (e.g., anaphylaxis) to Famotidine or other H2 receptor antagonists. **SIDE-EFFECT:** The most common adverse reactions are: headache, dizziness, constipation, and diarrhea. **WARNINGS AND PRECAUTIONS:** • Central Nervous System (CNS) Adverse Reactions: Elderly patients and patients with renal impairment at increased risk; reduce the dosage. GI Malignancy: Absence of GI symptoms does not preclude the presence of gastric malignancy; evaluate prior to initiating therapy.	20 & 40mg Tablet Famotidine 40mg/5ml Powder for Suspension Famotidine 10mg/ml IV Injection		নামঞ্জুরের সুপারিশ করা হয়।	প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
266.	Eskayef Pharmaceuticals Limited, Tongi, Gazipur	Famotidine MUPS 40mg Tablet	Famotidine USP 40mg	**H2 Receptor Blocking** Therapeutic code:**055**	is a histamine-2 (H 2) receptor antagonist indicated: In adult and pediatric patients 40kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer. • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. In adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). reduction of the risk of DU recurrence.	**CONTRAINDICATIONS:** History of serious hypersensitivity reactions (e.g., anaphylaxis) to Famotidine or other H2 receptor antagonists. **SIDE-EFFECT:** The most common adverse reactions are: headache, dizziness, constipation, and diarrhea. **WARNINGS AND PRECAUTIONS:** • Central Nervous System (CNS) Adverse Reactions: Elderly patients and patients with renal impairment at increased risk; reduce the dosage. GI Malignancy: Absence of GI symptoms does not preclude the presence of gastric malignancy; evaluate prior to initiating therapy.	Famotidine 20 & 40mg Tablet Famotidine 40mg/5ml Powder for Suspension Famotidine 10mg/ml IV Injection	রেফারেন্স নাই	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
267.	Eskayef Pharmaceuticals	Progesterone 200mg Sustained Release	Progesterone USP 200mg	**Hormone**	Progesterone is a progesterone indicated to support embryo	**CONTRAINDICATIONS:** Previous allergic reactions to progesterone or any	Progesterone 100 & 200mg	রেফারেন্স নাই	বর্তমানে প্রয়োজন নেই বিধায়	বর্তমানে প্রয়োজন নেই

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
	Limited, Rupganj, Narayanganj	Tablet		Therapeutic code: **056**	implantation and early pregnancy by supplementation of corpus luteal function as part of an Assisted Reproductive Technology (ART) treatment program for infertile women.	of the ingredients of Endometrin Vaginal Insert Known missed abortion or ectopic Pregnancy. **SIDE-EFFECT:** • Vomiting, Tiredness, Constipation • Upset Stomach **WARNINGS AND PRECAUTIONS:** Life-threatening arterial or venous thromboembolic disorders may occur during hormone treatment, including treatment with Endometrin. Discontinue Endometrin if any of these are suspected. Observe patients with a history of depression closely. Consider discontinuation if symptoms worsen.	Soft Gelatin Capsule Progesterone 25mg/ml Injection Progesterone 400mg Vaginal Pessary Progesterone 8% Vaginal Gel		নামঞ্জুরের সুপারিশ করা হয়।	বিধায় নামঞ্জুর করা হয়।
268.	Eskayef Pharmaceuticals Limited, Rupganj, Narayanganj	Progesterone 300mg Sustained Release Tablet	Progesterone USP 300mg	**Hormone** Therapeutic code: **056**	Progesterone is a progesterone indicated to support embryo implantation and early pregnancy by supplementation of corpus luteal function as part of an Assisted Reproductive Technology (ART) treatment program for infertile women.	**CONTRAINDICATIONS:** Previous allergic reactions to progesterone or any of the ingredients of Endometrin Vaginal Insert Known missed abortion or ectopic Pregnancy. **SIDE-EFFECT:** • Vomiting, Tiredness, Constipation, Upset Stomach **WARNINGS AND PRECAUTIONS:** Life-threatening arterial or venous thromboembolic disorders may occur during hormone treatment, including treatment with Endometrin. Discontinue Endometrin if any of these are suspected. Observe patients with a history of depression closely. Consider discontinuation if symptoms worsen.	Progesterone 100 & 200mg Soft Gelatin Capsule Progesterone 25mg/ml Injection Progesterone 400mg Vaginal Pessary Progesterone 8% Vaginal Gel	রেফারেন্স নাই	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
269.	Eskayef Pharmaceuticals Limited, Rupganj,	Progesterone 400mg Sustained Release Tablet	Progesterone USP 400mg	**Hormone** Therapeutic	Progesterone is a progesterone indicated to support embryo implantation and early pregnancy by	**CONTRAINDICATIONS:** Previous allergic reactions to progesterone or any of the ingredients of Endometrin Vaginal Insert	Progesterone 100 & 200mg Soft Gelatin	রেফারেন্স নাই	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
	Narayanganj			code: **056**	supplementation of corpus luteal function as part of an Assisted Reproductive Technology (ART) treatment program for infertile women.	Known missed abortion or ectopic Pregnancy. **SIDE-EFFECT:** • Vomiting • Tiredness • Constipation • Upset Stomach **WARNINGS AND PRECAUTIONS:** Life-threatening arterial or venous thromboembolic disorders may occur during hormone treatment, including treatment with Endometrin. Discontinue Endometrin if any of these are suspected. Observe patients with a history of depression closely. Consider discontinuation if symptoms worsen.	Capsule Progesterone 25mg/ml Injection Progesterone 400mg Vaginal Pessary Progesterone 8% Vaginal Gel		করা হয়।	করা হয়।
270.	Eskayef Pharmaceuticals Limited, Tongi, Gazipur	Zeaxanthin 1mg + Lutein 5mg + Vitamin C (Ascorbic Acid) 150mg + Vitamin E (d-Alfa Tocopherol) 20mg + Zinc (Zinc Oxide) 9mg + Copper (Cupric Oxide) 1mg + Total Omega-3 Fatty Acids from Fish Oil (EPA-160mg and DHA-90mg) 250mg Soft Gelatin capsules	Zeaxanthin USP 1mg + Lutein USP 5mg + Ascorbic Acid USP 150mg + d-Alfa Tocopherol INN 20mg + Zinc Oxide BP 11.205mg (Eq. to Zinc 9mg) + Cupric Acid INN 1.252mg (Eq. to Copper 1mg) + Omega-3 Fatty Acids (EPA-160mg and DHA-90mg) Pharma Grade 250mg	**Vitamins & Combinations** Therapeutic code: **078**	This preparation is indicated for Eye Disease. This is an advanced new antioxidant supplement formulated to provide nutritional support for the eye.	**CONTRAINDICATIONS:** This preparation should not be used in any patient known to be allergic to it or any of its contituents. **SIDE-EFFECT:** • Large doses of Vitamin C are reported to cause diarrhoea and other gastrointestinal disturbance. • Large doses of Vitamin E may cause diarrhoea, abdominal pain, and other gastrointestinal disturbances. • Fatigue and weakness have also been reported. • Side effects of Zinc salt are abdominal pain and dyspepsia. • Upset Stomach, Headache, Unusual or Unpleasant Taste in Mouth. **WARNINGS AND PRECAUTIONS:**	New	রেফারেন্স নাই	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						Life-threatening arterial or venous thromboembolic disorders may occur during hormone treatment, including treatment with Endometrin. Discontinue Endometrin if any of these are suspected. Observe patients with a history of depression closely. Consider discontinuation if symptoms worsen.				
271.	Eskayef Pharmaceuticals Limited, Tongi, Gazipur	Zeaxanthin 2mg + Lutein 10mg + Vitamin C (Ascorbic Acid) 150mg + Vitamin D (Cholecalciferol) 20mcg + Vitamin E (d-Alfa Tocopherol) 20mg + Zinc (Zinc Oxide) 9mg + Copper (Cupric Oxide) 1mg + Total Omega-3 Fatty Acids from Fish Oil (EPA-160mg and DHA-90mg) 250mg Soft Gelatin capsules	Zeaxanthin USP 2mg + Lutein USP 10mg + Ascorbic Acid USP 150mg + Cholecalciferol USP 0.8mg + d-Alfa Tocopherol INN 20mg + Zinc Oxide BP 11.205mg (Eq. to Zinc 9mg) + Cupric Acid INN 1.252mg (Eq. to Copper 1mg) + Omega-3 Fatty Acids (EPA-160mg and DHA-90mg) Pharma Grade 250mg	**Vitamins & Combinations** Therapeutic code: **078**	This preparation is indicated for Eye Disease. This is an advanced new antioxidant supplement formulated to provide nutritional support for the eye.	**CONTRAINDICATIONS:** This preparation should not be used in any patient known to be allergic to it or any of its contituents. **SIDE-EFFECT:** • Large doses of Vitamin C are reported to cause diarrhoea and other gastrointestinal disturbance. • Large doses of Vitamin E may cause diarrhoea, abdominal pain, and other gastrointestinal disturbances. • Fatigue and weakness have also been reported. • Side effects of Zinc salt are abdominal pain and dyspepsia. • Upset Stomach, Headache, Unusual or Unpleasant Taste in Mouth. **WARNINGS AND PRECAUTIONS:** Life-threatening arterial or venous thromboembolic disorders may occur during hormone treatment, including treatment with Endometrin. Discontinue Endometrin if any of these are suspected. Observe patients with a history of depression closely. Consider discontinuation if symptoms worsen.	New	রেফারেন্স নাই	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
272.	Renata Limited Mirpur, Dhaka	Testosterone Cypionate 2000mg/10ml Injection	Testosterone Cypionate USP 2000mg/ml	Hormone Therapeutic Code: 056	Testosterone Cypionate Injection is an androgen indicated for testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.	**Contra-indication:** Men with carcinoma of the breast or known or suspected carcinoma of the prostate. Women who are pregnant testosterone can cause virilization of the female fetus when administered to a pregnant woman. Men with hypogonadal conditions, such as “age-related hypogonadism”, that are not associated with structural or genetic etiologies. The efficacy of this medication has not been established for these conditions, and can increase BP which can increase the risk of MACE **Side-effects:** Headache, Nausea, Edema, Hypertension, Hematocrit increased, High-density lipoprotein decreased.	40mg Capsule 112.5mg Soft Gelatin Capsule	রেফারেন্স নাই	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
273.	Renata Limited Mirpur, Dhaka	Testosterone Cypionate 1000mg/10ml Injection	Testosterone Cypionate USP 1000mg/10ml	Hormone Therapeutic Code: 056	Testosterone Cypionate Injection is an androgen indicated for testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.	**Contra-indication:** Men with carcinoma of the breast or known or suspected carcinoma of the prostate. Women who are pregnant testosterone can cause virilization of the female fetus when administered to a pregnant woman. Men with hypogonadal conditions, such as “age-related hypogonadism”, that are not associated with structural or genetic etiologies. The efficacy of this medication has not been established for these conditions, and can increase BP which can increase the risk of MACE **Side-effects:** Headache, Nausea, Edema, Hypertension, Hematocrit increased, High-density lipoprotein decreased.	40mg Capsule 112.5mg Soft Gelatin Capsule	রেফারেন্স নাই	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
274.	Renata Limited Mirpur, Dhaka Popular Pharmaceuticals Ltd., 164, Tongi	Progesterone 100mg/ml Injection	Progesterone BP 100 mg/ml	Hormone Therapeutic Code: 056	It is indicated in adults for luteal support as part of an Assisted Reproductive Technology (ART) treatment program in infertile women who are unable to use or tolerate vaginal preparations.	**Contraindications:** should not be used in individuals with any of the following conditions: Hypersensitivity to progesterone or to any of the excipients. Undiagnosed vaginal bleeding. Known missed abortion or ectopic pregnancy. Severe hepatic dysfunction or disease. Known or suspected breast or genital tract cancer. Active	25mg/1.112 ml solution for Injection 100mg/ 200mg Soft Gelatine	রেফারেন্স নাই	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
	Industrial Area, Monnunagar, Gazipur					arterial or venous thromboembolism or severe thrombophlebitis, or a history of these events. Porphyria. A history of idiopathic jaundice, severe pruritus or pemphigoid gestationis during pregnancy. Adverse events: The most frequently reported adverse drug reactions during treatment with Lubionduring clinical trial are administration site reactions, breast and vulvo-vaginal disorders.	Capsule			
275.	Renata Limited Mirpur, Dhaka	Progesterone 500mg/ml Injection	Progesterone BP 500 mg/ml	Hormone Therapeutic Code: 056	It is indicated in adults for luteal support as part of an Assisted Reproductive Technology (ART) treatment program in infertile women who are unable to use or tolerate vaginal preparations.	**Contraindications:** should not be used in individuals with any of the following conditions: Hypersensitivity to progesterone or to any of the excipients. Undiagnosed vaginal bleeding. Known missed abortion or ectopic pregnancy. Severe hepatic dysfunction or disease. Known or suspected breast or genital tract cancer. Active arterial or venous thromboembolism or severe thrombophlebitis, or a history of these events. Porphyria. A history of idiopathic jaundice, severe pruritus or pemphigoid gestationis during pregnancy. **Adverse events:** The most frequently reported adverse drug reactions during treatment with Lubionduring clinical trial are administration site reactions, breast and vulvo-vaginal disorders.	25mg/1.112 ml solution for Injection 100mg/ 200mg Soft Gelatine Capsule	রেফারেন্স নাই	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
276.	Square Pharmaceuticals PLC, Kaliakor, Gazipur	Methocarbamol 380 mg + Paracetamol 300 mg Tablet	Methocarbamol USP 380 mg + Paracetamol BP 300 mg	Muscle Relaxant Therapeutic code : 070	Indicated for the use in short term, symptomatic treatment of painful muscle spasms associated with acute mucoskeletal disorder and for relief of back pain associated with muscle spasm, tense neck muscle, strains and sprains.	**Contraindication:** Methocarbamol may interfere with certain laboratory test. **Side effects:** Drowsiness, nausea or vomiting, headache, blurred vision or diarrhea may occur.	New	রেফারেন্স নাই	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
277.	Square Pharmaceuticals PLC, Kaliakor, Gazipur	Elemental Zinc 15mg Capsule	Zinc Bisglycinate INN 75mg eq. to Elemental Zinc 15 mg Capsule	Metals, Salts, Minerals and Calcium Preparations	Zinc Bisglycinate as a dietary supplement indicated to treat zinc deficiency. It is also used to treat zinc deficiency anemia. Zinc is essential for the proper functioning of the	**Contraindication:** Zinc Bisglycinate, like other zinc supplements, is generally safe for most people when used as directed. However, it's important to note that taking too much zinc can lead to harmful side effects. These can include	Zinc 10 mg Tablet, Zinc 20 mg Tablet	রেফারেন্স নাই	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
				Therapeutic Code: 062	nervous system, the immune system, and the brain. It plays a vital role in immunity, wound healing, acne prevention, and digestion. Furthermore, it provides essential nutrients and plays a vital role in the formation of red blood cells, which carry oxygen throughout the body.	nausea, vomiting, diarrhea, metallic taste, kidney and stomach damage, and other adverse effects. **Side Effect:** No data available **Warnings and Precautions:** When taking Zinc Bisglycinate tablets, there are several precautions to keep in mind: Food Interactions: When zinc combines with certain foods, it may not be absorbed into your body and it will do you no good. If you are taking zinc, the following foods should be avoided or taken 2 hours after you take zinc: Bran, Fiber-containing foods, Phosphorus-containing foods such as milk or poultry, Whole-grain breads and cereals. Supplement Interactions: Do not take zinc supplements and copper, iron, or phosphorus supplements at the same time. It is best to space doses of these products 2 hours apart, to get the full benefit from each dietary supplement.				
278.	Beacon Pharmaceuticals PLC, Kathali, Bhaluka, Mymensingh	Letrozole USP 5.00mg Tablet	Letrozole USP 5.00mg Tablet	Ferlility Agents (053)	letrozole has been extensively used to induce ovulation in anovulatory infertility patients and to augment follicles for ovulatory women.	**Contraindication**: known or suspected Hypersensitivity to letrozole, Contraindicated in during pregnancy, lactation & pre-menopausal women. Also contraindicated in severe hepatic dysfunction. **Side effects:** -Hot flashes. Dressing in layers that you can easily remove and avoiding caffeine and spicy foods can help manage this side effect. -Joint pain. This is the most common reason for stopping aromatase inhibitors like letrozole. If you experience swelling in your joints, applying an ice pack can help decrease the inflammation. A warm bath or a heating pad on the affected joint can help with joint stiffness. You can also ask your pharmacist to recommend an over-the-counter	2.5mg	রেফারেন্স নাই	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						pain reliever to help manage stiffness. • Muscle pain. • Abdominal bloating. • Weight change. Your weight may increase or decrease due to hormonal changes. • Nausea. You can take letrozole with or without food. But taking it with food may help with nausea. • Night sweats. Consider turning down the temperature in your room or using a bedside fan. • Fatigue and dizziness. Consider avoiding driving or doing activities that require you to be alert while taking letrozole. • Headache.				
279.	Popular Pharmaceuticals Ltd., 164, Tongi Industrial Area, **Monnunagar, Gazipur**	Progesterone BP 200 mg/ml Injection	Progesterone BP 200 mg/ml	Hormone Therapeutic Code: 056	This drug is indicated in amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer.	**Contra-indications:** If you have an allergy to Progesterone or any of the ingredients of the medicine If you have or ever had breast or uterine cancer If you experience vaginal bleeding If you are suffering from heart disease or clots in blood vessels If you are suffering from porphyria (inherited or acquired disorders of certain enzymes) If you have bleeding in your brain or stroke **SIDE-EFFECT:** Progesterone Injection may cause some side effects mostly in the cases in which a patient has any chronic diseases such as kidney failure, or any organ issue. Let the doctor know if the patient experiences any kind of serious side effects. Acne, Nausea, Headache, Weight Gain or Loss	Progesterone 100 & 200 mg Soft Gelatin Capsule Progesterone 25 mg/ ml Injection Progesterone 400 mg Vaginal Pessary Progesterone 8% Vaginal Gel	রেফারেন্স নাই	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						Loss of Scalp Hair, Breast Tenderness, Increased Body or Facial Hair, Pain and Swelling at Injection Site.				
280.	Popular Pharmaceuticals Ltd., 164, Tongi Industrial Area, Monnunagar, Gazipur	Dydrogesterone 20mg ER Tablet	Dydrogesterone BP 20mg ER	Hormone Therapeutic Code: 056	**INDICATIONS** • Progesterone deficiencies • Treatment of threatened miscarriage • Treatment of habitual miscarriage • Treatment of dysmenorrhea • Treatment of endometriosis • Treatment of secondary amenorrhoea • Treatment of irregular cycles • Treatment of dysfunctional uterine bleeding • Treatment of infertility due to luteal insufficiency • Luteal support as part of an Assisted Reproductive Technology (ART) • Hormone Replacement Therapy: To counteract the effects of unopposed oestrogen on the endometrium in hormone replacement therapy for women with disorders due to natural or surgical induced menopause with an intact uterus	**CONTRAINDICATIONS** Known hypersensitivity to the active substance or to any of the excipients. Known or suspected progestogen dependent neoplasms (e.g. meningioma). **SIDE EFFECTS:** The most commonly reported adverse drug reactions of patients treated with Dydrogesterone ER in clinical trials of indications without oestrogen treatment are migraines/headache, nausea, menstrual disorders and breast pain/tenderness.	Dydrogesterone 10 mg Tablet	রেফারেন্স নাই	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
281.	Popular Pharmaceuticals Ltd., 164, Tongi Industrial Area, Monnunagar,	Silodosin 8mg + Dutasteride 0.5mg Capsule	Silodosin INN 8mg + Dutasteride USP 0.5mg	Drug used in Obstratics Therapeutic Code:049	Combination of Silodosin and Dutasteride used in men for the management of enlarged prostate gland Benign Prostatic Hyperplasia.	**Contraindications:** Severe renal impairment (CCr < 0 mL/min). Severe hepatic impairment (Child-Pugh score ≥ 10) Concomitant administration with strong Cytochrome P40 A4 (CYPA4) inhibitors (e.g., ketoconazole,	Silodosin 4mg & 8mg Tablet	রেফারেন্স নাই	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
	Gazipur					clarithromycin, itraconazole, ritonavir). Patients with a history of hypersensitivity to silodosin. Pregnancy and women of childbearing potential. Patients with previously demonstrated, clinically significant hypersensitivity (e.g., serious skin reactions, angioedema) to Dutasteride. **Precautions:** Before taking Silodosin + Dutasteride Capsule, inform your doctor if you have low blood pressure or liver, kidney, or heart disease as a precaution. Women who are pregnant or can become pregnant should not handle the leaked medicine, as it may cause serious harm to the baby. Men being treated with Silodosin + Dutasteride CAPSULE should not donate blood for at least 6 months after their last dose, in order to prevent the exposure of the medicine to pregnant women via blood transfusion. Avoid consumption of alcohol while taking Silodosin + Dutasteride Capsule, as it may lower your blood pressure. It is not recommended for use in children or adolescents less than 18 years of age. The most common side effects of taking Silodosin + Dutasteride Capsule are orgasm with reduced or no semen, trouble getting or keeping an erection (impotence), a decrease in sex drive (libido), ejaculation problems (enlarged or painful breasts), dizziness, and low blood pressure while standing up from a sitting or lying position. Contact your doctor if any of the symptoms worsen.	Dutasteride 500mcg Capsule			
282.	UniMed UniHealth Pharmaceuticals Ltd., B.K Bari, Gazipur Sadar,	Phenazopyridine Hydrochloride 200mg Tablet	Phenazopyridine Hydrochloride USP 200mg Tablet	Nonopioid analgesics	Phenazopyridine is used to treat urinary symptoms such as pain or burning, increased urination, and increased urge to urinate. These	**Contraindications:** Patients who are hypersensitive to the drug or its ingredients, Patients with renal insufficiency or any liver disease.	New	রেফারেন্স নাই	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
	Gazipur				symptoms can be caused by infection, injury, surgery, catheter, or other conditions that irritate the bladder. Phenazopyridine will treat urinary symptoms, but this medication will not treat a urinary tract infection. Take any antibiotic that your doctor prescribes to treat an infection.	**Side Effects:** allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.				
283.	UniMed UniHealth Pharmaceuticals Ltd. B.K Bari, Gazipur Sadar, Gazipur	Mirabegron 50 mg + Solifenacin Succinate 5.00 mg Tablet	Mirabegron INN 50.00 mg + Solifenacin Succinate BP 5.00 mg Tablet	Adrenergic	It is used for Overactive Bladder Symptoms of Urinary Incontinence Urgent or Frequent Urination Increased vessels locally to prevent further bleeding.	**Contraindications:** In Overactive bladder (OAB) symptoms: Mirabegron + Solifenacin Succinate helps to treat uncontrollable contractions (spasms) of the bladder muscles that cause frequent urination, urgent need to urinate, and inability to control passing of urine. It also relieves painful, or frequent urination and reduces urgency to urinate that may occur with some infections of the urinary tract. This way it helps manage the overactive bladder symptoms efficiently.	Mirabegron 25 mg & 50 mg Tablet Solifenacin 5mg & 10 mg Tablet	রেফারেন্স নাই	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
284.	Advanced Chemical Industries Limited, 7 Hajeegonj, Godnyl, Narayangonj The ACME Laboratories Ltd. Dhamrai, Dhaka	Saroglitazar 4 mg Tablet	Saroglitazar Magnesium INN 8.20mg eqv to Saroglitazar 4.00 mg	Other Classification: Therapeutic Code: 075	Saroglitazar is indicated for the treatment of diabetic dyslipidemia and hyper Triglyceridemia with type II Diabetes mellitus not controlled by statin therapy. In clinical Studies Saroglitazar has demonstrated reduction of triglycerides (TG), Low Density Lipoprotein (LDL) Cholesterol and an increase in HDL Cholesterol.	**Contra-indication:** Hypersensitivity to Saroglitazar or any of the excipients used in the formulation. **Side Effects:** The Most Common Side Effects of Saroglitazar include: Gastritis, Asrhenia, and Pyrexia. **Warnings and Precautions:** Although clinical studies with Saroglitazar have not demonstrated any potential for myopathies or derangement of liver and/or renal function, Saroglitazar treatment should be initiated with caution in patients with abnormal liver or renal function, or history of myopathies. Saroglitazar has not been studied in patients with established New York Heart Association (NYHA) Class III or IV heart failure. Saroglitazar should be initiated with caution in patients with type 2 diabetes having cardiac disease with episodic congestive heart failure and such patients should be monitored for signs and symptoms of congestive heart failure. Although during the clinical studies, no significant weight gain and edema was reported with Saroglitazar, patients who experience rapid	2 mg Tablet	রেফারেন্স নাই	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						increase in weight should be assessed for fluid accumulation and volume-related events such as excessive edema and congestive heart failure				
285.	Advanced Chemical Industries Limited, 7 Hajeegonj, Godnyl, Narayangonj.	Cefuroxime 250 mg + Clavulanic Acid 62.5 mg/5ml Powder for Suspension	Cefuroxime Axetil BP 6.0144 g eqv. to Cefuroxime 5.0 g + Potassium Clavulanate BP 1.49 g eqv. to Clavulanic Acid 1.25 g/100ml	Anti-infective Therapeutic Code: 023	Pharyngitis/ Tonsillitis, Acute Bacterial, Otitis Media, Maxillary Sinusitis,Acute Bacterial Exacerbations of Chronic Bronchitis and Secondary Bacterial Infections of Acute Bronchitis	**Contraindication:** It is contraindicated in patients with history of known hypersensitivity to Cefuroxime Axetil and Clavulanic Acid or any other components of this product. **Side-effects:** Diarrhea, nausea, vomiting, transient elevation in AST, ALT, LDH, Eosinophilia. Other adverse effects that may occur are abdominal cramps, abdominal pain, flatulence, indigestion, headache and anorexia. **Warnings and precautions**: Before therapy is instituted, careful inquiry should be made to determine whether the patient has had previous hypersensitivity reactions to cephalosporins, penicillins or other drugs. Prescribing Cefuroxime in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria. Cephalosporins, including cefuroxime, should be given with caution to patients receiving concurrent treatment with potent diuretics because these diuretics are suspected of adversely affecting renal function. Cefuroxime, as with other broad-spectrum antibiotics, should be prescribed with caution in individuals with a history of colitis.	Cefuroxime 125mg + Clavulanic Acid 31.25mg/5ml Powder for Suspension	রেফারেন্স নাই	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
286.	Advanced Chemical Industries Limited, 7 Hajeegonj, Godnyl, Narayangonj	Azelastine Hydrochloride 140 mcg + Fluticasone Furoate 27.5 mcg/ Nasal Spray	Azelastine Hydrochloride BP 140 mcg + Fluticasone Furoate INN 27.5 mcg/ Nasal Spray	Ear and Nose preparation: 050	This combination is indicated for the treatment of symptoms of allergic rhinitis. It is recommended for the treatment of persistent, moderate to severe symptoms in adults and adolescents above 12 years of age.	**Contraindication:** This combination is contraindicated in patients with known hypersensitivity to Azelastine hydrochloride & Fluticasone furoate or any other components of this product. **Side Effects:** The most common side effects are nosebleeds (generally minor), nasal ulceration which may cause irritation or discomfort in the nose, headache and somnolence.	Azelastine 125 mcg + Fluticasone 50 mcg/Metered Inhalation Nasal Spray	রেফারেন্স নাই	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
287.	Advanced Chemical Industries Limited, 7 Hajeegonj,	Naphazoline Hydrochloride 50mcg + Chlorpheniramine Maleate	Naphazoline Hydrochloride USP 50mcg + Chlorpheniramine	Ear & Nose preparations Therapeutic	It is indicated for the treatment of acute rhinitis, stuffed nose, runny nose and excessive nasal mucus.	**Contraindication:** This combination is contraindicated in patients with history of known hypersensitivity to it or any other components of this product. **Side-effects:** The most common side effect is rhinitis	Naphazoline Hydrochloride 250mcg + Pheniramine	রেফারেন্স নাই	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
	Godnyl, Narayangonj	500mcg/100gm Nasal Spray	Maleate BP 500mcg/100gm	Code: 021		medicamentosa, a condition of rebound nasal congestion **Warnings and precautions**: Do not exceed recommended dosage because burning, sneezing or increase of nasal discharge may occur. Do not use for more than 3 days. Do not use if the patients with heart disease, high blood pressure, thyroid disease, diabetes or difficulty in urination due to enlargement of the prostate gland. Do not get into eyes.	Maleate 3mg/ml			
288.	The ACME Laboratories Ltd. Dhamrai, Dhaka	Gepotidacin 750mg Tablet	Gepotidacin 750mg	Anti-Infective Therapeutic Code023	For the treatment of uncomplicated urinary tract infections and urogenital gonorrhea.	**Contraindications:** Significant impairment of renal function (creatinine clearance under 60 mL per minute or clinically significant elevated serum creatinine) are contraindications. Treatment of this type of patient carries an increased risk of toxicity because of impaired excretion of the medicine. **Side effects:** Acute, subacute, or chronic pulmonary reactions have been observed in patients treated with gepotidacin. If these reactions occur, the medicine should be discontinued and appropriate measures taken. **Warning & Precautions:** Patients should be advised to take Gepotidacin with food to further enhance tolerance and improve its absorption.	NEW	রেফারেন্স নাই	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
289.	The ACME Laboratories Ltd. Dhamrai, Dhaka	Ensifentrine 150 micro gram, DPI	Ensifentrine 150 micro gram	**Antiasthmatic** Therapeutic Code: 044	For the treatment of 1. Chronic obstructive pulmonary disease (COPD) 2. Asthma 3. Cystic fibrosis	**Contra-indications:** N/A **Side-effects:** Headaches, COPD symptoms, cough and dyspnea **Warning & Precautions :** N/A	NEW	রেফারেন্স নাই	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
290.	The ACME Laboratories Ltd. Dhamrai, Dhaka	Ensifentrine 500 micro gram, DPI	Ensifentrine 500 micro gram	**Antiasthmatic** Therapeutic Code: 044	For the treatment of 1. Chronic obstructive pulmonary disease (COPD) 2. Asthma 3. Cystic fibrosis	**Contra-indications:** N/A **Side-effects:** Headaches, COPD symptoms, cough and dyspnea **Warning & Precautions :** N/A	NEW	রেফারেন্স নাই	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
291.	The ACME Laboratories Ltd.	Ensifentrine 1500 micro gram, DPI	Ensifentrine 1500 micro gram	**Antiasthmatic** Therapeutic	For the treatment of 1. Chronic obstructive pulmonary	**Contra-indications:** N/A **Side-effects:**	NEW	রেফারেন্স নাই	বর্তমানে প্রয়োজন নেই বিধায়	বর্তমানে প্রয়োজন নেই

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
	Dhamrai, Dhaka			Code: 044	disease (COPD) 2. Asthma 3. Cystic fibrosis	Headaches, COPD symptoms, cough and dyspnea **Warning & Precautions :** N/A			নামঞ্জুরের সুপারিশ করা হয়।	বিধায় নামঞ্জুর করা হয়।
292.	The ACME Laboratories Ltd. Dhamrai, Dhaka	Ensifentrine 3000 micro gram, DPI	Ensifentrine 3000 micro gram	**Antiasthmatic** Therapeutic Code: 044	For the treatment of 1. Chronic obstructive pulmonary disease (COPD) 2. Asthma 3. Cystic fibrosis	**Contra-indications:** N/A **Side-effects:** Headaches, COPD symptoms, cough and dyspnea **Warning & Precautions :** N/A	NEW	রেফারেন্স নাই	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
293.	The ACME Laboratories Ltd. Dhamrai, Dhaka	Ensifentrine 6000 micro gram, DPI	Ensifentrine 6000 micro gram	**Antiasthmatic** Therapeutic Code: 044	For the treatment of 1. Chronic obstructive pulmonary disease (COPD) 2. Asthma 3. Cystic fibrosis	**Contra-indications:** N/A **Side-effects:** Headaches, COPD symptoms, cough and dyspnea **Warning & Precautions :** N/A	NEW	রেফারেন্স নাই	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
294.	The ACME Laboratories Ltd. Dhamrai, Dhaka	Orforglipron 12 mg Capsule	Orforglipron INN 12 mg	**Antidiabetic Therapeutic Code:015**	Weight reductions in adults with obesity or overweight & type 2 diabetes	Contra-indications: N/A Side-effects : nausea, vomiting, constipation, and gastroesophageal reflux Warning & Precautions : N/A	NEW	রেফারেন্স নাই	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
295.	The ACME Laboratories Ltd. Dhamrai, Dhaka	Orforglipron 24 mg Capsule	Orforglipron INN 24 mg	**Antidiabetic Therapeutic Code:015**	Weight reductions in adults with obesity or overweight & type 2 diabetes	Contra-indications: N/A Side-effects : nausea, vomiting, constipation, and gastroesophageal reflux Warning & Precautions : N/A	NEW	রেফারেন্স নাই	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
296.	The ACME Laboratories Ltd. Dhamrai, Dhaka	Orforglipron 36 mg Capsule	Orforglipron INN 36 mg	**Antidiabetic Therapeutic Code:015**	Weight reductions in adults with obesity or overweight & type 2 diabetes	Contra-indications: N/A Side-effects : nausea, vomiting, constipation, and gastroesophageal reflux Warning & Precautions : N/A	NEW	রেফারেন্স নাই	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
297.	The ACME Laboratories Ltd. Dhamrai, Dhaka	Orforglipron 45 mg Capsule	Orforglipron INN 45 mg	**Antidiabetic Therapeutic Code:015**	Weight reductions in adults with obesity or overweight & type 2 diabetes	Contra-indications: N/A Side-effects : nausea, vomiting, constipation, and gastroesophageal reflux Warning & Precautions : N/A	NEW	রেফারেন্স নাই	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
298.	Incepta Pharmaceuticals Ltd.; Zirabo, Dhaka	Biapenem for Injection (sterile) 600mg/vial solution for Intravenous Injection	Biapenem for Injection (sterile) INN/In-house 600mg/vial	Therapeutic Class: Anti-infective Therapeutic Code: 023	Treatment of bacterial infection, sepsis, pneumonia, pulmonary abscess, secondary infection in chronic respiratory lesions. complicated cystitis, pyelonephritis.	**Contraindication:** Biapenem is well tolerated **Side-effects:** The following serious adverse reactions are discussed elsewhere in the label: Skin eruptions/rashes, Nausea, Diarrhoea, Eosinophilia, ALT/AST level increased **Warnings and Precautions**: This product should	New	রেফারেন্স নাই	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						be used with caution by patients who are allergic to carbopenems, penicillins and cephalosporins; This product should be used with caution by patients who or whose direct relatives are susceptible to induced hypersensitivities including bronchial asthma, rash, urticaria and so on; Patients with severe renal inadequacy take precautions before using this product; Senile patients should use this product with cautions (see "Medication for senile patients"); When this product is used by the patients with eating difficulty and poor body condition, symptoms of Vitamin k Deficiency may occur; Patients with history of epilepsy and illness of central nervous system shall use this product with caution; False positive findings may occur during clinical Urine Glucose Test, Benedict's test and Fehling's test for reducing sugar; Positive findings may occur in Kveim test.				
299.	Incepta Pharmaceuticals Ltd., Zirabo, Dhaka	Mecobalamin 0.5mg Sublingual tablet	Mecobalamin INN/In-house 0.5mg	Vitamins and Combinations Therapeutic Code: 078	Some of the uses of Mecobalamin are Mecobalamin is prescribed for treating certain nerve problems and anaemia by restoring the levels of vitamin B12 in the body. Replenishment of the vitamin helps in the regeneration and improvement of damaged and irritated nerves, which can be caused by medical conditions like pernicious anaemia, neuropathy, and neuralgia. It is also prescribed for people who experience back pain, anaemia, or other problems related to the nervous system that can be caused by a deficiency of vitamin B12. Mecobalamin also works as a painkiller	**Contraindication:** Contraindicated for those with known allergies to Astaxanthin **Side-effects:** Vomiting, Diarrhoea, Nausea, Headache, Loss of appetite Warnings and Precautions: No data Available.	0.5mg tablet, 0.5 mg/ml Injection	রেফারেন্স নাই	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
					for people with diabetes.					
300.	Incepta Pharmaceuticals Ltd.,Zirabo, Dhaka	Mecobalamin 1mg Sublingual tablet	Mecobalamin INN/In-house 1mg	Vitamins and Combinations Therapeutic Code: 078	Some of the uses of Mecobalamin are Mecobalamin is prescribed for treating certain nerve problems and anaemia by restoring the levels of vitamin B12 in the body. Replenishment of the vitamin helps in the regeneration and improvement of damaged and irritated nerves, which can be caused by medical conditions like pernicious anaemia, neuropathy, and neuralgia. It is also prescribed for people who experience back pain, anaemia, or other problems related to the nervous system that can be caused by a deficiency of vitamin B12. Mecobalamin also works as a painkiller for people with diabetes.	**Contraindication:** Contraindicated for those with known allergies to Astaxanthin **Side-effects:** Vomiting, Diarrhoea, Nausea, Headache, Loss of appetite Warnings and Precautions: No data Available.	0.5mg tablet, 0.5 mg/ml Injection	রেফারেন্স নাই	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
301.	Incepta Pharmaceuticals Ltd.Dhamrai Unit, Dhaka	Lactic Acid 4.5g + Glycogen 0.1g/100g Gel	Lactic Acid BP/Ph. Eur 4.5g + Glycogen INN 0.1g/100g Gel	Skin and Mucous Membrane Preparations Therapeutic Code: 071	The lactic acid gel that is clinically proven to treat and prevent Bacterial Vaginosis (BV). Giving relief from abnormal vaginal odour and discharge associated with BV.	**Contraindication:** Hypersensitivity to any of the ingredient. **Side-effects**: It may cause mild irritation during fungal infections (e.g. thrush) of the vagina or when there are tears in the vaginal tissue. **Warning & Precaution:** Lactic acid 4.5% and Glycogen 0.1% may cause mild irritation during fungal infections (e.g. thrush) of the vagina or when there are tears in the vaginal tissue. Lactic acid 4.5% and Glycogen 0.1% contains glycogen obtained from Oysters. Do not use if allergic to shellfish	New	রেফারেন্স নাই	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
302.	Beximco Pharmaceuticals Ltd., Tongi, Gazipur	Faropenem 50mg/100ml powder for suspension	Faropenem Sodium Hydrate JP 1.235 gm (eq. to Faropenem 50	Anti-Infective Therapeutic Code: 023	Faropenem Powder for Suspension is indicated in the treatment of the following infections: Superficial skin infection, Deep skin	**Contraindications:** Faropenem is contraindicated in patients with known hypersensitivity to any of the components of this product or to other drugs in the same class,	150mg & 200mg Tablet	রেফারেন্স নাই	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
	Incepta Pharmaceuticals Ltd., Zirabo, Savar, Dhaka		mg)/100 ml		infection, Lymphatic vessel/lymphadenitis, Chronic pyoderma, Pharyngitis/laryngitis, Tonsillitis, Acute bronchitis, Pneumonia, Cystitis, pyelonephritis, Otitis media, Sinusitis, Periodontitis, Scarlet fever, Pertussis.	or in patients who have demonstrated anaphylactic reactions to beta-lactams. **Side effects:** Common side effects of this drug are: • Headache • Nausea • Vomiting • Stomach pain • Diarrhea **Warnings and Precautions:** Faropenem should be administered with caution in the following: 1. Patients with a history of hypersensitivity to penicillin, cephem or carbapenem drugs. 2. Patients with a family history of atopy. 3. Patients with renal impairment. The dosage should be reduced or the interval between doses should be increased. 4. Geriatric patients. 5. Patients with poor oral intake or poor general state (since there are cases that show symptoms of vitamin K deficiency, proper monitoring should be done).				
303.	Ziska Pharmaceuticals Ltd.	Ceftobiprole 250 mg/Vial Powder for Injection	Ceftobiprole Medocaril Sodium INN 333.30 mg eq to 250mg /Vial	Anti-infective Therapeutic Code: 023	Indicated for the treatment of adult patients with Staphylococcus aureus bloodstream infections (bacteremia) (SAB), including those with right-sided infective endocarditis. It is additionally indicated in adult patients with acute bacterial skin and skin structure infections (ABSSSI).	**Contraindications:** Ceftobiprole is contraindicated in patients with a known history of severe hypersensitivity to Ceftobiprole, or to other members of the cephalosporin class **Side effects:** The following adverse reactions are discussed in greater detail in the Warnings and Precautions section: • Increased Mortality in Ventilator-Associated Bacterial Pneumonia Patients • Hypersensitivity Reactions • Seizures and Other Central Nervous System Reactions	Ceftobiprole 500mg/Vial Powder for Injection	রেফারেন্স নাই	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						• Clostridioides difficile-Associated Diarrhea **Warnings and precautions:** Increased Mortality with Unapproved use in Ventilator-Associated Bacterial Pneumonia (VABP) Patients: The safety and effectiveness of Ceftobiprole for the treatment of VABP has not been established and the use of Ceftobiprole for VABP is not approved				
304.	Nuvista Pharma Ltd.	Progesterone 50mg/2.237ml Solution	Progesterone USP 50mg/2.237ml Solution	Hormone Code: 056	Indicated in adults for luteal support as part of an Assisted Reproductive Technology (ART) treatment program in infertile women who are unable to use or tolerate vaginal preparations.	**Contraindication:** Aqueous Progesterone should not be used in individuals with any of the following conditions: • Hypersensitivity to progesterone or to any of the excipients • Undiagnosed vaginal bleeding • Known missed abortion or ectopic pregnancy • Severe hepatic dysfunction or disease • Known or suspected breast or genital tract cancer • Active arterial or venous thromboembolism or severe thrombophlebitis, or a history of these events • Porphyria, A history of idiopathic jaundice, severe pruritus or • pemphigoid gestationis during pregnancy. **Side Effects:** • Chest pain and discomfort • Fever and chills • Difficulty in passing urine • Breast pain and tenderness • Muscle or joint pain • White or brownish discharge from the vagina	Progesterone 25mg/ml Injection	রেফারেন্স নাই	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						• Headache, Dizziness • Depression, Viral infections, Breast lumps				
305.	Opsonin Pharma Limited, Rupatali, Barishal	Fenoterol hydrobromide + Ipratropium Bromide Metered Dose Inhaler	Fenoterol Hydrobromide BP 50 mcg + Ipratropium Bromide BP 20mcg	Drugs Used in Bronchial Asthma Preparations: Therpaeutic Code: 044	Asthma & COPD	**Contraindications:** Hypersensitivity to the active substances, to any of the excipients or to other atropine like substances. Hypertrophic obstructive cardiomyopathy or tachyarrhythmia. **Side effects:** The most frequent side effects reported in clinical trials were cough, dry mouth, headache, tremor, pharyngitis, nausea, dizziness, dysphonia, tachycardia, palpitations, vomiting, blood pressure systolic increased and nervousness. **Precautions & warnings:** Immediate hypersensitivity reactions may occur after administrationt as rare cases of urticaria, angio-oedema, rash, bronchospasm, oropharyngeal oedema and anaphylaxis.	New	রেফারেন্স নাই	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
306.	Opsonin Pharma Limited, Rupatali, Barishal	Hydroquinone + Tretinoin + mometasone furoate Cream	Hydroquinone USP 20 mg/gm + Mometasone BP mg/gm + Tretinoin BP 0.25 mg/gm	Skin & Mucous Membrane Preparation **Code:** 071	Short term treatment of mild to moderate melasma	**Contraindications:** It is not recommended for children below 12 years of age. **Side effects:** Skin pain, acne, redness, irritation, burning, itching. **Precautions & warnings:** Do not apply on ulcerated skin.	New	রেফারেন্স নাই	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
307.	Opsonin Pharma Limited, Rupatali, Barishal Navana Pharmaceuticals Ltd., Rupganj, Narayanaganj	Minoxidil 10% Topical Solution	Minoxidil USP 10% Topical Solution	Skin & Mucous Membrane Preparation **Code:** 071	Androgenic Alopecia (Hair Loss)	**Contraindication:** Topical minoxidil is contraindicated in patients with a history of hypersensitivity to minoxidil, propylene glycol or ethanol. Although, a warning for use in people with cardiovascular disease or cardiac arrhythmias is present in the datasheet, it is not a contraindication. **Side effects:** In general, Topical Minoxidil is well tolerated and the majority of side effects are dermatological in nature, due to skin intolerance	2%, 5% Scalp Lotion	রেফারেন্স নাই	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						of the topical formulation in some patients. These side effects resolve upon discontinuation of the product. **Precaution & Warning:** Do not use minoxidil topical if the skin of scalp is red, swollen, irritated, or infected.				
308.	Drug International Ltd 31/1, Satrong, Tongi I/A, Gazipur.	Somapacitan-beco INN 5mg/1.5ml Pre-filled Syringe pen Injection	Somapacitan-beco INN 5mg/1.5ml Pre-filled Syringe or pen Injection.	**Hormone** Code: 056	It is a human growth hormone analog indicated for treatment of **Pediatric Patients:** Treatment of pediatric patients aged 2.5 years and older who have growth failure due to inadequate secretion of endogenous growth hormone (GH). **Adults:** Replacement of endogenous growth hormone in adults with growth hormone deficiency.	**Contraindications**: It is Contraindicated in this drug is contraindicated in- Acute critical illness, Active malignancy, Hypersensitivity to somapacitan-beco or excipients, Active proliferative or severe non-proliferative diabetic retinopathy etc. **Precautions:** It should not be administered in the following conditions: Severe Hypersensitivity, Increased Risk of Neoplasms, Glucose Intolerance and Diabetes Mellitus, Intracranial Hypertension (IH) etc. **Warning:** As per precaution. **Side effects:** Pediatric patients with GHD: Adverse reactions reported in ≥5% of patients treated with SOGROYA are: nasopharyngitis, headache, pyrexia, pain in extremity, and injection site reaction. • Adult patients with GHD: Adverse reactions reported in >2% of patients treated with SOGROYA are: back pain, arthralgia, dyspepsia, sleep disorder, dizziness, tonsillitis, peripheral edema, vomiting, adrenal insufficiency, hypertension, blood creatine phosphokinase increase, weight increase, anemia	New	রেফারেন্স নাই	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
309.	Drug International Ltd	Somapacitan-beco INN 15mg/1.5ml Pre-	Somapacitan-beco INN	**Hormone** Code: 056	It is a human growth hormone analog indicated for treatment of **Pediatric**	**Contraindications**: It is Contraindicated in this drug is contraindicated in- Acute critical illness, Active malignancy, Hypersensitivity to somapacitan-beco or	New	রেফারেন্স নাই	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ	বর্তমানে প্রয়োজন নেই

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
	31/1, Satrong, Tongi I/A, Gazipur.	filled Syringe pen Injection	15mg/1.5ml Pre-filled Syringe or pen Injection.		**Patients:** Treatment of pediatric patients aged 2.5 years and older who have growth failure due to inadequate secretion of endogenous growth hormone (GH). **Adults:** Replacement of endogenous growth hormone in adults with growth hormone deficiency.	excipients, Active proliferative or severe non-proliferative diabetic retinopathy etc. **Precautions:** It should not be administered in the following conditions: Severe Hypersensitivity, Increased Risk of Neoplasms, Glucose Intolerance and Diabetes Mellitus, Intracranial Hypertension (IH) etc. **Warning:** As per precaution. **Side effects:** Pediatric patients with GHD: Adverse reactions reported in ≥5% of patients treated with SOGROYA are: nasopharyngitis, headache, pyrexia, pain in extremity, and injection site reaction. • Adult patients with GHD: Adverse reactions reported in >2% of patients treated with SOGROYA are: back pain, arthralgia, dyspepsia, sleep disorder, dizziness, tonsillitis, peripheral edema, vomiting, adrenal insufficiency, hypertension, blood creatine phosphokinase increase, weight increase, anemia			করা হয়।	বিধায় নামঞ্জুর করা হয়।
310.	Drug International Ltd 31/1, Satrong, Tongi I/A, Gazipur.	Minoxidil 5.0mg Tablet	Minoxidil INN 5.0mg	**Antihypertensive** Code No:-022	It is indicated for the treatment of severe Hypertension. It should not be used a the sole agent of initiate therapy.It is a peripheral vasodilator and should be given in conjunction with a diuretic, to control salt and water retention, and a beta adrenergic blocking agent or appropriate substitute to control reflex tachycardia.	**Contraindications**: This Tablet is contraindicated in patients with minoxidil or any other excipients of minoxidil. It is also contraindicated in patients with a phaeochromocytoma because it may stimulate secretion of catecholamines from the tumor through its antihypertensive action. **Precautions:** Salt and water retension, Thrombocytopenia and leucopenia have been rarely reported. Pericarditis, pericardial effusion and tamponade: there is no evidence of casual relationship and there have multiple reports of pericarditis occurring in association with minoxidil. Pateints with rare hereditary problems of galactose intolerance, total lactose deficiency or glucose-galactosemalabsorption should not take this medicine. **Warning:** As per precaution. **Side effects:** The most common adverse events are fluid retention, oedema, tachycardia, pericarditis, breast	2%, 5% Scalp Lotion	রেফারেন্স নাই	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						tenderness.				
311.	UniMed UniHealth Pharmaceuticals Ltd. B.K Bari, Gazipur Sadar, Gazipur	Itraconazole 200.00mg Capsule	Itraconazole Coated Pellets USP 400mg eqv. to 200.00mg Itraconazole Capsule	Antifungal	It is an azole antifungal, are indicated for the treatment of onychomycosis of the toenail caused by Trichophyton rubrum or T. mentagrophytes.	**Contraindications:** Do not administer for the treatment of onychomycosis in patients with evidence of ventricular dysfunction such as congestive heart failure (CHF) or a history of CHF. Do not be administer for the treatment of onychomycosis to pregnant patients or to women contemplating pregnancy. Coadministration of cisapride, dofetilide, ergot alkaloids such as dihydroergotamine, ergotamine, ergometrine (ergonovine), and methylergometrine (methylergonovine), felodipine, levacetylmethadol (levomethadyl), lovastatin, methadone, oral midazolam, nisoldipine, pimozide, quinidine, simvastatin, and triazolam with Itraconazole 200mg Tablet is contraindicated. Anaphylaxis and hypersensitivity have been reported with use of itraconazole. Itraconazole 200mg Tablet is contraindicated in patients who have shown hypersensitivity to itraconazole products. **Side Effects:** Most common adverse reactions observed in the treatment phase of the onychomycosis clinical trial (>1%) are upper respiratory tract infections, increased hepatic enzymes, hypoacusis, headache, abdominal pain, diarrhea, nausea, fatigue, arrhythmia, cough, sore throat and back pain. Itraconazole has been associated with rare cases of serious hepatotoxicity, including liver failure and death	10 mg/ml oral Solution, 100mg Capsule, 200mg Tablet, 65mg Capsule	রেফারেন্স নাই	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।

ঔষধ নিয়ন্ত্রণ কমিটির ২৫৭ তম সভার কার্যবিবরণী এর সংযুক্তি

Annex-B: আমদানীর জন্য হিউম্যান মেডিসিন এর তালিকা

Sl No	Name of the Manufacturer & Local Agent	Name of the Product	Generic Name with Strength	Therapeutic Class	Indication	Contraindication, Side-effects, Precautions & Warnings	Status (New Molecule/ Existing)	CPP/FSC (UK/USA/ Switzerland /Germany/France/ Japan/Australia/EMA)	টেকনিক্যাল সাব কমিটি সভার মতামত	সভার সিদ্ধান্ত
1	**Manufacturer:** Delpharm Mouvaux Rue Michel Raillard 59,420 Movals, France **Local Agent:** ZAS Corporation, 80/22 Mymenshing Road, Nurjehan Tower (3rd Floor) Dhaka-1000	a) **POLYIONIC** Concentrate for Solution for Infusion	Glucose Monohydrate 55.0 g + Sodium chloride 4.0 g + Potassium chloride 2.0g/Unit	Trace Element	This medication is recommended in the following situations: dehydration states hydro-electrolytic balancing (balance of water and body salts); Carbohydrate caloric intake (200 kcal /l).	**Contraindications:** Hypersensitivity to the active substance or to any of the excipients **Side effects:** Chills, nausea, vomiting Edema due to a hydro-soded overload (water and body salts) Nosocomial hyponatremia (acquired during hospitalization) and acute hyponatremic encephalopathy.	Anhydrous Glucose 6.75 gm + Potassium Chloride 750 mg + Sodium Chloride 1.3 gm + Trisodium Citrate 1.45 gm/Unit ORS Saline	CPP-France	প্রয়োজন নাই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
		b) Ketoprofene Concentrate for solution for Infusion	Ketoprofen 100mg/10ml	Anti-inflammatory drug	It is indicated in adults (over 15 years) in the treatment of post-operative pain and renal colic attacks (painful attacks of the lower back following blockage of the urinary tract).	**Contraindications:** Hypersensitivity to the active substance or to any of the excipients **Side effects:** Nausea, vomiting, difficulty digesting, abdominal pain, stomach ache.	100 mg/2 ml Injection	CPP-France	প্রয়োজন নাই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
2.	**Manufacturer :** Laboratoire Aguettant Lieu-Dit Chantecaille 07340 Champagne France. **Local Agent:** ZAS Corporation, 80/22 Mymenshing Road, Nurjehan Tower (3rd Floor) Dhaka-1000	a) **PHOCYTAN** Concentrate for solution for infusion	Glucose-1-Disodium Phosphate tetrahydrate 250.8mg/ml	Trace Element	Correction of moderate to severe hypo phosphoremia when recourse to the oral route is impossible supply of phosphorus during parenteral nutrition.	**Contraindications:** Severe chronic renal failure, with the exception of patients whose phosphoremia is closely monitored and who require phosphorus supplementation; hyperphosphoremia, hypercalcemia, due to the risk of calcium precipitation in soft tissue. **Side effects:** None	New	CPP-France	প্রয়োজন নাই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
		b) **Junyelt** Concentrate for solution for infusion	Zinc gluconate 6970µg + Copper gluconate 1428 µg + Manganese gluconate 40.52 µg + Potassium iodide 13.08 µg + Sodium selenite 43.81 µg/10ml ampoule	Trace Element	JUNYELT is used as part of the intravenous nutrition of preterm and term newborns, infants and children. It is intended to meet the basal requirements for trace elements	**Contraindications:** Patients with known hypersensitivity to one of the actives substances and to the excipients. In case of Wilson's disease and if serum concentrations of any of the trace elements contained in JUNYELT are elevated.	New	CPP-France	প্রয়োজন নাই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।

Sl No	Name of the Manufacturer & Local Agent	Name of the Product	Generic Name with Strength	Therapeutic Class	Indication	Contraindication, Side-effects, Precautions & Warnings	Status (New Molecule/ Existing)	CPP/FSC (UK/USA/ Switzerland /Germany/France/ Japan/Australia/EMA)	টেকনিক্যাল সাব কমিটি সভার মতামত	সভার সিদ্ধান্ত
						Side effects: None				
3.	**Manufacturer:** Central Pharma Limited Caxton Road, Bedford Mk41 0xz, United Kingdom **Local Agent:** ZAS Corporation, 80/22 Mymenshing Road, Nurjehan Tower (3rd Floor) Dhaka-1000,	Arganova 1mg/ml Solution for Infusion	Argatroban Monohydrate 1mg/ml (Strength: 50mg/50ml)	Anticoagulant drugs	Anticoagulation in adults with heparin-induced thrombocytopenia (HIT) type II, requiring parenteral antithrombotic therapy. The diagnosis should be confirmed by a heparin-induced platelet activation test or equivalent test. However, this confirmation should not delay the start of treatment.	**Contraindications:** Known, ARGANOVA is contraindicated: In patients with uncontrolled bleeding Hypersensitivity to argatroban or any of the excipients Severe liver failure. **Side effects:**	New	CPP-France	অনুমোদনের সুপারিশ করা হয়।	নামঞ্জুর করা হয়।
4.	**Manufacturer:** IBSA Biochimique SA, VIA Serta 12 6814 Lamone Switzerland **Local Agent:** Interhealth & Devices Ltd. H.M. Plaza (12th Floor), Suit 2&3, Plot 34, Road 2, Sector 3, Uttara Commercial Area Uttara, Dhaka	Merional HG 900 IU. Multidose powder and solvent for solution for i.m.,s.c (solvent in ampoule)	Highly Purified Menopausal Gonadotrophin (hMG) (Menotrophin) 900 IU	Hormone	Anovulation (including polycystic ovarian disease, PCOD) in women who have been unresponsive to treatment with clomiphene citrate. Stimulation of multifollicular development in patients undergoing assisted reproductive technologies (ART) such as in-vitro fertilization (IVF), gamete intrafallopian transfer (GIFT) and zygote intrafallopian transfer (ZIFT). Merional 75 IU may be given in combination with human Chorionic Gonadotrophin (hCG) for the stimulation of spermatogenesis in men who have congenital or acquired hypogonadotrophic hypogonadism. Merional is indicated for use in adults only.	Contraindications: Merional should not be administered to children or to patients who have: Hypersensitivity to the active substance menotrophin or to any of the excipients Tumours of the hypothalamus or pituitary gland and to females who have: Ovarian enlargement or a cyst not due to polycystic ovarian disease Gynaecological haemorrhages of unknown cause Ovarian, uterine or mammary carcinoma Motional should not be used when an effective response cannot be achieved, such as: In females: •Primary ovarian failure, •Malformation of sexual organs incompatible with pregnancy, •Fibroid tumors of the uterus incompatible with pregnancy In males: • Primary testicular insufficiency. **Side Effects:** The most common adverse reactions are ovarian cysts, injection site reactions and		CPP-Switzerland	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।

Sl No	Name of the Manufacturer & Local Agent	Name of the Product	Generic Name with Strength	Therapeutic Class	Indication	Contraindication, Side-effects, Precautions & Warnings	Status (New Molecule/ Existing)	CPP/FSC (UK/USA/ Switzerland /Germany/France/ Japan/Australia/EMA)	টেকনিক্যাল সাব কমিটি সভার মতামত	সভার সিদ্ধান্ত
						headache occurring in up to 10% of female patients. The most serious adverse reactions are severe OHSS and complications associated with this condition such as ovarian torsion and thromboembolism.				
5.	**Manufacturer:** Fresenius Kabi Deutschland GmbH, Germany **Importer:** Eskayef Pharmaceuticals Ltd.	SMOF Lipid 200mg/mL Emulsion for Infusion	Soya-bean Oil, Refined Ph. Euro 60.0gm + Triglycerides, medium Chain 60.0gm + Olive Oil, Refined 50.0gm + Fish Oil, rich in Omega-3-acids 30.0gm/Liter	Lipid Emulsion	SMOFlipid is indicated in adult and pediatric patients, including term and preterm neonates, as a source of calories and essential fatty acids for parenteral nutrition (PN) when oral or enteral nutrition is not possible, insufficient, or contraindicated.	**Contraindications:** Use of SMOFlipid is contraindicated in patients with: ➢ Known hypersensitivity to fish, egg, soybean, peanut or any of the active or inactive ingredients in SMOFlipid ➢ Severe disorders of lipid metabolism characterized by hypertriglyceridemia (serum triglyceride >1,000 mg/dL) **Side Effects:** Clinical Decompensation with Rapid Infusion of Intravenous Lipid Emulsion in Neonates and Infants, parenteral Nutrition-Associated Liver Disease and Other Hepatobiliary Disorders. hypersensitivity reactions, Infections, Fat Overload Syndrome, refeeding Syndrome, hypertriglyceridemia, Aluminum Toxicity, essential Fatty Acid Deficiency.	New	CPP-Germany, Austria	প্রয়োজন নাই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
6.	**Manufacturer:** Genzyme Ireland Limited, IDA Industrial Park, Old Kilmeaden Road, Waterford, Ireland. **Local agent:** Synovia Pharma PLC., Station Road, Tongi, Gazipur.	Thymoglobuline 25mg/Vial powder for solution for infusion After reconstitute 25mg/5ml	Rabbit anti-human thymocyte immunoglobulin 25mg/Vial	Immune-suppressant Therapeutic Code: 58	Thymoglobuline is an anti-human thymocyte immunoglobulin made from rabbit blood into which cells from the human thymus have been injected. Thymoglobuline is used for – - Immunosuppression in transplantation: prevention and treatment of graft rejection. When a patient receives an organ, the body's natural defense system tries to reject it. Thymoglobuline changes the body's defense mechanism and helps it accept the transplanted organ.	**Contra-indication**: Do not use Thymoglobulin: - If you are allergic to rabbit proteins or any of the other ingredients of this medicine. - If you have an acute or chronic infection that would prevent further immunosuppression (as Thymoglobuline decreases your body's ability to fight infections). **Side-effects:** Some side effects, such as fever, rash and headache, or other effects affecting pulse, blood pressure and breathing, as well as some allergic reactions, are more likely to occur with your first or second dose of Thymoglobuline than with subsequent doses.	20mg/ml	CPP- France, CPP – Ireland	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।

Sl No	Name of the Manufacturer & Local Agent	Name of the Product	Generic Name with Strength	Therapeutic Class	Indication	Contraindication, Side-effects, Precautions & Warnings	Status (New Molecule/ Existing)	CPP/FSC (UK/USA/ Switzerland /Germany/France/ Japan/Australia/EMA)	টেকনিক্যাল সাব কমিটি সভার মতামত	সভার সিদ্ধান্ত
					- Prevention of acute and chronic graft-versus-host disease (a disease in which the functional immune cells in the transplanted bone marrow recognize the recipient as "foreign" and mount an immune attack) in hematopoietic stem cell transplantation (transplantation of cells capable of forming blood cells). - Treatment of steroid-resistant acute graft-versus-host disease. - In hematology: treatment of bone marrow depression. Bone marrow depression is a rare type of blood disorder in which the body does not make enough blood cells.	Difficulty breathing, wheezing or cough, feeling sick or vomiting, dizziness or generally feeling ill, joint pain, bleeding or bruising more frequently than usual, irregular, or rapid heartbeat, symptoms of an infection such as fever, chills, sore throat, mouth ulcers. **Warning and Precautions:** Thymoglobuline should always be used under strict medical surveillance in a hospital setting. Thymoglobuline must only be administered according to the instructions of a physician with experience of immunosuppressive therapy in the transplant setting. Patients should be carefully monitored during the infusion. Particular attention must be paid to monitoring the patient for any symptoms of anaphylactic shock. Close monitoring of the patient must continue during the infusion and for a period following the end of the infusion until the patient is stable. Prior to administration of Thymoglobuline it is advisable to determine whether the patient is allergic to rabbit proteins. Medical personnel and equipment etc. must be readily at hand during the 1st days of therapy to provide emergency treatment if necessary.				
7.	**Marketing authorization holder**: Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285 USA. **Manufacturer:** BSP Pharmaceuticals S.p.A, Via Appia Km	Mounjaro 12.5 mg/0.5ml Injection Vial & Prefilled Pen	Tirzepatide USP 12.5mg/0.5ml	Antidiabetes Therapeutic code: 015	It is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise. The recommended starting dosage is 2.5 mg injected subcutaneously once weekly, after 4 weeks, increase to 5 mg & If additional glycemic control is needed, increase the dosage in 2.5 mg increments after at least 4 weeks on the current dose. • The maximum dosage is 15 mg	**Side Effects:** The most common adverse reactions, reported in ≥5% of patients treated with MOUNJARO are: nausea, diarrhoea, decreased appetite, vomiting, constipation, dyspepsia, and abdominal pain. **Contraindication:** Hypersensitivity to the active substance or to any of the excipients **Special warnings and precautions for use:** Tirzepatide has not been studied in patients with a	2.5 mg/0.5ml Inj. 5 mg/0.5ml Inj. 7.5 mg/0.5ml Inj.	CPP-USA EMA	অনুমোদনের সুপারিশ করা হয়।	নামঞ্জুর করা হয়।

Sl No	Name of the Manufacturer & Local Agent	Name of the Product	Generic Name with Strength	Therapeutic Class	Indication	Contraindication, Side-effects, Precautions & Warnings	Status (New Molecule/ Existing)	CPP/FSC (UK/USA/ Switzerland /Germany/France/ Japan/Australia/EMA)	টেকনিক্যাল সাব কমিটি সভার মতামত	সভার সিদ্ধান্ত
	65,561, Latina Scalo (LT) , Lazio 04013 ITALY **Local Agent:** Healthcare Pharmaceuticals Ltd				subcutaneously once weekly. The recommended	history of pancreatitis, and should be used with caution in these patients. Patients receiving tirzepatide in combination with an insulin secretagogue (for example, a sulphonyl urea) or insulin may have an increased risk of hypoglycemia.				
8.	Marketing authorization holder: Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285 USA. Manufacturer: BSP Pharmaceuticals S.p.A, Via Appia Km 65,561, Latina Scalo (LT) , Lazio 04013 ITALY Local Agent: Healthcare Pharmaceuticals Ltd	Mounjaro 10 mg/0.5ml Injection Vial & Prefilled Pen	Tirzepatide USP 10mg/0.5ml	Antidiabetes Therapeutic code: 015	It is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise The recommended starting dosage is 2.5 mg injected subcutaneously once weekly, after 4 weeks, increase to 5 mg & If additional glycemic control is needed, increase the dosage in 2.5 mg increments after at least 4 weeks on the current dose. The maximum dosage is 15 mg subcutaneously once weekly. The recommended	**Side Effects:** The most common adverse reactions, reported in ≥5% of patients treated with MOUNJARO are: nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, and abdominal pain. **Contraindication:** Hypersensitivity to the active substance or to any of the excipients **Special warnings and precautions for use:** Tirzepatide has not been studied in patients with a history of pancreatitis, and should be used with caution in these patients. Patients receiving tirzepatide in combination with an insulin secretagogue (for example, a sulphonylurea) or insulin may have an increased risk of hypoglycaemia.	2.5 mg/0.5ml Inj. 5 mg/0.5ml Inj. 7.5 mg/0.5ml Inj.	CPP-USA EMA	অনুমোদনের সুপারিশ করা হয়।	নামঞ্জুর করা হয়।
9.	Marketing authorization holder: Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285 USA. Manufacturer: BSP Pharmaceuticals S.p.A, Via Appia Km 65,561, Latina Scalo (LT) , Lazio	Mounjaro 15 mg/0.5ml Injection Vial & Prefilled Pen	Tirzepatide USP 15mg/0.5ml	Antidiabetes Therapeutic code: 015	Mounjaro is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise The recommended starting dosage is 2.5 mg injected subcutaneously once weekly, After 4 weeks, increase to 5 mg & If additional glycemic control is needed, increase the dosage in 2.5 mg increments after at least 4 weeks on the current dose. • The maximum dosage is 15 mg subcutaneously once weekly.	**Side Effects:** The most common adverse reactions, reported in ≥5% of patients treated with MOUNJARO are: nausea, diarrhoea, decreased appetite, vomiting, constipation, dyspepsia, and abdominal pain. **Contraindication:** Hypersensitivity to the active substance or to any of the excipients **Special warnings and precautions for use:** Tirzepatide has not been studied in patients with a history of pancreatitis, and should be used with caution in these patients. Patients receiving tirzepatide in combination with an	2.5 mg/0.5ml Inj. 5 mg/0.5ml Inj. 7.5 mg/0.5ml Inj.	CPP-USA EMA	অনুমোদনের সুপারিশ করা হয়।	নামঞ্জুর করা হয়।

Sl No	Name of the Manufacturer & Local Agent	Name of the Product	Generic Name with Strength	Therapeutic Class	Indication	Contraindication, Side-effects, Precautions & Warnings	Status (New Molecule/ Existing)	CPP/FSC (UK/USA/ Switzerland /Germany/France/ Japan/Australia/EMA)	টেকনিক্যাল সাব কমিটি সভার মতামত	সভার সিদ্ধান্ত
	04013 ITALY Local Agent: Healthcare Pharmaceuticals Ltd				The recommended	insulin secretagogue (for example, a sulphonyl urea) or insulin may have an increased risk of hypoglycemia.				
10	Made for F. Hoffmann-La Roche Ltd, Basel, Switzerland by Roche Diagnostics GmbH, Sandhofer Strasse 116, 68305 Mannheim, Germany. **Local agent:** Roche Bangladesh Limited	Tecentriq 1875 mg/Vial Solution for injection	Atezolizumab INN 1875mg/Vial	Anticancer	Urothelial carcinoma (UC) Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic UC: • after prior platinum-containing chemotherapy, or • who are considered cisplatin ineligible, and whose tumours have a PD-L1 expression ≥ 5%. Early-stage non-small cell lung cancer (NSCLC) Tecentriq as monotherapy is indicated as adjuvant treatment following complete resection for adult patients with Stage II to IIIA (7th edition of the UICC/AJCC-staging system) non-small cell lung cancer (NSCLC) whose tumours have PD-L1 expression on ≥ 50% of tumour cells (TC) and whose disease has not progressed following platinum-based adjuvant chemotherapy. Metastatic NSCLC Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous NSCLC. In patients with EGFR mutant or ALK-positive NSCLC, Tecentriq, in combination with bevacizumab, paclitaxel	**Contraindication**: Hypersensitivity to atezolizumab or any excipients used in the formulation. **Side effects**: Immune-mediated pneumonitis Immune-mediated hepatitis, Immune-mediated colitis, Hypophysitis, Diabetes mellitus, Immune-mediated neuropathies, Immune-mediated nephritis	840mg/Vial 1200mg/Vial	CPP-EMA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।

Sl No	Name of the Manufacturer & Local Agent	Name of the Product	Generic Name with Strength	Therapeutic Class	Indication	Contraindication, Side-effects, Precautions & Warnings	Status (New Molecule/ Existing)	CPP/FSC (UK/USA/ Switzerland /Germany/France/ Japan/Australia/EMA)	টেকনিক্যাল সাব কমিটি সভার মতামত	সভার সিদ্ধান্ত
					and carboplatin, is indicated only after failure of appropriate targeted therapies. Tecentriq, in combination with nab-paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous NSCLC who do not have EGFR mutant or ALK-positive NSCLC. Tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic NSCLC whose tumours have a PD-L1 expression ≥ 50% TC or ≥ 10% tumour-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC . Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR mutant or ALK-positive NSCLC should also have received targeted therapies before receiving Tecentriq . <u>Small cell lung cancer (SCLC)</u> Tecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). <u>Triple-negative breast cancer (TNBC)</u> Tecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic TNBC whose tumours have PD-L1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.					

Sl No	Name of the Manufacturer & Local Agent	Name of the Product	Generic Name with Strength	Therapeutic Class	Indication	Contraindication, Side-effects, Precautions & Warnings	Status (New Molecule/ Existing)	CPP/FSC (UK/USA/ Switzerland /Germany/France/ Japan/Australia/EMA)	টেকনিক্যাল সাব কমিটি সভার মতামত	সভার সিদ্ধান্ত
					Hepatocellular carcinoma (HCC) Tecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable HCC who have not received prior systemic therapy.					
11.	**Manufacturer:** Ferring Controlled Therapeutics Limited 1 Redwood Place, Peel Park Campus, East Kilbride, Glasgow, G74 5PB, United Kingdom **Local Agent:** Radiant Export Import Enterprise. Lubdhok, 4th Floor, 474 P, Road No.-3, Sector-12, Uttara, Dhaka-1230, Bangladesh	Propess 10mg Vaginal Delivery System **Pessary**	Dinoprostone 10mg	Prostaglandin	Initiation of cervical ripening in patients, at term (from 37 completed weeks of gestation)	**Contraindication:** Labour, when oxytocic drugs and/or other labour indication agents are being given, inappropriate strong prolong uterine contractions, previous major uterine surgery, previous major uterine cervix surgery, rupture of the uterine cervix, cephalopelvic disruption, fetal malpresentation, suspicion or evidence of fetal distress, pelvic inflammatory disease, unless adequate prior treatment, hypersensitivity to dinoprostone or to any of the excipients. **Side effect:** Fetal heart rate disorder, Abnormal labour affecting foetus, Fetal Distress Syndrome, Fetal Death, Stillbirth and neonatal death.	3mg Tablet	CPP- MHRA, UK	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।
12.	**Merck Serono S.p.A., Via Delle Magnolie 15, (loc. Frazione Zona Industriale) 70026, Modugno (BA), Italy** (anufacturing for all steps of the finished medicinal	Pergoveris Solution for injection in pre-filled pen	Follitropin alfa (r-hFSH) 300 IU (equivalent to 22µg) + Lutropin alfa (r-hLH) 150 IU (equivalent to 6 µg)/0.48mL pre-filled pen	Hormone	Pergoveris is indicated for the stimulation of follicular development in adult women with severe LH and FSH deficiency.	**Side Effects:** The most commonly reported adverse reactions are headache, ovarian cysts and local injection site reactions (e.g. pain, erythema, haematoma, swelling and/or irritation at the site of injection). Mild or moderate OHSS has been commonly reported and should be considered as an intrinsic risk of the stimulation procedure. Severe OHSS is uncommon. Thromboembolism may occur very rarely, usually associated with severe OHSS. **Contra Indications/ Warnings**	Pergoveris (150IU+75IU)	CPP-EMA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।

Sl No	Name of the Manufacturer & Local Agent	Name of the Product	Generic Name with Strength	Therapeutic Class	Indication	Contraindication, Side-effects, Precautions & Warnings	Status (New Molecule/ Existing)	CPP/FSC (UK/USA/ Switzerland /Germany/France/ Japan/Australia/EMA)	টেকনিক্যাল সাব কমিটি সভার মতামত	সভার সিদ্ধান্ত
	product) , **Merck Serono S.p.A. Guidonia Montecelio Site Via Luigi Einaudi,11 00012 Guidonia Montecelio (RM) Italy** (quality control of the finished medicinal product). **Local Agent:** Janata Traders 62/2 Purana Paltan Dhaka 1000					Pergoveris is contraindicated in patients with: • hypersensitivity to the active substances or to any of the excipients listed in section • tumours of the hypothalamus and pituitary gland • ovarian enlargement or ovarian cyst unrelated to polycystic ovarian disease and of unknown origin • gynaecological haemorrhages of unknown origin • ovarian, uterine or mammary carcinoma Pergoveris must not be used when an effective response cannot be obtained, such as: • primary ovarian failure • malformations of sexual organs incompatible with pregnancy • fibroid tumours of the uterus incompatible with pregnancy				
13.	**Merck Serono S.p.A., Via Delle Magnolie 15, (loc. Frazione Zona Industriale) 70026, Modugno (BA), Italy** (anufacturing for all steps of the finished medicinal product) , **Merck Serono S.p.A. Guidonia Montecelio Site Via Luigi Einaudi,11 00012 Guidonia Montecelio (RM)**	Pergoveris Solution for injection in pre-filled pen	Follitropin alfa (r-hFSH) 900 IU (equivalent to 66µg) + Lutropin alfa (r-hLH) 450 IU (equivalent to 18 µg)/1.44 mL pre-filled pen	Hormone	Pergoveris is indicated for the stimulation of follicular development in adult women with severe LH and FSH deficiency.	**Side Effects:** The most commonly reported adverse reactions are headache, ovarian cysts and local injection site reactions (e.g. pain, erythema, haematoma, swelling and/or irritation at the site of injection). Mild or moderate OHSS has been commonly reported and should be considered as an intrinsic risk of the stimulation procedure. Severe OHSS is uncommon. Thromboembolism may occur very rarely, usually associated with severe OHSS. **Contra Indications/ Warnings** Pergoveris is contraindicated in patients with: • hypersensitivity to the active substances or to any of the excipients listed in section • tumours of the hypothalamus and pituitary gland • ovarian enlargement or ovarian cyst unrelated to polycystic ovarian disease and of unknown origin • gynaecological haemorrhages of unknown origin • ovarian, uterine or mammary carcinoma	Pergoveris (150IU+75IU)	CPP-EMA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।

Sl No	Name of the Manufacturer & Local Agent	Name of the Product	Generic Name with Strength	Therapeutic Class	Indication	Contraindication, Side-effects, Precautions & Warnings	Status (New Molecule/ Existing)	CPP/FSC (UK/USA/ Switzerland /Germany/France/ Japan/Australia/EMA)	টেকনিক্যাল সাব কমিটি সভার মতামত	সভার সিদ্ধান্ত
	Italy (quality control of the finished medicinal product). **Local Agent:** Janata Traders 62/2 Purana Paltan Dhaka 1000					Pergoveris must not be used when an effective response cannot be obtained, such as: • primary ovarian failure • malformations of sexual organs incompatible with pregnancy • fibroid tumours of the uterus incompatible with pregnancy				
14.	**Manufacturer:** Lipomed AG Fabrikmattenweg 4, Switzerland **Local Agent:** ZAS Corporation, 80/22 Mymenshing Road, Nurjehan Tower (3rd Floor) Dhaka-1000,	LITAK 2mg/mL Solution for Injection	Cladribine INN 10.0mg/5mL	Anticancer	LITAK is indicated for the treatment of hairy cell leukemia.	**Contraindications:** Hypersensitivity to the active substance or any of the excipients listed. Pregnancy and lactation. Patients less than 18 years of age. Moderate to severe renal impairment (creatinine clearance ≤ 50 ml/min) or moderate to severe hepatic impairment (Child-Pugh score > 6) Concomitant use of other myelosuppressive medicinal products. **Side Effects:** Very common adverse reactions observed during the three most relevant clinical trials with cladribine in 279 patients treated for various indications and in 62 patients with hairy cell leukaemia (HCL) were myelosuppression, especially severe neutropenia (41% (113/279), HCL 98% (61/62)), severe thrombocytopenia (21% (58/279), HCL 50% (31/62)) and severe anaemia (14% (21/150), HCL 55% (34/62)), as well as severe immunosuppression/lymphopenia (63% (176/279), HCL 95% (59/62)), infections (39% (110/279), HCL 58% (36/62)) and fever (up to 64%). Culture-negative fever following treatment with cladribine occurs in 10-40% of patients with hairy cell leukaemia and is rarely observed in patients with other neoplastic disorders. Skin rashes (2-31%) are mainly described in patients with other concomitantly administered medicinal products	New	France	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।

Sl No	Name of the Manufacturer & Local Agent	Name of the Product	Generic Name with Strength	Therapeutic Class	Indication	Contraindication, Side-effects, Precautions & Warnings	Status (New Molecule/ Existing)	CPP/FSC (UK/USA/ Switzerland /Germany/France/ Japan/Australia/EMA)	টেকনিক্যাল সাব কমিটি সভার মতামত	সভার সিদ্ধান্ত
						known to cause rash (antibiotics and/or allopurinol). Gastrointestinal adverse reactions like nausea (5-28%), vomiting (1-13%), and diarrhoea (3-12%) as well as fatigue (2-48%), headache (1-23%), and decreased appetite (1-22%) have been reported during treatment with cladribine.Cladribine is unlikely to cause alopecia; mild and transient alopecia for a few days was observed in 4/523 patients during the treatment, but could not clearly be associated with cladribine.				
15.	**Manufacturer:** Semikal Teknoloji Sanayi Ve Ticaret A.S; Cunur Street, 102. Road, Technopark, No:252/213, 32260 Isparta, Turkey **Supplier:** Semikal Teknoloji Sanayi Ve Ticaret A.S; Cunur Street, 102. Road, Technopark, No:252/213, 32260 Isparta, Turkey **Importer:** Adventa Bangladesh. Address: 198-202, Nawabpur Tower, Nawabpur road, Dhaka	**Sectalon 40 mg** Intra-articular Injection	Hyaluronic acid as sodium hyaluronate 2%, (40 mg / 2 ml)	viscosupplement agent	It is indicated for knee osteoarthritis	**Contraindications:** Must not be injected if the joint is infected or seriously inflamed or if the patient has a skin infection or other problem in in the area where the injection is to be made. Must be administered with caution in patients with diabetes or affected by chronic pathologies. **Side Effects:** Infiltration may cause localised side effects. During the use, following symptoms may appear around the injection site: pain, heat, redness or swelling. These secondary effects may be alleviated by applying ice to the treated joint. These symptoms will normally disappear after a short period. The doctor must ensure that patients inform him of any adverse effects occurring after treatment.		FSC-Turkey Spain মেডিকেল ডিভাইস হিসেবে	প্রয়োজন নাই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
16.	**Manufacturer:** Semikal Teknoloji Sanayi Ve Ticaret A.S; Cunur Street, 102. Road,	**Sectalon Gel B Cross** 75 mg Intra-articular Injection	Hyaluronic acid as sodium hyaluronate 2.5%, (75 mg / 2.5 ml)	viscosupplement agent	It is indicated for knee osteoarthritis	Contraindications: Must not be injected if the joint is infected or seriously inflamed or if the patient has a skin infection or other problem in in the area where the injection is to be made. Must be administered with caution in patients with		FSC-Turkey Spain	প্রয়োজন নাই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।

Sl No	Name of the Manufacturer & Local Agent	Name of the Product	Generic Name with Strength	Therapeutic Class	Indication	Contraindication, Side-effects, Precautions & Warnings	Status (New Molecule/ Existing)	CPP/FSC (UK/USA/ Switzerland /Germany/France/ Japan/Australia/EMA)	টেকনিক্যাল সাব কমিটি সভার মতামত	সভার সিদ্ধান্ত
	Technopark, No:252/213, 32260 Isparta, Turkey **Supplier:** Semikal Teknoloji Sanayi Ve Ticaret A.S; Cunur Street, 102. Road, Technopark, No:252/213, 32260 Isparta, Turkey **Importer:** Adventa Bangladesh. Address: 198-202, Nawabpur Tower, Nawabpur road, Dhaka Bangladesh					diabetes or affected by chronic pathologies. Side Effects: Infiltration may cause localised side effects. During the use, following symptoms may appear around the injection site: pain, heat, redness or swelling. These secondary effects may be alleviated by applying ice to the treated joint. These symptoms will normally disappear after a short period. The doctor must ensure that patients inform him of any adverse effects occurring after treatment.				
17.	**Manufactured by:** BIODUE SPA; Address: Via` A. Lorenzetti, 3/A - Loc. Sambuca Val di Pesa 50028 Barberino Tavarnelle (FI), Italy **Distributed by:** RIVER PHARMA SRL; Viale Stazione 6, 26863 Orio Litta (LO), Italy	LEVICIKA 30 ml Cream	Cyclopentasiloxane USP 7% + Cetyl PEG USP 2% + Dimethicone USP 1.0 %	Skin & Mucous Preparation	It is indicated for the treatment of hypertrophic or keloid scar induced by burn, surgical procedures or traumas	**Contraindications:** Not to be used on children under 6 years old. Cream is for external use only. Direct contact with eyes, mucous membranes, third degree burns and open wounds, animal bites should be avoided. It should not be used on dermatological conditions that disrupt the integrity of the skin. **Side Effects:** Silicone may trigger allergic reactions and cause side effects like: Irritation, Dryness, Inflammation, Swelling, Burning, Itching, Redness. If anyone notice these symptoms, discontinue using the product and consult a doctor.	New	CPP-Italy	অনুমোদনের সুপারিশ করা হয়।	নামঞ্জুর করা হয়।

Sl No	Name of the Manufacturer & Local Agent	Name of the Product	Generic Name with Strength	Therapeutic Class	Indication	Contraindication, Side-effects, Precautions & Warnings	Status (New Molecule/ Existing)	CPP/FSC (UK/USA/ Switzerland /Germany/France/ Japan/Australia/EMA)	টেকনিক্যাল সাব কমিটি সভার মতামত	সভার সিদ্ধান্ত
	Importer: Benvue International Ltd. Address: 1512, O. R. Nizam Road, Chittagong									
18.	**Manufacturer:** Novartis Pharma Stein AG, Switzerland **Local Representative:** Novartis (Bangladesh) Limited Tower One One Seven (Level 5), Plot # 117/A, Tejgaon I/A, Dhaka 1208, Bangladesh.	Xolair	Omalizumab INN 300 mg/2.0 mL solution for injection in pre-filled syringe (PFS)	Antihistamines anti-allergies & hypo-sensitization drug Class: 010	Xolair is indicated for: **Allergic asthma:** Xolair is indicated in adults, adolescents and children (6 to <12 years of age). Xolair treatment should only be considered for patients with convincing IgE (immunoglobulin E) mediated asthma. **Adults and adolescents (12 years of age and older):** Xolair is indicated as add-on therapy to improve asthma control in patients with severe persistent allergic asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and who have reduced lung function (FEV1 <80%) as well as frequent daytime symptoms or night-time awakenings and who have had multiple documented severe asthma exacerbations despite daily high-dose inhaled corticosteroids, plus a long-acting inhaled beta2-agonist. **Children (6 to <12 years of age)** Xolair is indicated as add-on therapy to	**Contraindication:** Hypersensitivity to omalizumab or to any of the excipients **Side Effects: Rare (≥0.01 to <0.1%)**: Angioedema, anaphylactic reactions, and other allergic conditions, laryngoedema. **Uncommon (≥0.1 to <1%)**: allergic bronchospasm. **Not known:** Eosinophilic Granulomatosis with Polyangiitis (i.e., Churg Strauss syndrome), idiopatic severe thrombocytopenia, serum sickness.	Omalizumab 75mg & 150 mg PFS	EMA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।

Sl No	Name of the Manufacturer & Local Agent	Name of the Product	Generic Name with Strength	Therapeutic Class	Indication	Contraindication, Side-effects, Precautions & Warnings	Status (New Molecule/ Existing)	CPP/FSC (UK/USA/ Switzerland /Germany/France/ Japan/Australia/EMA)	টেকনিক্যাল সাব কমিটি সভার মতামত	সভার সিদ্ধান্ত
					improve asthma control in patients with severe persistent allergic asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and frequent daytime symptoms or night-time awakenings and who have had multiple documented severe asthma exacerbations despite daily high-dose inhaled corticosteroids, plus a long-acting inhaled beta2-agonist. **Chronic rhinosinusitis with nasal polyps (CRSwNP**) Xolair is indicated as an add-on therapy with intranasal corticosteroids (INC) for the treatment of adults (18 years and above) with severe CRSwNP for whom therapy with INC does not provide adequate disease control. **Chronic Spontaneous Urticaria (CSU)** Xolair is indicated as add-on therapy for the treatment of chronic spontaneous urticaria in adult and adolescents (12 years and above) patients with inadequate response to H1 antihistamine treatment					
19	**Merck Serono S.A**. Succursale d'Aubonne , Zone Industrile de l'ouriettaz , 1170 Aubonne, **Switzerland** (manufacturing the bulk finished product, quality control of the	**Bavencio** Concentrate for solution for infusion	Avelumab INN 200 mg/10mL Vial	Anticancer	Bavencio is indicated as monotherapy for the treatment of adult patients with metastatic Merkel cell carcinoma (MCC). Bavencio is indicated as monotherapy for the first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are progression-free following platinum-based chemotherapy. Bavencio in combination with axitinib is	**Contra Indications:** Hypersensitivity to the active substance or to any of the excipients. **Side Effects:** Most common adverse reactions (reported in ≥ 20% of patients) were fatigue, musculoskeletal pain, diarrhea, nausea, infusion-related reaction, rash, decreased appetite, and peripheral edema.	New	EMA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।

Sl No	Name of the Manufacturer & Local Agent	Name of the Product	Generic Name with Strength	Therapeutic Class	Indication	Contraindication, Side-effects, Precautions & Warnings	Status (New Molecule/ Existing)	CPP/FSC (UK/USA/ Switzerland /Germany/France/ Japan/Australia/EMA)	টেকনিক্যাল সাব কমিটি সভার মতামত	সভার সিদ্ধান্ত
	finished medicinal product , primary packaging of the dosage form & secondary packaging of the product) **Merck Serono S.P.A.** via Luigi Einaudi,11, 00012 Guidonia Montecelio (RM), **Italy** (quality control of the finished medicinal product) **Merck Seroni S.P.A.** via Delle Magnolie 15 (loc. Frazione Zona Industriale) 70026- Modugno (BA) , **Italy** (Batch release of the finished medicinal product in the EU) **Local Agent:** Janata Traders 62/2 Purana Paltan Dhaka 1000				indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC)					
20	**Manufacturer:** Laboratoire AGUETTANT 1 rue Alexander Fleming 69007 Lyon –	Adrenaline Aguettant 0.1 mg/ml sulfite free Solution for injection in pre-filled syringe	Adrenaline (Epinephrine)1mg/10 ml (1:10,000)	Adrenergic Agent	Adrenaline is a drug that leads to increased blood pressure, increased heart rate, increased air entry, increased blood glucose, stimulates cardiac activity and reduces allergic reactions by reducing inflammatory response caused by	**Contraindications:** Hypertension, arteriosclerosis, coronary disease and hyperthyroidism. Not to be given to patients taking monoamine oxidase inhibitors. **Side effects:** Common side effects are anxiety, restlessness, dizziness, headache, palpitations,	Adrenaline 1 mg/ml Injection	CPP- France	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।

Sl No	Name of the Manufacturer & Local Agent	Name of the Product	Generic Name with Strength	Therapeutic Class	Indication	Contraindication, Side-effects, Precautions & Warnings	Status (New Molecule/ Existing)	CPP/FSC (UK/USA/ Switzerland /Germany/France/ Japan/Australia/EMA)	টেকনিক্যাল সাব কমিটি সভার মতামত	সভার সিদ্ধান্ত
	France **Local Agent:** ZAS Corporation, 80/22 Mymenshing Road, Nurjehan Tower (3rd Floor) Dhaka-1000,				histamine. Due to these properties, it is used for the treatment of allergic and anaphylactic reactions. Adrenaline is the favored treatment for anaphylactic shock and should be administered immediately if a person begins exhibiting severe allergic reactions. Adrenaline is also used in life threatening asthma when failing ventilation and continued deterioration despite nebulizer therapy.	rapid pulse, tremors, weakness and coldness.				
21	**Manufacturer:** Laboratoire AGUETTANT 1 rue Alexander Fleming 69007 Lyon – France **Local Agent:** ZAS Corporation, 80/22 Mymenshing Road, Nurjehan Tower (3rd Floor) Dhaka-1000,	NICARDIPINE AGUETTANT 10mg/10ml Solution for Injection	Nicardipine Hydrochloride 10mg/10ml	Cardiovascular	Nicardipine hydrochloride, which belongs to a group of medicines called calcium channel blockers. Nicardipine solution for injection is used to treat very severe high blood pressure. It can also be used to control high blood pressure after an operation.	**Contraindications:** Hypersensitivity to the active substance or to any of the excipients. Severe aortic stenosis Compensatory hypertension, i.e. in case of an arteriovenous shunt or aortic coarctation Unstable angina Within 8 days after myocardial infarction Patients with rare hereditary problems of fructose intolerance should not take this medicine. **Side effects:** The majority of undesirable effects are the consequence of the vasodilator effects of nicardipine. The most frequent events are headache, dizziness, peripheral oedema, palpitations and flushing.	New	CPP- France	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।
22	**Manufacturer:** OM Pharma SA Rue du Bois-du-Lan 22 1217 Meyrin Switzerland. **Local Agent:** ZAS Corporation, 80/22 Mymenshing Road, Nurjehan	DICYNONE 250mg/2ml Solution for Injection	Etamsylate 250mg/2ml	Antihemorrhagic agent	**In surgery:** Prophylaxis and treatment of pre-operative and postoperative capillary haemorrhages in all delicate surgeries or in highly vascularised tissue: ENT, gynaecology, obstetrics, urology, Dentistry, ophthalmology, plastic surgery and reconstructive surgery. **In Internal Medicine:** Prophylaxis and treatment of capillary haemorrhages, regardless of their origin and location: haematuria, haematemesis and melena,	**Contraindications:** Acute porphyria. Hypersensitivity to any of the ingredients of the medicinal product. **Side effects**: Gastralgia, nausea, headache, skin rash. Etamsylate contains sulphite as antioxidant that may cause allergic reactions, nausea and diarrhea in susceptible patients.	New	CPP- Switzerland	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।

Sl No	Name of the Manufacturer & Local Agent	Name of the Product	Generic Name with Strength	Therapeutic Class	Indication	Contraindication, Side-effects, Precautions & Warnings	Status (New Molecule/ Existing)	CPP/FSC (UK/USA/ Switzerland /Germany/France/ Japan/Australia/EMA)	টেকনিক্যাল সাব কমিটি সভার মতামত	সভার সিদ্ধান্ত
	Tower (3rd Floor) Dhaka				epistaxis, gingivorrhagia. In Gynecology Metrorrhagia, primary menorrhagia or menorrhagia due to intrauterine devices, where there is no organic pathology.					
23	**Manufacturer:** Laboratoire AGUETTANT 1 rue Alexander Fleming 69007 Lyon – France **Local Agent:** ZAS Corporation, 80/22 Mymenshing Road, Nurjehan Tower (3rd Floor) Dhaka-1000,	ZINC INJECTABLE 1mg/ml Solution for Infusion	Zinc Gluconate 69.7mg/10ml	Trace Element	Supplementation solution in prolonged parenteral nutrition and in situations where a pronounced deficiency may occur: e.g. severe malnutrition, hypercatabolism, digestive fistula, chronic Diarrhea.	**Contraindications:** Hypersensitivity to the active substance or to any of the excipients. **Side effects:** None	New	CPP- France	অনুমোদনের সুপারিশ করা হয়।	নামঞ্জুর করা হয়।
24	**Manufacturer:** Laboratoire Aguettant Lieu-Dit Chantecaille 07340 Champagne. France **Local Agent:** ZAS Corporation, 80/22 Mymenshing Road, Nurjehan Tower (3rd Floor) Dhaka-1000,	PHOCYTAN 0.66mmol/ml Concentrate for solution for infusion	Glucose-1-Phosphate Disodium tetrahydrate 0.2508g/ml	Trace Element	This medicine is a solution of glucose and electrolytes (mineral salts). This treatment is indicated in the correction of hypophosphatemia and when a parenteral supply of phosphorus is necessary, in particular, during parenteral nutrition.	**Contraindications: S**evere chronic renal failure, with the exception of patients whose phosphoremia is closely monitored and who require phosphorus supplementation; hyperphosphoremia, hypercalcemia, due to the risk of calcium precipitation in soft tissue. **Side effects:** None	New	CPP- France	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।
25	**Manufacturer:** Laboratoire Aguettant Lieu-Dit	**JUNYELT** Concentrate for solution for infusion	Zinc gluconate 6970µg + Copper Gluconate 1428 µg + Manganese Gluconate 40.52 µg +	Trace Element	It is used as part of the intravenous nutrition of preterm and term newborns, infants and children. It is intended to meet the basal requirements for trace elements	**Contraindications:** Patients with known hypersensitivity to one of the actives substances and to the excipients. In case of Wilson's disease and if serum concentrations of any of the trace elements	New	CPP- France	অনুমোদনের সুপারিশ করা হয়।	নামঞ্জুর করা হয়।

Sl No	Name of the Manufacturer & Local Agent	Name of the Product	Generic Name with Strength	Therapeutic Class	Indication	Contraindication, Side-effects, Precautions & Warnings	Status (New Molecule/ Existing)	CPP/FSC (UK/USA/ Switzerland /Germany/France/ Japan/Australia/EMA)	টেকনিক্যাল সাব কমিটি সভার মতামত	সভার সিদ্ধান্ত
	Chantecaille 07340 Champagne. France **Local Agent:** ZAS Corporation, 80/22 Mymenshing Road, Nurjehan Tower (3rd Floor) Dhaka		Potassium Iodide 13.08µg + Sodium Selenite 43.81 µg/10ml			contained in JUNYELT are elevated. **Side effects:** None				
26	**Manufacturer:** Laboratoire Aguettant Lieu-Dit Chantecaille 07340 Champagne. France **Local Agent:** ZAS Corporation, 80/22 Mymenshing Road, Nurjehan Tower (3rd Floor) Dhaka-1000,	PHENYLEPHRINE AGUETTANT 50mcg/ml Solution for injection in pre-filled syringe 50mg/10ml Prefilled Syringe	Phenylephrine Hydrochloride 0.609mg eq. to 50mg Phenylephrine/10ml	Vasoconstrictor	Phenylephrine Hydrochloride injection is indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia.	**Contraindications:** Phenylephrine should not be used: - in patients with severe hypertension or peripheral vascular disease due to the risk of ischemic gangrene or vascular thrombosis; - in combination with non-selective monoamine oxidase inhibitors (MAOs) (or within 2 weeks of their withdrawal) due to risk of paroxysmal hypertension and possibly fatal hyperthermia; - in patients with severe hyperthyroidism. **Side effects:** Adverse reactions reported in published clinical studies, observational trials, and case reports of Phenylephrine are reflex bradycardia, ischemia, vomiting, nausea, neck pain & tremors by body system.	New	CPP- France	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।
27	Bayer Oy, Pansiontie 47, 20210 Turku, Finland **Local Agent:** Medicine Healthcare, 78/D Purana Paltan Line, Bijoy Nagar, Dhaka	**MIRENA** 20 mcg/24 hours intrauterine delivery system	Levonorgestrel USP 52 mg	Contraceptive Device	Contraception. Idiopathic menorrhagia. Protection from endometrial hyperplasia during oestrogen replacement therapy	**Side Effects:** The majority of women experience changes in menstrual bleeding pattern after insertion of Mirena. During the first 90 days, prolonged bleeding is experienced by 22 % and irregular bleeding by 67 % of women after postmenstrual insertion of Mirena, decreasing to 3 % and 19 % at the end of the first year of use, respectively. Concomitantly, amenorrhoea is experienced by 0 % and infrequent bleeding by 11 % during the first 90 days, increasing to 16 % and 57 % at the end of the first year of use, respectively. **Contra Indications:** Known or suspected pregnancy • Progestogen-dependent tumours, e.g. breast cancer • Current or recurrent pelvic inflammatory disease • Cervicitis • Lower genital tract infection • Postpartum endometritis • Infected abortion during the past three	New	**CPP-Finland** (USFDA approved)	অনুমোদনের সুপারিশ করা হয়।	পরবর্তী ঔষধ নিয়ন্ত্রন কমিটির সভায় স্ত্রী রোগ বিশেষজ্ঞ এর মতামত গ্রহনের সিদ্ধান্ত গৃহীত হয়।

Sl No	Name of the Manufacturer & Local Agent	Name of the Product	Generic Name with Strength	Therapeutic Class	Indication	Contraindication, Side-effects, Precautions & Warnings	Status (New Molecule/ Existing)	CPP/FSC (UK/USA/ Switzerland /Germany/France/ Japan/Australia/EMA)	টেকনিক্যাল সাব কমিটি সভার মতামত	সভার সিদ্ধান্ত
						months • Hypersensitivity to the active substance or to any of the excipients.				

ঔষধ নিয়ন্ত্রণ কমিটির ২৫৭ তম সভার কার্যবিবরণী এর সংযুক্তি

Annex-C: Locally Manufacture Veterinary Medicine

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
312.	The ACME Laboratories Ltd. Dhamrai, Dhaka	Poloxalene USP 530 mg/g Powder Water soluble Powder (For Veterinary Use Only)	Poloxalene USP 530 mg/g	**Veterinary Drugs** Non-ionic polyol surface-active agent Therapeutic Code: 077	For the prevention of frothy bloat in cattle grazing on legume pastures	**Contra Indications:** Contra-indicated in animals sensitive to Poloxalene. **Side effects:** Not known. **Withdrawal Period: None**	New	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।
313.	The ACME Laboratories Ltd. Dhamrai, Dhaka	Poloxalene USP 25g/29.5735 ml Oral Liquid (For Veterinary Use Only)	Poloxalene USP 25g/29.5735 ml	**Veterinary Drugs** Non-ionic polyol surface-active agent Therapeutic Code: 077	For the prevention of frothy bloat in cattle grazing on legume pastures	**Contra Indications:** Not to exceed the double dosage of Poloxalene in any 24-hour period. Animals should be fed the recommended amounts of Poloxalene starting 2 or 3 days before they are exposed to bloat-producing conditions. **Side effects:** Not known. **Withdrawal Period:** Milk: May be used in lactating animals. Meat: Not Known	New	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।
314.	The ACME Laboratories Ltd.	Carprofen USP 25 mg Tablet	Carprofen USP 25 mg	**Veterinary Drugs**	Carprofen is indicated in fever, pain, inflammatory diseases to control post	**Contra Indications:** Animals with cardiac, renal or hepatic disease,	**Existing** Carprofen USP	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
	Dhamrai, Dhaka	(For Veterinary Use Only)		**NSAID** Therapeutic Code: 077	operative surgical pain in dogs.	where there is the possibility of gastro-intestinal ulceration or bleeding, hypersensitivity to the drug; treatment with other NSAIDs concurrently or within 24 hours: race horses prior racing; pregnant mares. **Side effects:** Common side effects: Prolonged use may cause gastro-intestinal lesions, inappetence, vomiting and diarrhea. Rare Side effects: Not known. **Withdrawal Period:** Milk: Zero days. Meat and offal: 21 days.	100mg , 200mg tablet			
315.	The ACME Laboratories Ltd. Dhamrai, Dhaka	Carprofen USP 50mg Tablet (For Veterinary Use Only)	Carprofen USP 50 mg	**Veterinary Drugs NSAID** Therapeutic Code: 077	Carprofen is indicated in fever, pain, inflammatory diseases to control post operative surgical pain in dogs.	**Contra Indications:** Animals with cardiac, renal or hepatic disease, where there is the possibility of gastro-intestinal ulceration or bleeding, hypersensitivity to the drug; treatment with other NSAIDs concurrently or within 24 hours: race horses prior racing; pregnant mares. **Side effects:** Common side effects: Prolonged use may cause gastro-intestinal lesions, inappetence, vomiting and diarrhea. Rare Side effects: **Withdrawal Period:** Milk: Zero days. Meat and offal: 21 days.	**Existing** Carprofen USP 100mg , 200mg tablet	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।
316.	The ACME Laboratories Ltd. Dhamrai, Dhaka	Carprofen USP 75mg Tablet (For Veterinary Use Only)	Carprofen USP 75 mg	**Veterinary Drugs NSAID** Therapeutic Code: 077	Carprofen is indicated in fever, pain, inflammatory diseases to control post operative surgical pain in dogs.	**Contra Indications:** Animals with cardiac, renal or hepatic disease, where there is the possibility of gastro-intestinal ulceration or bleeding, hypersensitivity to the drug; treatment with other NSAIDs concurrently or within 24 hours: race horses prior racing; pregnant mares. **Side effects:** Common side effects: Prolonged use may cause gastro-intestinal lesions, inappetence, vomiting and diarrhea. Rare Side effects: Not known. **Withdrawal Period:**	**Existing** Carprofen USP 100mg , 200mg tablet	USFDA	বর্তমানে প্রয়োজন নাই বিধায় নামঞ্জুরের সুপারিশ করা হয় ।	অনুমোদন করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						Milk: Zero days. Meat and offal: 21 days.				
317.	The ACME Laboratories Ltd. Dhamrai, Dhaka	Furaltadone HCL INN 300 mg/g Water Soluble Powder (For Veterinary Use Only)	Furaltadone HCL INN 300 mg/g	**Veterinary Drugs** nitrofuran derivative Therapeutic Code: 077	Furaltadone is a nitrofuran derivative with bactericidal activity against both Gram-positive and Gram-negative bacteria. Prevention and treatment of gastro-intestinal infections (e.g. Enterococci, Staphylococci, Enterobacter aerogenes, Bacillus Anthracis, Brucella Abortus, Corynebacterium,diphtheria, E. Coli, Pasteurella multocida, Salmonella cholerae suis, Streptococcus faecalis, S. pyogenes, Erysipelothrix rhusiopathiae), some moulds and some Protozoa (Proteus spp. and Pseudomonas spp are resistant) and in cases of complicated Chronic Respiratory Disease (C.R.D.).	**Contraindications:** Renal dysfunction. Simultaneous administration with nalidixic acid, D.O.T., bromhexine preparations and carbadox. Do not overdose and do not use in birds laying eggs for human consumption. **Side effects:** No adverse effects occur in the recommended dosages. **Withdrawal Period:** Poultry: Meat- 5 days, Livestock: Meat- 5 days	new	No Reference (Product: The Netherland)	বর্তমানে প্রয়োজন নাই বিধায় নামঞ্জুরের সুপারিশ করা হয় ।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
318.	The ACME Laboratories Ltd. Dhamrai, Dhaka	Amprolium HCl 200 mg + Sulfaquinoxaline Na 200 mg + Vitamin K3 2 mg + Vitamin A 10,000 IU. / gm Water Soluble Powder (For Veterinary Use Only)	Amprolium HCl 200 mg + Sulfaquinoxaline Na 200 mg + Vitamin K3 2 mg + Vitamin A 10,000 IU. / gm	**Veterinary Drugs** Therapeutic Code: 077	Prevention & treatment of coccidiosis, diarrhea, enteritis & bacterial infections caused by E.coli,Salmonella, Pasteurella in poultry (Chicken, turkeys), rabbits & small ruminants.	**Contra Indications:** Administration to animals with impaired hepatic and/or renal functions.Hypersensitivity to amprolium and/or sulfaquinoxaline. **Side effects:**At high dosages in laying hens egg-drop and in broilers growth inhibition and polyneuritis can occur. Other side effects may include crystalluria, anaemia, leucopenia and thrombocytopenia. **Withdrawal Period:** Poultry: Meat & Egg- 10 days ; Livestock: Meat-10 days	new Existing Amprolium 170 gm + Sulfaquinoxaline Sodium 170 gm + Vitamin K 1 gm/KG Powder	NO Ref (Jordan)	বর্তমানে প্রয়োজন নাই বিধায় নামঞ্জুরের সুপারিশ করা হয় ।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
319.	The ACME Laboratories Ltd. Dhamrai, Dhaka	Flubendazole BP 100 mg /ml Oral Suspension (For Veterinary Use	Flubendazole BP 100 mg /ml	**Veterinary Drugs** Anthelmintic	Poultry: Prevention & treatment of helminthiasis caused by Ascaridia galli, Heterakis gallinarum, Capillaria spp.	**Contra indications** Do not use in cases of hypersensitivity to the active substance or to any of theexcipients. **Side effects:**	new	EMA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
		Only)		Therapeutic Code: 077	**Withdrawal Period:** Poultry: Meat-2 days, Egg- o day	In chickens, development disorders of the feathers observed after the administration of flubendazole.				
320.	The ACME Laboratories Ltd. Dhamrai, Dhaka	Tripelennamine HCl USP 20 mg/ml Injection Pack size: 10ml injection (For Veterinary Use Only)	Tripelennamine HCl USP 20 mg/ml	**Veterinary Drugs** Antihistamin Therapeutic Code: 077	Cattle & Horses: Conditions in which antihistaminic therapy may be expected to lead to alleviation of some signs of disease.	**Contra Indications:** **Cattle-**Not for use in beef calves less than 2 months of age, dairy calves, and veal calves. Contraindicated in animals sensitive to tripelennamine. **Side effects:** Administration of tripelennamine hydrochloride may give rise to excitement, ataxia, and convulsions. Central nervous system stimulation in the form of hyperexcitability, nervousness, and muscle tremors lasting up to 20 minutes have been noted in horses following administration. Depression of the central nervous system and incoordination may occur when the drug is used at therapeutic dose levels. Disturbances in gastrointestinal function may occur in some instances. **Withdrawal Period:** Cattle: Milk: 24 hours Meat: 4 days	new	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।
321.	The ACME Laboratories Ltd. Dhamrai, Dhaka	Tripelennamine HCl USP 20 mg/ml Injection Pack Size:30ml injection	Tripelennamine HCl USP 20 mg/ml	**Veterinary Drugs** Antihistamin Therapeutic Code: 077	Cattle & Horses: Conditions in which antihistaminic therapy may be expected to lead to alleviation of some signs of disease.	**Contra Indications:** **Cattle-**Not for use in beef calves less than 2 months of age, dairy calves, and veal calves. Contraindicated in animals sensitive to tripelennamine. **Horses** - Do not use in horses intended for human consumption.	new	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
		(For Veterinary Use Only)				**Side effects:** Administration of tripelennamine hydrochloride may give rise to excitement, ataxia, and convulsions. Central nervous system stimulation in the form of hyperexcitability, nervousness, and muscle tremors lasting up to 20 minutes have been noted in horses following administration. Depression of the central nervous system and incoordination may occur when the drug is used at therapeutic dose levels. Disturbances in gastrointestinal function may occur in some instances. **Withdrawal Period:** Cattle: Milk: 24 hours Meat: 4 days				
322.	The ACME Laboratories Ltd. Dhamrai, Dhaka	Tripelennamine HCl USP 20 mg/ml Injection Pack Size: 50ml injection (For Veterinary Use Only)	Tripelennamine HCl USP 20 mg/ml	**Veterinary Drugs** antihistamin Therapeutic Code: 077	Cattle & Horses: Conditions in which antihistaminic therapy may be expected to lead to alleviation of some signs of disease.	**Contra Indications:** **Cattle-**Not for use in beef calves less than 2 months of age, dairy calves, and veal calves. Contraindicated in animals sensitive to tripelennamine. **Horses** - Do not use in horses intended for human consumption. **Side effects:** Administration of tripelennamine hydrochloride may give rise to excitement, ataxia, and convulsions. Central nervous system stimulation in the form of hyperexcitability, nervousness, and muscle tremors lasting up to 20 minutes have been noted in horses following administration. Depression of the central nervous system and incoordination may occur when the drug is used at therapeutic dose levels. Disturbances in gastrointestinal function may occur in some	new	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						instances. **Withdrawal Period:** Cattle: Milk: 24 hours Meat: 4 days				
323.	The ACME Laboratories Ltd. Dhamrai, Dhaka	Tripelennamine HCl USP 20 mg/ml Injection Pack Size:100ml injection (For Veterinary Use Only)	Tripelennamine HCl USP 20 mg/ml	**Veterinary Drugs** antihistamin Therapeutic Code: 077	Cattle & Horses: Conditions in which antihistaminic therapy may be expected to lead to alleviation of some signs of disease.	**Contra Indications:** **Cattle-**Not for use in beef calves less than 2 months of age, dairy calves, and veal calves. Contraindicated in animals sensitive to tripelennamine. **Horses** - Do not use in horses intended for human consumption. **Side effects:** Administration of tripelennamine hydrochloride may give rise to excitement, ataxia, and convulsions. Central nervous system stimulation in the form of hyperexcitability, nervousness, and muscle tremors lasting up to 20 minutes have been noted in horses following administration. Depression of the central nervous system and incoordination may occur when the drug is used at therapeutic dose levels. Disturbances in gastrointestinal function may occur in some instances. **Withdrawal Period:** Cattle: Milk: 24 hours Meat: 4 days	new	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।
324.	The ACME Laboratories Ltd. Dhamrai, Dhaka	Ivermectin BP 5 mg + Praziquantel BP 60 mg /ml Oral Solution (For Veterinary Use	Ivermectin BP 5 mg + Praziquantel BP 60 mg /ml	**Veterinary Drugs** Anthelmintic Therapeutic	Indicated for the prevention & treatment of cestodiasis, pulmonary and gastrointestinal nematodosis in cattle, small ruminant and poultry.	**Contra Indications:** Contraindicated in animals hypersensitive to the components of the drug. **Side effects**:	new Existing: Ivermectin 1%	No reference (Russia)	বর্তমানে প্রয়োজন নাই বিধায় নামঞ্জুরের সুপারিশ করা হয় ।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
		Only)		Code: 077		Anaemia,thrombocytopenia,leukopenia. **Withdrawal Period:** Not Known	Solution			
325.	The ACME Laboratories Ltd. Dhamrai, Dhaka	Flumethasone Pivalate BP 0.5 mg/ml Injection Pack Size: 5ml Injection (For Veterinary Use Only)	Flumethasone Pivalate BP 0.5 mg/ml Injection	**Veterinary Drugs** corticosteroid Therapeutic Code: 077	It is indicated for musculoskeletal disorders, allergic reactions, ketosis & shock due to trauma, hemorrhage or endotoxins in animals. It is also indicated for supportive therapy in milk fever, shipping fever, pneumonia, during surgery and inflammatory diseases (acute mastitis, metritis, hepatitis, cystitis, tonsilitis etc.) in animals.	**Contra Indications:** The contraindications for adrenocorticoid hormones are applicable with this compound. The close observation of animals under treatment with this drug is necessary since the usual signs of adrenocorticoid overdosage which include sodium retention, potassium loss, fluid retention, weight gain, etc., may not be readily observed. Under clinical and experimental trials, few side effects have been noted but, if they occur, the veterinarian should be prepared to take the necessary steps to correct them. **Side effects**: Continuous therapy with Flumethasone Injection especially at high dose levels, may result in suppression of adrenal cortical function. In such cases, a temporary suspension of the therapy and stimulation of the adrenal cortex by the use of ACTH may be advisable. Flumethasone Injection like cortisone, through its anti-inflammatory action, may mask the usual signs of an infection such as pyrexia, inappetence, lassitude, etc. **Withdrawal Period:** Cattle Meat:4 days	new	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।
326.	The ACME Laboratories Ltd. Dhamrai, Dhaka	Flumethasone Pivalate BP 0.5 mg/ml Injection	Flumethasone Pivalate BP 0.5 mg/ml Injection	**Veterinary Drugs** corticosteroid	It is indicated for musculoskeletal disorders, allergic reactions, ketosis & shock due to trauma, hemorrhage	**Contra Indications:** The contraindications for adrenocorticoid hormones are applicable with this compound. The	new	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
		Pack Size:10ml Injection (For Veterinary Use Only)		Therapeutic Code: 077	or endotoxins in animals. It is also indicated for supportive therapy in milk fever, shipping fever, pneumonia, during surgery and inflammatory diseases (acute mastitis, metritis, hepatitis, cystitis, tonsilitis etc.) in animals.	close observation of animals under treatment with this drug is necessary since the usual signs of adrenocorticoid overdosage which include sodium retention, potassium loss, fluid retention, weight gain, etc., may not be readily observed. Under clinical and experimental trials, few side effects have been noted but, if they occur, the veterinarian should be prepared to take the necessary steps to correct them. **Side effects**: Continuous therapy with Flumethasone Injection especially at high dose levels, may result in suppression of adrenal cortical function. In such cases, a temporary suspension of the therapy and stimulation of the adrenal cortex by the use of ACTH may be advisable. Flumethasone Injection like cortisone, through its anti-inflammatory action, may mask the usual signs of an infection such as pyrexia, inappetence, lassitude, etc. **Withdrawal Period:** Cattle Meat:4 days				
327.	The ACME Laboratories Ltd. Dhamrai, Dhaka	Flumethasone Pivalate BP 0.5 mg/ml Injection Pack Size:30ml Injection (For Veterinary Use Only)	Flumethasone Pivalate BP 0.5 mg/ml Injection	**Veterinary Drugs** corticosteroid Therapeutic Code: 077	It is indicated for musculoskeletal disorders, allergic reactions, ketosis & shock due to trauma, hemorrhage or endotoxins in animals. It is also indicated for supportive therapy in milk fever, shipping fever, pneumonia, during surgery and inflammatory diseases (acute mastitis, metritis, hepatitis, cystitis, tonsilitis etc.) in animals.	**Contra Indications:** The contraindications for adrenocorticoid hormones are applicable with this compound. The close observation of animals under treatment with this drug is necessary since the usual signs of adrenocorticoid overdosage which include sodium retention, potassium loss, fluid retention, weight gain, etc., may not be readily observed. Under clinical and experimental trials, few side effects have been noted but, if they occur, the veterinarian should be prepared to take the necessary steps to correct them.	new	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						Side effects: Continuous therapy with Flumethasone Injection especially at high dose levels, may result in suppression of adrenal cortical function. In such cases, a temporary suspension of the therapy and stimulation of the adrenal cortex by the use of ACTH may be advisable. Flumethasone Injection like cortisone, through its anti-inflammatory action, may mask the usual signs of an infection such as pyrexia, inappetence, lassitude, etc. **Withdrawal Period:** Cattle Meat:4 days				
328.	The ACME Laboratories Ltd. Dhamrai, Dhaka	Flumethasone Pivalate BP 0.5 mg/ml Injection Pack Size:50ml Injection (For Veterinary Use Only)	Flumethasone Pivalate BP 0.5 mg/ml Injection	**Veterinary Drugs** corticosteroid Therapeutic Code: 077	It is indicated for musculoskeletal disorders, allergic reactions, ketosis & shock due to trauma, hemorrhage or endotoxins in animals. It is also indicated for supportive therapy in milk fever, shipping fever, pneumonia, during surgery and inflammatory diseases (acute mastitis, metritis, hepatitis, cystitis, tonsilitis etc.) in animals.	**Contra Indications:** The contraindications for adrenocorticoid hormones are applicable with this compound. The close observation of animals under treatment with this drug is necessary since the usual signs of adrenocorticoid overdosage which include sodium retention, potassium loss, fluid retention, weight gain, etc., may not be readily observed. Under clinical and experimental trials, few side effects have been noted but, if they occur, the veterinarian should be prepared to take the necessary steps to correct them. **Side effects**: Continuous therapy with Flumethasone Injection especially at high dose levels, may result in suppression of adrenal cortical function. In such cases, a temporary suspension of the therapy and stimulation of the adrenal cortex by the use of ACTH may be advisable. Flumethasone Injection like cortisone, through its anti-inflammatory action, may mask the usual signs of an infection such as pyrexia, inappetence, lassitude, etc.	new	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						Withdrawal Period: Cattle Meat:4 days				
329.	The ACME Laboratories Ltd. Dhamrai, Dhaka	Flumethasone Pivalate BP 0.5 mg/ml Injection Pack Size:100ml Injection (For Veterinary Use Only)	Flumethasone Pivalate BP 0.5 mg/ml Injection	**Veterinary Drugs** corticosteroid Therapeutic Code: 077	It is indicated for musculoskeletal disorders, allergic reactions, ketosis & shock due to trauma, hemorrhage or endotoxins in animals. It is also indicated for supportive therapy in milk fever, shipping fever, pneumonia, during surgery and inflammatory diseases (acute mastitis, metritis, hepatitis, cystitis, tonsilitis etc.) in animals.	**Contra Indications:** The contraindications for adrenocorticoid hormones are applicable with this compound. The close observation of animals under treatment with this drug is necessary since the usual signs of adrenocorticoid overdosage which include sodium retention, potassium loss, fluid retention, weight gain, etc., may not be readily observed. Under clinical and experimental trials, few side effects have been noted but, if they occur, the veterinarian should be prepared to take the necessary steps to correct them. **Side effects**: Continuous therapy with Flumethasone Injection especially at high dose levels, may result in suppression of adrenal cortical function. In such cases, a temporary suspension of the therapy and stimulation of the adrenal cortex by the use of ACTH may be advisable. Flumethasone Injection like cortisone, through its anti-inflammatory action, may mask the usual signs of an infection such as pyrexia, inappetence, lassitude, etc. **Withdrawal Period:** Cattle Meat:4 days	new	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।
330.	The ACME Laboratories Ltd. Dhamrai, Dhaka	Phosphorylcolamine INN 100.16 mg + Cobalt Gluconate INN 0.08 mg + Zinc Sulphate Heptahydrate BP 1.80 mg + Manganese Gluconate BP 2.28 mg + Sodium Selenite BP	Phosphorylcolamine INN 100.16 mg + Cobalt Gluconate INN 0.08 mg + Zinc Sulphate Heptahydrate BP 1.80 mg + Manganese	**Veterinary Drugs** Therapeutic Code: 077	Indicated for the the prevention and treatment of mineral deficiencies in cattle, sheep, goat, horse, cat and dogs. It helps to prevent the incidence of retained placenta, uterine prolapse, mastitis, metritis. It also favors the onset of estrous, higher fertility rate, increase conception and pregnancy rate and	**Contra Indications:** N/A **Side effects**: N/A **Withdrawal Period:** Not Known	new	**No Reference** (Peru)	বর্তমানে প্রয়োজন নাই বিধায় নামঞ্জুরের সুপারিশ করা হয় ।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
		0.34 mg + Potassium Iodide 1.10 mg /ml Injection Pack Size:10ml Injection (For Veterinary Use Only)	Gluconate BP 2.28 mg + Sodium Selenite BP 0.34 mg + Potassium Iodide 1.10 mg /ml		decrease calving intervals.					
331.	The ACME Laboratories Ltd. Dhamrai, Dhaka	Phosphorylcolamine INN 100.16 mg + Cobalt Gluconate INN 0.08 mg + Zinc Sulphate Heptahydrate BP 1.80 mg + Manganese Gluconate BP 2.28 mg + Sodium Selenite BP 0.34 mg + Potassium Iodide 1.10 mg /ml Injection Pack Size:30ml Injection (For Veterinary Use Only)	Phosphorylcolamine INN 100.16 mg + Cobalt Gluconate INN 0.08 mg + Zinc Sulphate Heptahydrate BP 1.80 mg + Manganese Gluconate BP 2.28 mg + Sodium Selenite BP 0.34 mg + Potassium Iodide 1.10 mg /ml	**Veterinary Drugs** Therapeutic Code: 077	Indicated for the the prevention and treatment of mineral deficiencies in cattle, sheep, goat, horse, cat and dogs. It helps to prevent the incidence of retained placenta, uterine prolapse, mastitis, metritis. It also favors the onset of estrous, higher fertility rate, increase conception and pregnancy rate and decrease calving intervals.	**Contra Indications:** N/A **Side effects**: N/A **Warning and Precautions:** Do not use by other route than the indicated one. **Withdrawal Period:** Not Known	new	**No Reference** (Peru)	বর্তমানে প্রয়োজন নাই বিধায় নামঞ্জুরের সুপারিশ করা হয় ।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
332.	The ACME Laboratories Ltd. Dhamrai, Dhaka	Phosphorylcolamine INN 100.16 mg + Cobalt Gluconate INN 0.08 mg + Zinc Sulphate Heptahydrate BP 1.80 mg + Manganese Gluconate BP 2.28 mg + Sodium Selenite BP 0.34 mg + Potassium Iodide 1.10 mg /ml Injection Pack Size:50ml	Phosphorylcolamine INN 100.16 mg + Cobalt Gluconate INN 0.08 mg + Zinc Sulphate Heptahydrate BP 1.80 mg + Manganese Gluconate BP 2.28 mg + Sodium Selenite BP 0.34 mg + Potassium Iodide	**Veterinary Drugs** Therapeutic Code: 077	Indicated for the the prevention and treatment of mineral deficiencies in cattle, sheep, goat, horse, cat and dogs. It helps to prevent the incidence of retained placenta, uterine prolapse, mastitis, metritis. It also favors the onset of estrous, higher fertility rate, increase conception and pregnancy rate and decrease calving intervals.	**Contra Indications:** N/A **Side effects**: N/A **Withdrawal Period:** Not Known	new	No Reference (Peru)	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
		Injection (For Veterinary Use Only)	1.10 mg /ml							
333.	The ACME Laboratories Ltd. Dhamrai, Dhaka	Phosphorylcolamine INN 100.16 mg + Cobalt Gluconate INN 0.08 mg + Zinc Sulphate Heptahydrate BP 1.80 mg + Manganese Gluconate BP 2.28 mg + Sodium Selenite BP 0.34 mg + Potassium Iodide 1.10 mg /ml Injection Pack Size:100ml Injection (For Veterinary Use Only)	Phosphorylcolamine INN 100.16 mg + Cobalt Gluconate INN 0.08 mg + Zinc Sulphate Heptahydrate BP 1.80 mg + Manganese Gluconate BP 2.28 mg + Sodium Selenite BP 0.34 mg + Potassium Iodide 1.10 mg /ml	**Veterinary Drugs** Therapeutic Code: 077	Indicated for the the prevention and treatment of mineral deficiencies in cattle, sheep, goat, horse, cat and dogs. It helps to prevent the incidence of retained placenta, uterine prolapse, mastitis, metritis. It also favors the onset of estrous, higher fertility rate, increase conception and pregnancy rate and decrease calving intervals.	**Contra Indications:** N/A **Side effects**: N/A **Withdrawal Period:** Not Known	new	No Reference Peru	রেফারেন্স নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	রেফারেন্স নেই বিধায় নামঞ্জুর করা হয়।
334.	The ACME Laboratories Ltd. Dhamrai, Dhaka	Sulphaquinoxaline USP 25.6 mg + Diaveridine USP 6.4 mg /ml Oral Solution (For Veterinary Use Only)	Sulphaquinoxaline USP 25.6 mg + Diaveridine USP 6.4 mg /ml	**Veterinary Drugs** quinoxalines Therapeutic Code: 077	Indicated for the prevention & treatment of haemorrhagic enteritis, coccidiosis, controlling mortality from fowl cholera, reducing prevalence of typhoid, preventing embryo mortality and decreasing hatchability of the breeder.	**Contra Indications:** Contraindicated in animals hypersensitive to the components of the drug. **Side effects**: Side effects and complications are usually not observed. A small short-term excitement immediately after taking the drug in farm birds may be observed. **Withdrawal Period:** Cattle: Meat-35 days; Poultry: Meat-20 days	new	No Reference Iran	বর্তমানে প্রয়োজন নাই বিধায় নামঞ্জুরের সুপারিশ করা হয় ।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
335.	The ACME Laboratories Ltd. Dhamrai, Dhaka	Tiamulin (as fumarate) BP10 g + Doxycycline (as a hyclate) INN 15 g /100gm Water Soluble Powder (For Veterinary Use Only)	Tiamulin (as fumarate) BP10 g + Doxycycline (as a hyclate) INN 15 g /100gm	**Veterinary Drugs** Antibiotic Therapeutic Code: 077	Chronic respiratory disease (CRD), Mycoplasma, infectious coryza, aerial sacculitis, infectious sinusitis and pneumonia. Necrotic enteritis, bacterial enteritis, colisepticemia, avian cholera, omphalitis, infectious synovitis.	**Contra Indications:** Do not use in case of hypersensitivity to the active substance or to any excipient. Do not use in animals that are receiving ionophore antibiotics. **Side effects**: Overdose can result in acute, sometimes fatal, heart muscle degeneration in calves. Teeth	new	No Reference Peru	বর্তমানে প্রয়োজন নাই বিধায় নামঞ্জুরের সুপারিশ করা হয় ।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						discolouration in young animals may be observed after prolonged period of administration. .**Withdrawal Period**: Poultry: Meat-8 days ; Egg: 0 day				
336.	The ACME Laboratories Ltd. Dhamrai, Dhaka	Amoxicillin (as trihydrate) BP 50 mg + Clavulanic Acid (as potassium salt) BP 12.5 mg/ml Oral Suspension drops (For Veterinary Use Only)	Amoxicillin (as trihydrate) BP 50 mg + Clavulanic Acid (as potassium salt) BP 12.5 mg/ml	**Veterinary Drugs** Antibiotic Therapeutic Code: 077	It is indicated for skin and soft tissue infections (GIT, UTI) caused by susceptible pathogenic bacteria.	**Contra indications** The use of this drug is contraindicated in animals with a history of an allergic reaction to any of the penicillins or cephalosporins. **Side effects:** It contains a semisynthetic penicillin (amoxicillin) and has the potential for producing allergic reactions. If an allergic reaction occurs, administer epinephrine and/or steroids **Withdrawal Period:** Not Known	new Existing: Amoxicillin 140 mg + Clavulanic Acid 35 mg/ml Injection	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।
337.	The ACME Laboratories Ltd. Dhamrai, Dhaka	Furosemide USP 50 mg + Dexamethasone Sodium Phosphate BP 2 mg/ml Injection Pack Size:5ml Injection (For Veterinary Use Only)	Furosemide USP 50 mg + Dexamethasone Sodium Phosphate BP 2 mg/ml	**Veterinary Drugs** Therapeutic Code: 077	For the treatment of edema, pulmonary congestion, renal failure, acute non-inflammatory tissue edema, ascites etc. It also helps to excrete poisons or drug overdose by increasing urine flow.	**Contra Indications** Contra-indicated in animals sensitive to Furosemide & Dexamethasone. **Side effects** **Not known.** **Withdrawal Period:** Not Known	new	**No Reference** Jordan	বর্তমানে প্রয়োজন নাই বিধায় নামঞ্জুরের সুপারিশ করা হয় ।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
338.	The ACME Laboratories Ltd. Dhamrai, Dhaka	Furosemide USP 50 mg + Dexamethasone Sodium Phosphate BP 2 mg/ml Injection Pack Size:10ml Injection (For Veterinary Use Only)	Furosemide USP 50 mg + Dexamethasone Sodium Phosphate BP 2 mg/ml	**Veterinary Drugs** Therapeutic Code: 077	For the treatment of edema, pulmonary congestion, renal failure, acute non-inflammatory tissue edema, ascites etc. It also helps to excrete poisons or drug overdose by increasing urine flow.	**Contra Indications** Contra-indicated in animals sensitive to Furosemide & Dexamethasone. **Side effects** **Not known.** **Withdrawal Period:** Not Known		**No Reference** Jordan	বর্তমানে প্রয়োজন নাই বিধায় নামঞ্জুরের সুপারিশ করা হয় ।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
339.	The ACME Laboratories Ltd.	Lincomycin Hydrochloride BP 50	Lincomycin Hydrochloride BP	**Veterinary Drugs**	Bovine: Treatment of respiratory infections caused by microorganisms	**Contra Indications** Contra-indicated in animals sensitive to	new Existing:	No Reference	বর্তমানে প্রয়োজন নাই বিধায় নামঞ্জুরের	বর্তমানে প্রয়োজন নেই বিধায়

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
	Dhamrai, Dhaka	mg + Spectinomycin Sulfate BP 100 mg + Bromhexine Hydrochloride BP 2.5 mg / ml Solution for injection Pack Size:10ml Injection (For Veterinary Use Only)	50 mg + Spectinomycin Sulfate BP 100 mg + Bromhexine Hydrochloride BP 2.5 mg / ml	Therapeutic Code: 077 Antibiotics	sensitive to the association of Lincomycin-Spectinomycin. Pneumonia caused by *Pasteurella multocida* & *Mycoplasma bovis*. Porcine: Treatment of respiratory infections caused by microorganisms sensitive to the association of Lincomycin-Spectinomycin. Enzootic pneumonia caused by *Mycoplasma hyopneumoniae*. Pleuropneumonia by *Actinobacillus Pleuropneumoniae*.	Lincomycin, Spectinomycin & Bromhexine. **Side effects** After intramuscular administration, local pain & irritation can appear. **Withdrawal Period:** Livestock: Meat-15 days; Milk: It is not authorized in animals whose milk is used for human consumption.	Lincomycin 50 mg + Spectinomycin 100 mg/ml Injection	(Spain)	সুপারিশ করা হয় ।	নামঞ্জুর করা হয়।
340.	The ACME Laboratories Ltd. Dhamrai, Dhaka	Lincomycin Hydrochloride BP 50 mg + Spectinomycin Sulfate BP 100 mg + Bromhexine Hydrochloride BP 2.5 mg / ml Solution for injection Pack Size:30ml Injection (For Veterinary Use Only)	Lincomycin Hydrochloride BP 50 mg + Spectinomycin Sulfate BP 100 mg + Bromhexine Hydrochloride BP 2.5 mg / ml	**Veterinary Drugs** Therapeutic Code: 077 Antibiotics	Bovine: Treatment of respiratory infections caused by microorganisms sensitive to the association of Lincomycin-Spectinomycin. Pneumonia caused by *Pasteurella multocida* & *Mycoplasma bovis*. Porcine: Treatment of respiratory infections caused by microorganisms sensitive to the association of Lincomycin-Spectinomycin. Enzootic pneumonia caused by *Mycoplasma hyopneumoniae*. Pleuropneumonia by *Actinobacillus Pleuropneumoniae*.	**Contra Indications** Contra-indicated in animals sensitive to Lincomycin, Spectinomycin & Bromhexine. **Side effects** After intramuscular administration, local pain & irritation can appear. **Withdrawal Period:** Livestock: Meat-15 days; Milk: It is not authorized in animals whose milk is used for human consumption.	new	No Reference (Spain)	বর্তমানে প্রয়োজন নাই বিধায় নামঞ্জুরের সুপারিশ করা হয় ।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
341.	The ACME Laboratories Ltd. Dhamrai, Dhaka	Lincomycin Hydrochloride BP 50 mg + Spectinomycin Sulfate BP 100 mg + Bromhexine Hydrochloride BP 2.5 mg / ml Solution for injection	Lincomycin Hydrochloride BP 50 mg + Spectinomycin Sulfate BP 100 mg + Bromhexine Hydrochloride BP 2.5 mg / ml	**Veterinary Drugs** Antibiotic Therapeutic Code: 077	Bovine: Treatment of respiratory infections caused by microorganisms sensitive to the association of Lincomycin-Spectinomycin. Pneumonia caused by *Pasteurella multocida* & *Mycoplasma bovis*. Porcine: Treatment of respiratory infections caused by microorganisms sensitive to the association of	**Contra Indications** Contra-indicated in animals sensitive to Lincomycin, Spectinomycin & Bromhexine. **Side effects** After intramuscular administration, local pain & irritation can appear. **Withdrawal Period:**	new	No Reference (Spain)	বর্তমানে প্রয়োজন নাই বিধায় নামঞ্জুরের সুপারিশ করা হয় ।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
		Pack Size:50ml Injection (For Veterinary Use Only)			Lincomycin-Spectinomycin. Enzootic pneumonia caused by *Mycoplasma hyopneumoniae*. Pleuropneumonia by *Actinobacillus Pleuropneumoniae.*	Livestock: Meat-15 days; Milk: It is not authorized in animals whose milk is used for human consumption.				
342.	The ACME Laboratories Ltd. Dhamrai, Dhaka	Lincomycin Hydrochloride BP 50 mg + Spectinomycin Sulfate BP 100 mg + Bromhexine Hydrochloride BP 2.5 mg / ml Solution for injection Pack Size:100ml Injection (For Veterinary Use Only)	Lincomycin Hydrochloride BP 50 mg + Spectinomycin Sulfate BP 100 mg + Bromhexine Hydrochloride BP 2.5 mg / ml	**Veterinary Drugs Antibiotic** Therapeutic Code: 077	Bovine: Treatment of respiratory infections caused by microorganisms sensitive to the association of Lincomycin-Spectinomycin. Pneumonia caused by *Pasteurella multocida* & *Mycoplasma bovis.* Porcine: Treatment of respiratory infections caused by microorganisms sensitive to the association of Lincomycin-Spectinomycin. Enzootic pneumonia caused by *Mycoplasma hyopneumoniae*. Pleuropneumonia by *Actinobacillus Pleuropneumoniae.*	**Contra Indications** Contra-indicated in animals sensitive to Lincomycin, Spectinomycin & Bromhexine. **Side effects** After intramuscular administration, local pain & irritation can appear. **Withdrawal Period:** Livestock: Meat-15 days; Milk: It is not authorized in animals whose milk is used for human consumption.	new	No Reference (Spain)	বর্তমানে প্রয়োজন নাই বিধায় নামঞ্জুরের সুপারিশ করা হয় ।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
343.	The ACME Laboratories Ltd. Dhamrai, Dhaka	Thioctic acid BP 15 mg + Orotic acid INN 5 mg + DL-Methionine BP 20 mg + Nicotinamide BP 10 mg + N-Acetyl-L-Methionine INN 50 mg + Cyanocobalamin BP 0.04 mg + Folic Acid BP 0.5 mg + D-Panthenol BP 3 mg + Pyridoxine HCl BP 2 mg + Choline Chloride BP 40 mg + Inositol BP 20 mg + Betaine HCl USP 2 mg /ml Injection	Thioctic acid BP 15 mg + Orotic acid INN 5 mg + DL-Methionine BP 20 mg + Nicotinamide BP 10 mg + N-Acetyl-L-Methionine INN 50 mg + Cyanocobalamin BP 0.04 mg + Folic Acid BP 0.5 mg + D-Panthenol BP 3 mg + Pyridoxine HCl BP 2 mg + Choline Chloride	**Veterinary Drugs** vitamins Therapeutic Code: 077	Indicated on serious or mild liver insufficiencies, fatty liver syndrome, acute and chronic hepatitis, intoxications with drugs, convalescence, lack of appetite, cirrhosis, asthenia, fatigue, bloating, photosensitization and nutritional disorders.	**Contra Indications:** N/A **Side effects**: N/A **Withdrawal Period:** Meat & Milk: 0 day.	new	No Reference (Peru)	বর্তমানে প্রয়োজন নাই বিধায় নামঞ্জুরের সুপারিশ করা হয় ।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
		Pack Size:5ml Injection (For Veterinary Use Only)	BP 40 mg + Inositol BP 20 mg + Betaine HCl USP 2 mg /ml							
344.	The ACME Laboratories Ltd. Dhamrai, Dhaka	Thioctic acid BP 15 mg + Orotic acid INN 5 mg + DL-Methionine BP 20 mg + Nicotinamide BP 10 mg + N-Acetyl-L-Methionine INN 50 mg + Cyanocobalamin BP 0.04 mg + Folic Acid BP 0.5 mg + D-Panthenol BP 3 mg + Pyridoxine HCl BP 2 mg + Choline Chloride BP 40 mg + Inositol BP 20 mg + Betaine HCl USP 2 mg /ml Injection 10ml Injection	Thioctic acid BP 15 mg + Orotic acid INN 5 mg + DL-Methionine BP 20 mg + Nicotinamide BP 10 mg + N-Acetyl-L-Methionine INN 50 mg + Cyanocobalamin BP 0.04 mg + Folic Acid BP 0.5 mg + D-Panthenol BP 3 mg + Pyridoxine HCl BP 2 mg + Choline Chloride BP 40 mg + Inositol BP 20 mg + Betaine HCl USP 2 mg /ml	**Veterinary Drugs** vitamins Therapeutic Code: 077	Indicated on serious or mild liver insufficiencies, fatty liver syndrome, acute and chronic hepatitis, intoxications with drugs, convalescence, lack of appetite, cirrhosis, asthenia, fatigue, bloating, photosensitization and nutritional disorders.	**Contra Indications:** N/A **Side effects**: N/A **Withdrawal Period:** Meat & Milk: 0 day.	new	No Reference (Peru)	বর্তমানে প্রয়োজন নাই বিধায় নামঞ্জুরের সুপারিশ করা হয় ।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
345.	The ACME Laboratories Ltd. Dhamrai, Dhaka	Thioctic acid BP 15 mg + Orotic acid INN 5 mg + DL-Methionine BP 20 mg + Nicotinamide BP 10 mg + N-Acetyl-L-Methionine INN 50 mg + Cyanocobalamin BP 0.04 mg + Folic Acid BP 0.5 mg + D-	Thioctic acid BP 15 mg + Orotic acid INN 5 mg + DL-Methionine BP 20 mg + Nicotinamide BP 10 mg + N-Acetyl-L-Methionine INN	**Veterinary Drugs** Therapeutic Code: 077	Indicated on serious or mild liver insufficiencies,fatty liver syndrome, acute and chronic hepatitis, intoxications with drugs, convalescence, lack of appetite, cirrhosis, asthenia, fatigue, bloating, photosensitization and nutritional disorders.	**Contra Indications:** N/A **Side effects**: N/A **Withdrawal Period:** Meat & Milk: 0 day.	new	No Reference (Peru)	বর্তমানে প্রয়োজন নাই বিধায় নামঞ্জুরের সুপারিশ করা হয় ।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
		Panthenol BP 3 mg + Pyridoxine HCl BP 2 mg + Choline Chloride BP 40 mg + Inositol BP 20 mg + Betaine HCl USP 2 mg /ml Injection Pack Size:30ml Injection (For Veterinary Use Only)	50 mg + Cyanocobalamin BP 0.04 mg + Folic Acid BP 0.5 mg + D-Panthenol BP 3 mg + Pyridoxine HCl BP 2 mg + Choline Chloride BP 40 mg + Inositol BP 20 mg + Betaine HCl USP 2 mg /ml							
346.	The ACME Laboratories Ltd. Dhamrai, Dhaka	Thioctic acid BP 15 mg + Orotic acid INN 5 mg + DL-Methionine BP 20 mg + Nicotinamide BP 10 mg + N-Acetyl-L-Methionine INN 50 mg + Cyanocobalamin BP 0.04 mg + Folic Acid BP 0.5 mg + D-Panthenol BP 3 mg + Pyridoxine HCl BP 2 mg + Choline Chloride BP 40 mg + Inositol BP 20 mg + Betaine HCl USP 2 mg /ml Injection Pack Size:60ml Injection (For Veterinary Use Only)	Thioctic acid BP 15 mg + Orotic acid INN 5 mg + DL-Methionine BP 20 mg + Nicotinamide BP 10 mg + N-Acetyl-L-Methionine INN 50 mg + Cyanocobalamin BP 0.04 mg + Folic Acid BP 0.5 mg + D-Panthenol BP 3 mg + Pyridoxine HCl BP 2 mg + Choline Chloride BP 40 mg + Inositol BP 20 mg + Betaine HCl USP 2 mg /ml	**Veterinary Drugs** vitamins Therapeutic Code: 077	Indicated on serious or mild liver insufficiencies, fatty liver syndrome, acute and chronic hepatitis, intoxications with drugs, convalescence, lack of appetite, cirrhosis, asthenia, fatigue, bloating, photosensitization and nutritional disorders.	**Contra Indications:** N/A **Side effects**: N/A **Withdrawal Period:** Meat & Milk: 0 day.	new	No Reference (Peru)	বর্তমানে প্রয়োজন নাই বিধায় নামঞ্জুরের সুপারিশ করা হয় ।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
347.	The ACME Laboratories Ltd. Dhamrai, Dhaka	Thioctic acid BP 15 mg + Orotic acid INN 5 mg + DL-Methionine BP 20 mg + Nicotinamide BP 10 mg + N-Acetyl-L-Methionine INN 50 mg + Cyanocobalamin BP 0.04 mg + Folic Acid BP 0.5 mg + D-Panthenol BP 3 mg + Pyridoxine HCl BP 2 mg + Choline Chloride BP 40 mg + Inositol BP 20 mg + Betaine HCl USP 2 mg /ml Injection Pack Size:100ml Injection (For Veterinary Use Only)	Thioctic acid BP 15 mg + Orotic acid INN 5 mg + DL-Methionine BP 20 mg + Nicotinamide BP 10 mg + N-Acetyl-L-Methionine INN 50 mg + Cyanocobalamin BP 0.04 mg + Folic Acid BP 0.5 mg + D-Panthenol BP 3 mg + Pyridoxine HCl BP 2 mg + Choline Chloride BP 40 mg + Inositol BP 20 mg + Betaine HCl USP 2 mg /ml	**Veterinary Drugs** vitamins Therapeutic Code: 077	Indicated on serious or mild liver insufficiencies,fatty liver syndrome, acute and chronic hepatitis, intoxications with drugs, convalescence, lack of appetite, cirrhosis, asthenia, fatigue, bloating, photosensitization and nutritional disorders.	**Contra Indications:** N/A **Side effects**: N/A **Withdrawal Period:** Meat & Milk: 0 day.	new	No Reference (Peru)	বর্তমানে প্রয়োজন নাই বিধায় নামঞ্জুরের সুপারিশ করা হয় ।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
348.	The ACME Laboratories Ltd. Dhamrai, Dhaka	Sodium Cacodylate INN 30 mg + Ferric Ammonium Citrate BP 20 mg + DL-Methionine BP 10 mg + Histidine BP 5 mg +Tryptophan BP 2.5 mg + Cobalt Acetate BP 500 mcg + Vitamin B12 (cyanocobalamin) BP 11 mcg + Riboflavin Sodium	Sodium Cacodylate INN 30 mg + Ferric Ammonium Citrate BP 20 mg + DL-Methionine BP 10 mg + Histidine BP 5 mg +Tryptophan BP 2.5 mg + Cobalt Acetate BP 500 mcg + Vitamin	**Veterinary Drugs** Therapeutic Code: 077	For prevention and treatment of all types of disorders of hematopoiesis, anemia of alimentary, infectious, parasitic or post-hemorrhagic origin (specific in cases of anaplasmosis and piroplasmosis), weakness, emaciation and convalescence. Powerful reconstituent, invigorating and stimulant of appetite, growth and production.	**Contra-Indications:** It is contraindicated to any ingredients of this product. **Side effects**: It can manifest infrequently hypersensitivity reactions, if they occur, discontinue treatment. • Local reaction (swelling) may occur at the injection site in animals for up to a week after administration. • During intravenous administration, shock may occur. In this case the medication be discontinued and appropriate measures will be	new	No Reference (Peru)	বর্তমানে প্রয়োজন নাই বিধায় নামঞ্জুরের সুপারিশ করা হয় ।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
		Phosphate BP 2 mg + Nicotinamide BP 50 mg + Pyridoxine Hydrochloride BP 10 mg + Sodium Glycerophostate BP10 mg / ml Injection Pack Size:10ml Injection (For Veterinary Use Only)	B12 (cyanocobalamin) BP 11 mcg + Riboflavin Sodium Phosphate BP 2 mg + Nicotinamide BP 50 mg + Pyridoxine Hydrochloride BP 10 mg + Sodium Glycerophostate BP10 mg / ml			taken. **Withdrawal Period:** Not Known.				
349.	The ACME Laboratories Ltd. Dhamrai, Dhaka	Sodium Cacodylate INN 30 mg + Ferric Ammonium Citrate BP 20 mg + DL-Methionine BP 10 mg + Histidine BP 5 mg +Tryptophan BP 2.5 mg + Cobalt Acetate BP 500 mcg + Vitamin B12 (cyanocobalamin) BP 11 mcg + Riboflavin Sodium Phosphate BP 2 mg + Nicotinamide BP 50 mg + Pyridoxine Hydrochloride BP 10 mg + Sodium Glycerophostate BP10 mg / ml Injection Pack Size:30ml	Sodium Cacodylate INN 30 mg + Ferric Ammonium Citrate BP 20 mg + DL-Methionine BP 10 mg + Histidine BP 5 mg +Tryptophan BP 2.5 mg + Cobalt Acetate BP 500 mcg + Vitamin B12 (cyanocobalamin) BP 11 mcg + Riboflavin Sodium Phosphate BP 2 mg + Nicotinamide BP 50 mg +	**Veterinary Drugs** Therapeutic Code: 077	For prevention and treatment of all types of disorders of hematopoiesis, anemia of alimentary, infectious, parasitic or post-hemorrhagic origin (specific in cases of anaplasmosis and piroplasmosis), weakness, emaciation and convalescence. Powerful reconstituent, invigorating and stimulant of appetite, growth and production.	**Contra-Indications:** It is contraindicated to any ingredients of this product. **Side effects**: It can manifest infrequently hypersensitivity reactions, if they occur, discontinue treatment. • Local reaction (swelling) may occur at the injection site in animals for up to a week after administration. • During intravenous administration, shock may occur. **Withdrawal Period:** Not Known.	new	No Reference (Peru)	বর্তমানে প্রয়োজন নাই বিধায় নামঞ্জুরের সুপারিশ করা হয় ।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
		Injection (For Veterinary Use Only)	Pyridoxine Hydrochloride BP 10 mg + Sodium Glycerophostate BP10 mg / ml							
350.	The ACME Laboratories Ltd. Dhamrai, Dhaka	Sodium Cacodylate INN 30 mg + Ferric Ammonium Citrate BP 20 mg + DL-Methionine BP 10 mg + Histidine BP 5 mg +Tryptophan BP 2.5 mg + Cobalt Acetate BP 500 mcg + Vitamin B12 (cyanocobalamin) BP 11 mcg + Riboflavin Sodium Phosphate BP 2 mg + Nicotinamide BP 50 mg + Pyridoxine Hydrochloride BP 10 mg + Sodium Glycerophostate BP10 mg / ml Injection Pack Size:100ml Injection (For Veterinary Use Only)	Sodium Cacodylate INN 30 mg + Ferric Ammonium Citrate BP 20 mg + DL-Methionine BP 10 mg + Histidine BP 5 mg +Tryptophan BP 2.5 mg + Cobalt Acetate BP 500 mcg + Vitamin B12 (cyanocobalamin) BP 11 mcg + Riboflavin Sodium Phosphate BP 2 mg + Nicotinamide BP 50 mg + Pyridoxine Hydrochloride BP 10 mg + Sodium Glycerophostate BP10 mg / ml	**Veterinary Drugs** Therapeutic Code: 077	For prevention and treatment of all types of disorders of hematopoiesis, anemia of alimentary, infectious, parasitic or post-hemorrhagic origin (specific in cases of anaplasmosis and piroplasmosis), weakness, emaciation and convalescence. Powerful reconstituent, invigorating and stimulant of appetite, growth and production.	**Contra-Indications:** It is contraindicated to any ingredients of this product. **Side effects**: It can manifest infrequently hypersensitivity reactions, if they occur, discontinue treatment. • Local reaction (swelling) may occur at the injection site in animals for up to a week after administration. • During intravenous administration, shock may occur.. **Withdrawal Period:** Not Known.	new	No Reference (Peru)	বর্তমানে প্রয়োজন নাই বিধায় নামঞ্জুরের সুপারিশ করা হয় ।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
351.	Bridge Pharmaceuticals Ltd, Demra, Dhaka	Pheniramine Maleate BP 500 mg, Bolus (Vet) (For Veterinary Use Only)	Pheniramine Maleate BP 500 mg	**Therapeutic Class:** Antihistamine **Code:** 077	Itching of unknown genesis and various localizations, eczema, dermatitis, urticaria, skin edema, insect bites, photodermatitis, rhinitis, tail eczema in horses, stomatitis, toxic hoof corns, puerperal toxemia, toxic etc.	**Contraindications:** The drug is contraindicated in animals hypersensitive to active ingredients. **Side Effects:** Drowsiness, dizziness, blurred vision, upset stomach, nausea, and constipation may occur. **Warning and Precaution:** Use during lactation is not recommended.	New	No Reference	বর্তমানে প্রয়োজন নাই বিধায় নামঞ্জুরের সুপারিশ করা হয় ।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
352.	Bridge Pharmaceuticals Ltd, Demra, Dhaka	Trichlorfon USP 100 mg/gm, Ointment (Vet.) (For Veterinary Use	Trichlorfon USP 100 mg/gm	**Therapeutic Class:** Antiparasitic	• Ectoparasites (such as ticks, mites, lice & flies) infestation of cattle, buffalo, sheep, goats, dogs, and cats.	**Contraindications:** The drug is contraindicated in animals hypersensitive to active ingredients. **Side Effects:** Signs of ingestion include vomiting, diarrhea, drooling, muscle tremors, and seizures.			বর্তমানে প্রয়োজন নাই বিধায় নামঞ্জুরের সুপারিশ করা হয় ।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
		Only)		**Therapeutic Code:** 077	. Humpsore and Dry gangrene of cattle.	**Warning and Precaution:** For external use only. Do not feed the animal for a certain time before and after applying the ointment. While applying the ointment, cover the animal's mouth.	New			
353.	Eskayef Pharmaceuticals Limited, Rupganj, Narayanganj	Danofloxacin 18% Solution for Injection (For Veterinary Use Only)	Danofloxacin Mesylate INN 2.284gm (eq. to Danofloxacin 1.8gm)/10 ml Vial	**Antibiotic**	For the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica and Pasteurella multocida and for the control of BRD in beef cattle at high risk of developing BRD associated with Mannheimia haemolytica and Pasteurella multocida.	**CONTRAINDICATIONS:** Danofloxacin is not recommended for use in the case of resistant bacteria to other fluoroquinolones. **SIDE-EFFECT:** Hypersensitivity reaction causing lameness. **WITHDRAWAL PERIOD:** Meat: 5 days	New Existing: Danofloxacin 2.5% & 5.0% Injection	**USFDA**	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।
354.	Eskayef Pharmaceuticals Limited, Rupganj, Narayanganj	Flunixin Meglumine 220mg Bolus (For Veterinary Use Only)	Flunixin Meglumine USP 220mg/Tablet	**Anti-inflammatory**	Its use in the horse is for the alleviation of inflammation and pain associated with musculoskeletal disorders and alleviation of visceral pain associated with colic. In cattle it is approved for the control of pyrexia associated with bovine respiratory disease and endotoxemia, and control of inflammation in endotoxemia. In swine, flunixin is approved for use to control pyrexia associated with swine respiratory disease. **WITHDRAWAL PERIOD:** • (Cattle): Milk 36hours; Slaughter 4 days • Slaughter 12 days	**CONTRAINDICATIONS:** The drug is contraindicated in animals that have shown prior hypersensitivity reactions. **SIDE-EFFECT:** When used for pain, if the animal does not respond to an initial dose, it is unlikely additional doses will be effective and may result in increased chance for toxicity.	Flunixin Meglumine 50mg/ml Injection	**No Reference**	বর্তমানে প্রয়োজন নাই বিধায় নামঞ্জুরের সুপারিশ করা হয় ।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
355.	Eskayef	Marbofloxacin 5mg	Marbofloxacin BP	Antibiotic	Treatment of infections caused by	**CONTRAINDICATIONS:**	**New**	EMA	অনুমোদনের	অনুমোদন করা

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
	Pharmaceuticals Limited, Rupganj, Narayanganj	Tablet (For Veterinary Use Only)	5mg Tablet		strains of microorganisms susceptible to marbofloxacin. **In dogs:** • skin and soft tissue infections (skinfold pyoderma, impetigo, folliculitis, • furunculosis, cellulitis); • urinary tract infections (UTI) associated or not with prostatitis or epididymitis; **In cats:** • skin and soft tissue infections (wounds, abscesses, phlegmons); • upper respiratory tract infections. • respiratory tract infections. **WITHDRAWAL PERIOD:** Not applicable	• Do not use in dogs aged less than 12 months, or less than 18 months for exceptionally large breeds of dogs, such as Great Danes, Briard, Bernese, Bouvier and Mastiffs, with a longer growth period. • Do not use in cats aged less than 16 weeks. • Do not use in animals with known hypersensitivity to marbofloxacin or other (fluoro) quinolones or to any of the excipients of the product. • Do not use in cases of resistance against quinolones, since (almost) complete crossresistance. • Exists against other fluoroquinolones. **SIDE-EFFECT:** Mild side effects such as vomiting, softening of faeces, and modification of thirst or transient increase in activity may very rarely occur. These signs cease spontaneously after treatment and do not necessitate cessation of treatment.	**Existing:** Marbofloxacin 50mg Bolus Marbofloxacin 100mg Bolus Marbofloxacin 200mg Bolus		সুপারিশ করা হয়।	হয়।
356.	Eskayef Pharmaceuticals Limited, Rupganj, Narayanganj	Marbofloxacin 20mg Tablet (For Veterinary Use Only)	Marbofloxacin BP 20mg Tablet	Antibiotic	Treatment of infections caused by strains of microorganisms susceptible to marbofloxacin. **In dogs:** • skin and soft tissue infections (skinfold pyoderma, impetigo, folliculitis) • respiratory infection • urinary tract infections (UTI) associated or not with prostatitis or epididymitis	**CONTRAINDICATIONS:** • Do not use in dogs aged less than 12 months, or less than 18 months for exceptionally large breeds of dogs, such as Great Danes, Briard, Bernese, Bouvier and Mastiffs, with a longer growth period. • Do not use in cats aged less than 16 weeks. • Do not use in animals with known hypersensitivity to marbofloxacin or other (fluoro) quinolones or to any of the excipients of the product. • Do not use in cases of resistance against quinolones, since (almost) complete	**New Existing:** Marbofloxacin 50mg Bolus Marbofloxacin 100mg Bolus Marbofloxacin 200mg Bolus	No Reference (Slovenia)	বর্তমানে প্রয়োজন নাই বিধায় নামঞ্জুরের সুপারিশ করা হয় ।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
					WITHDRAWAL PERIOD: Not applicable	crossresistance. • Exists against other fluoroquinolones. **SIDE-EFFECT:** Mild side effects such as vomiting, softening of faeces, and modification of thirst or transient increase in activity may very rarely occur. These signs cease spontaneously after treatment and do not necessitate cessation of treatment.				
357.	Eskayef Pharmaceuticals Limited, Rupganj, Narayanganj	Neomycin Sulfate 20% Veterinary Oral Solution (200mg/ml) (For Veterinary Use Only)	Neomycin Sulfate USP 20gm/100ml	Antibiotic	For the treatment and control of colibacillosis (bacterial enteritis) caused by Escherichia coli susceptible to neomycin sulfate in cattle (excluding veal calves), swine, sheep and goats. **WITHDRAWAL PERIOD:** : **Cattle - 1 day** (not to be used in veal calves); **Sheep - 2 days**; **Swine and Goats - 3 days**.	**CONTRAINDICATIONS:** Use of more than one product containing neomycin or failure to follow withdrawal times may result in illegal drug residues. **SIDE-EFFECT:** Unknown	New **Existing:** Neomycin Sulphate 70gm/100gm Powder Neomycin Sulphate 50gm/100gm Powder	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।
358.	Eskayef Pharmaceuticals Limited, Rupganj, Narayanganj	Triclabendazole 3.6gm + Ivermectin 0.06gm IM/SC Injection (For Veterinary Use Only)	Triclabendazole BP 3.6gm + Ivermectin BP 0.06gm/Vial	**Anthelmintic**	It is indicated for the control and simultaneous treatment of parasitosis caused by nematodes, Fasciola hepatica ectoparasites such as mites cause mange, blood-sucking lice and maggots. Formulation developed and tested exclusively for use in cattle, sheep, goats and camelids. **WITHDRAWAL PERIOD:** **Meat:** 35 days. **Milk:** Do not use in lactating dairy cattle and within 28 days before	**CONTRAINDICATIONS:** • It can manifest infrequently hypersensitivity reactions, if they occur, discontinue treatment. • It is not recommended for other species that are not authorized. • Do not use in lactating dairy cows. • Do not administer to animals in poor general conditions, in feverish state or in situations of intense stress. **SIDE-EFFECT:** • Free Ivermectin may adversely affect fish or certain aquatic organisms. • Local reaction (swelling) may occur at the	**New** **Existing:** Ivermectin 200mg + Triclabendazole 12gm/100ml Suspension	No Reference	বর্তমানে প্রয়োজন নাই বিধায় নামঞ্জুরের সুপারিশ করা হয় ।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
					calving.	injection site in animals for up to a week after administration. • If you develop symptoms following exposure, such as a skin rash, you should seek medical advice and show the doctor this warning. Swelling of the face, lips or eyes or difficulty with breathing are more serious symptoms and require urgent medical attention.				
359.	Eskayef Pharmaceuticals Limited, Rupganj, Narayanganj	Ivermectin 2% Oral Solution (For Veterinary Use Only)	Ivermectin BP 2gm/100ml	**Antehlmintic**	Therapeutic and prophylactic deworming and insect-acaricidal treatment of, poultry in invasive diseases caused by: – **in birds** (chickens, turkeys, geese, ducks, pigeons, ostriches) mature and larval forms of nematodes of the families: *Acuaridae, Amidostomatidae, Ascaridae, Capillariidae, Dioctophymidae, etc.* ectoparasitic diseases caused by: mites of the various species.	**CONTRAINDICATIONS:** Do not use in laying hens whose eggs are used for human consumption. **WITHDRAWAL PERIOD:** **Meat** : 10 days, **Egg: 07 days**	Ivermectin 0.5%, 1% Solution	No Reference	বর্তমানে প্রয়োজন নাই বিধায় নামঞ্জুরের সুপারিশ করা হয় ।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
360.	Eskayef Pharmaceuticals Limited, Rupganj, Narayanganj	Xylazine 2% IV Injection (For Veterinary Use Only)	Xylazine Hydrochloride USP 233mg (Eq. to Xylazine 200mg)/Vial		Xylazine has sedative, analgetic and central muscular relaxing properties, giving result 5-15 minutes after injection. In all cases where the use of a sedative is indicated, e.g. during transport, horseshoeing and operations, like f.i. dehorning. As a pre-anesthetic by operations (e.g. sectio caesaria). **WITHDRAWAL PERIOD:** **3 days before slaughtering.**	**CONTRAINDICATIONS:** Use during the last month of pregnancy (cattle), lung- and heart failures; Oesophageal obstruction, torsion of the stomach, and hernia (because of vomiting); administration in combination with neuroleptica. **SIDE-EFFECT:** Depression of heart-rate, blood pressure and respiration (when given in high doses), tympany (in ruminants) and in case of pyometritis, hypersensitivity to xylazine may occur. Be	New	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						carefully, if used in combination with barbiturates (lower the dosage) because of strong depression or respiration and myocard. Analeptica (e.g. ephedrine) may reduce the sedation period.				
361.	Eskayef Pharmaceuticals Limited, Rupganj, Narayanganj	Cyanocobalamin 0.05gm + Sodium Selenite 0.1gm + Adenosine Triphosphate (ATP) Tetrasodium Dihydrate Salt 0.1gm + Potassium Aspartate Semihydrate 1gm + Magnesium Aspartate Tetrahydrate 1.5gm/100ml IM/IV/SC Injection (For Veterinary Use Only)	Cyanocobalamin (100%) USP 0.05gm + Sodium Selenite BP 0.1gm + Adenosine Triphosphate (ATP) Tetrasodium Dihydrate Salt INN 0.1gm + Potassium Aspartate Semihydrate INN 1gm + Magnesium Aspartate Tetrahydrate INN 1.5gm/Vial	**Vitamin and mineral combination**	It can help increase work capacity and resistance to fatigue, in addition to promoting growth and muscle development, helping in the recovery of animals with muscle disorders of metabolic origin and stimulating the production of red blood cells. In calves, lambs, horses, pigs, dogs and cats: • Prevention and treatment of selenium deficiency states such as: Myopathies, Muscular dystrophies.	**CONTRAINDICATIONS:** Do not use if a history of hypersensitivity has already been reported in animals to one of the active substances or to one of the excipients. **SIDE-EFFECT:** • In very rare cases, local inflammatory reactions may appear at the injection site after administration. • In very rare cases, reactions such as anaphylactic shock with cardiovascular disorders, prostration, coma which may progress to death. **WITHDRAWAL PERIOD:** **Meat**: 0 days **Milk**: 0 days	New	No Reference	বর্তমানে প্রয়োজন নাই বিধায় নামঞ্জুরের সুপারিশ করা হয় ।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
362.	Eskayef Pharmaceuticals Limited, Rupganj, Narayanganj	Praziquantel 20mg + Pyrantel Embonate 230mg Film Coated Tablet (For Veterinary Use Only)	Praziquantel USP 20mg + Pyrantel Embonate BP 230mg	Anthelmintic	For the treatment of gastrointestinal roundworms and tapeworms of cats: *Toxocara cati, Toxascaris leonina, Dipylidium caninum, Taenia taeniaeformis.* **WITHDRAWAL PERIOD:** Unknown	**CONTRAINDICATIONS:** • Not intended for use in kittens less than 6 weeks of age. • Do not use simultaneously with piperazine compounds. • Until sufficient studies have been performed with this combination, do not use during pregnancy.	Praziquantel 18.2mg + Pyrantel 72.6mg Bolus	UK	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						SIDE-EFFECT: • In the interests of good hygiene, persons administering the tablets directly to a cat, or by adding them to the cat's food, should wash their hands afterwards.				
363.	Eskayef Pharmaceuticals Limited, Rupganj, Narayanganj	Spiramycin 6000000 IU/ml (60MIU/100ml) IM Injection (For Veterinary Use Only)	Spiramycin BP 12gm (Eq. to 60 MIU)/100ml	Antibiotic	Treatment of acute clinical mastitis in lactating cows caused by Staphylococcus aureus strains sensitive to spiramycin. Treatment of respiratory infections caused by Pasteurella multocida and Mannheimia haemolytica. **WITHDRAWAL PERIOD:** **Meat and offal**: 75 days **Milk**: 13.5 days	**CONTRAINDICATIONS:** Do not use in cases of hypersensitivity to the active substance or to any of the excipients. **SIDE-EFFECT:** • Macroscopic lesions at the injection site may occur after the treatment in cattle. • Hypersalivation may occur 3 hours after the treatment in cattle. • These lesions may still be present 42 days after injection.	Spiramycin 500000IU/gm Powder	EMA	প্রয়োজন নাই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
364.	Navana Pharma narayanganj	Enrofloxacin (vet) (For Veterinary Use Only)	Enrofloxacin BP 136 mg/tablet	Antibiotic 077	Dog & Cat: For management of diseases associated with bacteria susceptible to enrofloxacin. Withdrawal Period: N/A	**Contraindication:** Contraindicated in animals hypersensitive to Enrofloxacin. **Side-effects:** Vomiting, Diarrhea, Lack of appetite, Abdominal pain slaughtered within 28 days from the last treatment. Used with caution in animals with known or suspected Central Nervous System (CNS) disorders.	New Existing: Enrofloxacin 10% Solution	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।
365.	Navana Pharma narayanganj	Flunixin (vet) Solution (For Veterinary Use Only)	Each mL contains flunixin meglumine equivalent to 50 mg/ml flunixin. Transdermal/	Anti-Inflammatory 077	Horse & Cattle: For alleviation of inflammation and pain associated with musculoskeletal disorders, and alleviation of pain associated with colic **WITHDRAWAL PERIOD:** • (Cattle): Milk 36hours; Slaughter 4 days	**Contraindication:** Contraindicated in animals hypersensitive to Flunixin. **Side-effects:** Ingestion may cause GI irritation and bleeding, kidney and CNS effects.	New Existing: Flunixin 500 mg/10 ml Injection	USFDA	অনুমোদনের সুপারিশ করা হয়।	পরবর্তী টেকনিক্যাল সাব কমিটির সভায় পুনর্মূল্যায়নের সিদ্ধান্ত গৃহীত হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
					• Slaughter 12 days					
366.	Navana Pharma narayanganj	Mupirocin (vet) Ointment (For Veterinary Use Only)	Mupirocin USP 20 mg/g Ointment	Antibiotic 077	Dog and Cat: This ointment is indicated for the topical treatment of canine bacterial infections of the skin, including superficial pyoderma, caused by susceptible strains of *Staphylococcus aureus* and *Staphylococcus intermedius*	**Contraindication:** This drug is contraindicated in animals with a history of sensitivity reactions to any of its components. **Side effects:** No adverse reactions have been reported with this product. If a skin reaction such as irritation should occur, treatment should be discontinued and appropriate therapy instituted.	New	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।
367.	Navana Pharma Narayanganj	Thiabendazole + Neomycin + Dexamethasone (vet) Solution (For Veterinary Use Only)	Each ml contains: Thiabendazole BP 40 mg, Neomycin USP (as neomycin sulfate) 3.2 mg, and Dexamethasone USP 1 mg	Antibiotic, antifungal & antiinflammatory 077	**Dogs** The drug is recommended for use as an aid in the treatment of bacterial, mycotic, and inflammatory dermatoses and otitis externa in dogs. **Cats** The drug is recommended for use as an aid in the treatment of bacterial, mycotic, and inflammatory dermatoses and otitis externa in cats.	**Contraindication**: This drug is contraindicated in animals with a history of sensitivity reactions to any of its components. **Side-effects**: Localized erythema (redness) lasting 24 to 48 hours in cats with hypersensitivity to neomycin.Hearing loss if administered to cats with ruptured eardrums.	New	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।
368.	Navana Pharma Narayanganj	Tripelennamine (vet) Pack Size:30ml injection (For Veterinary Use Only)	Tripelennamine Hydrochloride BP 20 mg/ml, Injection **(30ml)**	Anti-histaminic 077	Allergic reaction and common cold in cattle and Horses **Withdrawal Period:** Cattle: Milk: 24 hours Meat: 4 days	**Contra Indications: Cattle-**Not for use in beef calves less than 2 months of age, dairy calves, and veal calves. Contraindicated in animals sensitive to tripelennamine. **Horses** - Do not use in horses intended for human consumption. **Side effects:** Administration of tripelennamine hydrochloride may give rise to excitement, ataxia, and convulsions. Central nervous system stimulation in the form of hyperexcitability, nervousness, and muscle tremors lasting up to 20 minutes have been noted in horses following administration.	New	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						Depression of the central nervous system and incoordination may occur when the drug is used at therapeutic dose levels. Disturbances in gastrointestinal function may occur in some instances.				
369.	Navana Pharma narayanganj	Tripelennamine (vet) Pack Size:10ml Injection (For Veterinary Use Only)	Tripelennamine Hydrochloride BP 20 mg/ml, Injection	Anti-histaminic 077	Allergic reaction and common cold in cattle and Horses **Withdrawal Period:** Cattle: Milk: 24 hours Meat: 4 days	**Contra Indications:** **Cattle-**Not for use in beef calves less than 2 months of age, dairy calves, and veal calves. Contraindicated in animals sensitive to tripelennamine. **Horses** - Do not use in horses intended for human consumption. **Side effects:** Administration of tripelennamine hydrochloride may give rise to excitement, ataxia, and convulsions. Central nervous system stimulation in the form of hyperexcitability, nervousness, and muscle tremors lasting up to 20 minutes have been noted in horses following administration. Depression of the central nervous system and incoordination may occur when the drug is used at therapeutic dose levels. Disturbances in gastrointestinal function may occur in some instances.	New	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।
370.	Navana Pharma narayanganj	Tripelennamine (vet) Pack Size:100 ml Injection (For Veterinary Use Only)	Tripelennamine Hydrochloride BP 20 mg/ml, Injection **(100ml)**	Anti-histaminic 077	Allergic reaction and common cold in cattle and horses. **Withdrawal Period:** Cattle: Milk: 24 hours Meat: 4 days	**Contra Indications:** **Cattle-**Not for use in beef calves less than 2 months of age, dairy calves, and veal calves. Contraindicated in animals sensitive to tripelennamine. **Horses** - Do not use in horses intended for human consumption. **Side effects:** Administration of tripelennamine hydrochloride may give rise to excitement, ataxia, and convulsions. Central nervous system stimulation in the form of hyperexcitability, nervousness, and muscle tremors lasting up to 20 minutes have been noted	New	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						in horses following administration. Depression of the central nervous system and incoordination may occur when the drug is used at therapeutic dose levels. Disturbances in gastrointestinal function may occur in some instances.				
371.	Navana Pharma Narayanganj	Griseofulvin (vet) (For Veterinary Use Only)	Griseofulvin BP 125 mg Tablet	Anti-fungal 077	**Dogs** For treatment of fungal infections of the skin, hair, and claws caused by Trichophyton mentagrophytes, T. rubrum, T. schoenleini, T. sulphurem, T. verrucosum, T. interdigitale, Epidermophyton floccosum Microsporum gypseum, M. canis, M. audouini. **Cats** For treatment of fungal infections of the skin, hair, and claws caused by Trichophyton mentagrophytes, T. rubrum, T. schoenleini, T. sulphurem, T. verrucosum, T. interdigitale, Epidermophyton floccosum Microsporum gypseum, M. canis, M. audouini.	**Contraindication**: Contraindicated in animals hypersensitive to Griseofulvin. **Side effects:** Common: In some cases, vomiting, and diarrhea may be found. Rare: Anemia, bone-marrow suppression, liver problems.	New	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।
372.	Navana Pharma Narayanganj	Griseofulvin (vet) (For Veterinary Use Only)	Griseofulvin BP 500 mg Tablet	Anti-fungal 077	**Dogs & Cats:** For treatment of fungal infections of the skin, hair, and claws caused by Trichophyton mentagrophytes, T. rubrum, T. schoenleini, T. sulphurem, T. verrucosum, T. interdigitale, Epidermophyton floccosum Microsporum gypseum, M. canis, M.	**Contraindication:**Contraindicated in animals hypersensitive to Griseofulvin. **Side effects:**Common: In some cases, vomiting, and diarrhea may be found. Rare: Anemia, bone-marrow suppression, liver problems.	New	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
					audouini.					
373.	Navana Pharma Narayanganj	Nystatin+ Neomycin sulfate + Thiostrepton + Triamcinolone acetonide. (vet) Ointment (For Veterinary Use Only)	Nystatin BP 100000 unit; + Neomycin sulfate BP 2.5mg equivalent to 2.5 mg Neomycin base + Thiostrepton USP 2500 unit + Triamcinolone Acetonide.BP1 thiostrepton; and 1.0 milligram of triamcinolone acetonide. mg/gm Ointment **vet**	Der matological 077	Dog and Cats: Topically: Use either ointment in dogs and cats for anti-inflammatory, antipruritic, antifungal, and antibacterial treatment of superficial bacterial infections, and for dermatologic disorders characterized by inflammation and dry or exudative dermatitis, particularly associated with bacterial or candidal (*Candida albicans*) infections.	**Contraindications:** Do not use in cases of known hypersensitivity to the active substance of this product or to any of the excipients. **Side effects:** Redness and irritation may occur in some cases.	New	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।
374.	Navana Pharm Narayanganj	Ambroxol (vet) (For Veterinary Use Only)	Ambroxol HCl BP 6 mg/ml, Solution	Expectaurant 077	Dog and Cat: Respiratory tract disorder, viscid cough, catarrhal inflammation in bronchi.	**Contraindication:** There are no absolute contraindications, but relative caution should be observed in patients with gastric ulceration. **Side effects:** Common: Nausea or vomiting, diarrhea, indigestion, abdominal pain, dry mouth, or dry throat may occur in some cases. Rare: Not known	New	Australian pesticides and Veterinary medicine authority (APVMA)	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
375.	Navana Pharma narayanganj	Sulfadiazine +Sulfadimidin + neomycin sulfate+ riboflavine + thiamine hydrochloride + hyoscine (For Veterinary Use Only)	Sulfadiazine USP 750 mg, sulfadimidine USP 750 mg, Neomycin sulfate USP 250 mg, Riboflavine USP 3 mg, Thiamine hydrochloride USP 2 mg, hyoscine INN 1.52 mg per bolus, Bolus	Antibiotic 077	Diarrhoea, Enteric disease in cattle and poultry	**Contraindications**: This drug is not recommended for use in the case of animals with known hypersensitivity to aminoglycoside and sulpha drugs. **Side effects:**Common: Itching, rash, allergic reaction, swelling, dizziness, drowsiness, nausea or vomiting, stomach pain or cramps, severe diarrheaRare: Burning or stinging.	New	Australian pesticides and Veterinary medicine authority (APVMA)	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।
376.	Navana Pharma Narayanganj	Butorphanol (vet)	Butorphanol (as tartrate) USP 10mg/tablet Tablet	Expectaurant 077	Dog: For the relief of chronic nonproductive cough associated with tracheo-bronchitis, tracheitis tonsillitis, laryngitis, and pharyngitis associated with inflammatory conditions of the upper respiratory tract.	**Contraindication:** Do not use in animals with a history of liver disease. **Side effects**: Ataxia, sleepiness, drowsiness **Warnings & precautions**: Butorphanol should be used with caution in elderly animals or in animals with kidney disease, hypothyroidism, and other serious conditions.	New	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।
377.	Navana Pharma Narayanganj	Butorphanol (vet) Pack Size: 10 ml inj. (For Veterinary Use Only)	Butorphanol (as tartrate) USP 0.5 mg/ml Injection	Expectaurant 077	Dog: For the relief of chronic nonproductive cough associated with tracheo-bronchitis, tracheitis tonsillitis, laryngitis, and pharyngitis associated with inflammatory conditions of the upper respiratory tract.	**Contraindication:** Do not use in animals with a history of liver disease. **Side effects:** Ataxia, sleepiness, drowsiness	New	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।
378.	Navana Pharma Narayanganj	Butorphanol (vet) Pack Size: 30 ml inj. (For Veterinary Use Only)	Butorphanol (as tartrate) USP 0.5 mg/ml Injection	Expectaurant 077	**Dog: For the relief of chronic nonproductive cough associated with tracheo-bronchitis, tracheitis tonsillitis, laryngitis, and pharyngitis associated with inflammatory conditions of the upper respiratory tract.**	**Contraindication:** Do not use in animals with a history of liver disease. **Side effects:** Ataxia, sleepiness, drowsiness	New	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।
379.	Navana	Denaverine (vet)	Denaverine HCl	Myometrial	Cows, heifers: - Promotes dilation of	**Contraindication:** Do not administer in cases of	New	EMA	অনুমোদনের	অনুমোদন করা

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
	Pharma Narayanganj	Pack Size: 10 ml inj. (For Veterinary Use Only)	BP 40 mg/ml, Injection	Relaxant 077	the soft tissues of the birth canal in cases where the birth canal is insufficiently opened. - Regulates uterine contractions in animals with hypertonic muscular contractions of the uterus. **Withdrawal Periods**: Cattle: Meat and offal: 1 day **Milk: 24 hours**	mechanical obstetrical obstructions. Do not use in cases of hypersensitivity to the active substance or to any of the excipients. **Side-effects**: Restlessness and swelling at injection site.			সুপারিশ করা হয়।	হয়।
380.	Navana Pharma Narayanganj	Paracetamol (vet) Oral Solution (For Veterinary Use Only)	Paracetamol BP 400 mg/ml,	Antipyretic 077	Fever & pain	**Contraindication**: Contraindicated in animals hypersensitive to paracetamol. **Side-effects:** Transient soft faeces may occur, but will resolve without any treatment.	New Paracetamol 50 gm/100 gm Water Soluble Powder	Australian Pesticides & Veterinary Medicine Authority (APVMA)	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।
381.	Navana Pharma Narayanganj	Apramycin (vet) (For Veterinary Use Only)	Apramycin BP (as sulfate) 500 mg/g, Water soluble powder (WSP)	Antibiotic 077	Colibacillosis, Salmonellosis in cattle and poultry	**Contraindication:** Do not use in case of hypersensitivity to apramycin. Do not use in calves with functional rumen. Do not use in animals suffering from kidney disorders. **Side-effects**: Well tolerated, sometimes diarrhoea may occur at high dose.	New	EMA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।
382.	Navana Pharma Narayanganj	Triamcinolone acetonide (vet) Pack Size: 5 ml (For Veterinary Use Only)	Triamcinolone Acetonide BP 6 mg/ml. Injection	Anti-Inflammatory 077	**Horses and Cattle:** Treatment of inflammation and related disorders. **Dogs and cats:** Treatment of inflammation and related disorders in dogs; and management and treatment of acute arthritis and allergic and dermatologic disorders in dogs and cats. Withdrawal Period: Horse meat and **offal: 12 days**	**Contraindications:** Use of Triamcinolone is contraindicated in systemic fungal infections, viral infection, animals with arrested tuberculosis, peptic ulcer, acute psychoses. corneal ulcer, &Cushingoid syndrome. **Side effects**: Common: Dullness, dry hair coat, weight gain, panting, vomiting, diarrhoea, GI ulceration, behavioural changes (depression, lethargy, viciousness) may be observed in some cases. Rare: Not known.	New	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।
383.	Navana	Triamcinolone	Triamcinolone	Anti-	**Horses and Cattle:**	**Contraindications:** Use of Triamcinolone is	New	USFDA	অনুমোদনের	অনুমোদন করা

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
	Pharma Narayanganj	acetonide (vet) Pack Size: 10 ml inj. (For Veterinary Use Only)	Acetonide BP 6 mg/ml. Injection	Inflammatory glucocorticoid 077	Treatment of inflammation and related disorders. **Dogs and cats:** Treatment of inflammation and related disorders in dogs; and management and treatment of acute arthritis and allergic and dermatologic disorders in dogs and cats. Withdrawal Period: **Horse meat and offal: 12 days**	contraindicated in systemic fungal infections, animals with arrested tuberculosis, peptic ulcer, acute psychoses. cornealulcer, &Cushingoid syndrome. **Side effects**: Common: Dullness, dry hair coat, weight gain, panting, vomiting, diarrhoea, GI ulceration, behavioural changes (depression, lethargy, viciousness) may be observed in some cases. Rare: Not known.			সুপারিশ করা হয়।	হয়।
384.	Navana Pharma narayanganj	Toltrazuril + Iron (vet) (For Veterinary Use Only)	Toltrazuril INN 36.4 mg and Iron INN 182 mg (as gleptoferron 484.7 mg) per ml, Solution	Anticoccidial 077	**Coccidiosis and iron deficiency anemia in poultry**	**Contraindications:** Should not be administered the animals with impaired hepatic and/or renal function. Should not be used in animals hypersensitive to active ingredients. **Side effects:** Growth inhibition and polyneuritis can occur in case of high doses.	New Toltrazuril 2.5gm/100ml	Australian Pesticides & Veterinary Medicine Authority (APVMA)	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।
385.	Navana Pharma Narayanganj	Zinc + Copper + Manganese + Selenium Pack Size: 5 ml Injection (For Veterinary Use Only)	Each ml contains Zinc USP (as disodium Zinc EDTA) 60 mg, Copper (as disodium Copper EDTA) 15 mg, manganese (as disodium Manganese EDTA) 10 mg and Selenium (sodium Selenite) 5 mg., Injection, **5ml**	Minerals 077	**Supply of trace minerals to correct concurrent clinical or subclinical deficiencies of selenium, copper, manganese and zinc which can arise during critical phases of the production or breeding life cycle.**	**Contraindications** Selenium and copper are toxic if administered in excess. Do not use concurrently with other injectable selenium and copper products. **Side effects**: Slight local reaction at the injection site, such as swelling, pain, inflammation, mild skin irritation. Stomach upset, vomiting, abdominal pain, or bleeding if the product is ingested.	New	Australian Pesticides & Veterinary Medicine Authority (APVMA)	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।
386.	Navana Pharma Narayanganj	Zinc + Copper + Manganese + Selenium (vet) Pack Size: 10 ml inj.	Each ml contains Zinc USP (as disodium Zinc EDTA) 60 mg,	Minerals 077	**Supply of trace minerals to correct concurrent clinical or subclinical deficiencies of selenium, copper, manganese and zinc which can**	**Contraindications** Selenium and copper are toxic if administered in excess. Do not use concurrently with other injectable selenium and copper products.	New	Australian Pesticides & Veterinary Medicine	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
		(For Veterinary Use Only)	Copper (as disodium Copper EDTA) 15 mg, manganese (as disodium Manganese EDTA) 10 mg and Selenium (sodium Selenite) 5 mg., Injection,		**arise during critical phases of the production or breeding life cycle.**	**Side effects**: Slight local reaction at the injection site, such as swelling, pain, inflammation, mild skin irritation. Stomach upset, vomiting, abdominal pain, or bleeding if the product is ingested.		Authority (APVMA)		
387.	**Opsonin Pharma Limited, Rupatali, Barishal.**	Flunixin(as flunixin meglumine) USP 50 mg/ml Pour-on solution (For Veterinary Use Only)	Flunixin (as flunixin meglumine) USP 50 mg/ml	Anti-Inflammatory 077	Horse & Cattle: For alleviation of inflammation and pain associated with musculoskeletal disorders, and alleviation of pain associated with colic **WITHDRAWAL PERIOD:** • (Cattle): Milk 36hours; Slaughter 4 days • Slaughter 12 days	**Contraindication:** Contraindicated in animals hypersensitive to Flunixin. **Side-effects:** Ingestion may cause GI irritation and bleeding, kidney and CNS effects.	New Existing: Flunixin 500 mg/10 ml Injection	USFDA UK-MHRA	অনুমোদনের সুপারিশ করা হয়।	পরবর্তী টেকনিক্যাল সাব কমিটির সভায় পুনর্মূল্যায়নের সিদ্ধান্ত গৃহীত হয়।
388.	**Opsonin Pharma Limited,** Rupatali, Barishal.	Chlorhexidine Digluconate BP 20 mg & Miconazole Nitrate BP 20 mg/ml Shampoo (For Veterinary Use Only)	Chlorhexidine Digluconate BP 20 mg & Miconazole Nitrate BP 20 mg/ml	Antifungal **Code:** 077	**Dogs:** For the treatment and control of seborrhoeic dermatitis associated with *Malassezia pachydermatis* and *Staphylococcus intermedius*. **Cats:** As an aid in the treatment of ringworm due to *Microsporum canis* in conjunction with griseofulvin	**Contraindication:** Do not use in case of hypersensitivity to the active substances or to any of the excipients. **Side effects**: Exceptionally a dog with atopy or a cat with allergic skin disease may develop a pruritic and/or erythematous reaction after treatment. In very rare circumstances, dogs and cats may develop a skin reaction (itching, redness) after treatment.	New	UK MHRA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।
389.	**Opsonin Pharma Limited, Rupatali, Barishal.**	Deltamethrin BP 10 mg/ml Pour-on Solution (For Veterinary Use Only)	Deltamethrin BP 10 mg/ml	Anthelmintics Code: 077	Deltamethrin is used as a topical application for the treatment and prevention of infestations by lice and flies on cattle; ticks, lice, keds and established blowfly strike on sheep and lice and ticks on lambs	**Contraindication:** Do not use in case of hypersensitivity to the active substances or to any of the excipients. **Side effects:** Application site reactions, including squamosis and pruritus have been very rarely seen in cattle during the 48 hours after treatment.	New	UK MHRA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
390.	**Opsonin Pharma Limited,** Rupatali, Barishal.	Moxidectin 5 mg & Triclabendazole 200 mg/ml Pour-On (For Veterinary Use Only)	Moxidectin USP 5 mg & Triclabendazole INN 200 mg/ml	Anthelmintic Code: P02	In cattle: Treatment of mixed trematode (fluke) and nematode infections & Certain arthropod infestations caused by moxidectin and triclabendazole sensitive strains.	**Contraindication:** Do not use in cases of hypersensitivity to the active substance or to any of the excipients. **Side effects:** Digestive tract disorders such as diarrhoea, neurological disorders such as ataxia, hypersensitivity/allergic reactions and skin irritation at application site may be observed very rarely. product persists, consult your physician.	New	UK MHRA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।
391.	**Opsonin Pharma Limited,** Rupatali, Barishal.	Florfenicol INN 400 mg & Meloxicam BP 5 mg/ml Solution for injection Pack Size:10 ml vial (For Veterinary Use Only)	Florfenicol INN 400 mg & Meloxicam BP 5 mg/ml	Anti-infective Code:077	For therapeutic treatment of bovine respiratory disease (BRD) associated with pyrexia due to *Mannheimia haemolytica*, *Pasteurella multocida* and *Histophilus somni* susceptible to florfenicol. Meat and offal: 56 days. Milk: Not authorised for use in lactating animals producing milk for human consumption	**Contraindications:** Do not use in adult bulls intended for breeding. Do not use in animals suffering from impaired hepatic, cardiac or renal function and hemorrhagic disorders, or when there is evidence of ulcerogenic gastrointestinal lesions. Do not use in case of hypersensitivity to the active substances or to any of the excipients. **Side effects:** Injection site reactions (mostly swelling, induration, heat and pain) were very commonly observed after subcutaneous administration of the product. During injection of this product animals may exhibit signs of moderate pain, Manifested as movement of the head or neck. water.	New Existing: Florfenicol 30 gm + Flunixin 1.65 gm/100 ml Injection	UK MHRA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।
392.	**Opsonin Pharma Limited,** Rupatali, Barishal.	Febantel BP 150 mg, Pyrantel embonate BP 144 mg & Praziquantel BP 50 mg / tablet (For Veterinary Use Only)	Febantel BP 150 mg, Pyrantel embonate BP 144 mg & Praziquantel BP 50 mg	Anthelmintic Code: 077	Dog and cat: For the control of the following gastrointestinal tapeworms and roundworms in dogs and puppies Ascarids: *Toxocara canis, Toxascaris leonina* (adult and late immature forms). Hookworms: *Uncinaria stenocephala, Ancylostoma canium* (adults). Whipworms: *Trichuris vulpis* (adults) Tapeworms: *Echinococcus*	**Contraindications:** Do not use simultaneously with piperazine compounds as piperazine may block the action of pyrantel embonate contained in Bob Martin Clear 3 in 1Flavoured Wormer 150/144/50 mg Tablets for Dogs. Other worming products may contain piperazine. **Side effects:** In very rare cases slight and transient digestive tract disorders such as vomiting and/or diarrhoea may occur. In individual	New	UK MHRA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
					spp., *Taenia spp., Dipylidium caninum* (adult and immature forms).	cases these signs can be accompanied by nonspecific signs such as lethargy, anorexia or hyperactivity.				
393.	**Opsonin Pharma Limited,** Rupatali, Barishal.	Pyrantel embonate BP 230 mg & Praziquantel BP 20 mg / Tablet (For Veterinary Use Only)	Pyrantel embonate BP 230 mg & Praziquantel BP 20 mg	Anthelmintic Code:077	Dog and cats: For the treatment of mixed infestations with roundworms, hookworms and tapeworms in cats, caused by: Adult stages of ascarids: *Toxocara cati (syn. mystax)*, adult stages of hookworms: *Ancylostoma tubaeforme, Ancylostoma braziliense*, tapeworms: *Echinococcus multilocularis, Dipylidium caninum, Hydatigera (Taenia) taeniaeformis, Mesocestoides spp., Joyeuxiella pasqualei*	**Contraindications:** Do not use simultaneously with piperazine compounds. Do not use simultaneously with other deworming products without veterinary advice. Do not use in kittens less than 6 weeks of age. Do not use in cases of known hypersensitivity to the active substances or to any of the excipients. Do not use during pregnancy. **Side effects:** Mild and transient digestive tract disorders such as hyper salivation and/or vomiting and mild and transient neurological disorders such as ataxia may occur in extremely rare cases.	New	UK MHRA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।
394.	Square Pharmaceuticals PLC., Pabna	Isoflupredone acetate Sterile USP 2 mg/ml injectable suspension Pack Size: 5 ml Inj. (For Veterinary Use Only)	Isoflupredone acetate Sterile USP 2 mg/ml	Veterinary Drugs Code: 077 glucocorticoid	Indicated in situations requiring glucocorticoid, anti-inflammatory and supportive effect. Withdrawal Period: Meat: 7 days. Milk: 0 days	B: Use of steroids is contraindicated in systemic fungal infections, animals with arrested tuberculosis, peptic ulcer, acute psychoses, corneal ulcer and cushingoid syndrome. The presence of diabetes, osteoporosis, chronic psychotic reactions, predisposition to thrombophlebitis, hypertension, CHF, renal insufficiency and active tuberculosis necessitates carefully controlled. **Side effects:** Vascular permeability is decreased, exudation diminished, and migration of the	New	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
						inflammatory cells markedly inhibited, systemic manifestations suppressed, infections can be hazardous. Hypokalemia may occur, anaphylactioid reaction (such as bronchospasm, laryngeal edema, urticaria)				
395.	Square PharmaceuticalsPLC., Salgaria Pabna	Sulfadimethoxine 15g Bolus (For Veterinary Use Only)	Sulfadimethoxine USP 15 g	Veterinary Drugs Code: 077 sulfonamide antibiotic	It is Indicated in the treatment of shipping fever complex and bacterial pneumonia associated with Pasteurella spp. sensitive to sulfadimethoxine; and calf diphtheria and foot rot associated with Fusobacterium necrophorum sensitive to sulfadimethoxine in cattle.	Contraindications and warnings: It is not for human use. It should not be used in calves to be possessed for veal. **Withdrawal Period:** Milk: 60 hours Chickens and Turkeys- withdraw 5 days Meat: 07 days	New	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।
396.	Square Pharmaceuticals PLC., Pabna	Sulfadimethoxin 5g Bolus (For Veterinary Use Only)	Sulfadimethoxine INN 5 g	Veterinary Drugs Code: 077 sulfonamide antibiotic	It is Indicated in the treatment of shipping fever complex and bacterial pneumonia associated with Pasteurella spp. sensitive to sulfadimethoxine; and calf diphtheria and foot rot associated with Fusobacterium necrophorum sensitive to sulfadimethoxine in cattle.	Contraindications and warnings: It is not for human use. It should not be used in calves to be possessed for veal. **Withdrawal Period:** Milk: 60 hours Chickens and Turkeys- withdraw 5 days Meat: 07 days	New	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।
397.	Square Pharmaceuticals PLC., Pabna	Sulfadimethoxine 12.500 g/100 ml concentrated Solution (For Veterinary Use Only)	Sulfadimethoxine USP 12.500 g/100 ml	Veterinary Drugs Code: 077	Indicated for the treatment of shipping fever complex and bacterial pneumonia associated with *Pasteuraella* spp. sensitive to sulfadimethoxine and calf diphtheria	Contraindications and warnings: It is not for human use. It should not be used in calves to be possessed for veal. Chickens and Turkeys- withdraw 5 days before slaughter. Do not administer to chickens over 16 weeks (112 days	New	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
					and foot rot associated with *Fusobacterium necrophorum* sensitive to sulfadimethoxine in cattle.**Withdrawal Period:** Milk: 60 hours Chickens and Turkeys- withdraw 5 daysMeat: 07 days	of age) or to turkeys over 24 weeks of age. Cattle- withdraw 7 days before slaughter.				
398.	Square Pharmaceuticals PLC., Pabna	Orbifloxacin BP 22.7 mg Bolus (For Veterinary Use Only)	Orbifloxacin BP 22.7 mg	Veterinary Drugs Code: 077 fluoroquinolone antibiotics	It is indicated for the management of diseases in dogs and cats associated with bacteria susceptible to orbifloxacin.	**Contraindications:** Orbifloxacilin and other quinolones cause arthropathy in immature animals of most species tested, the dog being particularly sensitive to this side effect. It is mainly contraindicated in dogs and cats known to be hypersensitive to quinolones. **Side effects:** Cat: Depression/lethargy, vomiting, convulsions, abnormal retina, hyper salivation. In some cases, blindness has been temporary. Dog: Vomiting, convulsions, depression/lethargy, anorexia.	New	Square Pharmaceuticals PLC., Pabna	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।
399.	Square Pharmaceuticals PLC., Pabna	Amikacin Sulfate 333.744 mg (Equivalent to 250 mg of Amikacin)/ ml injection Pack Size: 30 ml inj. (For Veterinary Use Only)	Amikacin Sulfate USP 333.744 mg (Equivalent to 250 mg of Amikacin)/ ml	Veterinary Drugs Code: 077 Antibitics	Indicated for the treatment of 1. Genitourinary tract infections caused by susceptible strains of *Escheria Coli* and *Proteus* sp. 2. skin and soft tissue infections caused by susceptible strains of *Pseudomonas* sp. and *Escheria Coli*	**Contraindication**: Aminoglycosides are contraindicated in patients who are hypersensitive to them. **Side effects:** Neuromuscular blockade, facial edema, and peripheral neuropathy. Gastrointestinal side effects are rare. Withdrawal Period: 28 days	New	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।
400.	The ACME Laboratories Ltd. Dhamrai, Dhaka	Maropitant (Citrate Monohydrate INN) Solution for Injection Pack Size: 5 ml Inj. (For Veterinary Use Only)	Each ml of solution contains 10 mg (1% w/v) maropitant as maropitant citrate INN)/	Veterinary Drugs	**Target Species: Dog & Cats** It is indicated for the prevention and treatment of acute vomiting in dogs and for the treatment of vomiting in cats.	**Contra-Indications:** None. **Side effects:** There is no adverse reaction at the recommended dosage. **Warning and Precautions:** Vomiting can be associated with serious, severely debilitating	New	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
			5ml injection			conditions including gastrointestinal obstructions; therefore, appropriate diagnostic evaluations should be employed. **Withdrawal Period:** Not applicable.				
401.	The ACME Laboratories Ltd. Dhamrai, Dhaka	Maropitant (Citrate Monohydrate INN) Solution for Injection Pack Size: 10 ml inj. (For Veterinary Use Only)	Each ml of solution contains 10 mg(1% w/v) maropitant as maropitant citrate INN)/ 10 ml Injection	Veterinary Drugs	**Target Species: Dog & Cats** It is indicated for the prevention and treatment of acute vomiting in dogs and for the treatment of vomiting in cats.	**Contra-Indications:** None. **Side effects:** There is no adverse reaction at the recommended dosage. **Warning and Precautions:** Vomiting can be associated with serious, severely debilitating conditions including gastrointestinal obstructions; therefore, appropriate diagnostic evaluations should be employed. **Withdrawal Period:** Not applicable.	New	USFDA	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
402.	The ACME Laboratories Ltd. Dhamrai, Dhaka	Maropitant (Citrate Monohydrate INN) Solution for Injection Pack Size: 30 ml inj. (For Veterinary Use Only)	Each ml of solution contains 10 mg(1% w/v) maropitant as maropitant citrate INN)/ 30 ml Injection	Veterinary Drugs	**Target Species: Dog & Cats** It is indicated for the prevention and treatment of acute vomiting in dogs and for the treatment of vomiting in cats.	**Contra-Indications:** None. **Side effects:** There is no adverse reaction at the recommended dosage. **Warning and Precautions:** Vomiting can be associated with serious, severely debilitating conditions including gastrointestinal obstructions; therefore, appropriate diagnostic evaluations should be employed. **Withdrawal Period:** Not applicable.	New	USFDA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।
403.	The ACME Laboratories Ltd. Dhamrai, Dhaka	Menbutone INN Solution for Injection Pack Size: 10 ml inj. (For Veterinary Use Only)	Menbutone INN 10% w/v (100 mg per mL) 10 ml inj.	Veterinary Drugs	**Target Species: Cattle, Sheep & goats** Bloat, impaction, constipation, indigestion, poisoning, toxemia, anorexia, hepatic and pancreatic insufficiencies and ketosis in cattle, sheep, goat.	**Contra Indications:** Contra-indicated in animals sensitive to Menbutone **Side effects:** Not known. **Withdrawal Period:** Meat and Offal: 0 days Milk: 0 days	New	EMA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।
404.	The ACME Laboratories Ltd.	Menbutone INN	Menbutone INN 10% w/v (100 mg	Veterinary Drugs	**Target Species: Cattle, Sheep & goats**	**Contra Indications:** Contra-indicated in animals sensitive to	New	EMA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
	Dhamrai, Dhaka	Solution for Injection Pack Size: 30 ml inj. (For Veterinary Use Only)	per mL) 30 ml inj.		Bloat, impaction, constipation, indigestion, poisoning, toxemia, anorexia, hepatic and pancreatic insufficiencies and ketosis in cattle, sheep, goat.	Menbutone **Side effects:** Not known. **Withdrawal Period:** Meat and Offal: 0 days Milk: 0 days				
405.	Renata Limited Mirpur, Dhaka	Afoxolaner 28 mg Tablet (Vet) (For Veterinary Use Only)	Afoxolaner INN 28 mg Chewable Tablet (Vet)	Anti-infective	**Target Species: Dogs** Treatment of flea infestation in dogs (*Ctenocephalides felis* and *C. canis*). The veterinary medicinal product provides immediate and persistent killing activity for at least 5 weeks. The product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD). Etc.	**Contra Indications:** Do not use in cases of hypersensitivity to the active substance or to any of the excipients. **Side effect/Adverse effect:** Very rare, may digestive tract disorders1 (vomiting, diarrhoea2) Lethargy, anorexia2 Pruritus **Withdrawal periods** Not applicable.	New	EMA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।
406.	Renata Limited Mirpur, Dhaka	Maropitant citrate 24 mg Tablet (Vet) (For Veterinary Use Only)	Maropitant citrate INN 24 mg Tablet (Vet)	Anticholinergic	**Target species** Dogs. Maropitant is used for the prevention of nausea induced by chemotherapy. For the prevention of vomiting induced by motion sickness.For the prevention and treatment of vomiting, in conjunction with Cerenia solution for injection and in combination with other supportive measures.	• **Contra-indication:** None **Side-effects:** Rarer side effects include lethargy, decreased appetite, diarrhea, allergic reactions, uncoordinated walking, and convulsions.	New	EMA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।
407.	Renata Limited Mirpur, Dhaka	Pradofloxacin Trihydrate 120 mg tablet (Vet) (For Veterinary Use Only)	Pradofloxacin Trihydrate INN 120 mg tablet (Vet)	Anti-Infective	**Target species** Dogs & Cats Pradofloxacin is an antibiotic. In dogs, It is used for the treatment of skin, urinary tract and gum infections	**Contraindications** Do not use in cases of hypersensitivity to the active substance or to any of the excipients. **Side-effects:** The most common side effects in dogs and cats	New	EMA	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
					caused by certain specific bacteria. In cats, it is used for the treatment of acute infections of the upper respiratory tract caused by certain specific bacteria.	are mild transient gastro-intestinal disturbances including vomiting, although these have only been observed rarely. **Withdrawal periods** Not applicable. •				
408.	Renata Limited Mirpur, Dhaka	Pradofloxacin Trihydrate 500 mg tablet (Vet) (For Veterinary Use Only)	Pradofloxacin Trihydrate INN 500 mg tablet (Vet)	Anti-Infective	**Target species:** Cattle For the treatment of BRD (bovine respiratory disease) associated with *Mannheimia haemolytica*, *Pasteurella multocida*, *Histophilus somni* and *Mycoplasma bovis* in cattle. Cattle meat: 04 days.	**Contraindications** Do not use in cases of hypersensitivity to the active substance or to any of the excipients. **Side-effects:** Mild to moderate inflammatory changes of the injection site may be seen in cattle **Withdrawal periods** Cattle meat: 04 days.	New	EMA	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
409.	Renata Limited Mirpur, Dhaka	Pradofloxacin Trihydrate 1000 mg (For Veterinary Use Only)tablet (Vet)	Pradofloxacin Trihydrate INN 1000 mg tablet (Vet)	Anti-Infective	**Target species:** Cattle For the treatment of BRD (bovine respiratory disease) associated with *Mannheimia haemolytica*, *Pasteurella multocida*, *Histophilus somni* and *Mycoplasma bovis* in cattle. Cattle meat: 04 days.	**Contraindications** Do not use in cases of hypersensitivity to the active substance or to any of the excipients. **Side-effects:** Mild to moderate inflammatory changes of the injection site may be seen in cattle **Withdrawal periods** Cattle meat: 04 days.	New	No Ref.	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
410.	Renata Limited Mirpur, Dhaka	Pradofloxacin Trihydrate 200 mg/ ml injection (10ml injection) (For Veterinary Use Only)	Pradofloxacin Trihydrate 2000 INN mg/10 ml (200mg/ml) injection (Vet)	Anti-Infective	**Target species:** Cattle For the treatment of BRD (bovine respiratory disease) associated with *Mannheimia haemolytica*, *Pasteurella multocida*, *Histophilus somni* and *Mycoplasma bovis* in cattle. Cattle meat: 04 days.	**Contraindications** Do not use in cases of hypersensitivity to the active substance or to any of the excipients. **Side-effects:** Mild to moderate inflammatory changes of the injection site may be seen in cattle **Withdrawal periods** Cattle meat: 04 days.	New	USFDA	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
411.	Renata Limited Mirpur, Dhaka	Pradofloxacin Trihydrate 200 mg/ ml Injection Pack Size: 30 ml inj. (For Veterinary Use	Pradofloxacin Trihydrate 200 mg/ ml Injection (30ml) Injection (Vet)		**Target species:** Cattle For the treatment of BRD (bovine respiratory disease) associated with *Mannheimia haemolytica*, *Pasteurella multocida*, *Histophilus*	**Contraindications** Do not use in cases of hypersensitivity to the active substance or to any of the excipients. **Side-effects:** Mild to moderate inflammatory changes of the injection site may be seen in cattle	New	USFDA	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।

Sl. No.	Name of the Manufacturer	Name of the Medicine with dosage form	Generic Name with Strength	Therapeutic Class and Code	Indication	Contra-indication, Side-effects, Warnings and Precautions	Status (New / Existing Molecule)	USFDA/ BNF/ UKMHRA/ EMA/PMDA/TGA	টেকনিক্যাল সাব কমিটির সভার সিদ্ধান্ত	সভার সিদ্ধান্ত
		Only)			*somni* and *Mycoplasma bovis* in cattle. Cattle meat: 04 days.	**Withdrawal periods** Cattle meat: 04 days.				
412.	Renata Limited Mirpur, Dhaka	Fenbendazole 3000mg + Ivermectin 100 mg Tablet (Vet) (For Veterinary Use Only)	Fenbendazole USP 3000 mg + Ivermectin BP 100 mg Tablet (Vet)	Anthelmintics Therapeutic Code: 077	**Target species:** Cattle, Buffalo, Horse It is used for the treatment of nematodiasis, cestodiasis of livestock and fowl. It is highly effective to remove gastro-intestinal nematodes, lung worms, and tape worms from animals including cattle, buffaloes, horses and pigs.	**Contra-indication:** None Side-effect: Salivation, vomiting, and diarrhea may occur in dogs or cats receiving this medication. **Withdrawal periods** Not Known	New	No Ref.	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।
413.	Renata Limited Mirpur, Dhaka	Velagliflozin L-proline Monohydrate 15 mg/ml oral solution (Vet) (For Veterinary Use Only)	Velagliflozin L-proline Monohydrate INN 15 mg/ml oral solution (Vet)	Anti-diabetic	**Target species:** Cats For the reduction of hyperglycaemia in cats with non-insulin-dependent diabetes mellitus.	• **Contraindications:** Do not use in cats with clinical signs of diabetic ketoacidosis (DKA) or laboratory values consistent with DKA. Do not use in cats with severe dehydration requiring i.v. fluid supplementation. **Side-effects:** Diarrhoea or loose stool may be transient. Polydipsia or polyuria, Weight loss. **Withdrawal periods** Not applicable.	New	EMA	অনুমোদনের সুপারিশ করা হয়।	অনুমোদন করা হয়।
414.	Renata Limited Mirpur, Dhaka	Piperacillin 2 gm + Tazobactam 0.25 gm Powder for Injection (Vet) (For Veterinary Use Only)	Piperacillin BP 2 gm + Tazobactam INN 0.25 gm Powder for Injection (Vet)	Anti-infective	Piperacillin and tazobactam for injection is a combination of piperacillin, a penicillin-class antibacterial and tazobactam, a beta-lactamase inhibitor, indicated for the treatment of: Intra-abdominal infections in cattle.	**Contraindications:** with a history of allergic reactions to any of the penicillins, cephalosporins, or beta-lactamase inhibitors. **Side-effects:** Not Known.	New	No Ref.	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুরের সুপারিশ করা হয়।	বর্তমানে প্রয়োজন নেই বিধায় নামঞ্জুর করা হয়।